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SUMMARY
Identification of patients at risk of thromboembolism poses a daunting 
problem. Nevertheless the availability of measurable plasma or serum factors may help to 
identify those patients at particular risk of thrombogenesis and whom may benefit from 
prophylactic anticoagulant therapy. My thesis investigates the roles of fibrinogen, fibrin 
turnover, endothelial dysfunction and lipoprotein(a) in thrombogenesis associated with two 
cardiovascular conditions at high thromboembolic risk, that is, atrial fibrillation and left 
ventricular dysfunction.
Atrial fibrillation was found to be a common cardiac arrhythmia in a survey of 
emergency admissions over a six month period to my hospital. Heart failure and 
cerebrovascular events were the commonest presenting features, accounting for about half 
of all emergency admissions who were found to be in atrial fibrillation. This survey gave a 
comprehensive profile of how patients with atrial fibrillation were investigated and managed in 
a district general hospital. For example, a suboptimal application of standard investigations in 
patients with atrial fibrillation was identified together with a reluctance to perform cardioversion 
or to commence anticoagulant therapy. This being despite the increasingly important roles for 
these two therapeutic manoeuvres in the current management of atrial fibrillation. One 
possible reason for the low rate of introducing anticoagulation may be the uncertainty of many 
physicians in identifying patients at high thromboembolic risk. The availability of a suitable 
plasma marker of thrombogenesis may assist decision-making in these patients.
Factors such as fibrinogen, von Willebrand factor and lipoprotein (a) have 
been associated with thrombosis, embolism and stroke. In addition, the fibrin D-dimer 
fragment is a marker of fibrin turnover and is indirectly a measure of intravascular thrombus 
formation. In my study, I have identified abnormalities of these plasma markers suggesting a 
prothrombotic state in patients with atrial fibrillation and left ventricular aneurysms.
Patients with chronic atrial fibrillation, for example, have significant elevations 
of plasma fibrinogen and von Willebrand factor when compared to normal population values; 
and this is irrespective of aspirin or warfarin therapy. Those who are on no antithrombotic
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therapy have the highest levels of plasma fibrin D-dimer, suggesting the highest levels of 
intravascular fibrin turnover in these patients. In contrast, patients whom are established on 
warfarin have the lowest fibrin D-dimer levels, consistent with the beneficial effect of warfarin in 
reducing thrombogenesis. No significant effect on these factors with respect to atrial size, 
ventricular function (as measured by echocardiography), or underlying valve or ischaemic 
heart disease was noted.
Cardioversion of atrial fibrillation to sinus rhythm replaces the irregular atrial 
activity of atrial fibrillation with the regular atria) systole of sinus rhythm. If thrombogenesis has 
a simple mechanical basis, cardioversion of atrial fibrillation should be expected to immediately 
normalise plasma fibrinogen and fibrin D-dimer levels. This does not appear to be the case, as 
in patients without warfarin therapy, plasma fibrin D-dimer falls sequentially over two weeks 
following cardioversion. This is partly due to the clearance of D-dimer from the circulation and 
that atrial systole may not resume immediately. In addition, there is little change in plasma 
fibrinogen levels, which may inpart be due to the individual variation in the return of atrial 
systole. Although clinical studies suggest a 'high risk* period for thromboembolism following 
cardioversion, no significant peak in plasma fibrinogen or fibrin D-dimer has been noted. This 
is in keeping with the hypothesis that any emboli are due to pre-formed thrombus rather than 
formation of new thrombus following cardioversion. Patients who are anticoagulated pre- and 
post-cardioversion have low plasma D-dimer levels, which do not alter over the two weeks' 
follow-up, consistent with the prophylactic effects of warfarin in reducing thromboembolic 
risks during cardioversion.
If fibrin D-dimer is a suitable indicator of intravascular thrombogenesis, further 
evidence may be obtained by a study of patients with paroxysmal atrial fibrillation. These 
patients are regarded as at intermediate thromboembolic risk when compared to chronic atrial 
fibrillation and those in sinus rhythm. Patients with paroxysmal atrial fibrillation (on no warfarin 
therapy) indeed do have intermediate levels of plasma fibrinogen and fibrin D-dimer, in 
keeping with clinical observations. This suggests that flow abnormalities may be important in 
thrombogenesis, as sustained irregular atrial activity (in chronic atrial fibrillation) causes greater 
abnormalities in markers of thrombogenesis when compared to patients with intermittent
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irregular atrial contractions (for example, paroxysmal atrial fibrillation) and those with normal, 
regular atrial systolic function (in sinus rhythm).
Patients with paroxysmal supraventricular tachycardia (whom have a 
paroxysmal tachycardia with normal regular atrial contractions) were also compared with 
matched patients manifesting paroxysmal atrial fibrillation. In this small study, patients with 
paroxysmal supraventricular tachycardia had lower levels (similar to population values) of 
plasma fibrinogen and fibrin D-dimer when compared with matched patients having 
paroxysmal atrial fibrillation. This again suggests a role for flow abnormalities associated with 
atrial fibrillation in influencing plasma fibrinogen and fibrin D-dimer levels.
Epidemiological evidence suggests that valvular heart abnormalities 
significantly add to the thromboembolic risk of patients with atrial fibrillation. All patients with 
valvular disease may not have similar risks of thromboembolism and this may in part be related 
to their inherent flow characteristics. I therefore studied a small series of patients with aortic 
stenosis and mitral regurgitation. Both groups had higher plasma fibrinogen levels when 
compared to population levels, in keeping with flow abnormalities in these patients. However, 
patients with mitral regurgitation have lower plasma D-dimer levels, indicating lower 
intravascular fibrin turnover. This finding is consistent with observations that the presence of 
mitral regurgitation reduces spontaneous echo contrast (associated with thrombus and 
embolism) and intraventricular thrombus formation (for example, in patients with dilated 
cardiomyopathy). This suggests that plasma D-dimer may be associated with stasis (allowing 
thrombus formation) within the atrial cavity which is reduced by the presence of mitral 
regurgitation. Patients with aortic stenosis, however, have similar plasma D-dimer levels to 
population values, in keeping with the different pathophysiology (calcific emboli and platelets) 
of emboli associated with aortic stenosis.
Epidemiological evidence also suggests that a further factor contributing to 
the risk of stroke in atrial fibrillation is the presence of heart failure. Patients with ischaemic 
heart disease have higher plasma fibrinogen and von Willebrand factor levels when compared 
with population controls, but those with left ventricular aneurysms (as defined by radionuclide 
ventriculography), however, have the highest levels of plasma fibrinogen, fibrin D-dimer and
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von Willebrand factor. This indicates the highest levels of intravascular thrombogenesis in 
patients with left ventricular aneurysms and may explain the association of heart failure 
(associated with left ventricular impairment) and thromboembolic events. As in patients with 
chronic atrial fibrillation, patients with left ventricular aneurysms who were established on 
warfarin therapy have low fibrin D-dimer levels, consistent with a reduction in thrombogenesis.
Clinical or epidemiological studies investigating the contribution of heart 
failure to thromboembolic risk do not, however, make a distinction between systolic and 
diastolic dysfunction. This is pertinent as 30% or more of admissions with clinical heart failure 
have normal systolic function. There were, however, no differences in plasma fibrinogen, 
fibrin D-dimer and von Willebrand factor between patients with and without diastolic 
dysfunction. This suggests that the flow abnormalities associated with systolic (rather than 
diastolic) impairment have the greatest influence upon fibrinogen and fibrin turnover (and 
thrombogenesis).
Recent prospective studies of patients with nonvalvular atrial fibrillation have 
shown that prophylactic anticoagulant therapy is beneficial in reducing thromboembolic risk. 
In patients with chronic atrial fibrillation and left ventricular aneurysms in whom anticoagulant 
therapy is introduced, there is a sequential reduction in plasma fibrin D-dimer (but not 
fibrinogen) levels with the introduction of warfarin therapy. In addition, in those with the 
highest initial D-dimer levels (>100ng/ml) this reduction is highly significant. This is again 
consistent with the beneficial effect of warfarin in reducing stroke and thromboembolism, and 
patients at highest risk (e.g. D-dimer >l00ng/ml) may be selected by measurement of plasma 
fibrin D-dimer levels.
Lipoprotein (a) is another factor associated with thrombogenesis, especially 
in ischaemic heart disease. I therefore measured lipoprotein (a) levels in the two conditions in 
which the highest intravascular fibrin turnover was demonstrated, those being chronic atrial 
fibrillation and left ventricular aneurysms. There were, however, no significant differences 
between patients and healthy controls and no alteration even with warfarin therapy. This is 
consistent with observations that lipoprotein (a) is predominantly genetically determined, and 
varies little with environmental influences.
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In summary, plasma levels of fibrinogen, D-dimer and von Willebrand factor 
are elevated in patients with chronic atrial fibrillation (without antithrombotic therapy) and 
patients with left ventricular aneurysms. Intermediate levels are seen in patients with 
paroxysmal atrial fibrillation. My thesis therefore suggests possible roles for fibrinogen, 
increased fibrin turnover (as measured by plasma D-dimer), endothelial dysfunction (as 
reflected by von Willebrand factor) and rheological abnormalities in thrombogenesis in these 
patients. Lipoprotein (a) appears to be little changed in these patients, with no relationship to 
other plasma factors, in keeping with the strong genetic influence of this prothrombotic factor. 
In addition, levels of these markers in patients with atrial fibrillation were not significantly 
influenced by cardiac chamber size and structural abnormalities; whilst in patients with left 
ventricular dysfunction, the presence of left ventricular aneurysms and systolic (rather than 
diastolic) dysfunction was found to be important.
Therapeutic interventions may also alter thrombogenesis. For example, 
cardioversion and anticoagulation both reduce plasma D-dimer levels, suggestive of the 
beneficial effects of these interventions. As my survey of admissions with atrial fibrillation 
demonstrated however that both of these procedures are infrequently considered, the 
availability of a suitable plasma marker to select patients at high risk (who would benefit most 
from intervention) may aid a physician in considering these interventions more frequently. My 
thesis suggests that measurement of plasma fibrin D-dimer may provide such a marker of 
thrombogenesis. Measurement of other factors such as fibrinogen and von Willebrand factor 
will also contribute to the overall risk profile, allowing the risk of thrombogenesis in such 
patients to be predicted.
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LAYOUT OF THESIS
The aim of this study was to investigate the haemo-rheological mechanisms 
of thrombogenesis in two cardiac conditions at high risk of thromboembolism: atrial fibrillation 
and left ventricular dysfunction.
In the introduction in CHAPTER 1 ,1 review the current literature on the role of 
haemorheological factors and lipoprotein (a) in thrombogenesis. I also summarise the 
background and aims of my thesis. In CHAPTER 2, I undertake a survey of emergency 
admissions with atrial fibrillation to a district general hospital. This survey gave a 
comprehensive profile of admissions with atrial fibrillation and how they are investigated or 
managed, allowing the identification of suitable patients for further study. In CHAPTER 3 
patients with chronic atrial fibrillation are studied. This is a group of 85 patients with chronic 
atrial fibrillation (divided into those on aspirin, warfarin and no antithrombotic therapy), whom 
are compared to population controls. Flow abnormalities in atrial fibrillation may contribute to 
thrombogenesis in these patients and conversion to sinus rhythm may alter this process. 
Therefore, patients whom were cardioverted from atrial fibrillation into sinus rhythm are 
studied in CHAPTER 4. The results of these studies stimulated an investigation into a group 
of patients with paroxysmal atrial fibrillation whom are at intermediate thromboembolic risk 
(CHAPTER 5). In CHAPTER 6 patients with paroxysmal supraventricular tachycardia are 
studied allowing comparison with patients with paroxysmal atrial fibrillation.
The presence of valve disease and left ventricular dysfunction are risk factors 
for thromboembolism and are additive to the risks of thrombogenesis in atrial fibrillation. In 
CHAPTER 7, the influence of heart valve disease is studied, whilst patients with left 
ventricular dysfunction are studied in CHAPTER 8. Current epidemiological studies do not 
differentiate between the effects of systolic and diastolic dysfunction in assessing 
thromboembolic risk. These patients with diastolic dysfunction are therefore studied in 
CHAPTER 9. The effects of introducing anticoagulation in patients with chronic atrial 
fibrillation and left ventricular aneurysm are studied in CHAPTER 10. CHAPTER 11 
addresses the contribution of lipoprotein (a) to the mechanisms of thrombogenesis.
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CHAPTER 12 comprises a discussion of the overall results, an examination of the inter­
relationship of factors studied in this thesis and concludes with a summary of the main findings 
of my thesis and suggestions for further study.
In summary, my thesis will commence with a review of the literature on plasma 
markers of thrombogenesis. This will follow with clinical studies set out as individual chapters. 
Each of these will include methodology used, results obtained and a critical discussion 
including relevant literature review.
CHAPTER 1
INTRODUCTION
19
1.1 THROMBOGENESIS AND PROTHROMBOTIC FACTORS
Introduction
Many cardiovascular conditions are associated with an increased 
thromboembolic risk: two notable ones being atrial fibrillation and poor left ventricular function. 
The mechanisms of thromboembolism in these two common conditions have not been fully 
elucidated. These mechanisms are likely to be complex, multifactorial and inter-related. For 
example, the presence of a dilated left atrium and poor left ventricular function are considered 
to be contributory risk factors to the thromboembolic risk in atrial fibrillation. In patients in sinus 
rhythm, however, the presence of poor left ventricular function (particularly in the presence of 
an associated left ventricular aneurysm) is also associated with an increased thromboembolic 
event rate. A possible mechanism common to both conditions is the presence of slow, 
sluggish or recirculating blood flow within a dilated left atrial cavity or a poorly contractile left 
ventricle (or aneurysm), which may result in an increased propensity toward clot or thrombus 
formation (thrombogenesis).
How does altered flow and rheology relate to this thromboembolic risk, and how can we 
quantify this risk?
The role of blood flow properties (rheology) in thrombogenesis has been 
long recognised. More than a century ago, Virchow (1856) postulated that a triad of 
abnormalities were key determinants of the process of thrombus formation: (i) slowing of 
blood flow; (ii) changes in the composition of the blood itself (that is, blood cells and clotting 
factors); and (iii) changes in (and blood interactions with) the blood vessel wall. A modern 
modification of this hypothesis suggests that turbulent blood flow, chronic damage to the 
endothelium (by injury from cigarette smoking and hypertension) and abnormalities in blood 
lipids result in functional abnormalities of the endothelium, leading to adhesion of monocytes 
and platelets, and the further accumulation of lipids. Continuation of this process leads to 
atheroma formation (atherogenesis). The process of arterial thrombogenesis is therefore very 
closely related to atherogenesis: it follows that specific thrombogenic factors may play key
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roles in the process of atherosclerotic lesion formation. Further evidence for this is the 
presence of platelets, fibrinogen, fibrin and fibrin degradation products in atheromatous 
plaques (especially at areas of thrombus formation) and the promotion of smooth muscle 
proliferation and lipid deposition by accumulated fibrinogen and fibrin (Hunt 1990).
The precise contributory factors to thrombogenesis and atherogenesis have, 
however, not been fully defined. Based on current clinical and epidemiological evidence, 
plasma factors, such as fibrinogen, fibrin D-dimer, von Willebrand factor and lipoprotein (a) may 
be suitable markers of thrombogenesis and atherogenesis; thus suggesting possible roles 
for increased fibrin formation, endothelial dysfunction and Theological disturbance in the 
mechanisms of promoting thrombus formation (thus contributing towards a prothrombotic or 
hypercoagulable state).
What then is the relative importance of these plasma prothrombotic factors in 
thrombogenesis and atherogenesis? Most evidence to date is from epidemiological studies. 
Increased plasma fibrinogen levels have been associated with an increase in risk of 
cardiovascular disease, including ischaemic heart disease, stroke and other thromboembolic 
events (Ernst et al 1992, Ernst and Resch 1993). Plasma fibrinogen is, however, also 
involved in blood coagulation and is an important determinant of blood viscosity and hence of 
blood flow (Lowe 1986). In the process of thrombus formation, fibrinogen is converted to 
fibrin by the action of thrombin, and the resulting fibrin monomers polymerise to form a soluble 
gel of non-crosslinked fibrin. The latter is then crosslinked by thrombin-activated Factor XIII to 
form an insoluble fibrin clot. Subsequent activation of the fibrinolytic system results in 
formation of the enzyme plasmin, which cleaves both fibrinogen and fibrin to yield fibrin 
degradation products (FDPs). Of these, only the degradation products from crosslinked fibrin 
(XL- FDP) contain the D-dimer fragment. The process of fibrin turnover can therefore be 
assessed by the measurement of plasma fibrin D-dimer levels, which are therefore an indirect 
marker of intravascular thrombus formation (thrombogenesis).
The blood vessel wall also contributes to thrombogenesis (Virchow's triad) 
and any endothelial disturbance can be assessed by measurement of plasma levels of von 
Willebrand factor (vWF), which is an increasingly recognised marker of endothelial dysfunction
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(Blann et al 1993, Jansson et al 1991). Another serum factor, lipoprotein (a) [Lp(a)], has been 
recognised for nearly 30 years as a partially genetically-determined lipoprotein which is 
associated with an increase in atherogenesis and thrombogenesis. Elevated Lp (a) levels 
have been associated with an increased risk for coronary artery disease, stroke and restenosis 
after coronary artery bypass surgery (Rees 1991, Scott 1991). The actual function of Lp(a), 
however, remains largely unknown. In vitro studies have shown that Lp(a) competes in 
equimolar concentrations with plasminogen for binding to plasminogen receptors on vascular 
endothelial cells, resulting in an inhibitory effect on endogenous fibrinolysis. Lp(a) may also 
deliver cholesterol to proliferating cells by binding fibrin at sites of vascular injury, therefore 
contributing to thrombus and atheroma formation (Lawn 1992).
The potential interactions between the plasma markers of thrombogenesis 
and atherogenesis are, therefore, complex. Their relative importance as useful markers 
remains to be demonstrated in prospective studies. Improved biochemical techniques have, 
however, allowed the easy measurement of these key factors in thrombogenesis. Study of 
the possible mechanisms of thrombogenesis in cardiac conditions with particular risk of 
thromboembolism is therefore feasible. Measuring and evaluating such markers of an 
apparent intravascular thrombogenic state may also be of value in clinical practice. For 
example, measurement of these plasma factors may allow screening of patients in order to 
identify those most at risk of thromboembolism and hence those whom might benefit most 
from antithrombotic therapy. Additionally, in the acute stage of a thrombotic occlusion 
(coronary arteries in the case of myocardial infarction, or in cerebrovascular events) these 
plasma factors may provide prognostic information and allow therapeutic monitoring. Such 
measurements also open the possibility of developing new strategies in antithrombotic 
therapy.
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1.2 FIBRINOGEN, FIBRIN D-DIMER FRAGMENT, VON WILLEBRAND 
FACTOR AND LIPOPROTEIN (a) IN CARDIOVASCULAR DISEASE:
A REVIEW OF THE LITERATURE
Introduction
The process of thrombus formation involves endothelial injury, platelet 
adherence, aggregation and release, thrombin generation and fibrin formation. In addition, 
thrombogenesis is closely associated with atheroma formation and both processes contribute 
to atherosclerotic cardiovascular disease. Interestingly, the hypothesis that thrombosis may 
contribute significantly to spontaneous atherogenesis was originally proposed by Rokitansky 
(1852), who postulated that atheroma formation results from irrtimal deposition of blood 
components, including thrombi and fibrin. There is now increasing pathological evidence that 
the progression of atherosclerosis is, probably to a significant extent, closely related to 
ongoing mural thrombus formation ('thrombogenesis') and organisation (Duguid 1946, Woolf 
and Davies 1992).
Plasma factors involved in the process of thrombogenesis which have been 
studied include plasma fibrinogen, factor VII, fibrin D-dimer fragments and plasma von 
Willebrand factor. In addition, plasma lipoprotein (a) has been shown to related to the intrinsic 
fibrinolytic tendency of the body, although the precise role of this lipoprotein and its 
relationship to other coagulation factors and thrombogenesis remains unclear (Figure 1.1).
PLASMA FIBRINOGEN.
Biochemistry and pathophysiology
Human fibrinogen is a large glycoprotein (340000 Daltons) composed of 3 
pairs of nonidentical polypeptide chains (A alpha, B beta and gamma) which are joined 
together by disulphide bonds at their amino-acids. It is well recognised that fibrinogen is an 
important determinant of the Theological characteristics of blood flow, as well as platelet 
aggregability (Lowe 1986). Fibrinogen is also an essential component of the blood 
coagulation system, being the precursor of fibrin. However, at the 'usual' plasma levels of 1.5
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to 4.5 g/l Its concentration far exceeds the minimum concentration of 0.5-1 g/l necessary for 
haemostasis.
It is postulated therefore that elevated plasma fibrinogen levels may reflect a 
prothrombotic or hypercoagulable state as it is a major determinant of fibrin formation, blood 
viscosity and platelet aggregation. This possibly enhanced thrombogenic tendency of 
fibrinogen may contribute to the development of the atheromatous lesion itself and the 
tendency of ruptured atheromatous plaques to occlude, for example, in coronary artery 
disease. In patients with an accelerated risk of atherosclerosis due to hyperlipidaemia, 
hypertension or diabetes, this is particularly important and raised plasma fibrinogen levels may 
be an independent and major additive risk factor to such patients (Ernst et al 1992). It is also 
proposed that elevated plasma fibrinogen may promote atherosclerotic vascular damage as 
high concentrations of fibrinogen and fibrin have been found in developing atherosclerotic 
lesions (Bini and Kudryk 1992, Smith et al 1990). The pathogenesis of such lesions is not 
solely due to fibrinogen and fibrin but likely to involve increased fibrin formation and 
degradation (Bini and Kudryk 1992), platelet aggregation (which fibrinogen increases) and 
changes in blood viscosity (which fibrinogen promotes) (Lowe 1986) (Figure 1.1).
The importance of the intimate interaction between plasma fibrinogen and 
platelets in thrombogenesis is suggested by the process of platelet recruitment. This involves 
the expression of the glycoproteins lib/ Ilia receptor for fibrinogen and other cytoadhesive 
proteins that include von Willebrand factor (Badimon et al 1992, Harker 1987). In addition, 
patients with poor left ventricular function have greater platelet activation (as reflected by 
increased plasma levels of factors which reflect platelet activity, such as platelet factor 4 and 6 
thromboglobulin), and together with an interaction with plasma fibrinogen, thrombogenesis 
may therefore be promoted (Schmitz-Huebner et al 1988). Similarly, patients with previous 
myocardial infarction demonstrate significant elevations in platelet factors due to the reaction 
of platelets with previously infarcted myocardium (rather than arteriosclerotic coronary arteries) 
(Nichols et al 1982). This suggests that enhanced platelet activation may be associated with 
the presence of left ventricular wall motion abnormalities (Nichols el al 1982).
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Plasma fibrinogen is an important contributory factor to the flow properties of 
the blood and is a major determinant of plasma viscosity and red cell aggregation (and hence, 
whole blood viscosity). An elevation in whole blood viscosity may lead to sluggish blood flow, 
which is associated with thrombus formation. Not surprisingly, this Theological index is high in 
patients with coronary artery disease and patients at high risk of ischaemic heart disease 
(Mares et al 1991).
Epidemiological studies
Plasma fibrinogen has been well established as a cardiovascular risk factor. 
Studies from different countries over the last 10 years have demonstrated a significant 
association between plasma fibrinogen and cardiovascular mortality and morbidity, including 
ischaemic heart disease and stroke (Garcia-Bolao et al 1990, Green and Humphries 1989, 
Ernst 1991, Ernst and Resch 1993). In addition to elevated fibrinogen levels, plasma viscosity 
(to which plasma fibrinogen contributes) and leucocyte count are at least as predictive for 
cardiovascular events as traditional' cardiovascular risk factors such as cholesterol, diastolic 
blood pressure and body mass index (Yarnell et al 1991). However, plasma fibrinogen has 
other 'external' influencing factors, and it is recognised that concentrations change with age, 
post-menopausal state, obesity and smoking, and fall with alcohol consumption (as will be 
discussed below) (Ernst and Resch 1993, Green and Humphries 1989, Meade et al 1979).
In the Northwick Park Heart study of white men, plasma fibrinogen levels were 
higher in those who died of cardiovascular disease (Meade et al 1986). An important finding is 
that an elevation of one standard deviation in fibrinogen concentration (about 0.6 g/l) was 
associated with an 84% increase in the risk of ischaemic heart disease within the next 5 years 
(In contrast, the corresponding risk progression for cholesterol was only 43% for all age 
groups) (Meade et al 1986).
In the Framingham study, the risk for coronary heart disease was also 
significantly related to the plasma fibrinogen level (Kannel et al 1987). This risk however 
diminished with age in women but not in men. The converse was demonstrated for the risk of 
stroke, which was related to plasma fibrinogen levels in men but not in women. Similar results
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are demonstrated in the PROCAM study of 2187 patients whom were prospectively followed- 
up for 48 months, where those with cardiac events had significantly elevated plasma 
fibrinogen levels (Heinrich et al 1991b). in the Gothenburg Study, there was also a clear 
relationship between plasma fibrinogen and the development of stroke and myocardial 
infarction, even after adjusting for blood pressure, serum cholesterol and smoking 
(Wilhelmsen et al 1984).
In the Caerphilly and Speedwell Collaborative Heart Study, a combined 
cohort of 4860 middle-aged men was studied and yet again, plasma fibrinogen and viscosity, 
and white blood cell count were important risk factors for ischaemic heart disease (Yarnell et al 
1991). These associations with ischaemic heart disease were independent of smoking 
status, although part of the adverse effects of smoking may be mediated through plasma 
fibrinogen, viscosity and white cell count (Yarnell et al 1991). Another British study, the Leigh 
general practice study of 297 males demonstrated that plasma fibrinogen was also a major 
independent coronary risk factor (Stone and Thorp 1985).
In the Scottish Heart Health Study, plasma fibrinogen was measured in 8824 
patients aged 40-59 years and related to cardiovascular risk factors. This large study 
demonstrated that women had higher plasma fibrinogen levels than men, and that there was a 
positive association with age, smoking, total cholesterol and body mass index and a negative 
association with alcohol consumption (Lee et al 1990, Lee et al 1993). As in the Caerphilly 
and Speedwell Collaborative Heart Study, the findings of the Scottish Heart Health Study do 
suggest that a raised plasma fibrinogen level was one mechanism by which several risk factors 
(including smoking) promoted coronary heart disease (Lee et al 1990, Yarnell et al 1991). The 
Scottish Heart Health Study, in addition, was the first large random population study to 
demonstrate that plasma fibrinogen was raised in subjects with a family history of premature 
heart disease and with a personal history of hypertension, diabetes, angina, myocardial 
infarction or intermittent claudication (Lee et al 1993). The latter finding was confirmed in the 
Edinburgh Artery Study (Lowe et al 1993).
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Ischaemic heart disease
An important relationship clearly demonstrated in the epidemiological studies 
discussed above is the association between risk factors for ischaemic heart disease and 
plasma fibrinogen levels. However, do the changes in plasma fibrinogen and other plasma 
factors extend to all categories of patients with ischaemic heart disease? Plasma fibrinogen 
and fibrin degradation products are generally elevated in coronary artery disease, but these 
concentrations appear to depend on the severity and time since onset of disease (Malaia et al 
1990). Plasma viscosity and fibrinogen levels are also higher in patients with unstable angina 
than in patients with stable angina (Leschke et al 1988), and in patients with more severe 
coronary artery disease (Lowe et al 1980). Importantly, the latter elevation was comparable to 
the increased values found in patients following acute myocardial infarction (Leschke et al 
1988). The abnormal blood viscosity in unstable angina (related in part to abnormal plasma 
fibrinogen levels) may contribute to increasing myocardial ischaemia and the progression of 
angina by slowing capillary blood flow and diminishing oxygen delivery. These results also 
suggest that the increased plasma fibrinogen levels during acute myocardial infarction are not 
solely a reactive (or infarction-related) mechanism, but are part of the pathogenesis of 
unstable angina by a Theological reduction in coronary perfusion and the promotion of 
thrombus formation.
The relationship to the extent or severity of coronary artery disease is 
consistent. In 9 out of 10 studies, plasma fibrinogen levels correlated significantly with the 
degree of coronary artery disease (Table 1.1). In a Glasgow study, for example, there was a 
modest association between the extent of coronary atheroma and plasma fibrinogen levels 
(but no relationship between the severity of coronary artery disease and components of the 
fibrinolytic enzyme system) (Small et al 1987). Recent large studies have also confirmed the 
association between plasma fibrinogen and extent of coronary atherosclerosis (ECAT Angina 
Pectoris Study Group 1993). The converse was demonstrated in one larger study of 225 
patients, where plasma fibrinogen, von Willebrand factor and other clotting factors did not 
contribute independently to the prediction of an angiographic score that indicated the extent 
of coronary artery disease (Schmitz-Huebner et al 1988). While the trend is clear, care has to
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be taken in the interpretation of the absolute values of plasma fibrinogen summarised in Table
1.1 due to regional variations in plasma fibrinogen levels (Ernst 1991, Machin and Mackie 
1993).
Despite the variation in time course and severity of ischaemic heart disease 
discussed above, an elevated plasma fibrinogen is nevertheless predictive of future 
cardiovascular events in patients with coronary heart disease (Dormandy et al 1982, Martin et 
al 1991), peripheral vascular disease (Banerjee et al 1992, Dormandy et al 1973, Fowkes et al 
1993) and survivors of a first stroke (Ernst et al 1991).
Atrial fibrillation
Atrial fibrillation is commonly associated with stroke and thromboembolic 
events and associated rheological abnormalities may be a significant contributing factor. 
Indeed, plasma fibrinogen levels are elevated in patients with chronic atrial fibrillation (Kumagai 
et al 1990). The role of plasma fibrinogen in contributing to thrombogenesis in atrial fibrillation 
(and the effects of interventions such as anticoagulation and cardioversion to sinus rhythm) is 
further investigated by my thesis. In patients with chronic atrial fibrillation after threadmill 
exercise, plasma fibrinogen levels are increased in association with enhanced platelet activity 
but lower levels of antifibrinolytic activity (Furui et al 1987). This suggests therefore that 
haemorheological abnormalities in atrial fibrillation are ’real’ and dynamic; and that the risk of 
thromboembolic complications may be enhanced by stress or physical exercise.
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TABLE 1.1
PLASMA FIBRINOGEN LEVELS (g/l) IN PATIENTS WITH 
CORONARY ARTERY DISEASE
one-vessel disease two-vessel disease three-vessel disease
Bailer etal 1991 3.16 3.43 3.40
Broadhurst et al 
1990
2.64 3.07 3.31
ECAT Angina 
Pectoris Study
3.02 3.08 3.05-3.10
Group 1993
Hamsten etal 1986 3.41 3.62 3.68
Handa et al 1989 M2.93 M3.13 M3.25
F2.72 F3.05 F3.24
Leschke et al 1988 2.65 2.76 3.05
Lowe et al 1980 2.73 3.19 3.19
Schmitz-Hubner et al 
1988
3.28 3.20 3.36
Small et al 1987 3.19 3.28 3.40
Psychological and mental stress
The effect of psychological and mental stresses has been shown to have a 
significant effect on plasma coagulation and fibrinolysis, with demonstrable increased levels of 
plasma fibrinogen, von Willebrand factor and factor VIII coagulant activity (Jem et al 1989). 
These changes appear to be adrenergic in origin, being similar to responses observed during 
exercise and with an adrenaline infusion (Jern et al 1989). Mental stress has been regarded 
as an important risk factor for cardiovascular disease, and this study provides suggests one 
possible mechanism for this. Stress also induces an increase in platelet count and activity, 
and this (in combination with the increased levels of vWF, coagulation factors VII and VIII, and 
plasma fibrinogen discussed above) may have an additive effect in promoting occlusive 
thrombus formation. There is also experimental evidence that chronic mental stress promotes 
the development of atherosclerosis, which is a process requiring (as discussed above) 
fibrinogen, von Willebrand factor and platelets (Clarkson et al 1987).
Cerebrovascular disease
There is epidemiological evidence suggesting that plasma fibrinogen levels 
are significantly associated with cerebrovascular events. The Framingham and Gothenburg 
studies have both shown that plasma fibrinogen is an independent prognostic risk factor for 
stroke (Kannel et al 1987, Wilhelmsen et al 1984). Similarly, the Oxfordshire community 
stroke project demonstrated that an elevated plasma fibrinogen level (in addition to 
generalised hypercholesterolaemia and elevated low density lipoproteins) was a risk factor for 
prevalent cerebrovascular events (Qizilbash et al 1991). In addition, an analysis of risk factors 
for stroke in a cohort of 789 men born in 1913 demonstrated that increased plasma fibrinogen 
levels correlated significantly with the incidence of stroke (Welin et al 1987). Levels of plasma 
fibrinogen are also raised in patients with transient ischaemic attacks (Coull et al 1991, 
Qizilbash et al 1991).
There is also evidence of a link between these haemorheological parameters 
in cerebrovascular disease and histopathological evidence of atherosclerotic lesions 
associated with stroke. When patients with stroke were studied, an association between
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atherosclerotic lesions of the extracranial carotid artery and age, plasma fibrinogen and whole 
blood filterability was noted (Mercuri et al 1989). In addition, an elevated plasma fibrinogen 
predicted the progression of atherosclerotic carotid stenosis (Grotta et al 1989).
Peripheral vascular disease
Patients with peripheral vascular disease demonstrate abnormalities of 
several coagulation, fibrinolytic and Theological variables. For example, plasma fibrinogen 
concentration was an important independent predictor of coronary death in patients with 
intermittent claudication (Fowkes et al 1993). This finding is similar to that demonstrated in 
the Northwick Park prospective study of stable claudicants (Banerjee et al 1992). In the latter 
study, an increase in plasma fibrinogen of 1 g/l was associated with a two-fold increase in the 
probability of death within the next six years (Banerjee et al 1992).
Hypertension
It is well recognised that hypertension adds to the risk factor profile for 
patients with coronary artery and cerebrovascular disease. In patients with hypertension, 
fibrinogen concentration and plasma viscosity are independent predictors of blood pressure. 
In a study of hypertensive diabetic Nigerians, for example, plasma fibrinogen was the 
strongest predictor of both systolic and diastolic blood pressure, followed by blood viscosity 
and body mass index (Mermeh 1990). In hypertensives with renoparenchymous and 
malignant forms of hypertension, marked rises of plasma fibrinogen are seen, with a linear 
correlation between the plasma-renin activity and the levels of systolic and diastolic blood 
pressure (Sonkodi et al 1979). This is pertinent as the haemorheological abnormalities in 
hypertension may have important implications for cardiovascular morbidity and mortality 
(Zannad and Stoltz 1992). An indication of these risks involved are demonstrated in the 
Leigh general practice study, where hypertensive subjects with plasma fibrinogen levels >3.5 
g/l had a 12-fold higher cardiovascular risk than those with plasma fibrinogen levels <2.9g/l 
(Stone and Thorp 1985).
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In addition, patients with hypertension and coronary artery disease are found 
to have higher levels of plasma fibrinogen and plasma viscosity than in patients with essential 
hypertension and normal coronary arteries (Leschke et al 1987, Leschke et al 1988, Leschke 
et al 1990). Importantly, however, hypertensive patients without coronary artery disease had 
significantly higher levels of plasma viscosity, red cell aggregation than did normotensive 
controls (Leschke et al 1987). These findings are of significance as the increased blood 
viscosity in hypertensive patients (both 'de novo' and secondary to increased plasma 
fibrinogen) may potentially contribute to angina pectoris and the reduction in coronary reserve 
observed in patients with hypertension and coronary artery disease (Leschke et al 1987, 
Leschke et al 1990).
Diabetes
Patients with diabetes mellitus are at increased risk of cardiovascular 
complications and interestingly, these patients also demonstrate abnormalities in plasma 
fibrinogen and other coagulation factors. In a study of 170 patients with Type II diabetes, 
plasma levels of fibrinogen were significantly higher than that of the normal population 
(Shihabi et al 1990). There was also a significant positive correlation between plasma 
fibrinogen and fasting glucose levels, serum cholesterol levels, glycosylated haemoglobin 
and urinary albumin excretion rates (Shihabi et al 1990). In the Framingham Study and 
Scottish Heart Health Study, diabetic subjects also had higher plasma fibrinogen 
concentrations than non-diabetic subjects (Kannel et al 1990, Lee et al 1993). These 
findings are important as elevated fibrinogen levels were a major determinant of cardiovascular 
complications in diabetics (Ganda and Arkin 1992, Kannel et al 1990).
One specific group of diabetics who are at particular cardiovascular risk are 
those who develop systemic complications such as renovascular disease and neuropathies. 
These patients also demonstrate significant plasma Theological and lipid abnormalities. In a 
case-control study of insulin dependant diabetics, patients with microalbuminuria (whom are 
those who tend to develop renal complications) had significant elevations of plasma 
fibrinogen, triglycerides, low density lipoprotein cholesterol, very low density lipoprotein
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cholesterol (but lower concentrations of high density lipoprotein cholesterol) when compared 
to controls (Jones et al 1989). Similarly when diabetic patients with neuropathies were 
studied, higher blood viscosity and elevations in coagulation factors including plasma 
fibrinogen and von Willebrand factor were found (Solerte et al 1988).
Plasma fibrinogen and lipid abnormalities therefore add significantly to the 
complex risk factor profile for cardiovascular disease in diabetic patients.
Body mass
In obese patients (Body Mass Index > 30) plasma viscosity and fibrinogen 
levels are significantly increased when compared to healthy subjects (BMI<25) (Craverei et al 
1987, Rosengren et al 1990). This increase is independent of the presence of 
atherosclerotic complications and other risk factors.
Hormonal influence
The incidence of myocardial infarction and cerebral thromboembolism is 
higher in women who use oral contraceptives and Theological abnormalities may partly explain 
this (Bogousslavsky and Regli 1987, Lidegaard 1993, RCGP Oral Contraception Study 1977, 
Shearman 1986). This patient group appears to have an increased thrombogenic tendency 
as measured by elevated platelet aggregation and plasma fibrinogen levels (Balleisen et al 
1985, Garcia-Bolao et al 1990, Ernst et al 1989, Lowe et al 1980, Green and Humphries
1989). In the Scottish Health Heart Study, however, women who had previously been taking 
oral contraceptives had lower plasma fibrinogen levels when compared to those who had no 
such history, although multivariate analysis showed no independent association of history of 
oral contraceptive use and fibrinogen (Lee et al 1990).
Further evidence for a hormonal influence on plasma fibrinogen comes from 
the observation that levels are significantly higher in post menopausal women when 
compared to premenopausal women (Bonithon-Kopp et al 1990, Lee et al 1990, Meade et al 
1983, Meade et al 1990). This increase in plasma fibrinogen (and Factor Vile and cholesterol) 
seen in post-menopausal women has been calculated to increase the risk of fatal ischaemic
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heart disease by 40% (Meade et al 1983). The occurrence of the menopause was also 
accompanied with significant increases in plasma antithrombin III, factor VII coagulant activity, 
and factor VIIc, which were greatest in those experiencing a natural menopause when 
compared to those with an artificial menopause (Meade et al 1990). All these findings 
therefore may partly account for the increased cardiovascular complications seen in 
postmenopausal women.
Smoking
Smoking is a very important influencing factor for plasma fibrinogen levels. In 
fact, a dose-effect relationship exists between the number of cigarettes per day and plasma 
fibrinogen levels (Kannel et al 1987). All epidemiological studies to date have found the 
highest plasma fibrinogen levels amongst smokers.
For example, in the large (15000 men) WHO Co-operative trial of clofibrate, 
the highest plasma fibrinogen levels were seen in smokers (Green et al 1989). In an 
interesting cross-sectional population study from Copenhagen, a total of 439 men (all aged 
51 years old) living in a certain area of Copenhagen were studied, and one of the strongest 
independent associations with plasma fibrinogen level was found for smoking (Moller and 
Kristensen 1991). A Swedish study of a cohort of 788 healthy men aged 54 years also 
showed that plasma fibrinogen positively correlated with cigarette smoking (Korsan-Bengtsen 
et al 1972). Similarly, in analysis of data from the Northwick Park Heart Study, there was a 
significant association between elevated plasma fibrinogen and ischaemic heart disease, and 
furthermore, the lifetime duration of smoking was also found to be a determinant of initial 
plasma fibrinogen levels (Meade et al 1987). Fibrinogen levels begin to fall soon after 
smoking is discontinued but it can take 5 to 10 years before they returned to the levels found 
in life-long non-smokers (Lee et al 1990, Meade et al 1987). A switch from cigarette to cigar 
smoking is inexplicably associated with a large increase in plasma fibrinogen (Meade et al
1987), which is in keeping with the observation that cigar smokers remain at an increased risk 
of ischaemic heart disease (Kaufman et al 1987). There is evidence that part of the 
relationship between smoking and ischaemic heart disease may be mediated through plasma
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fibrinogen (Lee et al 1990, Yarnell et al 1991), although the precise mechanism for this is 
unclear. Further evidence for the association between smoking, fibrinogen and ischaemic 
heart disease is shown by the correlation of plasma fibrinogen levels with smoking habit in 
patients with acute myocardial infarction (before thrombolytic therapy) (Poliak et al 1991).
The consistent observation of higher plasma fibrinogen levels in heavy 
smokers, independent of age, may be explained by two alternative hypotheses: (i) smoking 
may lead to endothelial damage (resulting in activation of the coagulation system and 
increased production and release of clotting factors); or (ii) smoking may directly lead to 
increase of clotting factors (resulting in a tendency to thrombosis and the formation of mural 
microthrombi on an otherwise damaged endothelium). In fact, there is evidence for both of 
these hypotheses. For example, cigarette smoking has been shown to cause endothelial 
damage and platelet activation, and post-mortem studies have demonstrated accelerated 
atherogenesis in the coronary arteries of young smokers (FitzGerald et al 1988). Another 
possible mechanism of the effects of smoking appears to be the activation of lung 
macrophages, which can produce hepatocyte stimulating factor, increasing the liver synthesis 
of fibrinogen (Ritchie et al 1982).
Miscellaneous conditions
Control of plasma fibrinogen levels is complex, as there are also associations 
of plasma fibrinogen not only with environmental factors (such as alcohol intake, smoking, 
exercise, social class, age, obesity) or the acute phase response, but also with genetic factors 
(Green and Humphries 1989).
Exercise Strenuous exercise is associated with lower plasma fibrinogen (and 
cholesterol) concentrations, equivalent to a difference of 15% in the risk of ischaemic heart 
disease, when compared to a sedentary lifestyle (Connelly et al 1992). Similar changes of 
plasma fibrinogen with exercise were seen in the Caerphilly Prospective Heart Study, the 
Scottish Health Heart Study and the Gothenburg study (Elwood et al 1993, Lee et al 1990, 
Rosengen et al 1990).
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Alcohol Increased alcohol consumption may have a small but significant effect on 
decreasing plasma fibrinogen (Lee et al 1990, Meade et al 1987). A decrease of 
approximately 0.78% per 10g of alcohol consumed has been noted (Meade et al 1987) and is 
consistent with the possibility that a moderate level of alcohol consumption confers some 
protection against ischaemic heart disease (Moore and Pearson 1986).
Social Class Psychosocial factors have important influences on cardiovascular mortality 
and morbidity, and plasma fibrinogen may be partly responsible (Rosengren et al 1990). The 
role of social class and psychosocial factors in determining plasma fibrinogen levels however 
remains controversial. The Northwick Park Heart Study, for example, demonstrated a greater 
increase in plasma fibrinogen in those of lower social classes with an additional increased risk 
of a cardiac event of 5% within the next 5 years in men from social classes IV and V (Meade et 
al 1987). Similar findings of a higher plasma fibrinogen in lower social classes were also 
demonstrated in a cross-sectional Danish population study (M oiler and Kristensen 1991) and 
in the Scottish Health Heart Study (Lee et al 1990). In contrast, however, the Gothenburg 
study found no independent association between fibrinogen concentration and occupational 
class (Rosengren et al 1990).
Hyperlipidaemia Plasma fibrinogen is also increased in patients with hyperlipidaemia
(Lowe et al 1979, Simpson et al 1983, Stone and Thorp 1985). The interaction between 
plasma fibrinogen and cholesterol levels is demonstrated in the Leigh Study, where the 
incidence of heart attack was six times greater in those with high plasma fibrinogen (>3.5 g/l) 
and cholesterol levels (>6.2 mmol/l) when compared to those with low fibrinogen levels 
(Stone and Thorp 1985). Patients with Type II hyperlipoproteinaemia also have increased 
levels of plasma fibrinogen and platelet aggregates, with the normal rise in fibrinogen during 
adult life being abolished by a premature increase (Lowe et al 1979). This finding is 
consistent with an increased risk of premature atherosclerosis and thrombotic complications in 
these patients. In the Copenhagen study discussed above, plasma fibrinogen was closely
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associated with LDL cholesterol and HDL cholesterol levels (Mailer and Kristensen 1991). 
One Swedish study (Korsan-Bengtsen et al 1972) and the Scottish Heart Health Study (Lee 
et al 1990) also showed a correlation between plasma fibrinogen and total cholesterol levels.
Patients with hypertriglyceridaemia (Type IV hyperlipidaemia) also have 
significantly higher concentrations of plasma fibrinogen when compared to controls, with an 
associated lowering of fibrinolytic activity (Simpson et al 1983). In contrast, one cross- 
sectional study demonstrated a negative correlation between plasma fibrinogen and 
triglyceride levels (Korsan-Bengtsen et al 1972). These inconsistent findings, therefore, 
mean that the relationship between fibrinogen and triglycerides is not yet established, 
although alcohol may be a confounding factor (as moderate alcohol consumption may 
increase triglycerides but reduce plasma fibrinogen levels).
The treatment of hyperlipidaemia may alter the hypercoagulable state seen in 
these patients. For example, patients with Type IV hyperlipidaemia treated with diet alone (or 
with diet and clofibrate) showed no change in plasma fibrinogen levels, although triglycerides 
and some clotting factors (Vile and Xc) were lowered (Simpson et al 1983). In contrast, the 
large (15000 men) WHO Co-operative trial of clofibrate (a drug which lowers cholesterol and 
triglycerides) showed a reduction in plasma fibrinogen levels (Green et al 1989).
Valve surgery Valve surgery is a risk factor for increased thromboembolic risk and
this has been investigated in one small study, where plasma fibrinogen, plasma viscosity, red 
cell aggregation and spontaneous platelet aggregation were all found to be increased in 
patients after both mechanical and bioprosthesis heart valve replacements when compared to 
normal subjects (Koppensteiner et al 1991).
Dental disease Dental disease is associated with myocardial infarction, and increased
plasma fibrinogen and white cell counts may partly explain this (Kweider et al 1993). For 
example, chronic inflammatory gingival and periodontol infection, which is common in 
populations with high rates of coronary artery disease (such as Glasgow), may increase plasma 
fibrinogen and white cell count levels (Kweider et al 1993).
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Genetic factors There is also a significant genetic influence on plasma fibrinogen
formation and genetic heritability may account for up to 51% of the variance of the plasma 
fibrinogen level (Hamsten et al 1987). The development of DNA typing may therefore identify 
genotypes at high risk of ischaemic heart disease (Humphries et al 1987). For example, the 
mean fibrinogen level in individuals with the genotype B1B2 is 2.98g/l which is similar to the 
levels found in those free from heart disease in the Northwick Park heart study (Humphries et 
al 1987, Meade et al 1986). However, individuals with the genotype B2B2 have a mean level 
of 3.7g/l which would potentially increase the risk of ischaemic heart disease by 75% 
(Humphries et al 1987, Meade et al 1986). Certain fibrinogen genotypes have also been 
associated with an increased risk of peripheral atherosclerosis, although the influence was not 
mediated simply by way of increased fibrinogen concentrations (Fowkes et al 1992). A 
prospective study of the predictive value of 'high fibrinogen* genotypes for cardiovascular 
disease is therefore needed.
Regional variations in plasma fibrinogen levels
A wide range of reference values for plasma fibrinogen appears to exist with a 
mean 'normal' value between 2.3 to 3.1 g/l in different population studies (Ernst 1991). This 
is independent of patient characteristics such as age and sex, and an unidentified 
environmental factor may well be the cause. However, these differences may also be 
methodological (Machin and Mackie 1993), hence an international standardisation is also 
required so that plasma fibrinogen values can become directly comparable between studies.
Measures reducing plasma fibrinogen
Preventive measures against cardiovascular disease risk from high plasma 
fibrinogen levels require the diagnostic determination of fibrinogen concentrations, with the 
aim of identifying and optimally treating high risk patients. General measures such as stopping 
smoking and increasing physical exercise should be attempted. Therapeutic strategies may
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potentially be developed to specifically lower plasma fibrinogen in the same way as 
cholesterol lowering drugs do today.
Several drugs have been reported to lower fibrinogen concentrations, 
including ticlopidine, stanzolol, oxypentifylline, calcium dobesilate, propanolol, nislodipine 
and the fibrates (Ernst 1991). However these drugs have pharmacological effects other than 
lowering fibrinogen concentrations and are not practical therapeutic options.
The role of diet in reducing plasma fibrinogen remains controversial. For 
example, fish oil supplementation (rich in omega-3 fatty acids) may result in reduction in 
plasma fibrinogen levels (Hostmark et al 1988, Radack et al 1989). In contrast, the Northwick 
Park study, however, did not show any significant effect of dietary changes (Meade et al 
1986). Moderate alcohol consumption, increased consumption of garlic, regular exercise, 
weight loss and better diabetic control are also reported to have favourable fibrinogen 
lowering effects (Ernst 1991, Machin and Mackie 1993).
Conclusion
Despite the intense interest in plasma fibrinogen as a cardiovascular risk 
factor, there is little or no information on the role of plasma fibrinogen in contributing to a 
prothrombotic state in conditions (and procedures) associated with an altered cardiac 
thromboembolic risk, for example, in patents with chronic and paroxysmal atrial fibrillation, the 
cardioversion of atrial fibrillation to sinus rhythm, the initiation of anticoagulation therapy and 
patients with left ventricular aneurysms. These areas will be investigated in this thesis.
FIBRIN D-DIMER FRAGMENT.
Introduction
Fibrin degradation products from crosslinked fibrin (XL- FDP) contain the D- 
dimer fragment, which is produced by fibrinolytic breakdown of insoluble clot (formed by 
cross-linked fibrin monomers). Measurement of this plasma factor reflects intravascular levels 
of fibrin turnover, without interference from fibrinogen or non-cross linked fibrin. Plasma D- 
dimer levels are therefore a potential indirect marker of intravascular thrombus formation,
41
reflecting a hypercoagulable intravascular state. However, there is little or no information on 
the clinical value of plasma fibrin D-dimer as a marker of a prothrombotic state.
Fibrin D-dimer and thrombogenesis
Elevated levels of D-dimer are found in conditions associated with 
intravascular (and possibly extravascular) activation of the coagulation system, including those 
with a predisposition to venous thrombosis (Declerck et al 1987). Abnormal levels of fibrin D- 
dimer in plasma have been found in patients with disseminated intravascular coagulation, 
pulmonary thromboembolism and deep venous thrombosis (Harrison et al 1993, Knecht et al 
1992). It is known, however, that the deposition of fibrin in thrombus formation is a function of 
the surface area of the clot and of the activity of the thrombotic factors associated with the clot. 
Hence, even the formation of very small clots can result in active fibrin deposition and the 
production of D-dimer (and other factors such as fibrinopeptide A and fibrinopeptide BI315- 
42, which are byproducts of the coagulation cascade) (Declerck et al 1987). This suggests 
that plasma fibrin D-dimer is a sensitive indicator of even small amounts of thrombus although 
its clinical value remains to be demonstrated.
Measurement of plasma D-dimer concentration may therefore be a useful 
screening method for patients at risk of mobile or 'active' thrombi. This was demonstrated in a 
prospective study of 63 patients with mitral stenosis in which a significantly elevated plasma D- 
dimer level was found in 10 patients having mobile intracardiac thrombus when compared to 
patients with a non-mobile thrombus (Yasaka et al 1991). Levels are also increased in 
patients with vascular disease (Fowkes et al 1993), with histopathological evidence for high 
amounts of fibrinogen and fibrin D-dimer in aortic thrombi, atherosclerosis plaques and early 
gelatinous arterial lesions (Bini and Kudryk 1992, Smith et al 1990).
Elevated fibrin D-dimer levels have been found in patients with peripheral 
vascular disease (Al-Zahrani et al 1992, Fowkes et al 1993) and this measurement has been 
shown to have prognostic implications in these patients. In a study of 617 patients with 
peripheral vascular disease, baseline fibrin D-dimer levels were closely related to future 
coronary events (both fatal and non-fatal, with a relative risk of 4.4 between upper and lower
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quintiles) and progression of peripheral vascular disease (Fowkes et al 1993). This study 
therefore suggests that fibrin formation contributes to the progression of coronary and 
peripheral atherosclerosis, and is consistent with the hypothesis that fibrin D-dimer may be a 
useful index of intravascular fibrin turnover and the contribution of thrombosis to arterial 
disease.
Plasma fibrin D-dimer may therefore prove useful in assessing the 
thrombogenic risk for patients with conditions that predispose to thromboembolism, for 
example, chronic atrial fibrillation. For example, two recent studies have suggested that 
plasma levels of D-dimer are increased in patients with atrial fibrillation, whether or not 
structural heart disease is present, when compared to controls in sinus rhythm (Gustafsson et 
al 1990, Kumagai et al 1990). However, these studies were small and the controls were not 
population-based. The usefulness of plasma D-dimer as a marker of thrombogenesis in other 
conditions at risk of thromboembolism, such as left ventricular aneurysms, paroxysmal atrial 
fibrillation, and in conditions that alter thromboembolic risk, such as anticoagulation and 
cardioversion from atrial fibrillation to sinus rhythm, have not been previously investigated and 
these areas will be addressed in this thesis.
Von WILLEBRAND FACTOR
Introduction
The vascular endothelium is intimately associated with the regulation of 
vessel tone and permeability, haemostasis, fibrinolysis and synthesis of growth factors. Von 
Willebrand factor (vWF) is one such factor, which is synthesised by and stored in endothelial 
cells (and also megakaryocytes and platelets) and when released appears to mediate platelet 
aggregation and adhesion to the vascular endothelium (Badimon et al 1992, Jansson et al 
1991).
Abnormalities in the blood vessel wall (including endothelial dysfunction) may 
result in an increased propensity towards thrombus formation (Virchow's triad). As vWF is 
released when endothelial cells are damaged, vWF and other fibrinolytic variables have been 
used as indicators of endothelial dysfunction (Boneu et al 1975). Plasma concentrations of
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vWF are increased therefore in disorders that affect the cardiovascular system, for example, 
ischaemic heart disease (Jansson et al 1991), pregnancy-induced hypertension (Brenner et 
al 1989), diabetes mellitus (Greaves et al 1987), cerebrovascular disease (Mettinger 1982, 
Wahlberg et al 1980) and deep venous thrombosis (Wahlberg et al 1980).
Cardiac disease
There is an association between vWF levels and ischaemic heart disease. For 
example, elevated concentrations of vWF are found in patients with previous myocardial 
infarction (Hamsten 1986, Schmitz-Huebner et al 1988) and also appear to be an index of 
increased risk for reinfarction and mortality in survivors of myocardial infarction (Jansson et al
1991). There is also an association with the clinical severity of angina (Moisseev 1988), 
indicating a role for endothelial dysfunction in the pathogenesis of coronary artery disease.
Thromboembolic events
High concentrations of vWF have been associated with an increased 
incidence of thromboembolic events. For example, there is an association with ischaemic 
cerebrovascular disease (Mettinger 1982, Uchiyama et al 1983, Wahlberg et al 1980) and 
deep venous thrombosis (Wahlberg et al 1980). These findings suggest that a high 
concentration of vWF may be an index of atherosclerosis and/or thrombosis.
Pulmonary vascular disease
The pulmonary vasculature also appears to have significant influences on 
plasma vWF levels. For example, in primary pulmonary hypertension, pulmonary endothelial 
cells show evidence of injury, and elevations of plasma vWF have been demonstrated in this 
condition, which may contribute to the risk of thrombosis (Geggel 1987). Elevated plasma 
vWF has also been demonstrated in patients with elevated pulmonary vascular resistance and 
decreased cardiac output, irrespective of the presence of mitral stenosis (Penny et al 1991). 
These findings are in keeping with a haemodynamically-induced increase in the endothelial 
release of vWF.
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Diabetes
Abnormalities of vWF have also been demonstrated in diabetics (Collier et al 
1992, Greaves et al 1987, Stehouwer et al 1992). For example, a raised urinary albumin 
excretion in non insulin dependent diabetes is associated with an increased risk of 
cardiovascular disease (Stehouwer et al 1992). Endothelial dysfunction is thought to a 
possible explanation for this association and the marker for this, plasma vWF, is found to be 
elevated in such patients (Collier et al 1992, Stehouwer et al 1992). It is therefore considered 
that dysfunction of vascular endothelium may be one link between the microalbuminuria and 
atherosclerotic cardiovascular disease found in non-insulin dependant diabetics.
Conclusion
Von Willebrand factor may be a good marker for endothelial dysfunction in a 
variety of disease states, with a significant potential contribution towards thrombogenesis via 
platelet adhesion and aggregation. There is little information, however, on its relationship to 
other prothrombotic markers, such as fibrinogen, D-dimer or lipoprotein (a). This aspect will be 
further studied in patients with chronic atrial fibrillation (chapter 3) and left ventricular 
dysfunction (chapters 8 and 9).
LIPOPROTEIN (a)
Introduction
Lipoprotein (a) [Lp (a)] has been recognised for nearly 30 years as a partly 
genetically-determined lipoprotein associated with an increase in atherogenesis and 
thrombogenesis (Rees 1991, Scott 1991). For example, elevated Lp (a) levels are 
associated with an increased risk for coronary artery disease, stroke, restenosis after coronary 
artery bypass surgery and thoracic aortic atherosclerosis (Hoff et al 1988, Nishino et al 1993, 
Shintani et al 1993, Woo et al 1991). Lp(a) has therefore stimulated great interest as yet 
another risk factor for cardiovascular and cerebrovascular disease.
I
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Despite intense interest in this enigmatic lipoprotein its function (and factors 
that influence its levels) remains largely unknown. It has been suggested, for example, that 
apolipoprotein (a) [a molecule contained within lipoprotein (a)] could offer some selective 
advantage in wound or tissue repair, as it may help deliver cholesterol by attaching (by its 
fibrin-binding capability) to thrombus (Lawn 1992, Scanu 1992). The importance of Lp(a) 
phenotypes in influencing the pathogenic effects of Lp(a) (Utermann et al 1988) and the 
significance of the associated homology of a molecule unique to Lp(a), apolipoprotein (a), 
with plasma plasminogen (which may reduce fibrinolysis) remain unanswered controversies 
(Scott 1991). In addition, the contribution of lipoprotein (a) to the mechanisms of 
thrombogenesis (for example, clotting factor abnormalities, fibrin turnover, endothelial 
dysfunction) has not been clearly defined.
Biochemistry and pathophysiology
Lp(a) is a variant of low density lipoprotein (LDL). Similarly to LDL, the main 
protein component of Lp(a) is apolipoprotein B (apo B), but in addition, there is also another 
large disulphide-linked glycoprotein molecule, apolipoprotein (a) (apo(a)) present. Genetic 
variation of this molecule [apo(a)] is the primary determinant of Lp(a) phenotypes. Size 
isoforms of apo(a) are inherited as Mendelian codominant traits and are associated with 
variations in the plasma concentrations of Lp (a), and thus with the various degrees of risk for 
coronary artery disease (Seed et al 1990, Utermann et al 1988).
Apo(a) is homologous with part of the plasminogen molecule, from which the 
enzyme plasmin is released by tissue plasminogen activator during the process of fibrinolysis. 
Indeed plasminogen and apo(a) are encoded by genes which both map to chromosome 
6q26-27 (Drayna et al 1988). This relationship is important as apo(a) size isoforms and plasma 
Lp(a) concentrations are each determined by genetic variation at the apo(a) locus (Drayna et al
1988). In a study of 473 patients, for example, apo(a) glycoprotein polymorphism accounted 
for 41.9% and 9.6% of the variability in Lp(a) and total cholesterol levels respectively, which 
represents the strongest effect of a single polymorphic gene on plasma lipid and lipoprotein 
levels reported so far (Boerwinkle et al 1989). Further evidence for a genetic influence on
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Lp(a) levels was demonstrated in the Bogalusa Heart Study, a study of 2438 children (aged 8- 
17) from a biracial community (Srinivasan et al 1991). Lp(a) levels were 1.7-fold higher in 
blacks than whites, and in white children the prevalence of parental myocardial infarction was 
higher in those with elevated levels of Lp(a); however, the latter observation was not seen in 
black children (Srinivasan et al 1991).
Experiments in vitro suggest that apo(a) interferes with uptake and activation 
of plasminogen by receptors on cell surfaces and fibrin (Gonzalez-Gronow et al 1989, Miles et 
al 1989). Plasminogen receptors, which are widely distributed on endothelial cells and blood 
cells, promote thrombolysis by accelerating plasminogen activation and protecting plasmin 
from inhibition. If, by molecular mimicry, Lp(a) competes with plasminogen for receptors then 
the binding of plasminogen to endothelial cells and thrombolysis would be inhibited and 
thrombosis promoted (Gonzalez-Gronow et al 1989, Miles et al 1989). Experimental evidence 
for this comes from the demonstration that high Lp(a) levels impair the binding of plasminogen 
to fibrin, thus reducing the generation of plasmin by fibrin-bound tissue-type plasminogen 
activator (Rouy et al 1991). Lp(a) also appears to regulate the synthesis by the endothelium 
of a major protein involved in the fibrinolytic system, plasminogen activator inhibitor-1 (PAI-1): 
Lp(a) may therefore promote a prothrombotic state by increasing in PAI-1 activity, thus 
interfering with endothelial cell and circulating plasmin generation (Etingin et al 1991).
Lp(a) is also associated with atherogenesis (Figure 1.1), and an interaction 
with fibrinogen (and other coagulation factors) may therefore exist. The accumulation of Lp(a) 
at sites of vascular injury, in association with impairment of fibrinolysis, may be important 
factors in the development of atherosclerosis and associated thrombosis (Rouy et al 1991). 
The mechanism for this detrimental effect of Lp(a) may relate to the macrophages that are also 
attracted to sites of vascular injury. When exposed to excessive Lp(a) and oxidised low 
density lipoprotein (LDL), these macrophages become foam cells, the precursors of the 
atherosclerotic plaque (Scanu 1992).
Epidemiological studies
Until now, few epidemiological studies have investigated the significance of 
this lipoprotein. Recently, the Framingham Offspring Study measured serum Lp(a) levels in 
1284 men and 1394 women free of cardiovascular disease (Jenner et al 1993). There was an 
inverse association between plasma Lp(a) and triglyceride levels, but this relationship was 
weak as triglycerides only accounted for 0.5% of the variation in lipoprotein (a) levels. There 
was no significant association of lipoprotein (a) levels with total and LDL cholesterol levels, 
body mass index, alcohol consumption and with age (although there was a trend towards 
higher levels in postmenopausal women) (Jenner et al 1993). In addition, healthy subjects in 
the Prospective Cardiovascular Munster (PROCAM) study demonstrated a weak relationship 
between plasma fibrinogen and plasma fibrinogen in both sexes, but not with D-dimer or other 
indicators of fibrinolysis (for example, tissue-type plasminogen activator) (Heinrich et al 
1991a). From this study, it appears that very few factors may influence plasma Lp(a) levels, 
which tend to remain remarkably constant within an individual (Rees 1991).
Ischaemic heart disease
Patients with coronary artery disease have higher Lp(a) levels than controls 
(Farrer et al 1993, Genest et al 1991, Genest et al 1992, Sandholzer et al 1992). In a 
prevalence study of 180 patients aged <60 years, this finding was also independent of 
conventional risk factors such as smoking, hypertension, diabetes, LDL and HDL cholesterol 
or apolipoprotein A-1 and B levels (Genest et al 1991). One recent study also showed that 
Lp(a) was not responsible for the risk association between impaired glucose tolerance and 
coronary artery disease (Farrer et al 1993). Family studies by Genest et al (1991) 
demonstrated a large genetic influence and little environmental influence on Lp(a) levels.
Coronary heart disease risk also correlates directly with plasma concentrations 
of Lp (a) (Rosengren et al 1990). The Gothenburg study, for example, was a prospective 
case-control study with a six-year follow up period, which found that men who had suffered a 
coronary event had significantly higher serum Lp(a) concentrations than controls, 
independent of other risk factors (Rosengren et al 1990). Additionally, in the PROCAM study,
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young (aged less than 46 years) male survivors of myocardial infarction showed that increased 
Lp(a) concentrations constituted an independent risk factor for early myocardial infarction 
(Sandkamp et al 1990). Concentrations of Lp(a) did not, however, correlate with age or other 
well-known risk factors for early myocardial infarction such as apolipoproteins Al and B, LDL 
cholesterol and HDL cholesterol (Sandkamp et al 1990). In addition, this study showed an 
association with fibrinogen concentration but not with euglobulin fibrinolysis activity and other 
fibrinolytic parameters (Sandkamp et al 1990).
An increased Lp(a) level also has implications for patients post-coronary artery 
bypass surgery. For example, a large angiographic study suggested that increased Lp(a) 
levels were associated with the degree of saphenous vein bypass graft restenosis, with a 
stepwise correlation of mean Lp(a) levels to increasing graft stenosis (Hoff et al 1988).
The large (4081 subjects) Helsinki Heart Study, in contrast, did not 
demonstrate that serum Lp(a) level was predictive of future coronary events, despite 5-years 
follow-up (Jauhiainen et al 1991). This is supported by an angiographic study of 56 men 
which showed that serum Lp(a) measurement did not discriminate between patients with and 
without progression of angiographic coronary artery lesions (Perski et al 1992). These two 
studies are therefore at variance with evidence discussed earlier.
Phenotypes of the apo(a) component of Lp(a) may explain the considerable 
variation between individuals with familial hypercholesterolaemia in susceptibility to coronary 
heart disease (Sandholzer et al 1992). In patients with familial hypercholesterolaemia, the 
frequencies of the apo(a) phenotypes and alleles differed significantly between patients with 
and without coronary heart disease thus suggesting a genetic influence (Seed et al 1990). 
For example, the allele LpS2, which is associated with high Lp(a) levels, was found more 
frequently amongst patients with coronary heart disease (Seed et al 1990). In contrast, the 
LpS4 allele, which is associated with low Lp(a) levels, was more frequent amongst those 
without coronary heart disease (Seed et al 1990). This increase in risk was independent of 
age, sex, smoking status and serum levels of total cholesterol, triglyceride or high density 
lipoprotein (HDL) cholesterol (Seed et al 1990). However, no agreement on the definite 
number of apo (a) alleles in the general population has been reached - reported numbers of
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apo(a) alleles or isoforms range between 11 and 24, although more may exist (Cohen et al 
1993, Jenner et al 1993).
Serial determinations of Lp(a) levels after an acute myocardial infarction 
demonstrate no change in Lp(a) following myocardial infarction. For example, a study of 124 
patients showed no difference between those with myocardial infarction, unstable angina and 
stable angina, between patients with myocardial infarction with or without thrombolytic 
treatment, nor between late (at 6 hours) and early measurements of Lp(a) in patients with 
unstable angina and myocardial infarction (Qiu et al 1989). The extent of decrease in levels of 
plasminogen, alpha-2 antiplasmin and fibrinogen in the patients given thrombolytic therapy 
did however correlate positively with higher Lp(a) blood levels (Qiu et al 1989). Patients with 
high Lp(a) levels also respond equally well (as reflected by angiographic reperfusion) to 
thrombolytic therapy as did patients with normal or low levels of Lp(a) when given either 
recombinant tissue plasminogen activator (rt-PA) or human single chain urokinase-type 
plasminogen activator (scu-PA) (von Hodenberg et al 1991). Similar results were also 
obtained in other studies using scu-PA and alteplase (rt-PA) (Armstrong et al 1990, Tranchesi 
et al 1990, Tranchesi et al 1991), indicating a poor relationship of pretreatment Lp(a) levels to 
angiographic recanalization. These studies therefore suggest that serum Lp(a) levels are not 
increased in acute myocardial infarction and unstable angina and are not influenced by 
thrombolytic therapy (Qiu et al 1989). However, in these studies (Armstrong et al 1990, von 
Hodenberg 1991, Qiu et al 1989, Tranchesi et al 1990), there was only a short time interval 
between serial measurements of Lp(a) and the isoforms of Lp(a) were not measured despite 
this polymorphism having an influence on total levels of Lp(a) and different alleles having 
different contributions to coronary artery disease (Qiu et al 1989, Sandholzer 1992).
In contrast, others have demonstrated an increase in Lp(a) following 
myocardial infarction, with a return to initial levels after one month (Abe et al 1989, Maeda et al
1989). Measurements of acute phase proteins also showed a rise and fall after the acute 
event, suggesting that Lp(a) may have some characteristics of an acute phase reactant, with a 
role in recovery from tissue damage. Another study showed no change in absolute Lp(a) 
values following myocardial infarction, but an increase was demonstrated if the relative change
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in Lp(a) values was plotted (Slunga et al 1992). This change, however, did not correlate with 
changes in acute-phase proteins, and individual Lp(a) responses were very inconsistent.
Cerebrovascular disease
The relationship between serum lipids and lipoproteins in cerebrovascular 
disease is not as clear-cut as in coronary artery disease. However, Lp (a) has been shown to 
be associated with ischaemic cerebrovascular disease (Shintani et al 1993, Woo et al 1991, 
Zenker et al 1986). Even in normolipaemic patients, increased serum lipoprotein (a) levels 
and intermediate density lipoprotein abnormalities (and decreased high density lipoprotein 
levels) are major risk factors for stroke (Pedro-Botet et al 1992, Shintani et al 1993). In 
addition, median Lp(a) levels in patients with cerebrovascular disease were similar to that 
found in patients with coronary artery disease (Zenker et al 1986).
These findings support the hypothesis that lipoprotein (a) is a marker for 
atherosclerosis and thrombogenesis. However, whether or not Lp(a) itself can cause 
atherosclerosis (or thrombosis) or is just a factor indicating an atherosclerotic or thrombogenic 
process is still unresolved (Woo et al 1991).
As for coronary artery disease, the genetic influence remains on the 
relationship between Lp(a) and cerebrovascular disease, which is associated with 
apolipoprotein E polymorphism. This polymorphism affects plasma levels of lipoprotein (a), 
and the presence of apolipoprotein E2 allele, for example, decreases the mean lipoprotein (a) 
level by 26%, whilst the E4 allele increases the lipoprotein (a) level by 26% (de Knijff et al
1991). The latter allele (E4) was found more prevalent in men with ischaemic strokes, 
suggesting a possible role for the E4 allele as a predisposing genetic marker for stroke 
(Pedro-Botet et al 1992).
Other conditions influencing Lp(a)
As discussed above, lipoprotein (a) is partially genetically-determined. The 
nearly constant blood levels of Lp(a) suggest that its gene is partially constitutive, that is, it is 
transcribed independently of the physiological state of the cell. This is in contrast to genes
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which are inducible (and can be turned on' by cellular signals) or repressive (which are 
normally 'on' and can be turned ’off). However, some portions of Lp(a) production may be 
regulated.
There is evidence, for example, that Lp(a) levels are elevated in certain 
acquired conditions, such as renal disease and poorly controlled diabetic patients, whilst liver 
disease leads to lower concentrations. In a cross-sectional study of 93 diabetics, those with 
high (>8.0%) HbA-|C (indicating poor diabetic control) had higher median levels of Lp(a) 
compared to controls or diabetics with HbAi c<8% (Ramirez et al 1992). Similarly, elevated 
Lp(a) levels have been found in association with impaired renal function and in patients on 
haemodialysis (Cressman et al 1992, Parra et al 1987). These findings may contribute to the 
high risk of atherosclerosis observed in such patients. In a study of patients with cirrhosis, 
however, lower Lp(a) levels were seen with increasing severity of liver disease (being 
undetected in a high proportion of patients with the most severe disease) (Feely et al 1992).
Some conditions are also well known to contribute to changes in plasma 
lipoproteins although the effects on Lp(a) are as yet uncertain. One notable example is the 
menopausal status, with adverse changes in lipids and lipoproteins postmenopausally, which 
may contribute to the risks of coronary artery disease in these patients (Bonithon-Kopp et a)
1990). A trend towards higher levels of Lp(a) in postmenopausal women was noted in the 
Framingham Offspring Study (Jenner et al 1993)
Measures to reduce Lp(a)
It has been suggested that the following persons should have Lp(a) levels 
measured: (i) those with personal or family histories of premature cardiovascular disease (Age 
<55 years); (ii) patients with cardiovascular disease but normal 'routine' lipid profile; (iii) patients 
with recurrent coronary artery stenosis; and (iv) family members of the above patients (Scanu
1992). Lowering raised Lp(a) levels however poses another problem. Modifying the diet 
does not appear to affect Lp(a) concentrations (Masarei et al 1984). In the Framingham 
Offspring Study, treatment with beta-blockers, cholesterol-lowering drugs, oral 
hypoglycaemics, insulin, thyroid replacement, diuretics and other antihypertensive
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medication did not have any significant effect on plasma Lp(a) levels (Jenner et al 1993). 
Serum Lp(a) concentrations may, however, respond to nicotinic acid (Carlson et al 1984) and 
bezafibrate (Bimmermann et al 1991). The use of bezafibrate in patients with high Lp(a) levels 
(above 30mg/dl), for example, may result in a significant reduction of Lp(a) by 39%, which was 
independent of sex and type of hyperlipoproteinaemia (Bimmermann et al 1991). Bezafibrate 
may therefore be a useful drug, with effects in lowering lipids (cholesterol and triglyceride), 
fibrinogen and Lp(a) levels.
Despite the beneficial effect of bezafibrate, there was, however, no 
difference with the use of another fibrate, gemfibrozil (Jauhiainen et al 1991). Other potential 
therapeutic interventions include neomycin and niacin (reducing Lp(a) by almost 50%) 
(Gurakar et al 1984), and anabolic steroids (Albers 1984). Extracoporeal removal by apheresis 
can achieve even greater reductions (Armstrong et al 1985, Rees 1991).
The influence of reducing Lp(a) levels on outcome in coronary artery disease 
and stroke, if any, is unknown. There is, to date, no published data showing any benefit in 
lowering Lp(a) concentrations in individual patients (Rees 1991).
Conclusion
The therapeutic implications of finding a raised level of Lp(a) depend upon 
the interpretation of suggestive but inconclusive data. An important question, therefore, is 
whether or not the increased risk of coronary artery disease associated with Lp(a) levels is 
related to other factors involved in thrombogenesis and atherogenesis (such as fibrinogen, 
von Willebrand factor, LDL-cholesterol, etc). In addition, if the association between Lp(a) and 
cardiovascular disease is causal, does the mechanism involved reflect the atherogenicity or 
thrombogenicity of Lp(a) or a combination of both? These questions may be answered by a 
study of Lp(a) levels in relation to other blood prothrombotic factors (fibrinogen, fibrin D-dimer, 
von Willebrand factor, etc) in conditions at high risk of thromboembolism, as is undertaken in 
this thesis.
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1.3 AIMS OF STUDIES REPORTED IN THIS THESIS
My thesis investigates the role of plasma fibrinogen (whose elevation is 
associated with the risk of increased thrombotic and cardiovascular events) and fibrin D-dimer 
(fibrin degradation products, which reflect intravascular fibrin turnover) in two common 
cardiovascular conditions associated with thromboembolism, that is, atrial fibrillation and left 
ventricular dysfunction. Endothelial dysfunction may interact with these coagulation factor 
abnormalities and therefore the role of von Willebrand factor (vWF), which is a marker of 
endothelial dysfunction with prothrombotic potential, will also be investigated. In view of the 
possible competitive antagonism (or inhibitory effects) of Lp(a) on fibrinolysis I also 
hypothesised an inverse relationship between Lp(a) and plasma D-dimer levels. Raised Lp(a) 
levels in conjunction with endothelial dysfunction (as reflected by plasma vWF levels) may 
contribute to the processes of thrombogenesis and atherogenesis. Measurement of these 
markers of thrombogenesis may therefore provide a possible approach to identify those 
patients who are at highest risk of thromboembolism.
Initially, I conducted a survey of emergency admissions with atrial fibrillation 
into a district general hospital, to determine the prevalence of the condition and to assess 
management strategies and whether or not risk factors were being identified. This survey also 
allowed identification of patients with chronic atrial fibrillation for further study, in whom 
markers of thrombogenesis were measured, detailed echocardiography performed and the 
effects of antithrombotic therapy (aspirin or warfarin) assessed. I also correlated my findings 
on detailed echocardiography (left atrial size and volume, left ventricular size and function, 
etc) with these prothrombotic markers.
The hypothesis that fibrin D-dimer is a useful marker for thrombus formation 
was also tested by looking at subgroups at intermediate risk of thromboembolism, such as 
patients with paroxysmal atrial fibrillation and valve disease, and by assessing the effects of 
therapy (in particular, cardioversion and anticoagulation). As cardioversion from atrial 
fibrillation to sinus rhythm is an additional thromboembolic risk, I therefore measured serial 
samples of these prothrombotic factors in patients undergoing cardioversion, to try to 
delineate the length of the 'risk period'. In addition, as anticoagulant therapy has been shown
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to reduce the risks of thromboembolism in patients with atrial fibrillation, I conducted serial 
measurements of these prothrombotic factors in order to determine the effects of introducing 
oral anticoagulant therapy in these patients.
Finally, as patients with left ventricular aneurysms are also at increased 
thromboembolic risk, I assessed the levels of these markers of thrombogenesis in patients 
with left ventricular aneurysms compared to patients with varying degrees of left ventricular 
dysfunction (other than aneurysm formation) and to patients with normal left ventricular 
function. I assessed left ventricular function by performing (and interpreting) detailed 
echocardiography and 99m Technetium isotope radionuclide ventriculograms, and 
determining the relative contributions of systolic and diastolic dysfunction to thromboembolic 
risk in patients with coronary artery disease. The effects of introducing oral anticoagulant 
therapy were also determined in these patients. I hypothesised that impaired ventricular 
contractility (systolic dysfunction) and impaired ventricular relaxation (diastolic dysfunction) 
might have different haemorheological effects, resulting in different contributions to 
thrombogenesis.
Specific hypotheses to be investigated:
1. That plasma levels of fibrinogen, D-dimer, von Willebrand factor and lipoprotein (a) may be
elevated in patients with cardiac disorders which predispose to systemic 
thromboembolism (such as sustained/paroxysmal atrial fibrillation, left ventricular 
aneurysm / dysfunction), suggesting possible roles for fibrinogen, increased fibrin 
formation, endothelial dysfunction, decreased fibrinolysis and Theological disturbance in 
thrombogenesis.
2. That levels of these markers may be related to size of cardiac chambers and other structural
abnormalities, and to the presence of ventricular dysfunction.
3. That therapeutic interventions which alter thromboembolic risk (for example, cardioversion,
warfarin, aspirin) may alter levels of these markers in the appropriate direction.
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4. That there is an inverse relationship between plasma lipoprotein (a) (Lp(a)) and plasma D- 
dimer levels, in view of the possible competitive antagonism (or inhibitory effects) of Lp(a) 
on fibrinolysis.
The results will be critically discussed, as will be the possible roles of these markers in the risk 
assessment and pathogenesis of cardiac thromboembolism.
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CHAPTER 2
A SURVEY OF ATRIAL FIBRILLATION
5 7
2.1 AN OVERVIEW OF ATRIAL FIBRILLATION
Introduction
Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder. It is 
also a clinically important condition, with significant prognostic and therapeutic implications. 
Atrial fibrillation is particularly prevalent among the elderly, ranging from 0.5% at 50-59 years to 
8.8% at 80-89 years (Kannel et al 1982, Wolf et al 1991), and can be either chronic or 
paroxysmal. The presence of atrial fibrillation confers a significant increase in overall morbidity 
and mortality (Kannel et al 1982, Repique et al 1992). Despite this, atrial fibrillation is 
sometimes regarded as a relatively trivial disorder, although many patients with chronic atrial 
fibrillation require long term treatment with potent antiarrhythmic and anticoagulant drugs, 
which can have important drug interactions and adverse effects.
Atrial fibrillation is encountered in a wide variety of clinical settings. It may, for 
example, be discovered incidentally in an asymptomatic patient, it may occur in a patient with 
lobar pneumonia, or it may be found in a patient with a ventricular rate of 200 beats per minute 
who is suddenly too lightheaded to stand! The commonest aetiological factors for atrial 
fibrillation remain ischaemic heart disease, hypertension, thyroid disorders and rheumatic 
valve disease (although the incidence of the latter is decreasing in the Western world) (Alpert 
et al 1988). In the Framingham Study, for example, hypertension, cardiac failure and 
rheumatic heart disease were the commonest precursors of atrial fibrillation (Kannel et al 
1982). Thyrotoxic atrial fibrillation may also be an underdiagnosed condition, as appropriate 
thyroid function tests are not often performed and hyperthyroidism (affecting about 1 % of the 
population) may co-exist with ischaemic and rheumatic heart disease (Forfar et al 1979, Forfar 
and Toft 1982). Other noncardiac causes of atrial fibrillation are also frequently encountered, 
and can include pneumonia, pulmonary thromboembolism and excessive alcohol 
consumption (Repique et al 1992).
There remains, however, a subgroup of patients with atrial fibrillation who 
have no predisposing factor, which is classified as 'lone' or 'idiopathic' atrial fibrillation (Brand et 
al 1985). This is a diagnosis of exclusion, and has been established in 2.7% to 11.4% of all
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patients with atrial fibrillation (Repique et al 1992). Epidemiological evidence suggests 
however that up to one third of patients with atrial fibrillation may have idiopathic atrial 
fibrillation, with different clinical manifestations - the paroxysmal form (characterised by long- 
lasting episodes), the transient recurrent form (characterised by frequent self-terminating 
episodes) or less commonly, the chronic form (Capucci and Boriani 1991, Houghton et al
1990). These patients (especially those aged <60) are generally accepted to be at a low 
thromboembolic risk with no requirement for antithrombotic therapy (Davidson et al 1989, 
Kopecky et al 1987). Data from the Framingham study (with an older study population; mean 
age 64 years), however, does suggest a fivefold increase in the incidence of stroke (28.2% vs 
6.8% in matched controls) for patients with lone atrial fibrillation (Brand et al 1985). Despite 
this, left atrial enlargement of >4.0cm is rarely found, and cardiac failure is unusual in such 
patients (Davidson et al 1989, Repique et al 1992).
The sudden onset of fast atrial fibrillation may precipitate overt heart failure, 
particularly if left ventricular function is already compromised by co-existing heart disease, for 
example, valvular or ischaemic heart disease. Less dramatic presentations of atrial fibrillation 
include palpitations, dyspnoea, angina or general fatigue or lethargy. Symptoms may be more 
marked on exercise, with a significant limitation of exercise tolerance. More important, 
however, is the finding that nonrheumatic atrial fibrillation increases the risk of stroke by a 
factor of five and is present in about 15% of patients with acute stroke (Brand et al 1985, Wolf 
et al 1978, Wolf et al 1991). The risk of stroke in someone with atrial fibrillation is about 5% a 
year and epidemiological evidence suggests that this risk increases with age, blood pressure, 
and other evidence of heart disease (Lowe 1992). The presence of atrial fibrillation may also 
increase the risk of recurrent stroke (Flegel and Hanley 1989, Sage and Van Uitert 1983) but 
this has not been confirmed in two other community studies (Wolf et al 1983, Sandercock et al
1992). However, in the Oxfordshire Community Stroke Project, the 17% of patients with 
acute stroke and atrial fibrillation had a significantly higher 30 day mortality than patients in 
sinus rhythm (23% vs 8%) (Sandercock et al 1992). This greater mortality is partly explained 
by the association of atrial fibrillation with large, total anterior cerebral infarcts, probably due to 
occlusion of the middle cerebral artery (Sandercock et al 1992). Similar mortality findings were
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found in a study of acute stroke patients where the 25% with atrial fibrillation had a significantly 
higher hospital mortality than patients in sinus rhythm (67% vs 44%) (Lowe et al 1983). The 
presence of atrial fibrillation as an adverse feature in elderly stroke patients was confirmed in 
the Waikato Stroke Registry (mean age 75.2 years), where those with atrial fibrillation were 
older, had more severe stroke deficits and a greater mortality, when compared to patients in 
sinus rhythm (Friedman 1991).
What, therefore, are the therapeutic benefits from treating atrial fibrillation? 
The major reasons for treating atrial fibrillation are as follows: to relieve symptoms of 
congestive heart failure, hypotension or angina that can be directly attributed to a rapid heart 
rate; to improve overall cardiac function; to improve exercise tolerance; and to reduce the risk 
of thromboembolism and stroke. The main reasons are therefore to ameliorate the adverse 
haemodynamic effects and the thromboembolic risks of atrial fibrillation.
Cardioversion to, and maintenance of, normal sinus rhythm remains the 
optimal strategy to enhance cardiac performance and reduce thromboembolic risk. The 
cardioversion of atrial fibrillation to normal sinus rhythm is playing an increasing role in the 
management of atrial fibrillation, and this (and its thromboembolic risk) is examined in chapter 4 
of this thesis. As there is now evidence that cardiac function and exercise tolerance may even 
improve following cardioversion to sinus rhythm, this therapeutic option is increasingly used. 
However, there is often variation in the use of this option and the use of anticoagulant therapy 
before and after cardioversion. This subject is further reviewed and investigated in chapter 4. 
The presence of impaired cardiac function may also contribute to an increased risk for 
thromboembolism and is further examined in chapters 8 and 9 of this thesis.
The role of anticoagulant therapy as prophylaxis against thromboembolism in 
atrial fibrillation has attracted much interest recently. There are now five large prospective 
randomised controlled trials on the use of oral anticoagulant therapy in the primary prevention 
of stroke in nonrheumatic atrial fibrillation (Boston Area Anticoagulation Trial for Atrial 
Fibrillation Investigators 1990, Connolly et al 1991, Ezekowitz et al 1992, Petersen et al 1989, 
Stroke Prevention in Atrial Fibrillation Study Group Investigators 1990, Stroke Prevention in 
Atrial Fibrillation Investigators 1991). Their results consistently show that moderate
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anticoagulation reduces the risk of strokes by about two-thirds without a significant rise in 
adverse effects. These studies have therefore established the role for oral anticoagulant 
therapy in atrial fibrillation. However, there continues to be some reluctance amongst 
physicians to introduce anticoagulant therapy, with a significant proportion of patients with 
atrial fibrillation still not on anticoagulant therapy in spite of there being no contra-indications 
(Bath et al 1993). This aspect is further investigated in this chapter and the role of 
anticoagulant therapy is reviewed and further studied in chapter 10 of this thesis.
Atrial fibrillation is therefore a common arrhythmia with different aetiologies, 
clinical presentations and therapeutic options. This opens it to wide variations in management 
strategies. Ideally, the management of atrial fibrillation should follow three phases: a search 
for an underlying cause (with appropriate investigations); control of the arrhythmia and 
reduction of thromboembolic risk; and finally, consideration of cardioversion to sinus rhythm. 
However, atrial fibrillation is frequently not managed appropriately. As atrial fibrillation is 
common among emergency medical admissions, I decided to conduct a prospective survey 
of admissions with atrial fibrillation to a district general hospital.
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2.2 ATRIAL FIBRILLATION IN A DISTRICT GENERAL HOSPITAL
Introduction
Atrial fibrillation presents a number of different investigation and management 
dilemmas. It is a common presenting arrhythmia amongst acute medical admissions to district 
general hospitals in the United Kingdom. However, there is little published information on the 
proportion of emergency admissions whom have atrial fibrillation, the admission rate relative to 
the population served, therapy prior to admission, therapy initiated following admission, 
investigations undertaken or the outcome. Additionally there appears to be a wide range of 
views on the optimal management of this arrhythmia amongst general physicians. This is not 
surprising as the management of the patient with atrial fibrillation is complicated by multiple 
causes, diverse therapeutic options, concerns about anticoagulation, and the proarrhythmic 
effects of antiarrhythmic therapy.
In view of this, I decided to survey the practice of investigation and 
management of this disorder in patients admitted as emergencies, amongst both general 
physicians and cardiologists, to Stobhill General Hospital. This is a 990-bed district general 
hospital with acute medical and surgical facilities, serving the North-East of the City of Glasgow 
and the borough of Strathkelvin. This survey also allowed me to appreciate the prevalence of 
the condition, the frequency of complications in my hospital, and to identify patients with 
established atrial fibrillation and those with paroxysmal atrial fibrillation for subsequent studies 
in this thesis.
Materials and methods
Stobhill General Hospital has a Coronary Care Unit, six medical wards, a Renal 
ward and a large Geriatric Department. There are 9 general physicians, one of whom has a 
major interest in Cardiology. In addition there is a one Cardiologist, two Renal physicians and 
4 physicians with an interest in Geriatric Medicine, none of whom undertake general medical 
receiving duties. The physicians were informed at the onset of the study that an audit was 
going to take place as this is part of hospital protocol. Thereafter, the information was
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collected from the case records and no further discussions were held with the physicians 
involved.
The total number of emergency admissions to the adult medical and geriatric 
services during the six-month period from 1st September 1991 to 28th February 1992 was 
obtained from hospital records. Patients were prospectively included in this study if they were 
found to be in established atrial fibrillation on the admission electrocardiograph (ECG), or had 
developed atrial fibrillation within 48 hours of admission. Patients were studied from the three 
medical units within the hospital, the coronary care unit, renal unit and the geriatric wards; and 
were identified by discussion with the on-call medical or geriatric teams or by visiting the 
admitting ward(s) and reviewing the admission notes and ECG.
The mode of presentation, cardiac investigations carried out, the aetiology of 
atrial fibrillation, the treatment prior to admission and that initiated following admission, and the 
inpatient mortality were also noted. The survey therefore assessed the characteristics of the 
inpatients admitted with atrial fibrillation, length of stay, whether the aetiology of atrial 
fibrillation was been assessed, what investigations were undertaken (and what their impact on 
management was) and also actual management undertaken on the patient (at the time of atrial 
fibrillation, throughout their stay in hospital and at the time of discharge). An attempt was also 
made to determine whether or not atrial fibrillation was new at the time of admission or was a 
more chronic problem.
Statistical correlations were performed using Spearman's Rank Correlation 
method and a probability of <0.05 was considered statistically significant.
Results
During the six months of the study the total number of emergency 
admissions to the medical and geriatric services was 2686, an average of 448 patients per 
month. Over this period, 170 patients (6.3%) were found to have atrial fibrillation (an average 
of 28 patients per month), with 100 (59%) female and 70 (41%) male patients (Figure 2.1). 
Their mean age was 73.5 years, with an age range of 38 - 95 years (s.d. 10.6). One hundred 
and two (60%) patients were previously noted to have atrial fibrillation (including 10 (3.5%)
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with a history of paroxysmal atrial fibrillation), whilst 68 (40%) were 'newly diagnosed' patients, 
with no previous record of the arrhythmia.
Past medical history and underlying cause(s) of atrial fibrillation
Seventy-nine (46.5%) of the 170 patients with atrial fibrillation had a history of 
ischaemic heart disease. Thirty (17.6%) had a history of hypertension; 26 (15.3%) rheumatic 
heart disease, predominantly mitral valve disease; and 6 (3.5%) dysthyroid disease (Figure 
2.2). In addition, 38 patients (22.4%) of the 170 patients with atrial fibrillation had prior a 
history of cerebrovascular disease (stroke or transient ischaemic attack).
Symptoms and presenting features on admission
The commonest presenting symptoms were typical of cardiorespiratory 
symptomatology. Of the 170 patients, 88 (51.8%) presented with dyspnoea, 58 (34.1%) with 
chest pain, 44 (25.9%) with palpitation, and 32 (18.8%) with dizziness or syncope.
The predominant presenting clinical features included heart failure in 61 
(35.9%), a cerebrovascular event in 23 (13.5%), myocardial infarction in 17 (10%), angina 
pectoris in 14 (8.2%), a chest infection in 12 (7.1%) and digitoxicity in 3 (1.8%) (Figure 2.3).
investigations
All patients with atrial fibrillation had an electrocardiogram and chest X-ray on 
admission. Recording of clinical data was variable, and complete information on investigations 
undertaken was only available for 146 patients (86% of 170). Echocardiography was 
performed in 48 patients (33%). Cardiac enzymes and thyroid function tests were performed 
in 92 (63%) and 92 (63%) respectively. A treadmill exercise test was performed in 5 patients 
(3.4%) whilst 24 hour Holter monitoring was performed in only 8 patients (5.5%)
In the 170 patients with atrial fibrillation, a new myocardial infarction was 
identified on the electrocardiograph in 12 patients (7.1%), whilst an old infarction was present 
in 15 patients (8.8%). The commonest site was an inferior myocardial infarction, being
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present in 17 patients (63% of the 27 patients with an infarct on the electrocardiograph). 
Cardiac ischaemic changes were found in 29 patients (17% of all admissions).
Chest X-rays revealed cardiomegaly in 93 patients (54.7%) of those admitted 
in atrial fibrillation and pulmonary congestion was present in 77 patients (45.3%). Of the 48 
patients in whom echocardiography was performed, findings included large left atria in 31 
patients (64.6% of 48), mitral valve disease in 39 (81.3%), poor left ventricular function in 30 
(62.5%) and left ventricular hypertrophy in 11 (22.9%).
Treatment prior to admission
In those previously noted to be in atrial fibrillation (102 patients, including 10 
with paroxysmal atrial fibrillation) the commonest therapy prior to admission was digoxin in 71 
(70%). A diuretic was administered in 89 (52.4%), whilst a beta-blocker was used in 16 
(9.5%). Out of these 102 patients, antithrombotic therapy was used in only 37 patients, with 
20 (20%) patients being on warfarin therapy and 17 (17%) on aspirin. Amongst the 17 
patients on aspirin, it was prescribed to 11 patients for concomitant vascular disease rather 
than prophylaxis against thromboembolism.
Treatment initiated following admission
In the 68 patients (40% of 170) not previously noted to be in atrial fibrillation, 
digoxin was used in 51 (75%) whilst amiodarone was used on 23 (34%) occasions. Additional 
therapy initiated in the group as a whole included a beta blocker in 6 patients (3.5%) [for rate 
control in atrial fibrillation and treatment of associated angina] and diuretics, with intravenous 
diuretic required on admission in 52 patients (30.6%), and subsequent maintenance oral 
diuretic required in 46 patients (27%). Antithrombotic therapy was initiated in 27 patients. 
Seven patients (5% of the 150 patients not previously on warfarin) were given warfarin, whilst 
20 (15% of the 138 patients not previously on aspirin) were commenced on aspirin therapy. 
Of these 20 patients only 5 were started on aspirin as prophylaxis against embolic events; the 
remainder (15 patients) were commenced on aspirin for concomitant vascular disease. 
Contraindications to anticoagulation were only identified in 49 patients (34% of those not on
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warfarin); and these included peptic ulcer or gastrointestinal bleeding in 18 (12%), dementia 
in 8 (6%), chronic renal failure/dialysis in 8 (6%), Crohn's Disease in 1 (0.6%), alcohol excess 
in 4 (3%) and other major illness in 10 (7%).
Cardioversion was attempted in 21 cases (12.4% of all admissions). 
Pharmacological cardioversion was the commonest method, being used in 19 patients 
(11.2%), particularly in the coronary care setting. Of these, 18 patients were given 
amiodarone, whilst one patient cardioverted with intravenous digoxin. Two patients failed to 
cardiovert. The remaining 2 patients (1.2%) underwent electrical (direct current) 
cardioversion.
Length of stay and inpatient mortality
Complete information on length of stay was available for 146 patients (86% of 
170). The median inpatient stay was 10 days, with a range of 1 -154  days (IQR 6-19), largely 
due to patients with stroke. There was a weak but significant positive correlation between age 
and length of stay (Spearman r =0.22; p=0.007).
There were a total of 26 (15.3%) inpatient deaths amongst these patients. 
The predominant causes of death were ischaemic heart disease and heart failure. No post­
mortem examinations were undertaken.
Discussion
The major reasons for treating atrial fibrillation are the prophylaxis of 
thromboembolic events and heart rate control, as a rapid ventricular rate may cause symptoms 
of angina, congestive heart failure or hypotension. Treatment of atrial fibrillation also improves 
overall cardiac function and exercise tolerance. However there is often wide variation in the 
management of this arrhythmia amongst physicians, both in the choice of investigations, and 
on specific aspects of treatment, such as the initiation of anticoagulant therapy (Chang et a)
1990).
Standard investigations in a patient with atrial fibrillation should include an 
assessment of history, clinical state and possible precipitating factors (alcohol, infection, etc);
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thyroid status by thyroid function tests, and an assessment of cardiac status using the 
electrocardiograph (ECG), chest X-ray and echocardiogram. This latter investigation will also 
provide information on cardiac function and structural heart disease. In addition, 
measurement of cardiac enzymes (in an acute presentation) and 24hour Holter monitoring 
may also be required.
This study demonstrates a suboptimal application of these standard 
investigations in the management of patients with atrial fibrillation. For example, 
echocardiography was performed only in 33% of patients. Interestingly, of these patients, 
65% had dilated left atria, 81% had mitral valve disease and 63% had poor left ventricular 
function; indicating that useful information was obtainable from this investigation. In addition, 
the high proportion of abnormal findings suggests a possible underutilization of the 
technique. Echocardiography is an important investigation, as demonstrated in analysis of 
echocardiographic data from the Stroke Prevention in Atrial Fibrillation study, where left 
ventricular dysfunction (on the 2-dimensional echocardiogram) and the size of the left atrium 
(from M-Mode echocardiograms) were the strongest independent predictors of later 
thromboembolism in patients with atrial fibrillation (Stroke Prevention in Atrial Fibrillation 
Investigators 1992b). In a further prospective echocardiographic study of 153 patients with 
thromboembolism, cardiac abnormalities were detected in 58% (by transthoracic and 
transoesophageal echocardiography) and in these patients, the incidence of left-sided 
thrombi was increased in patients with atrial fibrillation when compared with those in sinus 
rhythm (Hofmann et al 1990). Echocardiography should therefore be a mandatory 
investigation in all patients with atrial fibrillation, with a significant contribution to 
thromboembolic risk stratification (Stroke Prevention in Atrial Fibrillation Investigators 1992b).
In addition, 24 hour Holter monitoring was performed in only 5.5% of patients 
although 18.8% had a history of dizziness or syncope. This has important implications as 
prolonged ventricular standstill may commonly occur in patients with controlled atrial fibrillation 
who complain of dizziness or syncope (Rebello and Brownlie 1987). A majority of these 
patients will benefit from permanent cardiac pacing (Rebello and Brownlie 1987). Another 
mandatory investigation, thyroid function tests, was performed in only 63% of our patients.
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This also has important implications as atrial fibrillation commonly complicates hyperthyroidism 
and clinically occult thyrotoxicosis may be the cause of 'idiopathic atrial fibrillation in many 
cases (Forfar and Toft 1979).
Although the commonest underlying pathology in our patients was ischaemic 
heart disease, ischaemic non-infarct changes were seen on the electrocardiogram in only 
17% of patients, whilst infarction changes were present in a similar proportion (16%). Atrial 
fibrillation was present in association with acute myocardial infarction in 7% of patients in this 
study. This proportion is slightly lower than previous observations (10-15%), but the 
presence of the arrhythmia is pertinent in this situation as it is a marker of underlying 
ventricular dysfunction and a compromised myocardium (Pasternak et al 1993). This is in part 
related to left atrial ischaemia, the loss of atrial contribution to left ventricular filling, the 
increased ventricular rate with the arrhythmia and the association with anterior (rather than 
inferior) infarctions (Pasternak et al 1993). The presence of atrial fibrillation in acute myocardial 
infarction is therefore a marker of a worsened prognosis and increased mortality, particularly in 
patients with anterior wall infarction (Pasternak et al 1993). However, as the arrhythmia is more 
common in patients with extensive infarctions (and a poorer prognosis), there may be no 
independent effect of atrial fibrillation on mortality rate (Goldberg et al 1990, Pasternak et al 
1993).
The frequency with which heart failure accompanies atrial fibrillation is shown 
in this study. For example, 52% of our patients presented with dyspnoea, pulmonary 
congestion was evident on the chest X-ray in 45% of patients, 63% of patients had poor left 
ventricular function on the echocardiogram and intravenous diuretic was required acutely on 
admission in 31% of patients (with subsequent maintenance oral diuretic being required in 
27%). Overall clinical heart failure was present in 35% of our patients. A similar proportion 
(37.5%) of patients with atrial fibrillation has been demonstrated in a previous study of 
admissions with heart failure to a district general hospital (Parameshwar et al 1992) suggesting 
that my findings are quite typical. The presence of atrial fibrillation may also be a marker for an 
increased risk of death, particularly in heart failure patients (Middlekauff et al 1991). The 
presence of concomitant heart failure in patients with atrial fibrillation also appears to enhance
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the substantial risk for thromboembolism in these patients (Stroke Prevention in Atrial 
Fibrillation Study Group Investigators 1992).
Recent large scale, randomised, studies have established the importance of 
anticoagulation therapy in the prophylaxis against thromboembolic events in patients with 
chronic atrial fibrillation (Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators 
1990, Connolly et al 1991, Ezekowitz et al 1992, Petersen et al 1989, Stroke Prevention in 
Atrial Fibrillation Study Group Investigators 1990, Stroke Prevention in Atrial Fibrillation 
Investigators 1991). When my survey was performed only three of the five large scale studies 
had been published, but there was sufficient evidence that warfarin therapy reduced the risks 
of stroke by two-thirds in patients with chronic atrial fibrillation (Boston Area Anticoagulation 
Trial for Atrial Fibrillation Investigators 1990, Petersen et al 1989, Stroke Prevention in Atrial 
Fibrillation Study Group Investigators 1990). Despite this evidence, consensus about 
initiating oral anticoagulation therapy appears to be widely differing in view of the rate of 
anticoagulation in this study being surprisingly low, with only 5% of patients having warfarin 
added to their therapy. A suboptimal rate of prescribing warfarin was also shown in a 
retrospective audit of antithrombotic therapy use in 95 patients with atrial fibrillation (Bath et al 
1993). The main concerns about initiating warfarin appear to be the inconvenience and 
safety (Lowe 1992). The quality of life for patients on anticoagulants was one aspect further 
studied in the BAATAF study and no significant differences between warfarin-treated and 
controls were found on measures of functional status, well-being, and health perceptions; 
unless complicated by a bleeding episode (Lancaster et al 1991). Only 6.5% of patients in this 
study claimed that warfarin restricted their lifestyle, although 13.1% admitted to worrying 
about their side-effects (Lancaster et al 1991). However, these findings may not be 
applicable to all patients on warfarin. For example, the average age in the BAATAF was 68 
years, and younger, sports-active patients may find long-term warfarin therapy restrictive and 
an inconvenience. Further studies on this group of patients may be required.
Age should not be a contraindication to initiating oral anticoagulant therapy 
(Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators 1990, Gurwitz et al 1988, 
Kutner etal 1991, Lancaster et al 1991). One survey of physicians demonstrated, however,
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that 51.4% believed that in elderly patients with atrial fibrillation, the risk of haemorrhage 
associated with warfarin outweighed the benefit; whilst 24.3% were not convinced of the 
effectiveness of warfarin in preventing of strokes in these patients (Kutner et al 1991). In fact, 
the Havard Aging Study showed that the risk of haemorrhage associated with warfarin was no 
greater in elderly than in younger patients (Gurwitz et al 1988). Nonvaivular atrial fibrillation is 
also an important cause of fatal massive cerebral infarction in the elderly, suggesting that 
primary prophylaxis, as well as secondary prevention, against stroke should always be 
considered for these patients (Yamanouchi et al 1989). The main reason for variation amongst 
physicians in initiating such therapy appears to be the perceived differences in the estimated 
risk of systemic embolism for individual patients (Chang et al 1990, Kutner et al 1991). The 
availability of a suitable marker of increased thrombogenesis may therefore assist physicians in 
the risk stratification and allow identification of high risk patients with atrial fibrillation whom 
would particularly benefit from anticoagulant therapy - this aspect is further investigated in this 
thesis.
Aspirin is thought to be an alternative to warfarin as thromboprophylaxis 
particularly in patients with previous stroke or myocardial infarction (Antiplatelet Trialists' 
Collaboration 1988). Aspirin was only initiated in 20 patients in this study, although the 
majority of use was for concomitant vascular disease rather than prophylaxis against 
thromboembolism. However, only two of the five trials of warfarin in atrial fibrillation have 
reported a reduction (by about 25%) of thromboembolic risk with aspirin (Petersen et al 1989, 
Stroke Prevention in Atrial Fibrillation Study Group Investigators 1990, Stroke Prevention in 
Atrial Fibrillation Investigators 1991). The use of aspirin as an effective antithrombotic agent 
for atrial fibrillation therefore remains controversial (Lowe 1992).
The haemodynamic disturbance of atrial fibrillation results essentially from the 
absence of atrial systole and from the rapidity and irregularity of the ventricular response. With 
increasing age and/or heart failure, atrial systole contributes an increasing amount towards 
overall stroke volume. Indeed there is usually a significantly improved cardiac output and 
exercise capacity following cardioversion of atrial fibrillation to sinus rhythm (Lipkin et al 1988). 
Following cardioversion, there is also the additional advantage of avoiding the long-term
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thromboembolic risk associated with atrial fibrillation. In our study, there was a low rate of 
attempted cardioversion (12% of patients), with pharmacological cardioversion being the 
commonest method. Digoxin was also used in one patient for cardioversion despite evidence 
that it is no better than placebo (Falk et al 1987). For a patient in atrial fibrillation, the most 
complete relief of symptoms often occurs when sinus rhythm is restored. Cardioversion 
should therefore have been considered for most patients presenting with recent-onset atrial 
fibrillation. The procedure is generally most successful in younger patients with no underlying 
cardiac disorder and has the added advantage of being able to withdraw warfarin (for example, 
after two to four weeks (Dunn et al 1989)) if sinus rhythm is maintained.
This study establishes the importance of atrial fibrillation as a presenting 
arrhythmia amongst emergency medical admissions in the setting of a Scottish district general 
hospital. As complete information on length of stay and investigations undertaken was 
available in only 86% of patients, this study also highlights some of the problems which occur 
in producing accurate figures from admissions. This survey of atrial fibrillation provides useful 
information about a common condition and is particularly important at this time when there is 
an increasingly important role for medical audit in planning the allocation of resources. For 
example, the median inpatient stay in my study was 10 days, but with a wide range of between 
1 to 154 days. This finding and the significant correlation between age of patient and length 
of inpatient stay has important implications particularly as the general population becomes 
more elderly (with a greater life expectancy) and in view of the increased prevalence of atrial 
fibrillation with age, for example, increasing from 0.5% at 50-59 years to 8.8% at 80-89 years 
(Wolf etal 1991).
In conclusion, atrial fibrillation is a common finding amongst emergency 
medical admissions to a district general hospital. Heart failure is the commonest associated 
clinical feature, whilst ischaemic heart disease is the most frequent underlying cause. There is 
also a suboptimal application of standard investigations for patients with atrial fibrillation, and a 
reluctance to commence oral anticoagulant therapy or to consider cardioversion, both of 
which are playing an increasingly prominent role in the management of this group of patients.
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These issues need to be addressed in order to optimise management of this common 
arrhythmia.
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CHAPTER 3
THROMBOGENSIS IN 
CHRONIC ATRIAL FIBRILLATION
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3.1 STUDIES OF PLASMA FIBRINOGEN, VON WILLEBRAND
FACTOR AND FIBRIN D-DIMER IN CHRONIC ATRIAL
FIBRILLATION
Introduction
Chronic atrial fibrillation is associated with an increased incidence of stroke and
other thromboembolic events. Within the broad spectrum of patients with atrial fibrillation, the risk
for thromboembolism is not uniform, and subgroups at greater or less risk clearly exist. However, 
the mechanisms of thromboembolism in patients with atrial fibrillation have not been fully 
elucidated, and are likely to be multifactorial. The risk of thrombus formation and embolic events 
is, for example, higher with left atrial enlargement (Hinton et al 1977, Daniel et al 1988). However, 
atrial fibrillation per se can lead to and perpetuate atrial enlargement (Sanfillipo et al 1990). An 
enlarged left atrium may contribute to an increased thrombotic tendency as a result of abnormal 
flow patterns within the left atrium (Daniel et al 1988).
Abnormalities of plasma fibrinogen and von Willebrand factor are associated with 
thromboembolism. Elevated plasma fibrinogen levels are, for example, associated with an 
increased risk of cardiovascular disease, including ischaemic heart disease and stroke (Ernst 
1991, Ernst and Resch 1993, Hamsten et al 1986, Meade et al 1980, Wilhelmsen et al 1984). 
They may promote disease by increasing fibrin formation, platelet aggregation or by Theological 
effects (blood viscosity, red cell aggregation) which may promote disturbed blood flow. Plasma 
vWF is a marker of endothelial dysfunction which is associated with thromboembolic stroke 
(Uchiyama et al 1983) and atherosclerosis (Mettinger 1982). Another plasma factor, the D-dimer 
fibrin fragment, reflects intravascular clotting levels by identifying the presence of cross-linked 
fibrin degradation products without interference from fibrinogen or non-cross-linked fibrin. This 
means that fibrin D-dimer is a marker of intravascular thrombus formation and not just a reflection of 
plasma fibrinogen levels. Elevated levels of fibrin degradation products are found in conditions 
associated with intravascular (and sometimes extravascular) activation of the coagulation system, 
including those with a predisposition to venous thrombosis (Hunt et al 1985). In addition, two 
recent studies have suggested that plasma levels of D-dimer are increased in patients with atrial 
fibrillation, whether or not co-existing structural heart disease is present, when compared to
76
patients in sinus rhythm (Gustafsson et al 1990, Kumagai et al 1990). Abnormalities in these 
plasma factors may in part account for the variable risk of thromboembolism in different subgroups 
of patients with atrial fibrillation.
Five major, prospective studies have demonstrated that warfarin reduces the 
incidence of thromboembolic complications in patients in atrial fibrillation (Boston Area 
Anticoagulation Trial for Atrial Fibrillation Investigators 1990, Connolly et al 1991, Ezekowitz et al 
1992, Petersen et al 1989, Stroke Prevention in Atrial Fibrillation Investigators 1991). The effect 
of aspirin however is less certain (Lowe 1992).
This study was performed to determine if chronic atrial fibrillation is associated with 
abnormalities in plasma fibrinogen, vWF or D-dimer levels; and if so, whether or not such levels 
were related to the haemodynamic disturbance within an enlarged left atrium, with poor left 
ventricular function, or to existing treatment with warfarin or aspirin.
Materials and methods
Patients- The design was a prospective population controlled study of male and female
patients with chronic atrial fibrillation. Chronic atrial fibrillation was defined as atrial fibrillation 
documented electrocardiographically on two occasions at least 48 hours apart during the same 
inpatient stay, or on at least two visits to the outpatient clinic. Excluded were those patients aged 
over 75 and those with significant systemic illness (which influences fibrinogen, vWF and fibrin D- 
dimer levels) such as renal failure, liver impairment (defined as abnormal liver function tests with 
aspartate transaminase (AST) or alanine transaminase (ALT) levels more than twice the upper limit 
of normal), chronic infections or neoplastic disease. Patients with hypertension, limited venous 
access, those requiring transfusion or those actively bleeding were also excluded.
Results were compared to those of 158 population controls aged 55-64 years in 
sinus rhythm, sampled from a local population survey (Second North Glasgow MONICA Study; 
Lowe et al 1992; Lowe et al, in preparation (for D-dimer and vWF levels)). For patients taking 
warfarin therapy, a Thrombotest was performed to ensure satisfactory anticoagulation and to 
establish the intensity of effect of warfarin.
Echocardiography- Two dimensional and Doppler echocardiography were performed with 
the patient in the left lateral decubitus position using a Hewlett-Packard Sonos 500 machine 
(Hewlett-Packard, Arondale, Pa, USA) equipped with a standard 2.5 MHz transducer. Images 
were obtained in the standard parasternal long axis, parasternal short axis, and apical four- 
chamber planes. The transducer was angled to maximise cardiac chamber size and gain positions 
were adjusted to obtain the clearest outline of the endocardium. Doppler examination was 
performed using colour-flow, pulsed and continuous wave modes. Using the standard video 
facility of the ultrasound machine, off line analytical methodology was used to quantify 
measurements. In the parasternal long-axis view, the anteroposterior dimension of the left atrium 
was measured and in the standard apical four-chamber view, the superoinferior (base-to-roof) and 
mediolateral (transverse) dimensions of the left atrium were measured (Sanfillipo et al 1990) 
(Figures 3.1, 3.2). Left atrial volume was calculated using a standard ellipsoid formula (Figure 3.3) 
(Sanfillipo et al 1990). The apical four chamber view was used to measure the right atrium 
superoinferior and mediolateral dimensions and the volume estimated using the same ellipsoid 
formula, assuming anteroposterior dimension being equal to the mediolateral dimension (Figures 
3.1, 3.2) (Sanfillipo et al 1990). All measurements were taken at maximum separation of chamber 
walls at end-systole (that is, at the video frame just preceding mitral valve opening), using the 
leading edge to leading edge convention. Left ventricular dimensions were measured using M- 
mode echocardiography in the parasternal long axis view using the technique recommended by 
the American Society of Echocardiography (Sahn et al 1978) and the fractional shortening 
calculated as an index of left ventricular function (Figure 3.4).
All echocardiography was performed by one operator blinded to the patients 
clinical details. Echocardiography data were compared to 14 healthy volunteers who served as 
'normal controls. To allow validation of the measurements of atrial and ventricular dimensions, and 
to assess reproducibility, interobserver and intraobserver variability, a sample of 20 patients 
selected at random were studied twice on different occasions by the same observer (myself) and 
another 20 subjects on different occasions by two different observers (myself and one other 
observer).
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Blood samples- Blood samples were drawn from the antecubital vein by careful
venipuncture, anticoagulated with trisodium citrate (0.11M, 9:1 v:v) and centrifuged. The platelet- 
free plasma was immediately separated, frozen to - 40° C, and assayed in batches within 4 weeks 
of collection.
Assay procedures- Plasma D-dimer antigen levels were measured using an ELISA method 
(AGEN, Parsippany, NJ, USA). Plasma fibrinogen was assayed by the Clauss assay, using a Coag- 
A-mate coagulometer and Organon Teknika reagents and standards (Organon Teknika, 
Cambridge, UK). Plasma von Willebrand factor was assayed using an ELISA method 
(ASSERACHROM, Diagnostica Stago, France). The sensitivity of the assays used allowed 
measurement of plasma D-dimer, vWF and fibrinogen levels to a minimum of 30 ng/ml, 1% and 0.5 
g/l respectively. The reproducibility of all three methods allowed a coefficient of variation of less 
than 5%.
Statistical analysis- All the values of the Theological measurements and cardiac dimensions
were expressed as median ± interquartile range (IQR). Statistical comparison was performed 
using ANOVA and t-tests for normal distributions and the Kruskal-Wallis test and Mann-Whitney 
two sample rank test for non-parametric distribution, and 95% confidence intervals (c.i.) were 
calculated for the point estimate of the difference in medians. Correlations between clinical 
variables or Theological measurements were performed using Spearman's Rank correlation 
method. Stepwise multiple regression analyses were performed with plasma fibrinogen and fibrin 
D-dimer as the dependent variables to determine whether age, smoking habit, left atrial volume 
(ellipsoid), right atrial volume, left ventricular fractional shortening and body mass index 
contributed significantly to levels of these coagulation parameters. A probability of <0.05 was 
considered statistically significant.
Reproducibility for echocardiographic measurements was expressed as mean 
difference ± 2s.d (Bland and Altman 1986). A one-sample t-test test was performed to determine 
whether the mean difference was significantly different from zero. All statistical calculations were
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performed on a microcomputer using a commercially available statistical package (MINITAB v8, 
Minitab INC, PA.USA).
Results
Patient groups- A total of 85 patients (42 male and 43 female; mean age 63.1 years,
s.e.m. 1.01) with chronic atrial fibrillation were studied. At the time of the study, 36 were taking no 
antithrombotic therapy (Group 1), 31 were taking warfarin (including 2 on both warfarin and aspirin 
therapy) (Group 2) and 18 were taking aspirin alone (Group 3). They were compared to 158 
population controls derived from a pre-existing random healthy population sample, the 2nd 
MONICA study. Clinical variables in these groups are as shown in Table 3.1. Twenty patients 
(23.5%) were still smoking. There were no differences in sex ratio (X2=4.79, 3 d.f.; p=0.19) and 
proportions of smokers (X2 =7.36, 3 d.f.; p=0.06) between the groups studied.
Underlying aetiology - Of the 85 patients with atrial fibrillation, 73 were found to have a 
predisposing factor to atrial fibrillation. Valvular heart disease was the commonest factor (n=34), 
followed by ischaemic heart disease (n=30, including 10 patients with a clinical history of both 
valvular heart disease and ischaemic heart disease). Other causes included patients with dilated 
cardiomyopathy (n=3), predominantly idiopathic or alcoholic, but 12 patients did not have any 
obvious predisposing factors. There were 31 patients taking warfarin and all Thrombotest results 
were within the therapeutic range (5-15%).
Plasma fibrinogen, von Willebrand factor and fibrin D-dimer levels - Fibrinogen levels were
measured in all 85 patients (median 3.58 g/l, IQR 3.0-4.7) but due to technical problems, plasma 
D-dimer and von Willebrand factor levels were only measured in 81 patients (D-dimer: median 89 
ng/ml, IQR 50-193) and 67 patients (vWF: median 158 %, IQR 114-200) respectively. As a group, 
the patients with atrial fibrillation had significantly higher levels of fibrinogen than the population 
controls (Kruskal-Wallis test H=78, d.f.=3, p<0.0001; Mann-Whitney test, point estimate of 
difference between medians 1.23 g/l; 95% confidence interval (c.i.) 1.01 to 1.55, p<0.0001) and 
of vWF (Kruskal-Wallis test H=27, d.f.=3, p<0.0001; Mann-Whitney test, point estimate of
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difference between medians 63 %; 95% confidence interval (c.i.) 47 to 79, p<0.0001) when 
compared to population controls. The correlations between plasma fibrinogen and D-dimer 
(Spearman r = 0.23, p=0.03) and between vWF and D-dimer (r=0.29,p=0.01) were however weak.
In Group 1 (no antithrombotic therapy) (n=36), plasma fibrinogen remained 
significantly elevated compared with population controls (point estimate of difference between 
medians 1.23 g/l; 95% c.i. 0.88 to 1.62, p<0.0001) (Table 3.2, Figure 3.5). There was also a 
significant elevation of plasma D-dimer levels (point estimate of difference between medians 77 
ng/ml; 95% c.i. 38 to 122, p<0.01) and vWF (point estimate of difference between medians 63% ; 
95% c.i. 38 to 89, p<0.0001) in these patients when compared to population controls (Table 3.2; 
Figure 3.6, 3.7). There were no significant correlations between these coagulation parameters 
and atrial size or ventricular function (Table 3.4).
In Group 2 (warfarin therapy), there was no significant difference in plasma 
fibrinogen (point estimate of difference between medians 0.14g/l; 95% c.i. -0.44 to 0.77, p=0.65) 
or vWF (point estimate of difference between medians 3.5%; 95% c.i. -41 to 41, p=NS) when 
compared to patients in Group 1 (Table 3.2; Figure 3.5, 3.7). However, there was a significant 
difference in plasma D-dimer levels between the two groups (point estimate of difference 
between medians 90 ng/ml, 95% c.i. 39 to 150, p<0.0001) (Table 3.2, Figure 3.6). There were 
no significant correlations between the coagulation parameters and left atrial volume or ventricular 
function (Table 3.4).
In Group 3 (aspirin therapy alone) (n=18), there were no significant differences in 
plasma fibrinogen (point estimate of difference between medians 0.08 g /l; 95% c.i. -0.52 to 0.77, 
p=0.73), D-dimer (point estimate of difference between medians -34ng/ml; 95% c.i. -114 to 21.0, 
p=0.25) or vWF (point estimate of difference between medians 2 %; 95% c.i. -35 to 41, p=NS) 
levels when compared to Group 1 (Table 3.2; Figure 3.5,3.6, 3.7). In Group 1 and Group 3 
patients, there was a significant positive correlation between plasma fibrin D-dimer and vWF levels 
(p=0.52. p<0.001).
Influence of underlying aetiology, left atrial size and left ventricular function - 
As plasma fibrinogen, vWF and fibrin D-dimer levels are similar in patients with and without aspirin 
therapy, but not on warfarin (that is, Group 1 and Group 3), further subgroup analysis was 
performed on the 68 patients in these two groups with regard to the influence of underlying 
aetiology, atrial size and left ventricular function.
There were no significant differences for plasma fibrinogen (Kruskal-Wallis test 
H=3.06,p=0.38), fibrin D-dimer levels (Kruskal-Wallis test H=3.27, p=0.35) or vWF (Kruskal-Wallis 
test H=11.9, p=0.064) between patients with and without underlying heart disease. In particular, 
there were no statistically significant differences in plasma fibrinogen levels when patients with 
valve disease were compared to those with no obvious aetiology (Mann-Whitney test, point 
estimate of difference between medians -0.52; 95% c.i. -1.2 to 0.56, p=0.34) or when patients 
with ischaemic heart disease were compared to those with no obvious aetiology (point estimate of 
difference between medians -0.99 g/l; 95% c.i. -1.64 to 0.11, p=0.09). Similarly, there were no 
differences in plasma D-dimer levels when those with valve disease were compared to those with 
no obvious aetiology (point estimate of difference between medians -27 ng/ml; 95% c.i. -179 to 
66, p=0.81) or when patients with ischaemic heart disease were compared to those with no 
obvious aetiology (point estimate of difference between medians -5.5 ng/ml; 95% c.i. -132 to 77, 
p=0.83). There were also no differences in plasma vWF levels when those with valve disease 
were compared to those with no obvious aetiology (Mann-Whitney test, point estimate of 
difference between medians -38%; 95% c.i. -95 to 42, p=0.53) or when patients with ischaemic 
heart disease were compared to those with no obvious aetiology (point estimate of difference 
between medians -16%; 95% c.i. -99 to 65, p=0.40).
Technically adequate left and right atrial measurements were obtained in 81 and 
77 patients respectively. However, due to technical difficulties, left ventricular dimensions were 
only obtained in 72 patients. Echocardiographic measurements and dimensions are summarised 
in Table 3.3. Echocardiographic data (n=54) for patients not on warfarin (Group 1 and 3) were 
related to plasma fibrinogen, vWF and D-dimer. There were no significant correlations between 
left atrial dimension, left atrial volumes (ellipsoid) and left ventricular fractional shortening, and 
plasma fibrinogen, vWF or fibrin D-dimer levels. There was a weak negative correlation between
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plasma fibrinogen and right atrial volume (Spearman r = -0.3, p=0.03). In addition, amongst these 
patients, there were no differences in plasma fibrinogen (point estimate of difference between 
medians 0.18 g/l; 95% c.i. -0.38 to 0.95, p=0.48) or fibrin D-dimer levels (point estimate of 
difference between medians -25 ng/ml; 95% c.i. -76 to 47, p=0.29) when patients with a left atrial 
dimension >4.2cm were compared to those with a left atrial dimension of <4.2cm. There was, 
however, a higher plasma vWF in patients with a left atrium of >4.2cm when compared to those 
with a left atrium <4.2cm (point estimate of difference between medians 42%; 95% c.i. 3 to 87, 
p=0.045). There were no differences in plasma fibrinogen (point estimate of difference between 
medians 0.29g/l; 95% c.i. -0.25 to 1.06, p=0.34), fibrin D-dimer levels (point estimate of 
difference between medians 23 ng/ml; 95% c.i. -29 to 112, p=0.47) or vWF (point estimate of 
difference between medians 14%; 95% c.i. -32 to 63, p=0.49) when patients with a left 
ventricular fractional shortening of <25% were compared to those with a normal fractional 
shortening (FS >25%).
For patients not on warfarin, stepwise multiple regression analysis with plasma 
fibrin D-dimer as the dependent variable demonstrated that when age, left atrial volume (ellipsoid), 
right atrial volume, left ventricular fractional shortening, smoking habit, body mass index and 
plasma fibrinogen were considered, only body mass index (t=3.65, p<0.05) was a significant 
predictor for plasma fibrin D-dimer. Similar stepwise multiple regression analysis with plasma 
fibrinogen and vWF as dependent variables revealed no significant predictors among age, left 
atrial volume (ellipsoid), right atrial volume, left ventricular fractional shortening, smoking habit and 
body mass index. Amongst these patients there was a weak correlation between age and vWF 
(Spearman r=0.3l, p=0.02) and plasma fibrinogen and body mass index (r=-0.36,p=0.001).
Reproducibility of 2-dimensional and M-mode echocardiographic measurements These 
are summarised in Table 3.5. There was overall good agreement between inter- and intra­
observer measurements.
Discussion
Chronic atrial fibrillation has been established to carry an annual risk of 3-6% of 
thromboembolic complications, this being 5-7 times greater than that of controls in sinus rhythm 
(Peterson 1990). The female sex, smoking, heart failure, enlarged left atrial size, poor left 
ventricular function and a history of previous embolic episodes are additive risk factors. This was 
demonstrated in the Stroke Prevention in Atrial Fibrillation study where the presence of recent 
congestive heart failure, hypertension and previous thromboembolism were independent clinical 
risk factors for subsequent thromboembolism (Stroke Prevention in Atrial Fibrillation Investigators 
1992a). The presence of these three independent clinical predictors defined patients with rates 
of thromboembolism of 2.5% per year (no risk factors), 7.2% per year (one risk facta) and 17.6% 
(two a  3 risk factors) (Stroke Prevention in Atrial Fibrillation Investigatas 1992a). In addition to an 
increase in stroke and thromboembolism, the size of the left atrium has also been considered to 
contribute to an increased risk of atrial thrombi and spontaneous echo contrast on 
transoesophageal echocardiography (Caplan et al 1986, Daniel et al 1988, Manning 1993, SPAF 
Investigatas 1992b). Echocardiographic data from the Stroke Prevention in Atrial Fibrillation 
study demonstrated that left ventricular dysfunction (on the 2-dimensional echocardiogram) and 
the size of the left atrium (from M-Mode echocardiograms) were strong independent predictas of 
later thromboembolism in patients with atrial fibrillation (Stroke Prevention in Atrial Fibrillation 
Investigatas 1992b). These findings therefore point not only to the left atrium but also toward the 
left ventricle as a cause a  consequence of the pathology responsible for thromboembolic risk in 
patients with atrial fibrillation. In addition, recent studies have also suggested that left atria) 
enlargement may be a consequence of the duration of atrial fibrillation (Sanfillipo et al 1990, 
Petersen et al 1987, Sosa-Suarez et al 1989), although previous studies have suggested the 
converse, left atrial enlargement being a cause ratha than a consequence of atrial fibrillation 
(Takahashi et al 1982).
Left atrial enlargement may also be associated with increased spontaneous echo 
contrast on transoesophageal echocardiography, suggesting flow disturbance (stasis or slow 
blood flow) and resulting in red cell aggregation within the enlarged atrial cavity (Black et al 1991, 
Chen et al 1990, Daniel et al 1988). One study in patients with mitral valve disease suggested that
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there was no single factor responsible for the formation of spontaneous echo contrast; and mitral 
stenosis, atrial fibrillation and dilated left atria were all necessary (Chen et al 1990). In contrast, one 
study of patients with nonrheumatic atrial fibrillation did not demonstrate any association between 
left atrial diameter (or left ventricular size/function) and the presence of the phenomenon (Tsai et 
al 1992). Spontaneous echo contrast itself appears to be predictive for left atrial thrombus and 
suspected embolism in patients with atrial fibrillation, and is unrelated to age, gender, left 
ventricular dysfunction or anticoagulant therapy (Black et al 1991, Castello et al 1990, Manning 
1993, Tsai et al 1992). The rheological mechanism for spontaneous echo contrast is thought to 
involve the effect of fibrinogen, or its products, which under low flow and low shear rate conditions 
promote red cell aggregation and the rouleau formation of erythrocytes (Sigel et al 1981, Merino 
et al 1992). Spontaneous echo contrast therefore provides 'visual* evidence for a rheological 
mechanism for thrombogenesis in atrial fibrillation. Unfortunately, in this study, I was unable to 
assess the correlation of spontaneous echo contrast to rheological markers because the 
phenomenon was only demonstrated in one patient (on warfarin) using transthoracic 
echocardiography. This is not unexpected as transoesophageal echocardiography is more 
sensitive than transthoracic echocardiography in detecting spontaneous echo contrast (Chen et 
al 1990).
This study demonstrates that plasma levels of fibrinogen, fibrin degradation 
products (fibrin D-dimer) and von Willebrand factor (vWF) are increased in patients with chronic 
atrial fibrillation who are not taking any antithrombotic therapy, when compared to population 
controls of similar age in sinus rhythm. These results were not attributable to an excess of 
smokers in the atrial fibrillation group (Table 3.1); nor are they attributable to underlying cardiac 
disease, with no statistically significant differences between patients with an underlying cause for 
atrial fibrillation (ischaemic heart disease, valve disorders) when compared to those with no 
obvious cause. In this study, there was however a trend towards higher median plasma fibrinogen 
levels in patients with ischaemic heart disease. My findings in this study also suggest that it is atrial 
fibrillation itself which is the major contributory factor to the increased thrombotic tendency as 
reflected by the elevated fibrinogen and D-dimer levels, there being no significant correlation with 
atrial size or ventricular function. Similar findings were reported by two previous small studies of
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patients with atrial fibrillation (Gustafsson et al 1990, Kumagai et al 1990). The increased plasma 
fibrinogen levels in atrial fibrillation may promote thromboembolic events in patients with atrial 
fibrillation, either by increasing the tendency to thrombosis (as suggested by the correlation with 
plasma D-dimer levels)or by increasing flow disturbance through its rheological effects in 
increasing red cell aggregation and blood viscosity in areas of stasis, for example, in the dilated 
atria in patients with atrial fibrillation. In addition, there may be an interaction with underlying 
endothelial dysfunction, as reflected by the increased vWF levels in these patients and the 
positive correlation between vWF and fibrin D-dimer levels.
Although no significant correlations of plasma fibrinogen or D-dimer levels were 
found in association with left ventricular fractional shortening, this measurement poses certain 
problems. Firstly, there were insufficient numbers to fully assess a broad spectrum of left 
ventricular function. For example, only 5 patients in our study had a fractional shortening of <10% 
(normally regarded as 'poor1 left ventricular contractility). Additionally, the median fractional 
shortening in the whole study population was 21.5% (IQR 16.2 to 28.9%) is just below lower limit 
of the normal range (>25%) for our laboratory. Secondly, the measurement of fractional 
shortening is only a crude indicator of overall left ventricular function, as for example patients with 
a discrete apical wall motion abnormality may falsely appear to have normal ventricular function. 
There was, however, a weak negative correlation between plasma fibrinogen and left ventricular 
end-diastolic dimension, suggesting that some relationship may well exist with ventricular 
impairment. I therefore have reservations therefore about the lack of correlation between 
coagulation parameters and left ventricular function (as assessed by fractional shortening) in this 
study and this aspect will be the subject of a separate investigation.
Smoking is another factor associated with an increase in plasma fibrinogen, vWF 
and D-dimer levels (Petersen 1987, Ernst 1990). However, the proportion of smokers in 
population controls was 40% compared to 32% of patients with atrial fibrillation without any 
antithrombotic therapy (Group 1). Smoking should not be expected therefore to account for the 
elevation in plasma fibrinogen, vWF and D-dimer seen in Group 1. Patients on warfarin therapy 
(Group 2) and aspirin therapy (Group 3) had similar proportions of smokers (23% and 16% 
respectively), which were lower than for Group 1. The difference between the proportions of
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smokers in different groups was however not statistically significant, but some contribution of 
smoking to the elevated D-dimer levels in Group 1 compared to Group 2 is possible.
My study demonstrates that patients with atrial fibrillation continue to have 
elevated plasma fibrinogen and vWF levels despite treatment with warfarin or aspirin. As other 
studies have demonstrated that elevated fibrinogen (Hamsten et al 1986) or vWF (Jansson et al
1991) levels are predictors of cardiovascular disease, these patients may continue to be at 
increased risk despite being adequately anticoagulated. Chronic atrial fibrillation itself may 
increase plasma fibrinogen levels, and there may be a contribution from the increased left atrial 
size. A number of patients in this study had underlying ischaemic heart disease (n=30) and 
although this has been linked to elevated fibrinogen and vWF levels (Hamsten et al 1986, 
Wilhelmsen et al 1984), I do not feel that this was a significant contributory factor to the high levels 
of plasma fibrinogen and vWF in these patients. The main reasons for this include the 
demonstration that there is no significant difference in plasma fibrinogen and vWF levels in 
patients with atrial fibrillation with and without ischaemic heart disease. Secondly, observations in 
a large local population survey of patients (the 2nd North Glasgow MONICA Study) demonstrate 
that those with ischaemic heart disease and sinus rhythm had relatively minor elevations in plasma 
fibrinogen, vWF and D-dimer levels (Lowe et al 1992; Lowe et al, submitted for publication).
An important question is why is atrial fibrillation associated with an increased 
plasma fibrinogen or vWF level. It is unlikely that the increased fibrinogen or vWF levels are a 
secondary response to increased clot or thrombus formation, as in such cases D-dimer levels 
would have been elevated in the subgroups with and without warfarin therapy. Additionally, 
warfarin therapy is not known to influence any underlying pathological process and therefore 
fibrinogen or vWF levels would not have been expected to be different between the groups with 
and without warfarin therapy, as demonstrated here. Abnormalities in cardiac blood flow (for 
example, sluggish, slow flow within the atria) may be partly responsible, resulting in flow 
abnormalities and endothelial dysfunction (causing raised vWF) in the pulmonary vasculature. 
This latter effect may stimulate lung macrophages to produce hepatocyte stimulating factor, 
increasing the liver synthesis of fibrinogen (in a similar manner to smoking (Ritchie et al 1982). 
Further studies investigating the mechanisms by which fibrinogen and vWF synthesis are
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increased are needed. The precise mechanism for the elevated plasma fibrinogen and vWF 
levels is therefore uncertain.
As plasma D-dimer is a marker of intravascular cross-linked fibrin formation, my 
finding that plasma levels of D-dimer were significantly elevated in patients with atrial fibrillation 
(without any antithrombotic therapy), when compared to controls in sinus rhythm, suggests that 
there is ongoing intravascular fibrin formation in these patients. This finding is consistent with two 
previous small studies (Gustafsson et al 1990, Kumagai et al 1990). Additionally, in a small study 
of patients with atrial fibrillation and mitral stenosis, increased levels of other markers of a 
thrombotic state (fibrinopeptide A, thrombin-antithrombin III complex) have been demonstrated 
within the left atria of such patients (Yamamoto et al 1993). These thrombotic marker levels also 
did not correlate with the left atrial size, as in my study. If warfarin or aspirin therapy effectively 
prevented intravascular fibrin and thrombus formation, then D-dimer levels would be expected to 
be lower in patients on warfarin or aspirin therapy. This is indeed clearly demonstrated for warfarin 
in this study (which found that the median plasma D-dimer level was also reduced by about two- 
thirds, consistent with the finding the warfarin therapy reduced thromboembolic risk by about two- 
thirds, based on randomised clinical trials (range 35% to 86%)) (Lowe 1992, Stroke Prevention in 
Atrial Fibrillation Investigators 1992a). Patients on aspirin therapy had a lesser (approximately 
one-third) reduction in plasma D-dimer levels when compared to patients on no antithrombotic 
therapy but the difference was not statistically significant. This may be a reflection of either a lower 
antithrombotic efficacy of aspirin; or else the smaller number of patients within this group. In 
addition, the mechanisms of action of aspirin and warfarin differ. The former acts by inhibition of 
platelet function whilst the latter acts by the reduction of clotting factor synthesis. Larger studies 
of patients on aspirin are therefore required to assess risk reduction of thromboembolism in 
patients with chronic atrial fibrillation (current estimate is a risk reduction of about 25% ) (Lowe
1992).
Von Willebrand factor levels were also significantly increased in patients with 
chronic atrial fibrillation, irrespective of anticoagulant therapy. This finding is consistent with one 
previous small study of patients with atrial fibrillation (Gustafsson et al 1990). High vWF levels have 
previously also been associated with atherosclerosis and in particular, the recurrence of
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thromboembolic (rather than embolic) stroke (Mettinger et al 1982, Uchiyama et al 1983). My 
findings therefore suggest a role for vWF in the pathogenesis of thromboembolic risk in patients 
with chronic atrial fibrillation. As vWF is a marker of endothelial (which may extend to endocardial) 
dysfunction, this is consistent with Virchow's observation of the importance of the vessel wall in 
thrombogenesis (Virchow's triad) (Virchow 1856). The findings of a modest correlation between 
plasma vWF and fibrin D-dimer levels in patients not on warfarin therapy (r=0.52, p<0.001), and 
higher vWF levels in patients with a large left atrium (>4.2cm) are in support of this hypothesis.
Anticoagulant therapy carries a risk of bleeding, and to be able to select out those 
patients who would particularly benefit from warfarin (or aspirin) would be a major advance. My 
study suggests that measurement of plasma D-dimer may identify a subgroup of patients with atrial 
fibrillation (those with increased plasma D-dimer) who would particularly benefit from anticoagulant 
therapy. A prospective study of plasma D-dimer levels in a large cohort of patients with atrial 
fibrillation is required to test this hypothesis. Such a study might also assess the predictive value 
of plasma fibrinogen and vWF levels for thromboembolic complications. The apparent lack of 
effect of warfarin or aspirin therapy on plasma fibrinogen or vWF levels suggests that they could 
be used as risk markers even in patients taking antithrombotic therapy. For the present, however, 
this study confirms still further that anticoagulation should be considered for all patients with 
chronic atrial fibrillation as they appear to have increased intravascular thrombus generation. 
Prospective studies on the effects of introducing warfarin in these patients are required, as 
investigated in chapter 10 of this thesis.
In conclusion, my results confirm significantly elevated median plasma fibrinogen 
and vWF levels for patients with chronic atrial fibrillation. Plasma D-dimer levels were also elevated 
in patients with chronic atrial fibrillation whom were not on antithrombotic therapy, suggesting 
increased intravascular thrombogenesis in such patients. For patients taking warfarin therapy 
there was a strikingly lower level of circulating fibrin D-dimer, suggesting that warfarin therapy was 
effective in preventing intravascular thrombus formation. These results provide, therefore, a 
possible mechanism to both assess those patients with atrial fibrillation who are at high risk of 
thrombogenesis and also to measure the efficacy of anticoagulant therapy in reducing fibrin or 
thrombus formation.
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TABLE 3.1 
PATIENT CHARACTERISTICS
P A TIE N TS
GROUP 1
no
anti-thrombotic
therapy
WITH
GROUP 2 
warfarin
CHRONIC AF
GROUP 3
aspirin
C O N TR O L
GROUP
(sinus
rhythm )
num ber
(n )
37 31 19 158
m ales 19 12 13 88
<%) (51%) (39%) (68%) (55%)
sm okers 12 7 3 64
(% ) (32%) (23%) (16%) (40%)
AGE (yrs) 62.6 60.3 68.4 59.3
mean (s.e.m.) (16 ) (16) (16) (0.2)
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TABLE 3.2
PLASMA FIBRINOGEN, VON WILLEBRAND FACTOR 
AND FIBRIN D-DIMER IN CHRONIC ATRIAL FIBRILLATION
P A TIE N TS WITH CHRONIC AF
FIBRINO G EN
g /i
median
(IQR)
GROUP 1 
no
anti-thrombotic
therapy
3.78*
(3.00-4.7)
GROUP 2 
warfarin
3.50
(2.95-4.70)
GROUP 3
aspirin
3.83
(2.92-4.77)
D -dim er
ng/m l
median
(IQR)
158*
(81-292)
50s
(50-60)
102
(77-155)
von
W illebrand
factor
%
median (IQR)
152*
(108-198)
169
(118-227)
161
(118-196)
C O NTRO L
GROUP
(sinus
rhythm )
2.60
(2.24-2.99)
76
(53-103)
105
(80-147)
* p<0.0001 vs controls; sp<0.0001 vs patients on no antithrombotic therapy
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TABLE 3.3
ECHOCARDIOGRAPHY IN ATRIAL FIBRILLATION
P A TIEN TS W ITH CHRONIC AF
GROUP 1
no
anti-thrombotic
therapy
GROUP 2
warfarin
GROUP 3
aspirin
LEFT ATRIAL 
DIM ENSIO N
mm 
median (IQR)
45.0
(40.1-49.5)
51.0
(43.5-56.0)
46.8
(41.8-49.3)
LEFT ATRIAL 
VO LU M E
mm  ^
median (IQR)
47.6
(34.8-49.7)
63.3
(44.3-84.5)
51.7
(44.0-65.7)
RIGHT
ATRIAL
VO LUM E
mm 3
median (IQR)
40.1
(34.8-49.7)
46.1
(36.4-63.5)
44.9
(34.6-57.2)
LEFT
VEN TR IC LE
D IASTO LIC
DIM ENSIO N
cm
median (IQR)
5.48 
(5.0-6.1)
5.4 
(5.1-5.7)
5.3
(4.95-6.1)
LEFT
VEN TR IC LE
fractional
shortening
%
median (IQR)
21.8
(16.7-29.0)
20.3
(14.0-28.0)
27.2
(19.5-29.9)
CO NTRO L
GROUP
(sinus
rhythm )
(n=14)
3.37 
(3.1-3.7)
29.2
(26.2-31.5)
20.1
(17.2-23.0)
5.2  
(4.9-5.5)
35.3
(30.9-37.3)
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FIGURE 3.4 
CHRONIC ATRIAL FIBRILLATION 
- SPEARMAN CORRELATION WITH AGE, CARDIAC 
DIMENSIONS AND VENTRICULAR FUNCTION
fib rin o g en
g /i
r P
D -d im er
ng/m l
r P
von W illebrand  
fac to r %
r P
D -dim er 0.184 0.180
vW F 0.172 0.224 0.52 <0.001*
age -0.103 0.547 0.195 0.154 0.313 0.024*
body mass 
index
-0.36 0.007* -0.22 0.099 -0.021 0.878
Left atrial 
dim ension
-0.143 0.302 0.081 0.577 0.25 0.078
Left atrial 
volum e
-0.194 0.161 0.163 0.251 0.267 0.064
Right atrial 
volum e
-0.296 0.03* -0.018 0.89 0.057 0.707
LV
end-
diasto lic
dim ension
-0.362 0.011* 0.176 0.24 0.252 0.095
LV
fractional
shortening
-0.11 0.52 -0.18 0.242 -0.075 0.635
[LV=left ventricle]
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FIGURE 3.5
INTRA- AND BETWEEN-OBSERVER REPEATABILITY FOR 2- 
DIMENSIONAL AND M-MODE ECHOCARDIOGRAPHY
(a) intra-observer repeatability (IOR)
M EASUREM ENT Pearson
r
m ean
d iffe re n ce
± 2 s .d . o n e  
sam ple  
t-test T
p value
LEFT ATRIUM
D1 0.955 0.05 0.30 1.64 0.12
D2 0.879 0.01 0.34 0.34 0.74
D3 0.958 0.06 0.42 1.32 0.20
LA VOLUME 
RIGHT ATRIUM
0.872 0.88 11.4 0.73 0.48
D2 0.960 -0.03 0.32 -0.77 0.45
D3 0.949 0.01 0.40 0.15 0.89
RA VOLUME
LEFT
VEN TR IC LE
0.973 -0.39 6.28 -0.56 0.58
end-diastolic
dimension
0.963 0 0.36 -0.12 0.90
end-systolic
dimension
0.973 0.06 0.40 1.45 0.16
fractional
shortening
0.918 -0.01 0.06 -1.82 0.09
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(b) between-observer repeatability (BOR)
M EA SU R EM EN T Pearson
r
m ean
d iffe re n ce
± 2 s .d . o n e  
sam ple  
t-test T
p value
LEFT ATRIUM
D1 0.949 0.06 0.32 1.74 0.10
D2 0.955 0.05 0.24 1.83 0.082
D3 0.980 0.02 0.22 1.00 0.33
LA VOLUME 
RIGHT ATRIUM
0.917 0.59 9.1 0.59 0.56
D2 0.813 -0.07 0.66 -0.96 0.35
D3 0.883 -0.01 0.58 -0.09 0.93
RA VOLUME
LEFT
VEN TR IC LE
0.870 -1.1 13.4 -0.71 0.49
end-diastolic
dimension
0.955 0 0.40 0.11 0.91
end-systolic
dimension
0.968 -0.07 0.68 -0.47 0.64
fractional
shortening
0.847 -0.02 0.084 -1.68 0.11
p=NS
FIGURE 3.1 
2 - DIMENSIONAL ECHOCARDIOGRAPHY 
Parasternal long axis view with anteroposterior dimension (Di)
for left atrium (LA)
[marked 'B' on picture]
FIGURE 3.2 (a)
2 - DIMENSIONAL ECHOCARDIOGRAPHY 
Apical 4 - chamber view : mediolateral (D2 ) and superoinferior (D3 )
dimensions for left atrium (LA)
[marked 'A' and 'B' respectively on picture]
FIGURE 3.2 (b)
2 - DIMENSIONAL ECHOCARDIOGRAPHY 
Apical 4 - chamber view : mediolateral (D2 ) and superoinferior (D3 )
dimensions for right atrium (RA)
[marked 'A' and 'B' on picture]
ELLIPSOID 
Length - Diameter
D3
. . . . . . .  4jt D1 D2 D3Atrial Volume =  x  x  x ----
FIGURE 3.3
ELLIPSOID FORMULA USED FOR CALCULATION
OF ATRIAL VOLUMES
[for the right atrium, the anteroposterior dimension 
(D-|) is assumed equal to the mediolateral dimension (D2)]
---------------------------------------------------
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FIGURE 3.4
M-MOOE ECHOCARDIOGRAPHY OF LEFT VENTRICLE (LV) 
with septum (A), LV end-diastolic dimension (B),
LV posterior wall (C) and LV end-systolic dimension (D)
respectively
pl
as
m
a 
fib
rin
og
en
 
g/
l
100
6 .
3
• •
^— 3.79 3.91
•  •
-3.52
No
antithrombotic
therapy
aspirin
ATRIAL FIBRILLATION PATIENTS
warfarin
J
population
controls
FIGURE 3.5
PLASMA FIBRINOGEN AND CHRONIC ATRIAL
FIBRILLATION
2.6 (median)
101
O)a
<1>
E
~oi
Q
CU
Ecn_cc
CL
800
600
400
200 •t. (median)
153 -104 76
No
antithrombotic 
therapy 
I_______
aspirin
i
warfarin
I
population
controls
ATRIAL FIBRILLATION PATIENTS
FIGURE 3.6
PLASMA D-DIMER AND CHRONIC ATRIAL
FIBRILLATION
pla
sm
a 
vW
F 
%
102
400 _
300 _
200 _
100 _
,1
T
►
-152
-169 -169
• •
s
•s i
<:
&
-105
(median)
no
antithrombotic 
therapy 
I________
aspirin warfarin
ATRIAL FIBRILLATION PATIENTS
population
controls
FIGURE 3.7
von WILLEBRAND FACTOR AND CHRONIC ATRIAL
FIBRILLATION
CHAPTER 4
THROMBOGENESIS
AND
CARDIOVERSION OF 
ATRIAL FIBRILLATION
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4.1 ANTICOAGULATION AND CARDIOVERSION OF ATRIAL 
FIBRILLATION
Introduction
Atrial fibrillation is an arrhythmia which is unfortunately associated with an 
increased risk of thromboembolism and haemodynamic disturbance. Rather than to continue 
in a potentially serious cardiac arrhythmia (associated with an increased mortality, a fivefold risk 
of stroke and other major embolic events) and the requirement for drugs with potential 
adverse effects, including oral anticoagulants and antiarrhythmics, cardioversion from atrial 
fibrillation to sinus rhythm should be considered for suitable patients. The potential benefits 
of a return to sinus rhythm include an improvement in well-being and exercise capacity (due to 
the return of atrial filling, and consequent improved cardiac output) (Lipkin et al 1988); 
avoidance of (potentially dangerous) drug therapy and a reduction in thromboembolic risk.
However, in my survey of management of patients with atrial fibrillation 
(chapter 2), there was a low proportion of patients considered for cardioversion. This may be a 
reflection of perceived risk of the procedure, associated thromboembolic risk and the 
uncertainty of patient selection. In addition, if the procedure is undertaken, there is often 
uncertainty about the suitable length of anticoagulant therapy required pre- and post­
cardioversion.
Pathophysiology
With increasing age and any (progressive) impairment of left ventricular 
contraction, the dependence on atrial function increases and atrial systole contributes an 
increasing amount towards overall stroke volume. The ventricular rate is also the most 
important determinant of overall cardiac output in the physiologically normal heart. However, 
this observation is not true for very rapid heart rates or in the presence of certain pathology. 
In atrial fibrillation, the haemodynamic disturbances results essentially from the absence of 
atrial systole and from the rapidity and irregularity of the ventricular response. A sudden 
change to a very rapid heart rate may therefore significantly reduce the diastolic filling interval,
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resulting in a dramatic reduction in cardiac output. This will have particular importance in the 
presence of either valvular stenosis or reduced left ventricular compliance (for example, in left 
ventricular hypertrophy) (Naito et a! 1980). It has also been described that the onset of a rapid 
ventricular response may also lead to a degree of mitral incompetence thus further reducing 
forward flow (Naito et al 1980). The deleterious haemodynamic changes of atrial fibrillation 
have been substantiated by studies showing a significantly improved cardiac output following 
cardioversion of atrial fibrillation to sinus rhythm (Lipkin et al 1988).
Cardioversion from atrial fibrillation to sinus rhythm may therefore have 
haemodynamic advantages. It can be performed electrically, by means of a synchronous 
direct current discharge, or pharmacologically, by the use of a suitable antiarrhythmic drug. 
Electrical cardioversion works by repolarising the errant atrial conduction, restoring ordered 
conduction. During the initial asystolic period, the sino-atrial node rapidly resumes its role as 
cardiac pacemaker. External electrical cardioversion is effective in restoring sinus rhythm in 20 
to 90% of patients but is highly influenced by the underlying aetiology (Levy 1992, Pritchett
1992). The highest recorded success rates are seen in patients with atrial fibrillation 
secondary to hyperthyroidism, whilst the lowest rates are seen in patients with severe mitral 
regurgitation (Levy 1992). In patients who failed external cardioversion, internal cardioversion 
(using electric shocks delivered within the right atrium) is a specialist technique recently 
described, with a success rate of 83% (Levy 1992). Despite the high initial success rates for 
electrical cardioversion, there is often a high rate of reversion to atrial fibrillation without the 
concomitant use of an antiarrhythmic agent. For example, in one study, sinus rhythm was 
maintained in only 69% and 50% of patients at 1 and 6 months respectively (Dittrich et al
1989).
An alternative to electrical cardioversion is pharmacological cardioversion. 
Drugs that are usually employed to maintain sinus rhythm after electrical cardioversion may 
also be effective for pharmacological cardioversion. In addition, the use of prophylactic 
antiarrhythmic therapy has been shown to reduce the recurrence of atrial fibrillation post­
cardioversion (Levy 1992). In general, Class I and Class III antiarrhythmic drugs are the most 
useful agents for pharmacological cardioversion (Pritchett 1992). Class I drugs commonly in
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use are quinidine, flecainide and propafenone. Quinidine, for example, is very effective in 
patients with lone atrial fibrillation, but side effects can occur in 22% (de Nooijer and Sparling 
1990). Flecainide and propafenone are also effective, with a rate of successful cardioversion 
between 25-55% (Clark and Cotter 1993). Amiodarone, a Class III antiarrhythmic drug, has 
been shown to be highly effective in cardioversion of atrial fibrillation, even in previously 
refractory cases (Blevins et al 1987, Noc et al 1990). However, there is concern regarding an 
increased risk of mortality with the use of arrtiarrhythmics, for example, the Class 1 
antiarrhythmic drugs (Echt et al 1991, Repique et al 1992). It should be noted that digoxin is 
no better than placebo for the attempted restoration of sinus rhythm (Falk et al 1987).
Another therapeutic consideration during cardioversion (whether 
pharmacological or electrical) is the use of prophylactic anticoagulation to minimise the risk of 
thromboembolism following cardioversion. It has been estimated that peripheral emboli may 
complicate external cardioversion in 1-3% of cases (Levy 1992). Thromboembolism following 
chemical cardioversion with amiodarone may well have similar rates (Yapa and Green 1990).
Anticoagulant therapy is therefore advised, despite the absence of 
prospective randomised trials on the effectiveness of such therapy, in the cardioversion of 
such patients. However, why these patients should develop thromboembolism is only 
appreciated by an understanding of the underlying mechanisms promoting thromboembolism 
during cardioversion.
Mechanism of thromboembolism
The mechanisms of embolization following cardioversion of atrial fibrillation 
remain to be clearly defined and various possibilities have been suggested. Firstly, a 
mechanical explanation for thromboembolism after cardioversion has been suggested. The 
sudden resumption of mechanical atrial systole may result in the embolisation of any clot 
formed within the left atrium. However, the minimum time for such thrombi to form in the 
fM ating atria is as yet unknown (Mancini and Goldberger 1982), and the mechanisms of 
thromboembolism are not likely to be simply mechanical. In addition, the time for the return of 
atrial systole is variable between individual patients, and can take up to 3 weeks post
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cardioversion (Manning et al 1989). It is therefore suggested that anticoagulant therapy post­
cardioversion should at least be continued until the return of atrial systolic function.
Secondly, abnormalities in haemorheological function and prothrombotic 
markers intrinsic to atrial fibrillation (as discussed and studied by myself in Chapter 3 of this 
thesis) may contribute to the thromboembolic risk post-cardioversion. Indeed, patients with 
chronic atrial fibrillation have abnormalities in plasma fibrinogen and fibrin plasma D-dimer 
levels, as demonstrated in chapter 3 of this thesis and in other work (Kumagai et al 1990, 
Gustafsson et al 1990). Atrial fibrillation is also associated with elevated levels of atrial 
natiuretic peptide, which may contribute to haemoconcentration, a raised haematocrit and 
subsequent thromboembolism and stroke (Petersen et al 1988). However, if the 
mechanisms of thrombo-embolism are not simply mechanical but related to an underlying 
prothrombotic state, serial measurement of suitable markers of thrombogenesis (as 
undertaken in this thesis) may be useful in determining the duration and intensity of 
anticoagulant therapy required.
Another factor which may influence the mechanisms of thromboembolism 
with cardioversion is the left atrial size (Manning et al 1993). Patients with left atrial 
enlargement, for example, are associated with increased spontaneous echo contrast on 
transoesophageal echocardiography, suggesting slow or sluggish blood flow within the 
enlarged atrial cavity (Daniel et al 1988, Manning et al 1993). In addition, spontaneous echo 
contrast has also been noted during paroxysmal atrial fibrillation, and particularly localised to 
the left atrial appendage whereas the remainder of the left atrium was clear (Obarski et al
1990). The rheological mechanism for spontaneous echo contrast is thought to involve the 
presence of fibrinogen, or its products, and red cell aggregation or rouleau formation (Merino 
etal 1992, Sigel et al 1981), thus providing a 'link' between haemorheological abnormalities 
and visual demonstration of flow abnormalities with the left atrium, continuously in chronic 
atrial fibrillation, and intermittently in paroxysmal atrial fibrillation.
Finally, abnormalities in cerebral blood flow may be part of the mechanism for 
thromboembolic stroke following cardioversion. For example, there appears to be increased 
cerebral blood flow after cardioversion from atrial fibrillation to normal sinus rhythm, and this
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may predispose to cerebral embolism in the distribution of the middle cerebral artery 
(Petersen 1990).
The role of anticoagulation
The role of prophylactic anticoagulation in patients with chronic atrial 
fibrillation is now established and is discussed and investigated in chapter 10 of this thesis. 
However, the role of prophylactic anticoagulation to prevent thromboembolism following 
cardioversion, for patients in atrial fibrillation, has not been as intensely investigated. 
Consequently, there is a lack of consensus regarding the need for (and the duration of) such 
therapy before the procedure is undertaken. It is often suggested that the actual conversion 
to sinus rhythm is the actual risk factor for embolic events rather than the duration of atrial 
fibrillation. However, other factors may be important, including the haemorheological and 
prothrombotic abnormalities of atrial fibrillation.
It has been argued that recently formed, poorly adherent thrombus is more 
likely to dislodge at the time of cardioversion, when compared to older thrombus which is likely 
to be more firmly adherent by fibroblastic infiltration (Mancini and Goldberger 1982). An 
estimate of the time required for this infilterative process is approximately 14 days, so 
anticoagulation for this time period might prevent new clot formation and allow the most 
recently formed thrombi to become sufficiently adherent (Mancini and Goldberger 1982). 
However, this time period cannot be precisely defined and is very likely to vary according to 
the haemodynamic status, atrial size and underlying atrial pathology, together with the 
effectiveness of anticoagulation.
The role of prophylactic anticoagulation has been clinically examined in 
several large series. Bjerkelund and Orning (1969) reported a series of 437 patients with atrial 
arrhythmias in whom electrical cardioversion was attempted on 572 occasions: 228 patients 
were on long-term anticoagulant therapy, whilst 209 were not given anticoagulants. Thirteen 
patients (3%) experienced thromboembolic events, with 2 (1.1%) of the 186 patients in the 
anticoagulant group, compared to 11(6.8%) of the 162 patients who were not on 
anticoagulants and were successfully cardioverted (Bjerkelund and Orning 1969). These
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results were statistically significant, demonstrating that prior anticoagulant therapy was indeed 
beneficial in attempted cardioversion. Furthermore, the advantageous effect of warfarin 
occurred despite more patients with congestive heart failure, mitral valve disease and 
hypertension (factors that increase the risk for thromboembolism) being present in the 
anticoagulated group. The thromboembolic events that did occur were predominantly noted 
1 to 6 days following cardioversion, suggesting a 'high risk' period post-cardioversion. 
However, this study was not randomised, and as patients were on chronic anticoagulant 
therapy, the value of short term anticoagulant therapy could not therefore be defined from 
this study. In addition, this study included patients with atrial flutter and atrial tachycardia (in 
addition to atrial fibrillation), although the risk of thromboembolism in these subgroups has not 
been specifically defined (Bjerkelund and Orning 1969).
In another retrospective study of 79 patients who underwent cardioversion, 
none of the 51 patients who received anticoagulant therapy had an embolic event, whilst 2 of 
28 (7%) who were not anticoagulated had an embolic stroke (Weinberg and Mancini 1989). 
Although the numbers are small, their results do support short-term anticoagulant treatment, 
especially in high risk patients (who were defined in this study as patients aged >55 years, 
those with duration of atrial fibrillation >1 year, coronary artery disease, cardiomyopathy, or 
hypertension) (Weinberg and Mancini 1989).
More recently, Arnold et al (1992) retrospectively assessed 454 elective 
direct current cardioversions performed for atrial fibrillation or atrial flutter over a seven year 
period. The incidence of embolic complications was 1.32% (6 patients in total). All six had 
atrial fibrillation, none were on anticoagulants and the duration of atrial fibrillation was <1 week 
in 5 of them (Arnold et al 1992). None of the patients with atrial flutter had thromboembolic 
events confirming the low thromboembolic risk for cardioversion of this subgroup of patients 
(Arnold et al 1992).
Whilst the above-mentioned studies were not randomised, the evidence for 
anticoagulant therapy, prior to cardioversion of atrial fibrillation, appears to be very persuasive. 
Although anticoagulation is relatively safe, effective anticoagulation is not completely free of a 
risk of bleeding complications. Clearly, it would therefore be advantageous to avoid
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unnecessary anticoagulation. New developments are the availability of transoesophageal 
echocardiography, and the availability of plasma prothrombotic markers which may assist 
management (by avoiding anticoagulation) by detecting 'low risk' patients.
Transoesophageal echocardiography is superior to transthroracic 
echocardiography in detecting atrial thrombi, particularly those involving the atrial appendage 
(Manning et al 1993). For example, the sensitivity of transthoracic echocardiography for left 
atrial body and left atrial appendage thrombi has been reported as 78% and 35% respectively 
(Sherman et al 1990). Although the true sensitivity of transoesophageal echocardiography for 
detecting atrial thrombi is unknown, but it is likely to be related to the size of the thrombus and 
the ability to obtain adequate imaging of the atria. It is accepted however that even 
embolization of small thrombi may cause strokes and considerable morbidity. In a small series, 
early cardioversion was performed (in 78 patients) without long term oral anticoagulant therapy 
(but with intravenous heparin for 24 hours), with no excess in embolic events (Manning et al
1993). Larger trials on the use of transoesophageal echocardiography are still required, but 
for the present, it would probably be a useful investigation in patients in whom anticoagulation 
is especially hazardous. However, it should be noted that the mechanisms of thrombo­
embolism following cardioversion are unlikely to be simply mechanical (as discussed above), 
and that the potential for thrombus formation in the initial stages after cardioversion still exists.
Another advance would therefore be the identification of suitable 
prothrombotic markers, which could help in the risk stratification of patients pre- and post- 
cardioversion. Potential markers of thromboembolic risk include plasma fibrinogen and fibrin 
D-dimer (the latter as a marker of intravascular clotting), and this aspect is investigated further 
in this thesis.
Other findings following cardioversion
Following cardioversion, alterations in left atrial size, ventricular function and 
transient electrocardiographic changes (including conduction disturbances and arrhythmias) 
may be encountered. This is pertinent as thrombogenesis is related to dilated cardiac
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chambers and ventricular dysfunction; the latter may also be adversely affected by 
arrhythmias.
There is evidence that cardiac output and exercise capacity may be 
significantly improved following successful cardioversion to sinus rhythm (Alam and 
Thorstrand 1992, Atwood et al 1989, Lipkin et al 1988). These benefits may be due to a 
combination of a reduction in heart rate and the restoration of atrial systole. The former 
contributes to greater diastolic filling time, coronary flow and reduced myocardial oxygen 
demand; whilst the latter contributes to increased ventricular filling (Alam and Thorstrand 
1992, Atwood et al 1989, Khaja and Parker 1972). Atrial contraction may also contribute to 
improved mitral and tricuspid valve closure with diminution of valvular insufficiency, resulting in 
improved cardiac performance (Atwood et al 1989, Khaja and Parker 1972). Rarely, however, 
acute pulmonary oedema following cardioversion has been described, especially in patients 
with pre-existing left ventricular impairment (Levy 1992).
Following cardioversion, there is also a reduction in left atrial size with the 
restoration of atrial systole (Alam and Thorstrand 1992, Manning et al 1989, Van Gelder et al 
1991c). Full recovery of atrial mechanical activity may not, however, occur immediately 
following cardioversion. The resumption of atrial activity may be delayed for days despite the 
electrocardiogram (ECG) showing immediate onset of sinus P waves (Mancini and Goldberger 
1982). In a pulsed Doppler evaluation of atrial mechanical function post-cardioversion, peak A 
wave velocity and percent atrial contribution to total left ventricular filling did not return to 
normal until 3 weeks after cardioversion (Manning et al 1989). This finding may have 
implications for the onset of any clinical benefit (from the restoration of atrial systole) in 
patients with heart failure, and the delineation of any 'risk period' for thromboembolism (as if 
atrial systolic function is still suboptimal, patients may continue to be at risk for atrial thrombus). 
A further study does suggest, however, that the degree of atrial mechanical activity following 
cardioversion may be very variable and embolic episodes are not necessarily related to this 
delayed return of atrial mechanical activity following cardioversion (O'Neill et al 1990).
In general, arrhythmias post-cardioversion are due to either inadequate 
synchronisation or digoxin toxicity (Clark and Cotter 1993). The majority of these abnormal
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rhythms are atrial in origin and trivial (Lown 1967). For example, premature beats and 
conduction disturbances (first or second degree AV block) are also common (Lown 1967). 
Ventricular arrhythmias following cardioversion are less common but more serious. The most 
frequent of these is ventricular fibrillation, which may be induced in about 1% of cases but is 
usually reverted by repeat shock (Levy 1992). In addition, postcardioversion transient ST 
segment elevation may occur, usually related to previous pericardiotomy and age (Van Gelder 
et al 1991a). These ST segment changes were associated with an unfavourable arrhythmia 
prognosis, with a lower conversion rate (48% vs 76%) and diminished long-term maintenance 
of sinus rhythm (Van Gelder et al 1991a). They do not, however, indicate myocardial 
infarction, although small rises in creatine kinase may occur with electrical cardioversion. The 
enzyme usually arises from skeletal muscle and myocardial damage is unlikely, which is 
confirmed by radionuclide studies (Metcalfe et al 1988).
Post cardioversion management
Following successful cardioversion to sinus rhythm, it is important to continue 
with oral anticoagulants and possibly antiarrhythmic therapy. The latter is to maintain sinus 
rhythm and prevent arrhythmia recurrence.
Briefly, current practice favours the maintenance of oral anticoagulation 
following cardioversion (Clark and Cotter 1993). The risk of embolism continues even after 
successful cardioversion (Bjerkelund and Orning 1969) as atrial mechanical function may not 
be restored for several weeks (Mancini and Goldberger 1982). The optimal duration of 
anticoagulation is, as yet, unclear. Recent recommendations by the American College of 
Chest Physicians include (i) the administration of warfarin for 3 weeks before elective 
cardioversion of atrial fibrillation of > 3 days’ duration; (ii) continuation of warfarin therapy for 
two to four weeks after cardioversion; (iii) administration of intravenous heparin followed by 
warfarin if cardioversion cannot be postponed for 3 weeks; and (iv) no anticoagulant therapy 
for atrial fibrillation of < 2 days' duration or for atrial flutter (Dunn et al 1989).
Maintenance of sinus rhythm following cardioversion requires the use of 
antiarrhythmic drugs such as sotalol, quinidine or amiodarone (Juul-Moller et al 1990). The
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sequential use of different types of antiarrhythmic drugs may improve arrhythmia prognosis in 
chronic atrial fibrillation or flutter after successful cardioversion (Crijns et al 1991). For 
example, in a study of 127 patients undergoing cardioversion, serial drug treatment initially 
with flecainide (Stage I), followed by quinidine or sotalol if recurrence occurred (Stage II), and 
eventually amiodarone (Stage III), the two-year proportion of arrhythmia-free patients 
increased from 31% at Stage I to 63% at the end of serial treatment (Crijns et al 1991).
Prognosis following cardioversion
Predictors of refractoriness to cardioversion or unsuccessful maintenance of
sinus rhythm include the following: age, duration of arrhythmia, the presence of
hypertension, valve disease and other organic heart disease.
An older age, in combination with a large number of previous episodes of
arrhythmia, a long previous duration of arrhythmia and the presence of mitral valve disease,
were predictive of the unsuccessful maintenance of sinus rhythm (Crijns et al 1991, Dethy et 
al 1988, Mancini and Goldberger 1982, Van Gelder et al 1991b). In addition, the presence of 
coronary artery disease, hypertension and organic disease (such as mitral valve disease, aortic 
stenosis and cardiomyopathy) are detrimental factors for the maintenance of normal sinus 
rhythm following cardioversion (Mancini and Goldberger 1982, Van Gelder et a) 1991c). In a 
Doppler echocardiographic study, a slow increase (<10% in first 24 hours) in the magnitude of 
A wave post-cardioversion was also predictive for the recurrence of atrial fibrillation (Dethy et al 
1988).
The effects of left atrial size are less certain. In a small study (50 patients), a 
left atrial dimension of > 45mm was important, and had a positive predictive value of 66% for 
recurrence of atrial fibrillation (Dethy et al 1988). However, recent studies have, in contrast, 
demonstrated the converse (that is, left atrial size does not appear to influence outcome 
following cardioversion) (Brodsky et al 1989, Dalzell et al 1990, Dittrich et al 1989, Van Gelder 
et al 1991c). In these studies, duration of atrial fibrillation was the most important predictor for 
outcome following cardioversion. In another study of 100 patients, left atrial volume and other 
standard echocardiographic parameters (left atrial area, M-mode left atrial dimension, left
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ventricular ejection fraction or left ventricular mass) were not predictive of recurrent atrial 
fibrillation in patients successfully cardioverted (Truitte et al 1993). These studies suggest 
therefore that atrial size does not strongly influence outcome of cardioversion and patients 
should not be excluded on these grounds from consideration of cardioversion (Van Gelder et 
al 1991c). Even in the presence of a dilated left atrium, long term sinus rhythm (79% at 12 
months) is possible with the use of antiarrhythmic drugs (Brodsky et al 1989).
In general, factors accepted as predicting a high degree of success for 
cardioversion can therefore be identified, and these are summarised in Table 1 (Alpert et al
1988). Proper selection of patients may therefore improve the cost-benefit ratio of attempted 
cardioversion.
Conclusion
Cardioversion to sinus rhythm should be considered for all patients in atrial 
fibrillation in order to improve cardiac performance and to reduce the long-term risk of 
thromboembolic complications. Anticoagulant therapy begun before elective cardioversion is 
advised although data demonstrating the most effective regimen is still lacking. Until then, 
anticoagulant therapy should ideally be administered two to three weeks prior to and for at 
least two to three weeks following cardioversion. In emergency cases, anticoagulation should 
be commenced with full heparinisation together with warfarin on the day of cardioversion and 
continued for a further four weeks to reduce the possibility of late thromboembolism.
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TABLE 4.1
FACTORS AFFECTING THE EASE OF 
CONVERSION FROM ATRIAL FIBRILLATION AND 
MAINTENANCE OF SINUS RHYTHM
(adapted from Alpert et al 1988)
Beneficial factors 
Short duration of atrial fibrillation 
Minimal left atrial dilatation 
Large T waves in the ECG 
Absence or mild left ventricular failure 
Age < 50 years
Unfavourable factors  
Long duration of atrial fibrillation 
Marked left atrial dilatation 
Diminutive or absent T wave in the ECG 
Marked left ventricular failure 
Age > 50 years
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4.2 STUDIES OF PLASMA FIBRINOGEN AND D-DIMER IN PATIENTS WITH 
ATRIAL FIBRILLATION : THE EFFECTS OF CARDIOVERSION TO SINUS 
RHYTHM
Introduction
As patients with atrial fibrillation have a potentially serious cardiac arrhythmia, 
cardioversion from atrial fibrillation to sinus rhythm is often considered as a therapeutic option. 
However, if patients with atrial fibrillation are successfully cardioverted to sinus rhythm, their 
overall thromboembolic risk, as measured by plasma prothrombotic markers (fibrinogen and D- 
dimer), may be significantly altered by the change in cardiac rhythm.
This thesis investigates the thrombogenic potential in atrial fibrillation and as 
there is clinical evidence that the actual procedure of cardioversion is associated with a 
significant thromboembolic risk (Arnold et al 1992, Bjerkelund and Orning 1969, Weinberg 
and Mancini 1989), there may be a potential role for plasma markers (fibrinogen, D-dimer) in 
assessing this. In particular, the highest thromboembolic risk has been clinically noted in the 
first six days following cardioversion, suggesting that there may well be a 'high risk' period 
following this procedure (Bjerkelund and Orning 1969). Prophylactic anticoagulant therapy 
has therefore been advised to minimise the risk of thromboembolism.
Guidelines on anticoagulation during cardioversion have been 
recommended by the American College of Chest Physicians, as discussed above (Dunn et al
1989). Despite this, there continues to be wide variation between cardiologists in policy 
regarding anticoagulation therapy before cardioversion. In particular, there is debate over 
when (and in whom) to start anticoagulation pre-cardioversion and for how long such therapy 
should be maintained post-cardioversion.
The aim of this study therefore was to undertake serial samples of plasma 
fibrinogen and fibrin D-dimer in patients, with atrial fibrillation, who underwent cardioversion in 
our unit, to determine any change in these plasma markers of thromboembolic risk and define 
any ’high risk* period for this risk postcardioversion.
Methods
All patients with atrial fibrillation undergoing cardioversion to sinus rhythm 
were selected for study. In our Coronary Care Unit, there was a variation in individual policy 
regarding the use of anticoagulation therapy prior to cardioversion which allowed investigation 
in different settings. Two different regimens were employed by the four different 
cardiologists in charge of the Coronary Care Unit for the week: Regime (i) anticoagulation prior 
to (usually for about two or more weeks), and for two or more months following cardioversion; 
and regime (ii) intravenous heparin for the day (24 hours) of cardioversion only with no oral 
anticoagulant therapy pre or post cardioversion. This variation allowed a study of the 
difference in thrombogenic potential between the two regimes, as assessed by measurement 
of prothrombotic markers. Patients with atrial flutter were considered at low thromboembolic 
risk during cardioversion and were excluded from this study.
Prior to the procedure, all patients underwent echocardiography by myself 
primarily to exclude the presence of intracardiac thrombus and to determine cardiac function. 
All patients underwent either electrical or pharmacological cardioversion, decided on clinical 
grounds by the consultant in charge. Electrical cardioversion was performed following 
induction of a light general anaesthesia (preoxygenation and intravenous etomidate 300 
mcg/kg in aliqouts to achieve anaesthesia) with an initial synchronised direct current shock at 
50 Joules. In no instance was endotracheal intubation necessary. If unsuccessful, the 
procedure was repeated with successively higher energies (100 Joules, 200J, 30QJ, 360J) 
up to a maximum of two 360 Joule shocks. If pharmacological cardioversion was attempted, 
intravenous amiodarone (5mg/kg over 30 minutes, followed by an infusion of 1.2g over 24 
hours) was used in all cases. All patients underwent monitoring in the coronary care unit 
during the procedure.
As previously described (in chapter 3), blood samples were taken 
atraumatically and placed in citrate tubes (trisodium citrate 0.11M, 9:1 v:v). The plasma was 
immediately separated and frozen at -40 °C. Blood samples were taken pre-cardioversion, 
and also at 3 days, 7 days and 14 days post cardioversion and assayed for fibrinogen and D- 
dimer, as previously described. In patients on warfarin therapy, a Thrombotest or INR
(International Normalised Ratio) was measured to ensure a satisfactory level of 
anticoagulation. Initial plasma levels of fibrinogen and D-dimer of patients in Group I (no 
warfarin) were compared with normal population values derived from 158 patients in sinus 
rhythm sampled from a random population survey (2nd North Glasgow MONICA study), as in 
chapter 3.
All the values of the blood measurements were expressed as median ± 
interquartile range (IQR). Statistical comparison was performed using the Mann-Whitney test and 
two-sample paired Wilcoxon test for non-parametric distributions. A probability of <0.05 was 
considered statistically significant for paired comparisons.
Results
A total of 19 patients (14 male, 5 female) in atrial fibrillation were admitted to 
our Coronary Care Unit for elective cardioversion over a one year period: 7 patients (5 male, 2 
female; mean age 60.3 years, range 50 to 72 years, s.e.m. 3.71) were on no anticoagulant 
therapy (Group I), whilst 12 patients (9 male, 3 female; mean age 60.2 years, range 41 to 72 
years, s.e.m. 2.70) had anticoagulant therapy pre- and post-cardioversion (Group II).
Echocardiography was performed in all patients. There was no evidence of 
intracardiac thrombus in any patient. Cardioversion was attempted in all patients - in Group I, 3 
patients underwent electrical cardioversion, whilst 4 underwent pharmacological 
cardioversion; in Group II, 8 underwent electrical cardioversion, whilst 4 underwent 
pharmacological cardioversion. Cardioversion was considered unsuccessful in 4 cases (3 
male, 1 female) from Group II with a reversion to atrial fibrillation within 24 hours whilst as an 
inpatient. These patients were excluded from further analysis, which was therefore 
performed on 8 patients in Group II (6 male, 2 female; mean age 64.6 years, range 54-72 
years, s.e.m. 2.31). Patient characteristics are summarised in Table 4.2. One patient from 
Group II reverted to atrial fibrillation at the two-week follow-up visit - no blood sample was 
therefore taken at this visit. There were no instances of systemic thromboembolism in any 
patient.
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In Group I (no warfarin), pre-cardioversion plasma fibrinogen and fibrin D-dimer 
levels were significantly elevated when compared to population controls in sinus rhythm 
(point estimate of difference between medians; for plasma fibrinogen 0.59 g/l; 95% C.l. 0.06 
to 1.25, Mann-Whitney test p=0.03; for plasma D-dimer 98 ng/ml; 95% C.l. 15 to 150, 
p=0.01) (Tables 4.3, 4.4). In Group II (warfarin), pre-cardioversion plasma fibrinogen was not 
significantly different when compared to similar patients in Group I (no warfarin) (point estimate 
of difference between medians 0.58 g/l; 95% C.l. -1.42 to 0.59, p=NS) (Table 4.3). However, 
patients in Group I (no warfarin) had increased plasma D-dimer levels when compared to similar 
patients in Group II (warfarin therapy) (point estimate of difference between medians 109 
ng/ml; 95% C.l. 13 to 193, p=0.03) (Table 4.4).
In Group I (no warfarin), there were no significant changes in plasma 
fibrinogen at Day 3, Day 7 or Day 14 (p=NS) following cardioversion (Table 4.3, Figure 4.1). 
Sequential measurements of plasma fibrin D-dimer following cardioversion also demonstrated 
no significant differences at Day 3 or Day 7, but there was however a significant reduction of 
median plasma D-dimer at Day 14 (200 ng/ml vs 42 ng/ml, paired Wilcoxon test p=0.02) (Table 
4.4, Figure 4.1). This was a median reduction of plasma D-dimer by 69% (95% c.i. 31% to 
79%) in these patients.
In Group II there were no significant differences in median plasma fibrinogen 
or fibrin D-dimer at Day 3, day 7 or Day 14 post cardioversion (Tables 4.3, 4.4; Figure 4.2).
When patients from Group I and II were analysed together (n=15; mean age 
62.6; range 50-72; s.e.m. 2.1) they had an elevated median plasma fibrinogen when 
compared to population controls (median difference 0.89g/l; 95%c.i. 0.48 to 1.29, 
p=0.0001). However there was no significant difference between plasma fibrinogen at Day 
14 post cardioversion when compared to pre-cardioversion levels (3.56 vs 3.69g/l; paired 
Wilcoxon p=0.68).
Discussion
The mechanisms by which many patients with atrial fibrillation develop either 
intracardiac thrombus or systemic embolism following cardioversion remain uncertain. For
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example, emboli may be due to pre-existing thrombus, which is dislodged by the mechanical 
effect of a change in rhythm during cardioversion. If these mechanisms are not simply 
mechanical (which is likely) then merely cardioverting a subject back into sinus rhythm may not 
immediately reduce the risk until other associated factors (for example, plasma fibrinogen and 
other rheological factors) have been substantially normalised. This is particularly pertinent as 
normal haemodynamics would be expected to return (with 'normal' flow characteristics) as atrial 
systole eventually resumes following cardioversion. However, this may be an 
oversimplification as in the early post-cardioversion period, atrial asystole may still be present, 
leading to intra-atrial stasis, thus promoting thrombogenesis.
In this study, no significant differences in plasma fibrinogen levels are 
demonstrated, however, when pre-cardioversion levels are compared to levels at Day 14. It is 
long recognised that there is individual variation in the return of atrial systolic function, which 
can take up to three weeks to return fully following cardioversion (Manning et al 1989). During 
the period before the return of atrial systolic function, the patient may still be at risk of forming 
intracardiac thrombus. This 'delay1 may therefore account for the lack of any significant 
reduction in plasma fibrinogen levels in these patients at two weeks following cardioversion. 
As plasma fibrinogen is associated with increased cardiovascular and thromboembolic risk, my 
results therefore suggest that caution should be employed in withholding anticoagulant 
therapy in patients being considered for cardioversion. In fact, this study substantiates the 
feeling that anticoagulation should be continued for some time after cardioversion in all 
patients. Another argument for prolonged anticoagulation is the fact that several patients will 
revert back to atrial fibrillation following cardioversion.
This study however demonstrates a significant reduction in plasma fibrin D- 
dimer following cardioversion of atrial fibrillation to sinus rhythm in patients who were not on 
any oral anticoagulant therapy. As plasma fibrin D-dimer is a marker of ongoing fibrin turnover 
and intravascular thrombus formation, this study demonstrates that these processes are 
reduced in patients following cardioversion (at two weeks) to sinus rhythm. Although clinical 
studies have demonstrated a rise in thromboembolic risk in the first six days after 
cardioversion (Bjerkelund and Orning 1969) there was no significant elevation in plasma fibrin
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D-dimer at Day 3 and Day 7 following cardioversion in this study. This suggests that any 
thromboembolic event (as suggested in clinical studies) is likely to be due to preformed 
thrombus rather than formation of actual new thrombus. Longer term studies are possibly 
therefore required to assess any further changes in plasma fibrinogen and D-dimer following 
cardioversion in patients who are not anticoagulated. As there is now increasing evidence for 
the routine use of anticoagulation therapy pre- and post-cardioversion, there remains an 
ethical consideration if warfarin is to be withheld from these patients in any further study. 
(Following the initial results of this study, new guidelines for full anticoagulation pre- and post 
cardioversion have since been implemented in our coronary care unit).
In patients taking warfarin therapy before and after cardioversion, there were 
no significant differences in plasma fibrinogen or D-dimer following cardioversion to sinus 
rhythm. Warfarin therapy therefore beneficially reduces the processes of fibrin turnover and 
thrombogenesis (as indicated by plasma D-dimer levels) in patients with atrial fibrillation 
resulting in a ’low' thrombogenic state prior to cardioversion. These results are also consistent 
with my findings in chapter 3 demonstrating higher plasma fibrin D-dimer in patients with atrial 
fibrillation when compared to similar patients in sinus rhythm.
This study therefore gives additional evidence to the long term advantages in 
reducing thromboembolic risk by the cardioversion from atrial fibrillation to sinus rhythm. This 
study also reinforces the view that warfarin therapy prior to cardioversion would be 
advantageous in minimising the potential thromboembolic risk.
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TABLE 4.2
CARDIOVERSION OF ATRIAL FIBRILLATION 
- PATIENT CHARACTERISTICS
GROUP I GROUP II WHOLE GROUP
no warfarin anticoagulation
8 15
age 
mean (s.e.m.)
60.3
(3.7)
64.6
(2.3)
62.6
(2 .12)
sex (M:F) 5:2 6:2 11:4
body mass 
index 
(kg/m2) 
median (IQR)
36.1
(35.7-40.1)
37.8
(22.8-38.8)
36.9
(35.7-38.8)
left atrial 
dimension 
mm 
median (IQR)
4.24
(3.64-4.34)
4.36
(4.15-4.7)
4.28
(4.06-4.5)
left atrial volume 
(ellipsoid) 
mm3 
median (IQR)
41.4
(24.3-49.3)
40.5
(33.9-47.5)
40.9
(32.4-47.6)
LV fractional 
shortening
%
median (IQR)
23.8
(22.0-29.5)
27.2
(20.4-33.8)
24.0
(22.0-33.4)
[only successfully cardioverted patients are tabulated]
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TABLE 4.3 
PLASMA FIBRINOGEN LEVELS AND 
CARDIOVERSION OF ATRIAL FIBRILLATION
median (IQR) g/l
Precardioversioni Day 3 Day 7 Day 14
GROUP I 3.0 3.41 3.07 3.18
(2.63-3.97) (2.58-4.75) (2.63-3.5) (2.75-4.2)
GROUP II 3.62 3.93 4.06 3.58
(3.41-4.08) (3.23-4.29) (3.03-4.57) (3.42-4.04)
W HOLE 3.60 3.69 3.50 3.56
GROUP (2.83-4.05) (3.16-4.350 (2.76-4.22) (2.96-4.1)
Median plasma Fibrinogen values for population controls (n=158): 2.6g/l (IQR 2.24-2.99)
(p=NS)
TABLE 4.4 
PLASMA D-DIMER LEVELS AND 
CARDIOVERSION OF ATRIAL FIBRILLATION
median (IQR) ng/ml 
Precardioversion Day 3 Day 7 Day 14
GROUP I 200 188 142 52*
(63-223) (56-142) (49-208) (30-74)
GROUP II 47 48 62 47
(33-99) (32-75) (32-84) (30-111)
Median plasma D-Dimer values for population controls (n=158): 76mg/dl (IQR 53-103) 
(*p<0.05 when compared to pre-cardioversion levels)
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FIGURE 4.1 (a) 
CARDIOVERSION AND PLASMA FIBRINOGEN IN 
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FIGURE 4.1 (b) 
CARDIOVERSION AND PLASMA D-DIMER IN 
ATRIAL FIBRILLATION
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FIGURE 4.2 (a) 
CARDIOVERSION AND PLASMA FIBRINOGEN IN 
ATRIAL FIBRILLATION
(warfarin group)
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CARDIOVERSION AND PLASMA D-DIMER IN 
ATRIAL FIBRILLATION
(warfarin group)
CHAPTER 5
THROMBOGENESIS IN 
PAROXYSMAL 
ATRIAL FIBRILLATION
Introduction
The importance of paroxysmal atrial fibrillation as a thromboembolic risk factor has 
been relatively neglected. In addition, the effective use of antiarrhythmic therapy and the role of 
prophylactic anticoagulation therapy in this condition remain controversial areas.
As the management of this common condition is often difficult, I shall initially 
review the current management of paroxysmal atrial fibrillation and this will be followed by a study 
of thrombogenesis in such patients.
5.1 A REVIEW OF THE MANAGEMENT OF PAROXYSMAL ATRIAL FIBRILLATION
Introduction
Patients with atrial fibrillation can be divided into a group permanently in atrial 
fibrillation ("chronic atrial fibrillation") and a group with sinus rhythm punctuated by attacks of atrial 
fibrillation ("paroxysmal atrial fibrillation"). The two groups overlap, however, as many patients with 
chronic atrial fibrillation first present with paroxysmal atrial fibrillation (Kopecky 1987) and patients 
with paroxysmal atrial fibrillation may occasionally revert to sinus rhythm (Chevalier 1979, Olsson et 
al 1980). In one series, 25% of patients with paroxysmal atrial fibrillation and normal hearts 
progressed to chronic atrial fibrillation within a year (Takahashi et al 1981).
Paroxysmal atrial fibrillation, however, remains one of the commonest arrhythmias, 
one of the least understood and one of the most difficult to treat. The condition is more prevalent 
in the elderly and can be associated with underlying structural heart disease including mitral valve 
disease or congenital heart disease, ischaemic heart disease, sick sinus syndrome, hypertension 
or thyrotoxicosis, in a similar way to chronic atrial fibrillation. There is a tendency therefore to treat 
this paroxysmal atrial fibrillation in a similar fashion to chronic atrial fibrillation. However, the 
pathophysiology of paroxysmal atrial fibrillation is different, and drugs such as digoxin, which are 
commonly used in chronic atrial fibrillation, are of limited value in paroxysmal atrial fibrillation. In 
addition, a broad range of clinical features may occur and even in the asymptomatic patient, there
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is concern about the risk of serious thromboembolic events. In practice, effective control of 
paroxysms is often difficult and the role of anticoagulation remains controversial.
Pathophysiology and clinical features
The haemodynamic disturbance of atrial fibrillation results essentially from the 
absence of atrial systole ('atrial kick*) and from the rapidity and irregularity of the ventricular 
response, with a consequent loss of cardiac output. The presence of atrial fibrillation is associated 
with a fall in cardiac stroke output of approximately 10% in normal individuals (Broch and Muller 
1957). This is more important with increasing age and/or progressive impairment of left ventricular 
contraction, as atrial systole contributes an increasing amount towards overall stroke volume. 
Loss of this sequential atrio-ventricular contraction mechanism, in association with a rapid and 
irregular ventricular response during a paroxysm of atrial fibrillation, reduces the diastolic filling 
interval and can therefore lead to a dramatic reduction in cardiac output. This is substantiated by 
evidence of a significantly improved cardiac output following cardioversion of atrial fibrillation to 
sinus rhythm (Lipkin et al 1988).
For these reasons, many patients, following the onset of a paroxysm of atrial 
fibrillation, experience not only palpitation but often a combination of presyncope, syncope, 
fatigue, dyspnoea and lethargy. Occasionally pulmonary oedema, angina or even cerebral 
impairment may be precipitated. Indeed, paroxysmal atrial fibrillation may be associated with 
considerably more disabling symptoms than chronic atrial fibrillation, due to the very rapid heart 
rates during the arrhythmia.
M anagem ent
Arrhythmia control
One of the most important principles of arrhythmia control is to treat only 
symptomatic patients. If a patient is experiencing only mild and infrequent symptoms it is 
advisable to try and avoid antiarrhythmic drug therapy if at all possible (Singh et al 1991). This
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management stratagem is justified by evidence of substantial morbidity associated with 
antiarrhythmic therapy and the concern over worsened long-term prognosis, particularly with 
Class I agents (Pritchett 1992, Singh et al 1991). General measures should always be 
contemplated, for example, withdrawal of caffeine or alcohol, stress counselling and consideration 
of conditions which may benefit from atrial pacing, for example, sick sinus syndrome. It is also 
important to distinguish between atrial fibrillation and atrial flutter as there are important 
management differences between these two conditions.
Digoxin
Of the antiarrhythmic drugs in use, digoxin continues to be commonly prescribed 
in paroxysmal atrial fibrillation, in an attempt to both suppress the arrhythmia and to control the 
initial heart rate if any such paroxysms occur (Falk and Leavitt 1991). Although it remains an 
effective treatment for chronic atrial fibrillation, its use in paroxysmal atrial fibrillation is more 
controversial and may even be detrimental (Falk and Leavitt 1991, Galun et al 1991, Rawles et al 
1990).
In fact, clinical evidence has shown that paroxysms of atrial fibrillation occur more 
frequently and for significantly longer in patients receiving digoxin (Galun et al 1991, Rawles et al
1990). Furthermore, during an episode of paroxysmal atrial fibrillation, the initial heart rate appears 
no better controlled whether or not digoxin is being taken (Galun et al 1991, Rawles et al 1990). 
The mechanism for this is unclear but digoxin increases vagal tone, moderating the speed of atrio­
ventricular conduction, and also reduces the atrial refractory period. This latter property may 
paradoxically render the atrium more susceptible to fibrillation and may reduce or even prevent the 
chance of reversion to sinus rhythm (Rawles et al 1990).
Verapamil
Another commonly prescribed drug, verapamil increases atrioventricular block 
and the effective refractory period of the atrioventricular node. This results in control of the
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ventricular rate in sustained atrial fibrillation and may lead to significantly improved exercise 
capacity (Klein and Kaplinsky 1982).
Whilst occasionally effective in converting atrial fibrillation to sinus rhythm, 
verapamil has, however, a much lower rale of conversion than either amiodarone, flecainide, 
propafenone or esmolol (Kondili et al 1990, Noc et al 1990, Platia et al 1989, Suttorp et al 1989). 
Although this is obviously indirect evidence, these studies nevertheless suggest that verapamil 
may be relatively ineffective in controlling paroxysmal atrial fibrillation. In addition, its administration 
to patients with underlying Wolf-Parkinson-White syndrome who present with paroxysmal atrial 
fibrillation may occasionally lead to serious adverse effects, including ventricular fibrillation and 
severe haemodynamic impairment (Strasberg et al 1989).
Class I antiarrhythmics
Class I antiarrhythmics remain popular drugs for use in paroxysmal atrial fibrillation. 
It is important, however, to distinguish between paroxysmal atrial fibrillation and flutter, as the use 
of a Class 1 agent (for example, quinidine, disopyramide and flecainide) in patients with atrial flutter 
may accelerate the ventricular response with a 1:1 atrioventricular conduction (Nathan et al 1984, 
Singh et al 1991). This may be due in part to the slowing in atrial rate and the anticholinergic 
effects (especially with disopyramide and quinidine) which result in an increase in atrioventricular 
conduction (Nathan et al 1984, Singh et al 1991). With atrial flutter it is therefore advisable to co­
administer these agents with digoxin, beta-blocker or verapamil to avoid the potential for the 
accelerated atrioventricular conduction (Nathan et al 1984, Singh et al 1991).
Quinidine remains a frequently used Class la drug especially in North America for 
maintaining sinus rhythm after cardioversion or for reducing the number of paroxysms of atrial 
fibrillation (Pritchett 1992). This stratagem is supported by a meta-analysis of six controlled trials 
which showed that patients treated with quinidine were less likely to have a recurrence of atrial 
fibrillation (Coplen et al 1990). Importantly however this analysis also demonstrated an excess of 
mortality for the treated group - total mortality in the quinidine group (12 deaths) was significantly
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higher than in the control group (3 deaths) (Coplen et al 1990). Quinidine therapy also interacts 
with concurrent digoxin administration and is associated with serious side effects such as 
precipitation of polymorphic ventricular tachycardia, blood dyscrasias and cinchonism (Singh et al
1991).
Another Class 1a drug, disopyramide, may also prevent recurrences of 
paroxysmal atrial fibrillation but its effects are inconsistent (Ito et a) 1989). It is also poorly 
tolerated, particularly in the elderly and those with glaucoma and prostatism, due primarily to its 
profound anticholinergic properties (Singh et al 1991). Procainamide also shares some 
electrophysiological properties with quinidine and disopyramide, but to date there have been no 
placebo-controlled studies of this drug (Pritchett 1992).
In contrast, Class Ic antiarrhythmics such as flecainide have been well 
investigated. They have very potent effects on conduction within cardiac cell membranes and 
lengthen the PR interval and QRS complex on the electrocardiogram. Flecainide, for example, 
has been shown to be effective in preventing recurrences of paroxysmal atrial fibrillation in up to 
60% of patients but the drug does not limit the ventricular response (Sonnhag et al 1988). 
Studies of flecainide have also confirmed a significant increase in the median length of time to first 
recurrence of atrial fibrillation (Anderson et al 1989, Pietersen and Hellemann 1991). Adverse 
effects have been reported in up to 74% of patients, but these were mostly tolerable (Anderson 
et al 1989, Pietersen and Hellemann 1991). Nevertheless, doubts on the safety of flecainide 
have been raised by the Cardiac Arrhythmia Suppression Trial, in which patients (post myocardial 
infarction) given flecainide for ventricular arrhythmias had a worsened prognosis (Echt et al 1991). 
The risks to patients with atrial fibrillation and other supraventricular arrhythmias, however, are not 
known (Pratt et al 1990).
Propafenone, another class Ic compound, may also be effective in paroxysmal 
atrial fibrillation (Connolly and Hoffert 1989, Pritchett et al 1991). This is particularly pertinent in 
view of its inherent rate limiting (class II) properties, allowing potentially greater ventricular rate 
control. In one study, however, of 50 patients with paroxysmal atrial fibrillation, flecainide was
134
found to be more effective than propafenone in converting patients to sinus rhythm (with a 90% 
vs 55% conversion rate to sinus rhythm respectively) (Suttorp et al 1990). Propafenone has also 
been compared to sotalol and both are equally effective in maintaining sinus rhythm in patients 
with recurrent atrial fibrillation (Reimold et al 1993).
Class III antiarrhythmics
Sotalol, another commonly prescribed drug, combines both Class II (beta 
blockade) and Class III (prolongation of repolarisation) antiarrhythmic effects. This latter property is 
thought mainly due to the dextro (d) isomer of the sotalol compound (Kato et al 1986, Lynch et al 
1985). There is little evidence, however, substantiating the efficacy of sotalol specifically in 
paroxysmal atrial fibrillation. Both the conventional racemic mixture and d-sotalol have been found 
effective in generally treating paroxysmal supraventricular tachycardias (Sahar et al 1989). Sotalol 
also appears effective in controlling the ventricular response in atrial fibrillation (Juul-Mbller et al
1990).
Another Class III drug, amiodarone, is a very effective drug for the treatment of 
paroxysmal atrial fibrillation but its use has to be moderated by its potentially serious, albeit 
relatively rare, side effects (Singh et al 1991). These are, however, more common with higher 
doses of amiodarone and with prolonged therapy, although some side effects may be reversible 
on withdrawal of the drug (Singh et al 1991). Nevertheless, amiodarone is of particular value in 
paroxysmal atrial fibrillation for treating patients refractory to other measures, and low doses (often 
much less than those required for the control of ventricular arrhythmias) may be effective with little 
risk of side effects. For example, amiodarone has been shown to be highly effective in converting 
paroxysmal atrial fibrillation to sinus rhythm (Noc et al 1990) and has been shown to be capable of 
maintaining sinus rhythm long-term (Blevins et al 1987). Amiodarone also appears more effective 
than either verapamil (Noc et al 1990) or quinidine (Vitolo et al 1981) and is highly effective in 
controlling symptoms possibly by moderating the ventricular response even if an attack occurs 
(Horowitz et al 1985). The drug can be used both orally and intravenously, and unlike oral
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administration (which has a slow onset of action due to the long half-life of the drug), intravenous 
amiodarone may act relatively rapidly (Singh et al 1991). However, there are seldom indications for 
the use of a rapid loading regimen using intravenous amiodarone in the suppression of 
paroxysmal atrial fibrillation. Care should also be taken when using amiodarone as it can 
significantly increase the plasma concentrations of digoxin thereby leading to potential toxicity 
(Singh et al 1991). It can also lead to overanticoagulation in patients taking warfarin, perhaps by a 
hepatic interaction (Hamer et al 1982).
Non-drug therapy
If paroxysmal atrial fibrillation is part of the spectrum of the sick sinus syndrome 
then permanent pacemaker implantation should be considered. Either an atrial or dual chamber 
pacemaker should be used, dependent upon the integrity of the atrio-ventricular pathway. This is 
further discussed below. If successful control of the arrhythmia cannot be achieved then, as a last 
resort, ablation of the atrioventricular node (with concomitant implantation of a rate-responsive 
permanent pacemaker) could be contemplated (Egorov et al 1990, Zipes 1992a).
Surgical therapy for paroxysmal atrial fibrillation has also been advocated but 
although effective, it is unlikely (at least in the United Kingdom) to become a generally useful 
therapeutic option except for specific groups (Cox et al 1991, Defauw et al 1992, Leitch et al
1991). The two most promising surgical options are the 'corridor' and 'maze' procedures. The 
'corridor' procedure effectively isolates both left and right atria, leaving a strip of myocardium 
connecting the sinus node to the atrioventricular node (Defauw et al 1992). This procedure does 
not prevent atrial fibrillation, but essentially 'isolates' the fibrillating atria from a strip of tissue 
connecting the sinus and atrioventricular nodes. In contrast, the 'maze' procedure attempts to 
completely prevent atrial fibrillation by channelling the atrial activation between a series of incisions 
(Cox et al 1991). This latter procedure therefore restores coordinated atrial as well as ventricular 
electrical activity, allowing atrial transport with good haemodynamic results and low
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thromboembolic risk. Initial reports from these procedures are encouraging, but post-operative 
pacemaker implantation may still be necessary (Defauw et al 1992).
Sick sinus syndrome
One condition commonly associated with paroxysmal atrial fibrillation is sick sinus 
syndrome. Management of this condition deserves special discussion. It is usually a disease of 
the elderly, which is produced by idiopathic degeneration of the sinoatrial node, and its 
manifestations can range from asymptomatic to nonspecific. These include dizziness, 
palpitations, fatigue, syncope and even sudden death.
Electrocardiographic evidence of sick sinus syndrome includes inappropriate 
sinus bradycardia, sinus pauses or arrest, and sinus exit block. These bradycardias may alternate 
with tachyarrhythmias, especially slow and fast atrial fibrillation, resulting in the tachy-brady* 
syndrome.
The use of drugs such as digoxin, beta-blockers and calcium antagonists may 
initiate or exacerbate symptoms in these patients. In the presence of symptomatic 
bradyarrhythmias, permanent pacing is indicated. There is evidence that simple ventricular pacing 
systems may result in an increase in the incidence of permanent and paroxysmal atrial fibrillation, 
congestive heart failure and worsened prognosis (Hesselson et al 1992, Rosenqvist et al 1988, 
Stangl et al 1990, Zanini et al 1990). Regular atrial pacing, in contrast, either alone or combined 
with ventricular pacing, is often effective in preventing paroxysmal atrial fibrillation associated with 
the tachy-brady syndrome (perhaps by stabilising the atrium electrically) and can therefore 
improve the overall prognosis (Ohe et al 1987, Stangl et al 1990).
Patients with sick sinus syndrome also appear to be at increased thromboembolic 
risk (Bathen et al 1978, Fairfax et al 1976, Rosenqvist et al 1988), and this is thought to be 
associated with the tachy-brady syndrome. Therefore, formal anticoagulation should also be 
initiated in addition to antiarrhythmic therapy.
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Prophylaxis against thromboembolic events
Some physicians seem to regard paroxysmal atrial fibrillation as conferring a 
greater risk of serious thrombo-embolic complications than chronic atrial fibrillation. The data 
available however does not substantiate such beliefs and patients appear to be in an intermediate 
risk category between normal sinus rhythm and chronic atrial fibrillation.
Data from the Framingham study has shown that men with chronic atrial fibrillation 
had an annual stroke rate of 5.4% (with a relative risk of 4.7), whereas for paroxysmal atrial 
fibrillation the corresponding figure was 1.3% (and 0) (Kannel et al 1983). Other studies have 
also confirmed similar or lower incidences of thrombo-emboli for paroxysmal as opposed to 
chronic atrial fibrillation (Petersen and Godtfredsen 1986, Petersen et al 1989, Shimomura et al 
1989, Takahashi et al 1981). For example, in a Danish study of 426 patients, the mean yearly 
incidence of systemic emboli was 2.0% for paroxysmal atrial fibrillation, which rose to 5.6% after 
progression to chronic atrial fibrillation (Petersen and Godtfredsen 1986). Further evidence for a 
low thromboembolic risk in these patients comes from a computed tomography (CT Scan) study 
where no significant differences in cerebral infarction were seen in patients with paroxysmal atrial 
fibrillation when compared to matched controls in sinus rhythm (Petersen et al 1989).
In contrast, however, the Montreal Heart Institute study (although retrospective) 
demonstrated that the incidence of embolic events associated with paroxysmal atrial fibrillation 
was similar to that observed with chronic atrial fibrillation (Roy et al 1986). Paroxysmal, intermittent 
and recent-onset atrial fibrillation seem particularly hazardous, with an excess of strokes, 
especially during the transition to chronic atrial fibrillation (Petersen 1990a, Petersen 1990b, 
Selzer 1982). In addition, the presence of spontaneous echo contrast during paroxysms of atrial 
fibrillation has been described in a patient who presented with a cerebral embolus (Obarski et al 
1990). As spontaneous echo contrast is associated with systemic emboli in sustained atrial 
fibrillation, its presence during paroxysms of paroxysmal atrial fibrillation is consistent with 
evidence for some thromboembolic risk in these patients.
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An important risk factor however is the influence of underlying pathology, such as 
rheumatic heart disease and hypertension. For example, there is evidence demonstrating that 
the presence of rheumatic heart disease is a major additive risk factor with respect to progression 
to both thrombo-embolic events and chronic atrial fibrillation (Takahashi et al 1981). In addition, a 
study of 63 consecutive patients with paroxysmal atrial fibrillation demonstrated that an older age, 
hypertension and an increased left atrial diameter (on 2-D echocardiography) were risk factors for 
systemic embolism (Corbalan et al 1992). Another important group at risk are those patients with 
paroxysmal atrial tachyarrhythmias associated with the sick sinus syndrome (Bathen et al 1978, 
Fairfax et al 1976, Rosenqvist et al 1988).
Although there have been five major studies establishing the benefits of 
antithrombotic therapy in chronic atrial fibrillation, there are few data available for paroxysmal atrial 
fibrillation (Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators 1990, Connolly et al 
1991, Ezekowitz et al 1992, Petersen et al 1989, Stroke Prevention in Atrial Fibrillation 
Investigators 1991). This is unfortunate as with the overall risk of thrombo-embolic events being 
lower, the benefits of warfarin therapy may be significantly offset by its associated morbidity. 
Aspirin therapy may be safer and appears to be reasonably effective in chronic atrial fibrillation, at 
least for those patients aged below 75 years with no structural heart disease (Stroke Prevention in 
Atrial Fibrillation Investigators 1990). In similarity to warfarin, however, its effects in paroxysmal 
atrial fibrillation are unknown. The precise role of antithrombotic therapy thus remains to be 
defined.
Discussion
Following appropriate investigation, patients with symptomatic paroxysms of atrial 
fibrillation should be treated using both an antiarrhythmic and an antithrombotic agent. Although 
accepting the paucity of supporting evidence, treatment should be initiated using sotalol, 
reserving Class 1 agents for second choice. If patients do not have underlying coronary artery 
disease, Class 1c agents (for example, propafenone, in view of its rate limiting properties, or
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flecainide) could be used as second line therapy. Class 1a agents (for example, quinidine), 
amiodarone and ablation of the atrio-ventricular pathway are further useful options for the 
problematic case. Despite its potential toxicity, amiodarone can be of particular value in the 
elderly. This group are often intolerant of alternative therapy and it is often possible to achieve 
good control with very low doses of amiodarone (i.e. 10Omg daily or lower). At this dosage the 
risks of serious toxicity should be low.
There is little evidence however to support the traditional use of digoxin or 
verapamil. In patients with sick sinus syndrome, atrial or dual chamber pacing should be 
considered in addition to antithrombotic therapy. Intractable disabling paroxysmal atrial fibrillation 
should, however, be referred for specialist advice. The role of antithrombotic therapy is unclear 
but until clarification becomes available it is advisable to give all patients an antithrombotic agent. 
Those patients deemed to be at high risk, for example, patients with underlying structural 
abnormalities (such as rheumatically damaged valves, patients who have already experienced a 
prior thromboembolic event or poor left ventricular contraction) or sick sinus syndrome should be 
treated by formal anticoagulation. Patients with frequent paroxysms of atrial fibrillation are most 
probably at increased risk and should be formally anticoagulated. It would seem reasonable to 
treat all other patients with aspirin.
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5.2 STUDIES OF PLASMA FIBRINOGEN AND D-DIMER IN PAROXYSMAL ATR IA L  
FIB R ILLA TIO N
Introduction
Paroxysmal atrial fibrillation may confer a significant risk of serious thrombo­
embolic complications, although whether this risk is any greater than patients in chronic atrial 
fibrillation remains controversial. As discussed above, however, the data available (especially 
from epidemiological studies) seems to put patients with paroxysmal atrial fibrillation in an 
intermediate risk category between normal sinus rhythm and chronic atrial fibrillation (Petersen 
1990).
As discussed in chapter 3, patients with chronic atrial fibrillation have significant 
abnormalities of plasma fibrinogen and fibrin degradation products (fibrin D-dimer). If patients with 
paroxysmal atrial fibrillation are at intermediate thrombo-embolic risk, and if plasma fibrinogen and 
fibrin D-dimer were suitable indicators of thrombogenesis, I would hypothesise that intermediate 
levels of these plasma markers will be found in patients with paroxysmal atrial fibrillation when 
compared to patients with chronic atrial fibrillation and sinus rhythm. The aim of the study reported 
in this chapter was to determine whether or not paroxysmal atrial fibrillation is associated with 
increased plasma fibrinogen or D-dimer levels; and if so, whether or not such levels were related 
to any underlying cardiac abnormalities.
Materials and Methods
A prospective case controlled study of male and female patients with paroxysmal 
atrial fibrillation was undertaken. Paroxysmal atrial fibrillation was defined as episodes of atrial 
fibrillation lasting for 10 or more complexes documented on at least two occasions by a 24 hour 
Holter monitor put on outpatients, or the presence of similar paroxysms noted on a cardiac monitor 
during an inpatient stay. Exclusion criteria were similar to that described in chapter 3.
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Standard two dimensional and Doppler echocardiography was also performed in 
all patients using a Hewlett-Packard Sonos 500 machine (Hewlett-Packard, Arondale, Pa, USA.) 
equipped with a standard 2.5 MHz transducer, using techniques and methods previously 
described in chapter 3. Using the standard video facility of the ultrasound machine, off line 
analytical methodology was again used to quantify measurements. Assays for plasma fibrinogen 
and fibrin D-dimer levels were as previously described (chapter 3).
Plasma fibrinogen and fibrin D-dimer results for patients were compared to the 85 
patients in chronic atrial fibrillation described in chapter 3 (56 of whom were not on warfarin 
therapy), 27 hospital controls [age ±5 years and sex-matched patients with coronary artery 
disease and with normal left ventricular function] and 158 population controls (patients aged 55- 
65 years, sampled from a local population study, the North Glasgow MONICA Study). 
Echocardiographic data for the patients with paroxysmal atrial fibrillation were compared to 
corresponding results for patients with chronic atrial fibrillation (as described in chapter 3) on no 
antithrombotic therapy and 14 healthy volunteers which served as 'normal' echocardiograms.
All the values were expressed as median ± interquartile range (IQR). Statistical 
comparisons were performed using the Kruskal-Wallis test and Mann-Whitney two sample rank 
test for non-parametric distributions; and the 95% confidence intervals (c.i.) calculated for the 
point estimate of the difference in medians. Correlations between clinical variables or Theological 
measurements were performed using Spearman's Rank correlation method. A probability of 
<0.05 was considered statistically significant.
Results
A total of 33 patients (18 male and 15 female; mean age 60.8 years, s.e.m.1.42) 
with paroxysmal atrial fibrillation were studied. At the time of the study, 3 patients were taking 
warfarin therapy and their plasma D-dimer results were excluded from further analyses (see 
chapter 3). A past history of ischaemic heart disease was present in 15, mitral valve disease in 2
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and Wolf-Parkinson-White Syndrome in one patient. There were six smokers in the paroxysmal 
atrial fibrillation group.
For the whole patient group, patients with paroxysmal atrial fibrillation had 
intermediate levels of plasma fibrinogen (median 3.07g/l; IQR 2.79-3.76) when compared to 
patients with chronic atrial fibrillation (median 3.58g/l; IQR 3.0-4.7) and sinus rhythm (hospital 
controls - median 2.85g/l; IQR 2.48-3.12; population controls - median 2.6 g/l ; IQR 2.23-3.0). 
These differences were statistically significant (Kruskal-Wallis test H= 86.6, d.f.=3; p<0.001) 
(Table 5.1).
As warfarin (but not aspirin) significantly influences intravascular clotting and 
therefore plasma D-dimer levels, patients with atrial fibrillation who were not on warfarin therapy 
were compared further (Table 5.2). Patients with chronic atrial fibrillation who were not on warfarin 
therapy (n=56) again had the highest median plasma fibrinogen (3.79g/l; IQR 3.0-4.7) and fibrin D- 
dimer (146ng/ml; IQR 78-228) levels. Patients with paroxysmal atrial fibrillation (n=30) however 
had intermediate levels of median plasma fibrinogen (3.04g/l IQR 2.79-3.75) and plasma fibrin D- 
dimer (97ng/ml IQR 53-140) when compared to patients with chronic atrial fibrillation and controls 
in sinus rhythm. These differences were again statistically significant (for plasma fibrinogen: 
Kruskal-Wallis test H= 70.4, d.f.=3; p<0.001; and for D-dimer: Kruskal-Wallis test H= 58.8, d.f.=3; 
p<0.001 ) (Table 5.2).
Suitable left and right atrial echocardiographic measurements were obtained in 23 
and 17 patients with paroxysmal atrial fibrillation (who were not on warfarin) respectively. However, 
technically adequate M-Mode left ventricular measurements were obtained in only 13 patients. 
They were compared to atrial echocardiographic measurements of 56 patients with chronic atrial 
fibrillation who were not on warfarin therapy (obtained from chapter 3) and 14 healthy patients who 
served as 'normals' (Table 5.3). Patients with paroxysmal atrial fibrillation had intermediate median 
left atrial dimensions (anteroposterior, mediolateral and superoinferior), and left and right atrial 
volumes (ellipsoid) when compared to patients with chronic atrial fibrillation and 'normals' in sinus
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rhythm (p<0.05). There were however no significant differences in left ventricular dimensions and 
fractional shortening between patients with chronic and paroxysmal atrial fibrillation.
There was a weak correlation between age and plasma fibrinogen in patients with 
paroxysmal atrial fibrillation (Table 5.4). There were no significant correlations between body mass 
index, left atrial dimension, left atrial volume, right atrial volume, left ventricular dimensions or 
fractional shortening with plasma fibrinogen or fibrin D-dimer levels (Table 5.4).
Discussion
This study demonstrates intermediate levels of plasma fibrinogen and fibrin D- 
dimer levels in patients with paroxysmal atrial fibrillation when compared to similar patients in 
chronic atrial fibrillation and those in sinus rhythm. The intermediate levels of plasma fibrinogen 
gives added support to my hypothesis that haemorheological factors may partly account for the 
risk of thrombogenesis in atrial fibrillation, which also appears intermediate in paroxysmal atrial 
fibrillation (when compared to chronic atrial fibrillation and sinus rhythm). The elevated levels of 
plasma fibrinogen in these patients are not just due to underlying coronary artery disease, as 
plasma levels in patients with paroxysmal atrial fibrillation were significantly higher when compared 
to levels in age- and sex-matched hospital controls who were patients with known ischaemic heart 
disease attending the outpatient clinic.
As demonstrated in chapter 3, patients with chronic atrial fibrillation are at high 
thromboembolic risk and the highest levels of plasma fibrin D-dimer in these patients indicate 
greatly enhanced fibrin turnover and intravascular clotting in these patients. Epidemiological data 
from the Framingham Study demonstrate that patients with paroxysmal atrial fibrillation are at lower 
thromboembolic risk when compared to patients with chronic atrial fibrillation. This study provides 
rheological support for this, as intermediate plasma levels of fibrinogen and fibrin D-dimer are 
found in these patients. Although patients with chronic atrial fibrillation had significantly higher left 
atrial dimensions and left atrial volumes when compared to patients with paroxysmal atrial 
fibrillation, there was no significant correlation between plasma fibrinogen or fibrin D-dimer with
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atrial dimension or volume, as demonstrated in chapter 3. There was also no difference in left 
ventricular function (as assessed by fractional shortening) between patients with chronic and 
paroxysmal atrial fibrillation. Finally, there were no significant correlations between left atrial 
dimension, left atrial volume, left ventricular fractional shortening or body mass index with plasma 
fibrinogen or D-dimer in patients with paroxysmal atrial fibrillation. These findings suggest that it is 
atrial fibrillation itself which is the main contributory factor to thromboembolic risk, with little 
contribution from structural factors, such as left atrial size.
As discussed in chapter 3 the phenomenon of spontaneous echo contrast may 
provide visual demonstration of blood stasis within the left atrial cavity. This may predispose to 
thrombus formation and is unrelated to age, gender, left ventricular dysfunction or anticoagulant 
therapy (Black et al 1991, Castello et al 1990, Manning 1993). However, spontaneous echo 
contrast is not a universal finding in all patients with chronic atrial fibrillation, possibly accounting for 
the variability in plasma fibrinogen and fibrin D-dimer in these patients. In paroxysmal atrial 
fibrillation, however, transient spontaneous echo contrast has been demonstrated within the left 
atrium during a paroxysm of atrial fibrillation suggesting that intermittent flow abnormalities or stasis 
may exist in these patients (Obarski et al 1990). On theoretical grounds, patients with the most 
frequent paroxysms of atrial fibrillation would be at highest risk of flow abnormalities or stasis and 
these patients would therefore be at greatest thromboembolic risk. Unfortunately, my study was 
not designed to quantify the episodes of atrial fibrillation and to correlate these frequency of 
paroxysms with plasma fibrinogen or fibrin D-dimer levels.
This study provides therefore haemorheological support for the increased risk of 
thromboembolism in all patients with atrial fibrillation. In addition, patients with paroxysmal atrial 
fibrillation have intermediate levels of plasma fibrinogen and fibrin D-dimer when compared to 
patients in chronic atrial fibrillation and sinus rhythm. This is in keeping with the majority of the 
literature and suggests that whilst the group of patients with paroxysmal atrial fibrillation are at an 
intermediate risk of stroke and thromboembolism, measurement of fibrinogen and fibrin D-dimer
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may allow individual risk stratification. This study also supports the hypothesis that plasma D-dimer 
may provide a suitable marker for intravascular thrombogenesis and thromboembolic risk.
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TABLE 5.1 
PAROXYSMAL ATRIAL FIBRILLATION AND 
PLASMA FIBRINOGEN LEVELS
(WHOLE STUDY GROUP)
WHOLE GROUP number age plasma fibrinogen
(n) mean median
M:F (s.e.m.) g/l (IQR)
paroxysmal atrial 33 61 3.07*
fib rilla tion 18M; 15F (1.42) (2.79-3.76)
chronic atrial fibrillation 85 64 3.58
43M; 42F (1 01) (3.0-4.7)
HOSPITAL 27 60 2.85
CONTROLS 14M; 13F (139) (2.48-3.12)
POPULATION 158 58.9 2.60
CONTROLS 88M; 70F (0.22) (2.23-3.00)
* significantly different when compared to hospital controls (Mann-Whitney test, p=0.004), 
chronic atrial fibrillation group (p=0.0078) and population controls (p<0.0001);
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TABLE 5.2 
PLASMA FIBRINOGEN AND D-DIMER IN 
PAROXYSMAL ATRIAL FIBRILLATION
(NO WARFARIN GROUPS)
NO WARFARIN 
THERAPY
number
(n)
plasma fibrinogen
median
g/l(s.e.m.)
plasma fibrin 
D-dim er
median
ng/ml(s.e.m.)
paroxysmal atrial 30 3.04* 97@
fib rilla tio n (2.79-3.75) (53-140)
chronic atrial fibrillation 56 3.79 146
(3.0-4.7) (78-228)
HOSPITAL 27 2.85 38
CONTROLS (2.48-3.12) (30-59)
POPULATION 158 2.60 76
CONTROLS (2.23-3.0) (54-104)
PLA SM A  FIB R IN O G EN
* significantly different when compared to chronic atrial fibrillation group (Mann-Whitney test, 
p=0.011), hospital controls (p=0.044) and population controls (p<0.0001).
PLASMA FIBRIN D-DIMER
@  significantly different when compared to chronic atrial fibrillation group (Mann-Whitney test, 
p=0.012), hospital controls (p<0.0001) and population controls (p=0.045).
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patients with 
echocardiograms 
LEFT ATRIUM
D 1 
cm (IQR)
D 2 
cm (IQR)
D 3 
cm (IQR)
LEFT ATRIAL 
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CM3 (IQR)
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TABLE 5.3 
ECHOCARDIOGRAPHY AND 
PAROXYSMAL ATRIAL FIBRILLATION
(no warfarin groups)
paroxysmal 
atrial fibrillation
23
4.15*
(3.56-4.47)
4.03*
(3.80-4.30)
5.12*
(4.62-5.5)
32.8
(25.3-41.4)
27.9*
(21.0-30.6)
chronic atrial 
fib rilla tion  
54
4.6**
(4.14-5.00)
4.66“
(3.8-4.3)
6 .0“
(5.08-6.90)
48.8**
(38.7-65.2)
42.4
(35.3-56.7)
norm als
14
3.37
(3.09-3.65)
3.67
(4.20-4.79)
4.61
(4.2-4.79)
29.2 
(26.3-31.5)
20.1
(17.2-23.0)
6 . 02 *
(5.32-6.59)
5.5 
(5.0-6.1)
5.17
(4.86-5.50)
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end-systo lic  
dim ension  
cm (IQR)
fractional 28.16* 24.0 35.5
shorten ing (21.0-30.6)
% (IQ R )
* significantly different when compared to healthy controls (p<0.01);
* *  significantly different when compared to patients with paroxysmal atrial fibrillation (p<0.01).
4.29*
(3.76-5.2)
4.14
(3.24-4.88)
3.4
(3.24-3.60)
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TABLE 5.4 
PAROXYSMAL ATRIAL FIBRILLATION 
- SPEARMAN CORRELATIONS
age
body mass 
index
Left atrial
dim ension
(d 1 )
Left atrial 
volum e
Right atrial 
volum e
Left ventricle  
end-d iasto lic  
dim ension
Left ventricle  
end-systo lic  0 5 6  
dim ension
L e ft
ventricu lar
fractional
shorten ing
FIBRINOGEN  
r P
0..8 0.046*
-0.04 0.83
0.096 0.689
0.39 0.09
0.25 0.63
0.55 0.074
0.069
-0.48 0.13
r
0.30
-0.23
0.16
0.16
0.25
-0.04
-0.03
-0.14
D- DIM ER
P
0.12
0.26
0.51
0.51
0.64
0.91
0.93
0.69
kp<0.05
pla
sm
a 
fib
rin
og
en
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FIGURE 5.1
PLASMA FIBRINOGEN AND PAROXYSMAL ATRIAL
FIBRILLATION
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FIGURE 5.2 
PLASMA D-DIMER AND PAROXYSMAL 
ATRIAL FIBRILLATION
CHAPTER 6
THROMBOGENESIS
IN
PAROXYSMAL
SUPRAVENTRICULAR
TACHYCARDIA
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6.1 STUDIES OF PLASMA FIBRINOGEN AND D-DIMER IN PAROXYSMAL 
SUPRAVENTRICULAR TACHYCARDIA
Introduction
Contrary to popular belief, supraventricular tachycardia is not an entirely 
benign condition. Patients can be considerably symptomatic and haemodynamic sequelae 
(for example, heart failure), can often occur. There is some evidence, for example, that 
chronic supraventricular tachycardia can result in left ventricular dysfunction, left ventricular 
dilatation and occasionally even a dilated cardiomyopathy (Packer et al 1986, Spinale et al 
1991, Tomita et al 1991, Zipes 1992b). Such left ventricular dilatation and functional 
impairment may constitute an important thromboembolic risk, as reviewed and explored in 
chapter 8. Interestingly, termination of the arrhythmia improves symptoms of heart failure. 
There is also experimental evidence that supraventricular tachycardia (especially chronic) may 
result in systolic and diastolic dysfunction, with reduced collagen support of adjoining 
myocytes (Spinale et al 1991, Tomita et al 1991). In these studies, early recovery from the 
arrhythmia was associated with left ventricular hypertrophy, increased collagen synthesis and 
increased left ventricular stiffness; all leading to diastolic dysfunction (Spinale et al 1991, 
Tomita etal 1991). Despite the important haemodynamic and structural consequences, the 
risks of thromboembolism in patients with supraventricular tachycardia have not been studied.
There is clinical evidence that patients with paroxysmal atrial fibrillation are at 
intermediate risk of thromboembolism when compared with patients in chronic atrial fibrillation 
and subjects in sinus rhythm. In chapter 4 ,1 have demonstrated that these patients also have 
intermediate levels of plasma fibrinogen and fibrin D-dimer. My findings are therefore in 
keeping with clinical observations of a thromboembolic risk which is graded between chronic 
and paroxysmal atrial fibrillation.
It remains unclear, however, whether it is simply the paroxysmal nature of the 
arrhythmia which results in the rheological abnormalities; or whether or not it is the 
incoordinate atrial contractions of atrial fibrillation (whether intermittent or not) which results in 
the abnormalities in plasma fibrinogen and D-dimer as demonstrated in chapters 3 and 5. 
Patients with paroxysmal supraventricular tachycardia (and paroxysmal tachycardias other than
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atrial fibrillation) continue to have co-ordinated atrial activity abeit rapid. In view of this, I would 
hypothesise that it is the atrial fibrillation which is the most important component and if this 
were true, patients with paroxysmal supraventricular tachycardia (with rapid coordinated atrial 
activity) should not manifest these haemorheological abnormalities.
The aim of this study therefore was to determine whether the thrombogenic 
potential (as reflected by abnormalities in plasma fibrinogen or fibrin D-dimer) demonstrated in 
paroxysmal atrial fibrillation also exists in patients with paroxysmal supraventricular tachycardia.
Methods
A prospective study of patients with paroxysmal tachycardias was 
undertaken. Patients were identified at outpatient clinics and the nature of the paroxysmal 
arrhythmia defined by a 24 hour Holter monitor or cardiomemo (transtelephonic monitor). 
Patients were enrolled if the presence of probable paroxysmal supraventricular tachycardia 
was documented on the 24hour Holter or cardiomemo. This was defined as the presence of 
10 or more complexes of a regular narrow complex tachycardia on one or more occasions. 
Exclusion criteria were similar to previous studies, namely age greater than 75 years, those 
with systemic illnesses (liver/renal impairment, malignancy), hypertension, and those who 
were actively bleeding or requiring transfusion. Patients on warfarin therapy were also 
excluded.
Blood samples were taken for plasma fibrinogen and fibrin D-dimer and 
assayed using methods and techniques outlined in chapter 3. Results were compared to 
'normal' population values derived from the 2nd MONICA study as in previous chapters.
Statistical comparisons were made using the Mann-Whitney U test for non- 
parametric populations. A probability of <0.05 was considered as representing statistical 
significance.
Results
A total of 12 patients (3 male, 9 female; mean age 51 years, s.e.m. 4.2) were 
studied. Analysis of the 24hour Holter or cardiomemo demonstrated definite episodes of
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supraventricular tachycardia (PSVT) in nine patients, whilst 3 patients had probable episodes 
of supraventricular tachycardia. These 12 patients were compared to 12 age (±5 years) and 
sex-matched patients (mean age 56 years, s.e.m. 3.1) with paroxysmal atrial fibrillation (PAF), 
and 'normal' population values derived from 158 subjects in sinus rhythm from a random 
population survey (2nd North Glasgow MONICA study) as in previous chapters. There were 4 
smokers in the PSVT group, whilst the PAF group had 2 smokers.
Patients with PSVT had a lower median plasma fibrinogen level when 
compared to patients with PAF, but this was of borderline significance only (point estimate 
difference between medians 0.64g/l; 95% c.i. -0.02 to 1.5, p=0.06). The median plasma 
fibrinogen level in patients with PSVT (2.6g/l; IQR 2.4-3.0) was also similar to the median level 
of the population controls (point estimate difference between medians 0.08g/l; 95% c.i. -0.22 
to 0.38, p=0.57, NS).
Patients with PSVT also had a lower median plasma fibrin D-dimer level when 
compared with patients manifesting PAF (67 vs 95 ng/ml), but this did not reach statistical 
significance (point estimate difference between medians 23ng/ml; 95% c.i. -64 to 9, p=0.19, 
NS). There was no difference in median plasma fibrin D-dimer level in patients with PSVT 
when compared with population values (point estimate difference between medians 6ng/ml; 
95% c.i. -27 to 15, p=0.52, NS).
Discussion
This study demonstrates a trend towards lower plasma fibrinogen and D- 
dimer levels in patients with paroxysmal supraventricular tachycardia when compared to 
matched patients with paroxysmal atrial fibrillation. In addition, patients with paroxysmal 
supraventricular tachycardia had levels of plasma fibrinogen and fibrin D-dimer that were similar 
to population values derived from a random population sample in sinus rhythm. This was a 
small study, however, with difficulties in patient recruitment, and only 12 patients with 
paroxysmal supraventricular tachycardia were studied.
Patients with paroxysmal atrial fibrillation were slightly older than patients in 
the PSVT group (mean age 51 vs 56 years) and this may have partly accounted for the higher
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plasma fibrinogen levels in the paroxysmal atrial fibrillation group. However, as there were 
slightly more smokers in the PSVT group, compared to the patients with paroxysmal atrial 
fibrillation group, it is most unlikely therefore that the elevated plasma fibrinogen or fibrin D- 
dimer, in patients with paroxysmal atrial fibrillation, was due to an excess of smokers. No 
comparison of intracardiac dimensions was made in this study as previous chapters have 
examined this aspect in detail, with no significant effects demonstrable for plasma levels of 
fibrinogen and fibrin D-dimer.
My findings are consistent with previous observations (chapter 3) that it is 
likely to be atrial fibrillation itself which is related to the changes in plasma fibrinogen and fibrin 
D-dimer. This suggests abnormalities in rheology and fibrin turnover in association with this 
arrhythmia. Atrial fibrillation (whether sustained or paroxysmal) is associated with incoordinate, 
irregular atrial systolic activity and this may result in abnormalities of intracardiac blood flow 
which may contribute to a prothrombotic state. As discussed in previous chapters, these 
abnormalities in blood flow are visualised as spontaneous echo contrast during 
transoesophageal echocardiography, suggesting slow or sluggish blood flow (Black et al
1991). Transient abnormalities of spontaneous echo contrast are also seen during 
paroxysms of atrial fibrillation (Obarski et al 1990), but to date spontaneous echo contrast has 
not been documented in patients with paroxysmal supraventricular tachycardia. It is likely that 
these latter patients have coordinate, regular atrial activity and contractions that would result in 
alow thromboembolic potential. This is in keeping with the clinical observations of a low 
thromboembolic risk for these patients with paroxysmal supraventricular tachycardia. My 
findings are also in keeping with the recommendation that anticoagulation before 
cardioversion of such patients is not necessary (Dunn et al 1989).
In conclusion, patients with paroxysmal supraventricular tachycardia have a 
low thromboembolic risk (as reflected by the trend towards lower plasma fibrinogen and fibrin 
D-dimer levels) when compared to patients with paroxysmal atrial fibrillation. Levels of plasma 
fibrinogen and fibrin D-dimer in patients with paroxysmal supraventricular tachycardia are in 
fact similar to population ('normal') values, suggesting that there is no excess thromboembolic
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risk in this group. Further studies with larger numbers of patients with paroxysmal 
supraventricular tachycardia are required to clearly define this risk, if any.
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TABLE 6.1 
PLASMA FIBRINOGEN AND FIBRIN D-DIMER IN 
PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
P S V T
(n=12)
PAF
(n=12)
PO PU LA TIO N
C O N TR O LS
(n=158)
age 51 55 59
mean (s.e.m.) (4.2) (3.1) (0.2)
sm okers 4 2
FIBRINOGEN 2.6* 3.3 2.6
m edian (2.39-2.98) (2.2-4.5) (2.3-3.0)
g/l (IQR)
D-D IM ER 67 96 76
m edian (42-114) (64-138) (64-104)
ng/ml (IQR)
*p=0.06
I______________________________I
p = NS
[PSVT=paroxysmal supraventricular tachycardia; PAF=paroxysmal atrial fibrillation]
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PLASMA FIBRINOGEN AND PAROXYSMAL 
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CHAPTER 7
THROMBOGENESIS 
AND VALVE DISEASE
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7.1 THE INFLUENCE OF HEART VALVE DISEASE ON THROMBOEMBOLIC 
RISK
Introduction
In Chapter 3 of this thesis, an increase of plasma factors of thrombogenesis 
was demonstrated in a heterogeneous group of patients with atrial fibrillation which included 
those with ischaemic heart disease, rheumatic valvular disease and cardiomyopathy. The role 
of ischaemic heart disease will be addressed in Chapter 8 of this thesis, in which patients with 
coronary artery disease will be investigated in relation to cardiac function. A variety of other 
cardiac disorders can, however, be frequently found in patients diagnosed as having 
thromboembolic events and stroke (Hofmann et al 1990, Nishide et al 1983). This chapter will 
address the influence of underlying valve disease.
Rheumatic heart disease is a common echocardiographic finding in patients 
with embolic cerebrovascular disease (Hofmann et al 1990, Nishide et al 1983). In patients 
with valve disease who suffer an initial embolus, recurrent embolism occurs in 30-75% of 
patients, an annual rate of almost 10% (Sherman et al 1990). Indeed, significant valvular 
stenosis and regurgitation may contribute to abnormalities of blood flow sufficient to promote 
thrombogenesis. Patients with aortic stenosis, for example, have marked alterations in blood 
flow through the stenosed valve (a high velocity jet demonstrable on continuous or pulsed 
wave Doppler echocardiography and visible as turbulence on colour Doppler). In addition, 
there may be secondary impaired compliance (and diastolic dysfunction) with left ventricular 
hypertrophy.
Echocardiography is a useful investigation in the assessment of patients with 
thromboembolism. The yield of echocardiography in identifying potential cardioembolic 
causes of stroke and other thromboembolic events varies widely in the literature depending 
upon the patient population and criteria of a cardioembolic source. Using restricted criteria, 
about 10% (range 4% to 16%) of patients with ischaemic stroke will have a potential embolic 
source by echocardiography (Sherman et al 1989). Similarly, in a prospective study of 153 
patients with arterial embolic events, transthoracic echocardiography was normal in only 60%, 
whilst after both transthoracic and transoesophageal echocardiography only 42% had normal
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findings (Hofmann et al 1990). Of those with abnormal examinations in this study, a large 
proportion (25%) had valvular heart disease (Hofmann et al 1990). It should be noted 
however that the definition of pathological valvular heart disease is increasingly difficult, as 
technology becomes more sensitive (Houston 1993). For example, there is an increase in 
the detection of valvular regurgitation with age, but this may be physiological (Houston 1993).
Mitral valve disease
The presence of mitral stenosis has a well-recognised increased 
thromboembolic risk, with an association of systemic embolization in 9-20% of patients (most 
of whom (60-75%) have cerebral emboli) (Cohen et al 1993, Sherman et al 1990). The most 
important contributing factor to mitral stenosis in terms of risk is coexistent atrial fibrillation, 
which increases the risk of embolism from 3 to 7 times that of solitary mitral stenosis (Sherman 
et al 1990). Further evidence for this was noted in a study in which 16% of 622 patients with 
mitral stenosis and atrial fibrillation had left atrial thrombi identified by echocardiography, 
compared to only 1% of 192 patients with mitral stenosis in sinus rhythm (Beppu et al 1984).
The position with mitral regurgitation is less clear. Mitral valve prolapse has 
been reported as a cause of cerebral embolism and this diagnosis has to be considered 
especially in younger patients (Alpert 1993, Bogousslavsky and Regli 1987, Nishide et al 
1983). These patients are often asymptomatic, and abnormal auscultatory findings are 
infrequent (Bogousslavsky and Regli 1987). Abnormalities of platelets and thrombosis may 
be the underlying cause of stroke in these patients. For example, thrombi have been 
detected on mitral valve leaflets of patients with mitral valve prolapse who have died of 
cerebral embolism (Lewis 1988). Abnormalities of platelet survival and increased platelet 
coagulant activity have also been shown in these patients (Lewis 1988), although a more 
recent study (23 patients) suggested the converse, with no differences in beta- 
thromboglobulin (a marker of platelet activation) demonstrable in patients with mitral valve 
prolapse (Lin et al 1989). However, it should be noted that mitral valve prolapse is often 
regarded as a heterogeneous diagnosis, resulting from diverse pathogenic mechanisms of 
the mitral valve apparatus (Braunwald 1993), which may in part account for the differences
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seen. The role of mitral regurgitation therefore in decreasing or increasing (as in mitral valve 
prolapse) any risk of thromboembolism remains unclear. Some evidence for a rheological 
mechanism may be obtained by considering the phenomenon of spontaneous echo 
contrast.
Spontaneous echo contrast refers to dynamic smoke-like echoes seen 
occasionally in the left atrial cavity during transthoracic echocardiography, but more commonly 
seen on transoesophageal echocardiography. The significance of spontaneous echo 
contrast has already been discussed in Chapter 3 of this thesis. Briefly, the mechanism of its 
formation is thought to be due to erythrocyte aggregation in low shear rate conditions, with a 
possible interaction of platelets and plasma fibrinogen. The latter is intimately involved in the 
rheological characteristics of blood flow. The presence of spontaneous echo contrast is 
associated with conditions favouring stasis of left atrial blood (for example, severe mitral 
stenosis), and appears to be a marker of previous thromboembolism in patients with 
nonvalvular atrial fibrillation and those with mitral valve disease or mitral valve replacement 
(Black et al 1991). Importantly, the presence of left atrial spontaneous echo contrast has 
been found to be highly specific (94%) and predictive for thromboembolic events (Tsai et al
1992).
In a large series (400 patients), mitral regurgitation was an independent 
predictor of the absence of left atrial spontaneous echo contrast, as only 7% of patients with 
moderate to severe mitral regurgitation were found to have the finding (Black et al 1991). 
Similarly, in two smaller series those with left atrial spontaneous echo contrast were less likely 
to have moderate or severe mitral regurgitation present (Chen et al 1990, Tsai et al 1992). 
These studies are however in contrast to an earlier study of 150 patients where there was a 
positive association between the presence of spontaneous echo contrast and mitral 
regurgitation (Castello et al 1990). The discrepancy may reflect differences in the patients 
studied, with a higher proportion of patients with mitral valve prostheses in the study by 
Castello et al (1990). From the rheological viewpoint, the presence of mitral regurgitation may 
preclude the development of spontaneous echo contrast by a 'stirring effect' on left atrial 
blood, thus eliminating blood stasis (Beppu et al 1985, Chen et al 1990).
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In addition, mitral regurgitation appears to protect against left ventricular 
thrombus in patients with dilated cardiomyopathy (Maze et al 1989). The development of left 
atiial thrombus postoperatively after mitral valve surgery for preoperative severe mitral 
regurgitation (which perhaps made the preoperative left atrial blood 'less stagnant') has also 
been reported (Iga et al 1993). If mitral regurgitation 'reduces' the formation of spontaneous 
echo contrast (and therefore, any rheological 'disturbance') and also protects against 
intracardiac thrombus formation, the presence of mitral regurgitation may therefore be a 
protective factor against thrombus formation. The situation is however far from clear. A study 
of prothrombotic markers may, however, provide the answer, and this is undertaken in this 
chapter. For the present, the indications for antithrombotic therapy in patients with mitral valve 
disease have been suggested as follows (Meitzer et al 1986): atrial fibrillation, patients in sinus 
rhythm with a left atrium larger than 55mm (by echocardiography), a history of previous 
systemic embolization, mechanical prosthetic heart valves and bioprosthetic heart valves 
(usually for the first 3 months after implantation but indefinitely if atrial fibrillation or a dilated left 
atrium are present).
Aortic valve disease
The presence of aortic valve calcification and thickening is associated with 
systemic embolism (Hart 1992, Meitzer et al 1986, Nishide et al 1983). This is pertinent as 
calcification and degeneration of the aortic valve becomes more prevalent with increasing 
age. For example, in the Helsinki Ageing Study, some degree of valvular calcification was 
found in 28% of those aged 55-71 years, with the prevalence rising to 75% of those aged 85 
to 86 years (Lindroos et al 1993). In the absence of atrial fibrillation, however, calcific aortic 
(and mitral) stenosis are relatively uncommon causes of embolic stroke (Cohen et al 1993, 
Kapila and Hart 1986, Rancurel et al 1989). This is despite the demonstration of fibrin-platelet 
deposits on disrupted valvular endothelium, and the observation of calcific retinal emboli in 
patients with aortic stenosis (Sherman et al 1990). Calcific aortic stenosis may also be a source 
of embolization complicating cardiac catheterisation (Cohen et al 1993).
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Patients with aortic stenosis may develop left ventricular hypertrophy and 
heart failure (due to 'pressure overload'), and (as will be discussed in chapters 8 and 9) heart 
failure adds to the risks of thromboembolism. The presence of left ventricular hypertrophy (in 
association with aortic stenosis) in these patients can significantly contribute to diastolic 
dysfunction (Villari et al 1992). For example, diastolic dysfunction was present, despite 
normal systolic function, in 9 of 18 patients (50%)of patients with aortic stenosis ('pressure 
overload') and 20 of 22 patients with aortic regurgitation ('volume overload*) (Villari et al 1992). 
Indeed, it is increasingly recognised that diastolic dysfunction may be a common feature in 
valvular heart disease, and is independent of any coexisting systolic dysfunction (Hess et al 
1991). In such patients, diastolic dysfunction is characterised by an impaired isovolumetric 
relaxation, an enhanced early diastolic filling rate and an increased myocardial stiffness (Hess 
etal 1991).
Discussion
Echocardiography has permitted an improved assessment of the heart in 
patients with thromboembolism and stroke, facilitating the diagnosis of cardiogenic embolism. 
It is now accepted, for example, that structural heart disease may dramatically increase the risk 
of thromboembolism in atrial fibrillation. However, it remains uncertain whether or not the 
presence of valvular heart disease in patients who are in sinus rhythm constitutes a significant 
thromboembolic risk (perhaps related to haemorheological abnormalities). Some answers 
may be provided by a study of possible haemorheological and prothrombotic factor 
abnormalities in two groups of such patients: those with mitral valve regurgitation (who are 
associated with flow abnormalities discussed above) and aortic stenosis.
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7.2 STUDIES OF PLASMA FIBRINOGEN AND D-DIMER IN MITRAL 
REGURGITATION AND AORTIC STENOSIS
Introduction
In various chapters (3 and 8) of this thesis, I have demonstrated that plasma 
fibrinogen is elevated for all groups of patients with chronic atrial fibrillation (irrespective of 
antithrombotic therapy) and coronary artery disease. One influencing factor in the assessment of 
these prothrombotic factors may be the presence of structural heart disease. This aspect has 
been addressed in this thesis for patients with chronic atrial fibrillation (chapter 3), whereby there 
was no significant difference in plasma fibrinogen or D-dimer levels for patients with or without 
structural heart disease. This finding is consistent with results of other investigators (Kumagai et al 
1990). In contrast epidemiological evidence, from the Framingham study and other clinical 
studies, does suggest that the presence of rheumatic heart disease increases the thrombo­
embolic risk of patients with chronic atrial fibrillation by approximately 18-fold (Cairns and Connolly 
1991, Koenig et al 1992).
All valvular lesions may not have similar haemorheological effects and 
thromboembolic risks. For example, as previously discussed in section 7.1, the haemodynamic 
effects of valvular regurgitation may not be similar to that of valvular stenosis. This is supported by 
a lower incidence of spontaneous echo contrast (usually associated with blood stasis and 
thromboembolism) (Black et al 1991) and a reduction in left ventricular thrombus in patients with 
cardiomyopathy (Maze et al 1989) with associated mitral regurgitation. The presence of other 
valve lesions such as aortic valve disease may also provide an additional risk for thromboembolism 
but this has not been established.
The exact mechanisms for thrombus formation in patients with structural heart 
disease have not been clearly defined. The aim of this study therefore was to determine the 
effects of valvular heart disease (mitral regurgitation, aortic stenosis) on plasma fibrinogen or D- 
dimer levels as indices of a prothrombotic state.
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Materials and methods
The design of this study was a prospective population controlled study of male 
and female patients with valve disease in sinus rhythm. Patients were identified at the outpatient 
clinic or following routine cardiac catheterisation. I selected patients in sinus rhythm for further 
study if they had clinically demonstrable aortic stenosis or mitral regurgitation (the severity of the 
valve lesion was defined at echocardiography, as described later). Exclusion criteria were similar 
to previous studies and included those patients aged over 75 and those with significant systemic 
illnesses, hypertension, chronic infections or neoplastic disease. Patients with limited venous 
access, requiring transfusion or actively bleeding were also excluded. In addition, patients with 
significant coronary artery disease (defined at coronary angiography as the presence of one or 
more coronary artery lesions >50%) were also excluded. In patients who did not have coronary 
angiography, a history of ischaemic heart disease (previous myocardial infarction, angina or a 
positive exercise stress test) were grounds for exclusion from the study.
All patients had echocardiography performed to confirm the presence of 
structural heart disease (2-dimensional, M-Mode and Doppler), using a Hewlett-Packard Sonos 
500 machine machine and techniques described in chapter 3. Patients with significant (moderate 
to severe) mitral regurgitation were identified from Doppler echocardiography by subjectively 
assessing the area of colour flow regurgitation jet in relation to the left atrial area (Helmcke et al 
1987) (Figure 7.1); and by the presence of a dense continuous wave Doppler spectral signal with 
a peak transmitral flow velocity of >4.0cm/s. In addition the presence of mitral stenosis was 
assessed by reviewing 2-dimensional and M-mode echocardiographic appearances and 
assessment of the mitral valve pressure half-time. The presence of significant mitral stenosis was 
defined as patients with a mitral valve pressure half-time greater than 100 seconds, and these 
patients were excluded from further analysis. Patients with aortic stenosis were defined from the 
transaortic valve gradient demonstrated by continuous wave Doppler (Figure 7.2). An aortic valve 
gradient of >35mm Hg was considered indicative of significant aortic valve stenosis.
Methods for blood sampling and assays for plasma fibrinogen and fibrin D-dimer 
have been described previously (chapter 3). Results for patients were compared to 158 patients 
aged 55-65 years, sampled from a random local population study of healthy subjects (North
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Glasgow MONICA Study) which gave 'population' values. The sensitivity and reproducibility of the 
assays have been previously described. Detailed relationships were not examined for left atrial 
and ventricular sizes as other chapters have investigated this in detail.
All the values of the prothrombotic factor measurements were expressed as 
median ± interquartile range (IQR). Statistical comparison was performed using the Mann-Whitney 
two sample rank test for non-parametric distributions and 95% confidence intervals (c.i.) calculated 
for the point estimate of the difference in medians. Correlations between clinical variables or 
rheological measurements were performed using Spearman's Rank correlation method. A 
probability of <0.05 was considered statistically significant. Stepwise multiple regression analysis 
and multiple regression analysis was performed using plasma fibrinogen and D-dimer as 
dependent variables and age, body mass index, smoking, and the presence of mixed mitral valve 
disease as predictors in patients with mitral regurgitation. For patients with aortic stenosis, the age 
of the patient, body mass index, smoking, sex and aortic valve gradient were used as predictors in 
the analyses.
Results
A total of 25 patients with valve disease in sinus rhythm were studied: 12 
patients (all female; mean age 55 years, s.e.m. 3.3) with mitral regurgitation (4 with mixed mitral 
valve disease, but with mild mitral stenosis (MV P1/2 <100)); and 13 patients (7 male, 6 
female; mean age 57 years, s.e.m. 3.4) with aortic stenosis (3 with mixed aortic valve disease) 
were studied. Patient characteristics are summarised in Table 7.1. Eight (5 male, 3 female) of 
these patients had coronary angiography as a preoperative assessment - none of these 
patients had significant coronary artery lesions.
Patients with mitral regurgitation had a median plasma fibrinogen which was 
significantly elevated when compared to female population values (point estimate of 
difference between medians 0.62g/l; 95%c.i. 0.27 to 1.05, p=0.0016) (Figure 7.3).
However, these patients had a median plasma D-dimer which was lower than that for 
population controls (point estimate of difference between medians 21ng/ml; 95%c.i. 0 to 38, 
p=0.05) (Figure 7.4).
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Patients with aortic valve disease had a median plasma fibrinogen which was 
significantly increased when compared to population controls (point estimate of difference 
between medians 0.82g/l; 95% c.i. 0.34 to 1.24, p=0.001) (Figure 7.3). These patients had a 
plasma fibrin D-dimer level which was similar to population values (point estimate of difference 
between medians 3 ng/ml; 95%c.i. -25 to 22, p=0.80, NS) (Figure 7.4).
In patients with mitral regurgitation, stepwise multiple regression analysis with 
plasma fibrinogen and D-dimer as dependent factor demonstrated no significant influence of 
age, smoking habit, body mass index or the presence of mixed mitral valve disease on these 
plasma factors. There were no significant correlations between plasma fibrinogen or D-dimer 
and age or body mass index in these patients (Table 7.1). In patients with aortic stenosis, 
stepwise multiple regression analysis with plasma fibrinogen and plasma fibrin D-dimer as 
dependent factors demonstrated no significant influence of age, sex, smoking habit, body 
mass index or aortic valve gradient on these plasma factors. There were also no significant 
correlations between plasma fibrinogen or D-dimer and age, body mass index or aortic valve 
gradient in these patients (Table 7.1)
Discussion
This study demonstrates increased levels of plasma fibrinogen in both patient 
groups studied (mitral regurgitation and aortic stenosis). Both conditions are associated with 
abnormalities of blood flow and the elevation in plasma fibrinogen may be a reflection of 
rheological abnormalities present in these patients. However, the relationship to any 
thromboembolic risk is uncertain. The high plasma fibrinogen may, for example, reflect 
underlying coronary heart disease, although I have attempted to exclude such patients from 
this study. The elevation of plasma fibrinogen is not, however, due to an excess of smokers 
in the patients with valve disease when compared with population controls (Table 7.1).
The clinical significance of the altered plasma fibrinogen and D-dimer levels in 
these patients is uncertain, but may be related to flow (or haemorheological) abnormalities. 
Patients with mitral regurgitation exhibit abnormalities of blood flow due to the regurgitant 'jet' 
(although not the abnormalities associated with increased spontaneous echo contrast), and
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plasma fibrinogen changes may reflect this. The presence of mitral regurgitation may 
preclude the development of spontaneous echo contrast and intracardiac thrombus by a 
'stirring' effect on left atrial blood (as discussed in section 7.1). As the presence of 
spontaneous echo contrast reflects stasis (and is associated with thromboembolism) its 
absence in patients with mitral regurgitation may account for the lack of elevation of [and a 
trend (reaching borderline significance) towards lower] plasma D-dimer levels in these 
patients. My findings are also in keeping with the majority of the literature suggesting a lower 
thromboembolic risk for patients who do not exhibit spontaneous echo contrast. Further 
studies associating the presence (or absence) of spontaneous echo contrast with changes in 
plasma fibrinogen and fibrin D-dimer are required however to fully answer this hypothesis. My 
findings are also consistent with the lower prevalence of left ventricular thrombus formed in 
patients with dilated cardiomyopathy and mitral regurgitation (Maze et al 1989).
Similarly to those patients with mitral regurgitation, patients with aortic 
stenosis also have increased plasma fibrinogen levels. This finding may again reflect flow 
abnormalities, visible (with colour Doppler) as a high velocity jet through the narrowed aortic 
valve orifice. It may be speculative to suggest that rheological abnormalities may partially 
contribute to the symptoms of syncope or presyncope in these patients. However, my study 
was small, with difficulties in patient recruitment; and only a small range of aortic valve 
gradients was studied. Further studies of patients with significant aortic stenosis are therefore 
required, with closer study of other rheological indices, such as plasma or blood viscosity and 
haematocrit.
Interestingly, patients with aortic stenosis had plasma fibrin D-dimer levels 
which were similar to control population levels. Intravascular fibrin turnover is, therefore, no 
different in these patients when compared with population levels and is consistent with the 
reported low incidence of thromboembolism in patients with aortic stenosis. However, 
thromboembolic events are associated with aortic stenosis, and the mechanisms of 
thrombogenesis in these patients may be different from that of atrial fibrillation and (as shown 
in chapter 8) left ventricular dysfunction. For example, fibrin-platelet deposits (demonstrated 
on disrupted valvular endothelium), and emboli from calcific aortic stenosis appear to be the
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principal pathological processes for emboli associated with aortic stenosis (Sherman et al 
1990). This finding suggests that a different pathophysiological mechanism for emboli 
formation in aortic stenosis exists to that intimately associated with rheological factors 
(involving instead platelets and calcific emboli). This is possibly why no change in D-dimer 
levels is observed. In addition, the value of anticoagulation therapy in preventing these 
calcific emboli has not been established and the finding of 'normal' plasma D-dimer levels in 
this group of patients is consistent with this.
In conclusion, patients with mitral regurgitation or aortic stenosis have higher 
plasma fibrinogen levels when compared to 'normal' population values, suggesting possible 
rheological abnormalities in these patients. However, subjects with mitral regurgitation have 
lower plasma D-dimer levels suggesting lower intravascular clotting, consistent with clinical 
echocardiographic studies. Subjects with aortic stenosis have plasma D-dimer levels similar to 
the 'normal' population values, consistent with a different pathophysiological mechanism for 
the thromboembolic risk in these patients. These findings add to an improved understanding 
of the relationship between clinical and echocardiographic observations and the significance 
of plasma fibrinogen and fibrin D-dimer levels in thrombogenesis.
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TABLE 7.1 
PLASMA FIBRINOGEN AND D-DIMER IN 
MITRAL REGURGITATION AND AORTIC STENOSIS
(a) patient characteristics and results:
MITRAL
VALVE
DISEASE
AORTIC
STENOSIS
male
PO PU LA TIO N
female ALL
n
age
mean
(s.e.m.)
12
55.3
(3.3)
13
57.5
(3.5)
88
59.2
(0.27)
70
59.4
(0.37)
158
59.3
(0.22)
M :F 0:12 7:6 88:70
sm okers 2 1 64
(40%)
FIBRINO G EN
fl/l
median (IQR)
3.02*
(2.77-3.99)
3.68@
(2.59-3.95)
2.60
(2.25-3.01)
2.61
(2.23-2.98)
2.60
(2.25-3.0)
D-D IM ER
ng/ml 
median (IQR)
50‘ *
(40-90)
65
(42-117)
75
(51-103)
77
(59-106)
76
(54-104)
*p=0.0007; **p=0.05
i__________________
@ p=0.001
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(b) Spearman correlations for plasma fibrinogen and D-dimer:
r
(p value)
mitral
fibrinogen
regurg itation
D-dimer
aortic
fibrinogen
stenosis
D-dimer
fib rinogen 0.31 0.21
(0.327) (0.53)
D-dim er 0.31 0.21
(0.327) (0.53)
A ge 0.31 0.33 0.35 0.26
(0.324) (0.303) (0.23) (0.58)
Body mass 0.48 0.21 -0.46 -0.18
index (0.14) (0.52) (0.13) (0.60)
Aortic valve -0.24 0.06
gradient (0.57) (0.85)
(p=NS)
FIGURE 7.1
AN EXAMPLE OF COLOUR FLOW DOPPLER 
ECHOCARDIOGRAPHY 
demonstrating mitral regurgitation
Aortic Regurgitation
Aortic forward flow
Maximum transaortlc valve velocity (v)
[Maximum aortic valve gradient =  4 v 2]
FIGURE 7.2
AN EXAMPLE OF CONTINUOUS WAVE DOPPLER 
ECHOCARDIOGRAPHY 
demonstrating mixed aortic valve disease
(with an aortic valve gradient of 73 mmHg and associated mild aortic regurgitation)
pla
sm
a 
fib
rin
og
en
 
g/
l
178
p=0.0007
6
p=0.05
4
3.02
(median)
2
0
mitral
regurgitation
aortic
stenosis
female
population
controls
whole
population
control
group
FIGURE 7.3 
PLASMA FIBRINOGEN AND VALVE DISEASE
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FIGURE 7.4 
PLASMA D-DIMER AND VALVE DISEASE
CHAPTER 8
THROMBOGENESIS IN 
LEFT VENTRICULAR SYSTOLIC 
DYSFUNCTION
181
8.1 IS SYSTOLIC DYSFUNCTION IMPORTANT IN THROMBOGENESIS?
Introduction
Patients with impaired left ventricular function are at high risk of intracardiac 
thrombus and thromboembolism. The presence of left ventricular dysfunction is also an 
additive risk factor to the risk of stroke and thromboembolism in patients with atrial fibrillation 
(Hart 1992, Stroke Prevention in Atrial Fibrillation Investigators 1992a, Stroke Prevention in 
Atrial Fibrillation Investigators 1992b). In addition, it is well recognised that thromboembolism 
is a frequent cause of death in patients with heart failure (Griffith et al 1952). One specific 
group of patients with left ventricular dysfunction who appear to be at particular risk of 
intracardiac thrombus are patients with left ventricular aneurysm (Nixon 1983).
Overall, the incidence of left ventricular aneurysm following myocardial 
infarction is about 7 to 10% and surgical, autopsy and echocardiographic studies indicate that 
about half of all patients, with post-infarction ventricular aneurysm, have mural thrombus 
present (Cabin and Roberts 1980, Cregler 1992, Weinreich et al 1984). Despite the 
associated theoretical increase in thromboembolic risk, there is some evidence that these 
thrombi may only rarely embolise (Cregler 1992). The precise reasons for this are unclear, but 
the haemodynamic effects of left ventricular dysfunction or aneurysm may contribute to any 
altered thromboembolic risk in such patients.
Investigations
In patients with left ventricular systolic dysfunction, investigations are 
required to determine the degree of cardiac impairment, to diagnose the presence of 
aneurysm and finally, to detect the presence or absence of thrombus. Techniques employed 
in the assessment of left ventricular dysfunction include contrast cineangiography, 
echocardiography, and radionuclide methods.
Left ventricular contrast cineangiography may be useful for the diagnosis of 
significant wall motion abnormalities, including the presence of a left ventricular aneurysm. 
However, the investigation is less useful for the diagnosis of mural thrombus with a reported
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sensitivity of 31%, a specificity of 75% and a predictive accuracy of only 54% (Reeder et al 
1981).
Echocardiography, however, is widely available and relatively inexpensive. It 
is now the method of choice for detecting left ventricular thrombus, although the sensitivity of 
two-dimensional echocardiography in the detection of left ventricular thrombus varies 
between 77 to 95% with a specificity of 86 to 93% (Cregler 1992, Ezekowitz et al 1982, 
Stratton et al 1982, Visser et al 1983). About 15% (with a quoted range of between 5% and 
25%) of studies are, however, technically inadequate and cannot exclude the presence of a 
thrombus (Cregler 1992, Ezekowitz et al 1982). Two-dimensional echocardiography may also 
have disadvantages in visualising the left ventricular apex for characteristic wall thinning and 
possible apical thrombus formation (seen in aneurysm formation), as the sector angle is 90 
degrees and the apex is usually too near the probe in the 4-chamber view (Iga et al 1992). 
Overall cardiac motion towards the apex in systole also tends to accentuate apical dyskinesis 
and to obscure inferoposterior wall dyskinesia (Kessler 1990). A final limitation of 
echocardiography is its inability to reflect thrombus activity, that is, whether or not ongoing 
thrombogenesis is present. It is useful, however, in quantifying thrombus size and mass. 
Echocardiographic indications of left ventricular thrombi are summarised in Table 8.1.
Radionuclide techniques are increasingly used in the diagnosis of left 
ventricular dysfunction and the presence of intracardiac thrombus. For example, equilibrium 
gated radionuclide ventriculography, employing 99m Technetium isotope, is useful as an 
objective measure of left ventricular function. It also allows assessment of wall motion 
abnormalities, particularly by the study of phase and amplitude images. In addition, one useful 
radionuclide method of identifying left ventricular thrombus employs indium-111 platelet 
scintigraphy (Ezekowitz et al 1982, Kessler et al 1987). This has a specificity of 100% and 
sensitivity of 71%, which is even greater than that of echocardiography (Cregler 1992, 
Ezekowitz et al 1982, Vandenberg 1990). One further advantage of this method is its ability 
in assessing the surface activity of the thrombus, which may therefore complement any 
echocardiographic assessment.
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Other useful techniques for the investigation of left ventricular function and 
thrombus include magnetic resonance imaging (Higgins et al 1985, Iga et al 1992) and 
computed tomography (CT) (Nair et al 1981), but these techniques are limited to few centres.
Left ventricular aneurysms
The definition of what a left ventricular aneurysm is remains controversial and 
may vary considerably between different studies and with different investigational methods 
(Cabin and Roberts 1980). Obviously, if definitions vary from study to study, the results or 
conclusions may do so likewise; this may make some comparisons between the studies 
difficult to interprete.
It is generally accepted that the presence of a left ventricular aneurysm may 
result in significant haemodynamic consequences. This includes the reduction in stroke 
volume and ejection fraction, and the presence of life-threatening arrhythmias. All of these 
changes may result in increased susceptibility to congestive heart failure and a lower exercise 
tolerance (La Rovere et al 1987). The presence of such haemodynamic changes may have 
important implications for patient survival. In one series, for example, the survival rates of 
patients with ventricular aneurysm at 1, 3 and 5 years were 88, 82 and 75% respectively 
(Heras et al 1992). In such patients, an increased left ventricular end diastolic pressure (>20 
mm Hg), a greater number of diseased vessels and the presence of bifascicular block were 
independent predictors of high mortality (Faxon et al 1982, Heras et al 1992). Other 
predictors of mortality include age, clinical severity of heart failure, the left ventricular ejection 
fraction, the presence of left anterior descending artery obstruction and the presence or 
absence of coronary collaterals (Faxon et al 1982, Shen et al 1992). However it appears that 
the prognosis of this group of patients is primarily related to left ventricular dysfunction, whilst 
the presence of an aneurysm alone may not independently alter survival (Faxon et al 1982, 
Shen et al 1992).
Systemic embolism is a commonly cited complication of left ventricular 
aneurysm. Indeed, apical akinesis, dyskinesis or both appear to be a prerequisite for the 
development of thrombus (Weinreich et al 1984). Late thrombi are common in patients with
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congestive heart failure and deteriorating left ventricular systolic function, although there is 
some evidence that impaired left ventricular function on its own is not a prerequisite for 
thrombus formation (Weinreich et al 1984). This is complemented by evidence that the 
reduction in heart rate and left ventricular apical wall motion with the early use of beta-blocker 
therapy may actually increase the risk of thrombus formation (Johannessen et al 1988). 
Contrary to expectation, the introduction of thrombolytic therapy (streptokinase or 
recombinant tissue plasminogen activator) in the acute management of patients with anterior 
myocardial infarction does not appear to reduce the risk of left ventricular thrombus formation 
(Cregler 1992). Few data exist on whether early intervention with coronary angioplasty may 
reduce the risk of subsequent left ventricular thromboembolism (Cregler 1992).
Reported incidences of systemic embolism in patients with left ventricular 
aneurysm can vary widely - ranging from 0 to 52% (Lapeyre et al 1985, Mullen et al 1977, 
Schlichter et al 1954). However, mural thrombus does appears to occur more frequently in 
the presence of an aneurysm (Schlichter et al 1954). One reason for this wide variation in 
incidence is the lack of uniformity in defining what an aneurysm is, as discussed above (Cabin 
and Roberts 1980). It is usually accepted that the identification of mural thrombus in patients 
with left ventricular aneurysm warrants long-term oral anticoagulation as part of any medical 
management strategy (Keating et al 1983, Nixon 1983, Reeder et al 1981, Sherman et al 
1990). For example, in an overview of six studies (mean follow-ups 6 to 15 months), Sherman 
et al (1990) demonstrate that late emboli occurred in only 1% of 98 anticoagulated patients, 
when compared to 13% of 46 non-anticoagulated patients. It is also argued, however, that in 
chronic left ventricular aneurysms diagnosed at least six months after myocardial infarction, 
thrombus is common but the risk of embolism is low (an incidence of 0.35 per 100 patient- 
years) and that anticoagulation may not be warranted (Cabin and Roberts 1980, LaPeyre et al 
1985, Meftzer et al 1986).
The role of preventive strategies against thromboembolism in patients with 
left ventricular aneurysms therefore remains controversial, since the haemodynamic status of 
the patient may continue to alter with time. For example, aneurysm expansion may result in 
progressive haemodynamic deterioration with increasingly impaired left ventricular function.
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Left ventricular dysfunction
There is clinical evidence for a high thromboembolic risk in patients with 
impaired left ventricular function (but without aneurysm formation). For example, poor left 
ventricular function adds to the risk of stroke and thromboembolism in atrial fibrillation (Stroke 
Prevention in Atrial Fibrillation Investigators 1992a, Stroke Prevention in Atrial Fibrillation 
Investigators 1992b). In addition, thromboemboli are a frequent cause of death in patients 
with congestive heart failure, as shown in an postmortem study of 565 patients with heart 
failure, where evidence of thromboemboli was found in 30.3% (Griffith et al 1952). The 
mechanisms for this increased risk are uncertain, but poor systolic function may cause stasis 
of blood within the dilated left ventricular cavity resulting in mural thrombus formation (Meltzer 
etal 1986)
Thrombus has been found in approximately 36% of patients with chronic 
dilated cardiomyopathy on two dimensional echocardiography (Gottdiener et al 1983). 
Systemic emboli occurred in 11% of these patients, but there was no difference in the 
incidence of emboli when compared to those with no thrombus visualised at 
echocardiography (Gottdiener et al 1983). It is therefore felt that the embolic potential of left 
ventricular thrombus may be directly related to the presence of adjacent segments of normally 
functioning myocardium (with altered flow characteristics) and inversely related to the stability 
of the thrombus. For example, in an echocardiographic study of 40 patients with 
cardiomyopathy, there were specific abnormally low flow profiles at the ventricular apex 
associated with the presence of left ventricular thrombus (Maze et al 1989). Similar abnormal 
flow profiles have been demonstrated by pulsed Doppler echocardiography in patients post 
myocardial infarction who subsequently develop intracardiac thrombus (Delemarre et al 1990). 
In this latter study, the abnormalities were evident in diastole, suggesting that the absence of 
diastolic recoil of the apex of the heart was additive to the impaired systolic contraction in 
creating disturbed flow patterns (Delemarre et al 1990). This finding may explain the 
increased risk of intracardiac thrombus in patients with left ventricular aneurysms. 
Interestingly, in the cardiomyopathy patients without intracardiac thrombus, there was a higher
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prevalence of mitral regurgitation despite abnormal Doppler flow profiles (Maze et al 1989). 
The presence of mitral regurgitation may therefore serve as a protective factor against 
thrombus formation as the higher inflow velocities may result in a lower tendency for thrombus 
formation. The findings of these two studies therefore suggest that flow abnormalities are 
important in promoting thrombogenesis, and that Doppler echocardiography may be useful in 
patient risk stratification by the identification of a high risk group (with abnormal flow patterns), 
who would benefit from prophylactic anticoagulation (Kessler 1990).
Whether not all patients with poor left ventricular function should be treated 
with anticoagulants is debatable. There are few data advocating routine use of oral 
anticoagulant therapy in these patients. In one study (390 patients) there was a significant 
reduction in thromboembolism in patients with chronic heart failure, especially in those with 
coexisting rheumatic heart disease (Griffith et al 1952). More importantly, warfarin therapy is 
associated with a higher incidence of thrombus resolution at echocardiography when 
compared to patients on no therapy (59% vs 29% respectively) (Stratton et al 1988). In 
contrast to these findings, however, another echocardiographic study demonstrated that 
anticoagulant therapy provided protection against embolic events but the presence of 
thrombi on follow-up echocardiography at six months was the same regardless of treatment 
(Weinreich et al 1984). Further evidence comes from two series in which there was also no 
apparent effect of anticoagulation on the prevalence of mural thrombus, identified at 
aneurysmectomy (Reeder et al 1981, Simpson et al 1980). However, the duration of warfarin 
therapy correlated inversely with the presence of thrombus, and this consideration may 
account for the discrepancy in thrombus prevalence with warfarin therapy in the different 
studies (Reeder et al 1981).
An argument against the use of routine anticoagulant therapy is the finding 
that the presence of left ventricular thrombus on echocardiography may not be predictive of 
systemic emboli (Gottdiener et al 1983). Although the prevalence of mural thrombi is high in 
left ventricular aneurysms, these thrombi only rarely embolise (Simpson et al 1980). The 
factors that may predict the likelihood of embolization of any left ventricular thrombus are 
therefore important.
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The morphology of a thrombus can often help to predict subsequent 
embolization. For example, thrombus protrusion and mobility, especially those related to a 
recent myocardial infarction, are associated with an increased embolic risk (Haughland et al 
1984, Stratton et al 1988). The use of indium111 platelet scintigraphy may be helpful in 
identifying patients with chronic left ventricular thrombi at increased risk of embolisation. In 
one study, embolization occurred in 23% of patients with a positive platelet scintigram and 
echocardiogram, when compared with embolization in only 4% of patients with a negative 
platelet scintigram but positive echocardiogram (Stratton and Ritchie 1990). This method may 
therefore detect 'active' thrombi, which are at high risk of embolisation, and ongoing 
thrombogenesis may account for the positive platelet scintigraphy in these patients. 
Measurement of a suitable plasma marker of ongoing thrombogenesis (for example, plasma D- 
dimer) may complement this investigation.
The situation is therefore far from clear - just who is at risk of 
thromboembolism? Suggested guidelines for initiating anticoagulant therapy in patients with 
left ventricular thrombi are summarised in Table 8.2. For a mural thrombus to embolise, a large 
portion of its surface must be unattached to the underlying wall. For example, in patients 
sustaining a large anterior myocardial infarction with poor cardiac function, a protruding, mobile 
left ventricular thrombus requires anticoagulant therapy. The identification of patients at risk 
of systemic embolization is of particular importance - echocardiography and/or platelet 
scintigraphy may be useful, but the availability of a simply measured plasma marker of 
thrombogenesis might allow stratification of risk and assist in the management of such 
patients. Further discussion on the role of anticoagulation is to be found in chapter 10 of this 
thesis.
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TABLE 8.1 
ECHOCARDIOGRAPHIC INDICATIONS OF 
LEFT VENTRICULAR THROMBI (adapted from Meltzner etal 1986)
Mass of echoes in the left ventricular cavity with a well circumscribed, defined border. 
Abnormal motion pattern of the underlying myocardium, usually dyskinetic.
Distinct border shown between underlying myocardium and thrombus. 
Echocardiographic texture' different from that of underlying myocardium.
Usually apical position.
Ability to be recorded from more than one position.
TABLE 8.2 
INDICATIONS FOR ANTICOAGULATION THERAPY FOR 
POSSIBLE LEFT VENTRICULAR THROMBI
(adapted from Meltzner et al 1986)
Left ventricular aneurysm 3 months or more after acute myocardial infarction - usually no need 
for echocardiography or anticoagulation treatment, unless established heart failure 
Dilated cardiomyopathy
- treatment regardless of presence or absence of left ventricular thrombi.
Acute myocardial infarction
- large infarction, with associated congestive cardiac failure.
- anterior myocardial infarction without heart failure, especially if left ventricular thrombi 
are found on 2-D echocardiogram.
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8.2 STUDIES OF FIBRINOGEN, VON WILLEBRAND FACTOR AND FIBRIN D- 
DIMER IN LEFT VENTRICULAR SYSTOLIC DYSFUNCTION.
Introduction
Clinical evidence has demonstrated that the presence of heart failure significantly 
contributes to the thromboembolic risk of patients with chronic atrial fibrillation. This was 
confirmed in the Stroke Prevention in Atrial Fibrillation study, where congestive heart failure was 
one of three independent clinical predictors of thromboembolism, the others being a history of 
hypertension and previous thromboembolism (Stroke Prevention in Atrial Fibrillation Investigators 
1992a). In addition, left ventricular dysfunction seen on the 2-D echocardiogram appeared to be a 
strong predictor of later thromboembolic events (Stroke Prevention in Atrial Fibrillation 
Investigators 1992b). Patients with left ventricular dysfunction (especially those in whom a left 
ventricular aneurysm is present) are therefore thought to be at an increased thromboembolic risk 
despite being in sinus rhythm (Nixon 1983). The exact mechanism for thrombus formation in left 
ventricular aneurysms has not been clearly defined but may involve contributions from poor left 
ventricular function, increased stasis within a dilated left ventricle (or within the area of the 
aneurysm), and possibly, additional alterations of flow characteristics within the heart. Poor 
systolic function in an impaired ventricle may therefore result in sufficient stasis within a dilated left 
ventricular cavity to promote thrombus formation (Meltzer et al 1986). A high prothrombotic state 
may therefore exist in these patients, with a high degree of intravascular thrombogenesis.
As I have demonstrated in chapter 3 of this thesis, plasma fibrinogen is elevated 
in all groups of patients with chronic atrial fibrillation, irrespective of antithrombotic therapy. An 
attempt to correlate plasma levels of these haemorheological and prothrombotic factors with left 
ventricular function in this study of patients with chronic atrial fibrillation did not demonstrate any 
significant associations. The measurement of left ventricular function in the patients with chronic 
atrial fibrillation was based, however, on fractional shortening, which may not be an accurate 
assessment of left ventricular dysfunction especially in the presence of large wall motion 
abnormalities.
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The aim of this study was therefore to specifically determine the effects of left 
ventricular aneurysm formation and left ventricular dysfunction upon plasma fibrinogen and fibrin 
D-dimer levels. This would possibly provide evidence for a prothrombotic state with increased 
intravascular fibrin turnover or thrombogenesis in patients with left ventricular systolic dysfunction.
Materials and Methods
The design was a prospective population controlled study of male and female 
patients with coronary artery disease. Patients were initially selected following routine cardiac 
catheterisation. I selected patients for further study if they were felt to have either normal left 
ventricular contraction or a significant wall motion abnormality on left ventriculography. Exclusion 
criteria were identical to that in chapter 3. Results for patients were also compared to 158 patients 
aged 55-65 years, sampled from a local population study (North Glasgow MONICA Study) as in 
chapter 3. In addition, as all patients undergoing cardiac catheterisation were on aspirin therapy, I 
also included a population of patients with documented ischaemic heart disease (previous 
myocardial ischaemia or infarction) with normal cardiac function (no history of cardiac failure and 
normal echocardiography), but were not on aspirin therapy due to drug allergy or intolerance (for 
example, peptic ulcer disease). This group served as hospital controls.
Assessment of left ventricular function All patients had left ventricular function initially assessed 
by review of the dynamic single-plane left ventriculogram (performed at cardiac catheterisation). A 
consensus opinion of 2 observers for cardiac function as seen on the left ventriculogram was 
obtained before inclusion. Patients with possible wall motion abnormalities were then further 
assessed by echocardiography and by a radionuclide ventriculogram (RNVG).
Radionuclide ventriculography was performed using a low energy general 
purpose collimator following in vivo red cell labelling with 99m-technetium pertechnetate. Sixteen 
frames per cycle were obtained using a frame-mode algorithm with exclusion of 'bad beats', 
acquiring 200,000 counts per frame. Two projections were imaged (the standard 40° left anterior 
oblique view (which may be slightly adjusted to visualise the best view of the interventricular 
septum) and a left lateral view) and used for subsequent wall motion analysis. Analysis of the left
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ventricular ejection fraction was performed using the 'best septal' left anterior oblique view. The 
left ventricular region of interest was carefully delineated to exclude the left atrium, pulmonary 
veins and right ventricle throughout the cardiac cycle. After the background region of interest was 
chosen, a time-activity curve was generated. Left ventricular ejection fractions were then 
calculated by computer-analysis of the time-activity curves, normalised to background counts. In 
our laboratory, the normal left ventricular ejection fraction was considered £ 40%. This equilibrium 
gated study gave an objective measurement of left ventricular ejection fraction and categorisation 
of wall motion. A left ventricular aneurysm was therefore defined from the RNVG by the presence 
of a paradoxical wall motion abnormality. This was determined by abnormal phase (within the atrial 
range), presence of amplitude but evidence of a reversed stroke volume in the aneurysm region.
Echocardiography All of these patients had echocardiography performed primarily to assess 
for the presence or absence of intracardiac thrombus and also for the presence of wall thinning in 
aneurysm formation. The presence of a left ventricular aneurysm was identified by 
echocardiography as the presence of a regional wall motion abnormality with diastolic distortion 
and systolic dyskinesis. As in chapter 3, two dimensional and Doppler echocardiography was 
performed with the patient in the left lateral decubitus position using a Hewlett-Packard Sonos 
500 machine (Hewlett-Packard, Arondale, Pa, USA.) equipped with a standard 2.5 MHz 
transducer. Standard images were obtained, with the transducer was angled to maximise cardiac 
chamber size and gain positions were adjusted to obtain the clearest outline of the endocardium. 
Off line analytical methodology was used to quantify measurements of left atrial dimensions and 
left ventricular dimensions (similar to that in chapter 3). Left atrial volume was calculated using a 
standard ellipsoid formula (Sanfillipo et al 1990). The thickness of the septum and posterior wall, 
and left ventricular dimensions were measured using M-mode echocardiography in the 
parasternal long axis view (Sahn et al 1978). Left ventricular fractional shortening was calculated 
and the ejection fractions were estimated for those without significant wall motion abnormalities. 
The echocardiographic left ventricular ejection fraction (EF) was also calculated (with standard 
software on the echocardiography machine) using the method of Teichholz et al (1976), which 
was derived from the equation EF = 1-ESV/EDV, and involved the calculation of ventricular
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volumes at end-diastole (EDV) and end-systole (ESV) (using the formula: V= (7/2.4 + D] D^, 
where V = volume, and D = the echocardiographically measured Internal dimension].
The interobserver and intraobserver variability for 2-D and M-mode 
echocardiographic measurements have been described in chapter 3. A sample of 20 patients 
selected at random were studied twice on different occasions by the same observer (myself) and 
also by one other observer. Detailed Doppler echocardiography allowed assessment of the role 
of diastolic dysfunction and this is discussed in detail in chapter 9.
Plasma fibrinogen, von Willebrand factor and D-dimer assays Plasma fibrinogen, von Wille- 
brand factor (vWF) and fibrin D-dimer were assayed using techniques previously described in 
chapter 3.
Statistical methods All the values of the prothrombotic factor measurements were expressed 
as median ± interquartile range (IQR). Statistical comparison was performed using the Kruskal- 
Wallis test for multiple comparisons and Mann-Whitney two sample rank test for non-parametric 
distributions. For parametric distributions, oneway ANOVA and student's paired t-test were used. 
Correlations between clinical and echocardiographic measurements and Theological values were 
performed using Spearman's Rank correlation method. A probability of <0.05 was considered 
statistically significant.
Results
A total of 112 patients (89 male and 23 female; mean age 57.5 years, s.e.m. 
0.86) with coronary artery disease documented by coronary angiography were studied. At the 
time of the study, 34 patients had normal left ventricular function (Group 1), 30 had left ventricular 
dysfunction without aneurysm formation (Group 2) and 29 had left ventricular aneurysm (Group 
3a). In addition, 19 patients with left ventricular aneurysms were established on warfarin therapy 
(Group 3b). These patients on warfarin had Thrombotest results within the therapeutic range (5- 
15%). As patients were all on aspirin therapy, results for patients in Group 1 were compared to 24 
hospital controls (14M, 10F; mean age 57.8, s.e.m. 2.35) who were patients with ischaemic heart
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disease in sinus rhythm and normal cardiac function who were not on aspirin therapy due to 
contraindications such as dyspepsia and gastrointestinal intolerance. All the results were also 
compared to 158 population controls [subjects aged 55-65 years, sampled from a local population 
study (North Glasgow MONICA Study; described earlier]. Clinical variables in these groups are as 
shown in Table 8.3 There were no differences in age (one way ANOVA F=0.28,p=0.84) and 
body mass index (one way ANOVA F=1.08, p=0.362) between the groups. Similarly there were 
no differences in sex ratio (X2=3.6, 3 d.f.;p=0.31), proportion of smokers (X2=1.35, 3 d.f.; 
p=0.72) or severity of coronary artery disease (that is, proportions with single-, two- or three- 
vessel disease; X2=6.32, 6 d.f;p=0.39) between the groups studied.
Plasma fibrinogen, von Willebrand factor and D-dimer levels Plasma fibrinogen (median 
3.18g/l IQR 2.64-3.58) and D-dimer (median 58ng/ml, IQR 34-88) levels were measured in all 
patients, but von Willebrand factor was only assayed in 95 patients from Groups 1,2 and 3a 
(median 124%, IQR 93 to 172). As a group, all patients had significantly elevated plasma 
fibrinogen levels when compared to population controls (point estimate of difference between 
medians 0.53 g/l; 95% C.l. 0.38 to 0.67, p<0.0001). Plasma vWF levels were also increased 
when compared to population controls (point estimate of difference between medians 18%; 95% 
C.l. 6 to 31, p=0.005). There were significant differences in plasma fibrinogen (Kruskal-Wallis test 
H=50.5, 4 d.f.;p<0.0001), D-dimer (Kruskal-Wallis test H=33, 4 d.f.;p<0.0001) and vWF (Kruskal- 
Wallis test H=12.3, 3d.f.; p=0.007) between the groups (Groups 1,2,3a and 3b).
In Group 1 (Normal LV function), plasma fibrinogen (point estimate of difference 
between medians 0.36 g/l; 95% C.l. 0.15 to 0.57, p=0.0009) and vWF (point estimate of 
difference between medians 17%; 95% C.l. 1 to 33, p = 0.04) was significantly elevated when 
compared to population controls (Table 8.4). There was a lower plasma D-dimer level in these 
patients when compared to population controls (point estimate of difference between medians
23.0 ng/ml; 95% C.l. 9 to 36, p=0.001) (Table 8.4). There were no significant differences in 
plasma fibrinogen (point estimate of difference between medians -0.16 g/l; 95% C.l. -0.53 to 
0.15, p = NS) or fibrin D-dimer (point estimate of difference between medians 8.25 ng/ml; 95% 
C.l. -33 to 10, p=NS) when compared to hospital controls (Table 8.5).
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In Group 2 (LV dysfunction but no aneurysm), there was no significant difference 
in plasma fibrinogen (point estimate of difference between medians 0.14 g/l; 95% C.l. -0.23 to 
0.44, p=NS), vWF (point estimate of difference between medians 10%; 95% C.l. -13 to 13, p = 
NS) or D-dimer levels (point estimate of difference between medians 0 ng/ml; 95% C.l. -7 to 29, 
p=NS) in these patients when compared to Group 1 (Table 8.4).
In Group 3a (LV aneurysm without warfarin), plasma fibrinogen was significantly 
elevated when compared to Group 1 (point estimate of difference between medians 0.6 g/l; 95% 
C.l. 0.23 to 1.0, p=0.0001). In these patients, plasma D-dimer was also significantly elevated 
when compared to Group 1 (point estimate of difference between medians 55 ng/ml; 95% C.l. 23 
to 103, p=0.0007). There was a trend towards higher vWF levels in Group 3a compared to Group
1 (point estimate of difference between medians 24%; 95% c.i. -53 to 8, p=0.13). In similar 
patients on warfarin therapy (Group 3b), there was no significant difference in plasma fibrinogen 
(point estimate of difference between medians 0.39 g/l; 95% C.l. -0.04 to 0.91, p=NS), but there 
was a significantly lower plasma fibrin D-dimer level when compared to Group 3a (no warfarin 
therapy) (point estimate of difference between medians 65.5 ng/ml; 95% C.l. 28 to 132, 
p=0.0003) (Table 8.4).
Radionuclide ventriculography and echocardiography data All patients in Group 2 and 
3a had equilibrium radionuclide ventriculography performed. However, two patients in Group
2 and one from Group 3a had uninterpretable RNVGs due to multiple extrasystoles. Only 15 
patients from Group 1 were referred for RNVG but normal left ventricular function was 
established for all members of this group by both a normal left ventriculogram at cardiac 
catherisation and normal echocardiography. As expected, patients in Group 2 and 3 had 
lower ejection fractions by RNVG (median ejection fractions 28% and 29% respectively) and 
echocardiography (median ejection fractions 43% and 40% respectively) when compared to 
patients in Group 1 (47% by RNVG, 55% by echocardiography).
Mural thrombus was only visualised in one patient by echocardiography; a 38 
year male who also had an recent cerebrovascular event. His prothrombotic markers were
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high, with plasma fibrinogen, vWF and D-dimer levels of 4.48g/l, 192% and 131 ng/ml 
respectively.
Effects of cardiac chamber size and ventricular function on plasma fibrinogen, D-dimer and 
vWF levels.
In Group 1 (normal left ventricular function) there were significant correlations 
between plasma fibrinogen and left ventricular fractional shortening (r=-0.43, p=0.023) and 
echocardiographically-derived ejection fraction (r=-0.42, p=0.02); and vWF and left ventricular 
end-diastolic dimension (r=0.43,p=0.026). (Table 8.7) Stepwise multiple regression analysis 
and multiple regression analysis with plasma fibrinogen, D-dimer and vWF as dependent 
factors demonstrated no significant predictors amongst age, sex, smoking habit, ejection 
fraction (RNVG), body mass index, left atrial volume and left ventricular fractional shortening 
(fibrinogen F 2.77, p=0.17; D-dimer F1.74, p=0.53; vWF F=0.51,p=0.81).
In Group 2 (left ventricular dysfunction), there were significant correlations 
between plasma D-dimer and age (r=0.57, p=0.001), left ventricular end-diastolic dimension 
(r=0.418, p=0.04) and left atrial dimension (r=0.472, p=0.007). In addition, there were 
correlations between vWF and left atrial dimension (r= -0.44,p=0.013) and left atrial volume 
(r=-0.37,p=0.04) (Table 8.7). Stepwise multiple regression analysis and multiple regression 
analysis with plasma fibrinogen, D-dimer and vWF as dependent factors demonstrated no 
significant predictors amongst age, sex, smoking habit, ejection fraction (RNVG), body mass 
index, left atrial volume and left ventricular fractional shortening (fibrinogen F 1.22,p=0.36; D- 
dimer F2.0, p=0.16; vWF F=0.74,p=0.66).
In Group 3 (aneurysms) there were no significant correlations between 
plasma fibrinogen, vWF and D-dimer with cardiac chamber size or cardiac function. Stepwise 
multiple regression analysis and multiple regression analysis with plasma fibrinogen, D-dimer 
and vWF as dependent factors demonstrated no significant predictors for D-dimer and vWF 
amongst age, sex, smoking habit, ejection fraction (RNVG), body mass index, left atrial volume 
and left ventricular fractional shortening (D-dimer F=0.7, p=0.70; vWF F=0.69,p=0.69). For 
plasma fibrinogen, however, smoking was a significant predictor (t=2.29, p<0.05) using
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stepwise multiple regression analysis, although multiple regression with the same variables 
demonstrated no significant predictors (F=0.70,p=0.699).
Discussion
This study demonstrates that as a group, patients with coronary artery 
disease have significantly elevated plasma fibrinogen and von Willebrand factor (vWF) levels 
when compared to random population sample controls of similar age in sinus rhythm. This is in 
keeping with epidemiological evidence of an association between plasma fibrinogen, vWF 
and ischaemic heart disease. However, some differences emerge when these patients are 
subdivided on the basis of cardiac function. Patients with left ventricular aneurysms, for 
example, have the highest levels of plasma fibrinogen, vWF and D-dimer. These findings are 
not due to an excess of smokers, nor are they attributable to an increase in the extent of 
coronary artery disease in view of similar proportions of patients with 2 or 3 vessel disease in 
the groups studied (Table 8 .3 ).
As epidemiological and clinical evidence suggests that elevated plasma 
fibrinogen levels are associated with increased cardiovascular mortality and morbidity, this 
finding would suggest that these patients are at increased cardiovascular risk. In addition, 
these patients have higher plasma vWF levels when compared to population controls. This is 
pertinent as an elevated vWF level is associated with an increased risk of reinfarction and 
subsequent mortality in survivors of myocardial infarction (Jansson et al 1991). Patients with 
left ventricular aneurysms have the highest levels of plasma vWF, which may be explained by 
two possible mechanisms. Firstly, they would appear to have the greatest endothelial 
dysfunction (as reflected by vWF levels), potentially leading to the highest intravascular 
thrombogenesis (consistent with the highest plasma D-dimer levels being found in these 
patients). Secondly, patients with the highest vWF levels have the greatest cardiovascular 
risk and consequently these patients may sustain the largest myocardial infactions, resulting 
in the most cardiac 'damage' (and aneurysm formation). Further prospective studies 
examining the predictive effects of high plasma vWF for cardiovascular events and 
thromboembolism in healthy population surveys are required to assess these hypotheses.
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The high plasma fibrin D-dimer in patients with left ventricular aneurysms 
suggests ongoing intravascular fibrin turnover in these patients. In addition, the increased 
plasma fibrinogen levels may promote thrombogenesis in these patients either by increasing 
the tendency towards thrombosis or by increasing flow disturbance through rheological 
effects by increasing red cell aggregation and blood viscosity in areas of stasis. My findings in 
this study (and the possible haemorheological explanation) is in keeping with experimental 
evidence demonstrating regional stasis of blood in hearts with severe apical dysfunction 
(Mikell et al 1982). In an aneurysm, there is both diastolic and systolic bulging, resulting in 
severe stasis of blood, with consequent predisposition towards thrombus formation. As 
abnormalities in blood flow predispose towards thrombus formation (as part of Virchow's triad), 
this study is the first haemorheological demonstration of abnormally enhanced fibrin turnover 
and thrombogenesis in patients with left ventricular aneurysms. As plasma fibrin D-dimer is a 
marker of intravascular thrombus formation, my findings are also consistent with the 
hypothesis that the more severe the degree of blood stasis, the more likely that intravascular 
thrombogenesis will occur.
In the setting of ischaemic heart disease, the risk of thrombus formation is 
proportional to the size of the infarct (and therefore the extent of wall motion abnormality). For 
example, stroke is a known complication of an anterior myocardial infarction, occurring in 
approximately 6% of patients (Cerebral Embolism Task Force 1989). Most cardiac thrombi 
form in close association to dyskinetic wall motion abnormalities and embolization is most 
common in the first 4 months (Weinreich et al 1984). Inferior myocardial infarction is less 
commonly a precursor of embolic stroke unless significant ventricular dysfunction is also 
present (Weinreich et al 1984). It has been noted that apical left ventricular aneurysms are 
usually associated with thrombus formation, but the embolic risk is usually smaller than that for 
other dyskinetic segments (Lapeyre et al 1985). However, transthoracic echocardiography is 
a sensitive and specific method only for the detection of mural thrombus of >5mm in diameter 
(Hildebrand et al 1993). For example, mural thrombus was detected by echocardiography in 
only one patient, who also had a recent cerebrovascular event. Echocardiography may 
therefore still miss smaller collections of thrombus that are still capable of producing
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devastating strokes and other serious thromboembolic complications. As measurement of 
plasma fibrin D-dimer is a marker of intravascular thrombus formation, elevated levels may 
indicate the presence of thrombus although not visualised at echocardiography. In contrast, 
patients with left ventricular aneurysms whom are established on oral anticoagulant therapy 
have significantly lower median plasma D-dimer levels, which is consistent with the 
prophylactic benefit of warfarin therapy in reducing thromboembolic risk.
The interaction between prothrombotic factors and cardiac structure or 
function is illustrated in this study. In Group 1, for example, plasma fibrinogen levels are 
negatively correlated with left ventricular fractional shortening and echocardiographically- 
derived ejection fraction; and von Wilebrand factor is positively correlated with left ventricular 
end-diastolic dimension. This would suggest that those with poorer left ventricular function 
would have higher plasma fibrinogen levels and that endothelial dysfunction is greater in 
patients with dilated left ventricles, although these relationships are not seen in Group 2 or 3. 
In Group 2, however, there was a modest positive correlation between plasma D-dimer and 
age, left atrial size and left ventricular end-diastolic dimension, suggesting a relationship 
between intravascular thrombogenesis and age and dilated cardiac chambers. Again these 
associations are not seen in the other groups. Multiple regression analysis did not, however, 
show any significant predictors for plasma fibrinogen, vWF or D-dimer. The relationships 
between prothrombotic factors and cardiac structure and function is therefore complex, and in 
view of the differences between the subgroups, the relationships appear to be altered by the 
degree of overall cardiac function.
It is surprising that patients with ischaemic heart disease (and normal left 
ventricular function, Group 1) had significantly lower plasma D-dimer levels when compared to 
population controls. This may be in part explained by the use of aspirin therapy in Group 1, 
although the effect was not significant when Group 1 patients were compared to hospital 
controls (Table 8.5) or in patients with chronic atrial fibrillation on aspirin therapy (chapter 3). In 
addition, several subjects in the 'healthy1 population controls may have (undiagnosed) 
underlying cardiovascular disease which may affect the levels of these prothrombotic factors.
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My findings in this chapter would therefore be compatible with the 
conclusions of chapter 3 for patients with chronic atrial fibrillation. Again, measurement of 
plasma fibrin D-dimer may identify a subgroup of patients, with left ventricular aneurysms 
(those with increased D-dimer), whom would benefit particularly from the introduction of oral 
anticoagulation therapy. This would be of clinical advantage as prophylactic anticoagulation 
continues to have two problems; inconvenience and safety (Lowe 1992). A prospective 
study of the effects of initiating oral anticoagulation therapy is required to test this hypothesis, 
and this will be further studied in chapter 10.
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TABLE 8.3 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
- PATIENT CHARACTERISTICS
AGE
years 
mean (s.e.m.)
GROUP 1 
normal LV
(n=34)
57.5
(1.4)
GROUP 2 
LV dys
(n=30)
58.7
(1.4)
GROUP 3a 
aneurysm
(n=29) 
no warfarin
57.0 
(1-9)
GROUP 3b 
aneurysm
(n=19) 
on warfarin
56.5 
(18)
BMI
kg/m2 
median (IQR)
40.7
(37.9-43.5)
40
(38.1-42.1)
38.6
(37.1-40.7)
EF %
median (IQR)
47
(42-53)
28.0
(23.0-37.0)
28.0
(20.0-33.0)
21
(14.0-25.5)
M :F 28:6 26:4 20:9 15:4
sm okers
angiography
1 :2 :3
vessel
d isease
5:7:22 2:4:24 1:6:22 1:1:17
[LV = left ventricle; dys= dysfunction]
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TABLE 8.4 
LEFT VENTRICULAR FUNCTION AND 
PROTHROMBOTIC FACTORS
population  GROUP 1 G RO UP2 GROUP 3a
contro ls Normal LV LV  ANEURYSM
dysfunction no warfarin
FIBRINOGEN
median 
g/l (IQR)
158
2.6
(2.5-3.0)
34
2.97*
(2.65-3.35)
30
2.73
(2.34-3.30)
29
3.50®
(3.00-4.40)
D-D IM ER
median 
ng/ml (IQR) 
von  
W illebrand  
factor 
median 
mg/l (IQR)
76
(54-104)
105
(80-147)
48**
(30-84)
123***
(100-156)
61.0
(30-106)
117
(76-161)
10i@@
(60-190)
156
(101-201)
GROUP 3b 
ANEURYSM
warfarin
19
3.24
(2.89-3.61)
57+
(32-66)
[*p=0.0004, **p=0.0015, ***p=0.0398 vs population controls; 
@p=0.002, @@p=0.0001 vs Group 1;
+p=0.0001 vs Group 3a.]
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TABLE 8.5 
ASPIRIN AND PLASMA FIBRINOGEN & D-DIMER LEVELS
n
AGE
mean (s.d.)
GROUP 1 
Normal LV
on aspirin 
34 
57.8  
(8.1)
HOSPITAL CONTROLS  
IH D ,S R
no aspirin 
24
57.8  
(11.5)
FIBRINO G EN
median
fl/l
median (IQR)
2.96
(2.65-3.35)
3.07
(2.68-3.55)
FIBRIN D-DIMER
ng/ml 
median (IQR)
48
(30-84)
63
(40-90)
p=NS
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TABLE 8.6 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
-ECHOCARDIOGRAPHY DATA
GROUP 1 GROUP 2 GROUP 3 HEALTHY
Normal LV LV dysfunction LV aneurysm C O N TR O LS
33 30 29 14
LEFT ATRIUM  
D1 cm 
median (IQR)
3.89**
(3.54-4.18)
4.10 4.04 3.37
(3.73-4.48) (3.47-4.46) (3.09-3.65)
D2 cm 3.82 4.14@ 4.01 3.67
median (IQR) (3.5-4.11) (3.72-4.34) (3.68-4.39) (3.45-3.89)
D3 cm 
median (IQR)
5.13**
(4.67-5.50)
5.25
(4.81-5.67)
5.18
(4.75-5.64)
4.61
(4.20-4.79)
LEFT ATRIAL 
VO LU M E
cm^
median (IQR)
37.6**
(30.5-53.8)
45.4
(34.4-55.9)
41.1
(32.9-59.4)
29.2
(26.2-31.5)
LE FT  
V EN TR IC LE  
ESD cm
median (IQR)
3.6* 
(3.4-4.1)
4 4@@
(4.0-4.8)
4.5°®° 
(3.6-5.7)
3.4 
(3.2-3.6)
EDD cm
median (IQR)
5.3  
(5.1-5.6)
5 8@@ 
(5.3-6.2)
5.7°° 
(5.3-6.9)
5.2 
(4.9-5.5)
fractional
shorten ing
%
median (IQR)
30.0*
(26.9-35.2)
22 1@@ 
(16.4-26.9)
19.8°®° 34.5
(15.1-27.2) (30.9-37.3)
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EDV
cm3 
median (IQR)
135
(124-150)
166@@
(134-193) (130-242)
163° ° 128
(111-147)
ESV
cm3
median (IQR)
55*
(48.3-71)
87@@
(68-109)
99° ® °
(57-167)
48
(43-54)
E jection
Fraction
56.5
(51.7-62.9)
44.1@@ 39.6°®°
(34-53.5) (31.3-52.7)
64.0
(58.8-66.5)
(ECHO) %
median (IQR)
[*p<0.05, **d<0.005 compared to population controls; 
@p<0.05, ^@ p<0.005 compared to Group 1; 
‘’'frO.OS, °®°p<0.0005 compared to Group 1]
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TABLE 8.7
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
- SPEARMAN CORRELATIONS
GROUP 1 (Normal LV function)
FIBRINO G EN D- DIMER
D -dim er
r
0.26
P
0.135
von W illebrand  
factor
r P
vW F 0.28 0.118 0.009 0.956
age -0.170 0.662 0.212 0.227 -0.076 0.68
e jec tio n
fraction
(R N VG )
-0.36 0.187 -0.436 0.101 -0.26 0.618
body
mass index
-0.054 0.761 -0.149 0.595 0.166 0.633
left atrial 
dim ension
(long-axis)
0.26 0.14 0.126 0.51 0.33 0.068
left atrial 
volum e
0.02 0.901 0.142 0.555 0.342 0.062
LV end- 
diasto lic  
dim ension
0.106 0.599 ■0.157 0.57 0.43 0.026'
LV fractional -0.425 0.023'
shorten ing
LVEF (echo)
■0.182 0.644 -0.009 0.963
LV EF -0.42 0.024* -0.27 0.166 0.0195 0.92
(ech o )
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GROUP 2 (LV dysfunction)
FIB R IN O G EN  D -D IM E R  von W illebrand
r p r p r p
D -dim er 0.034 0.85
vW F -0.02 0.904 -0.087 0.651
age 0.114 0.549 0.57 0.001* -0.09 0.65
e jec tio n  0.000 0.99 -0.04 0.831 -0.144 0.512
fraction
(R N VG )
body 0.094 0.62 -0.05 0.773 -0.149 0.561
mass index
left atrial 0.133 0.52 0.472 0.007* -0.444 0.013*
dim ension
(long-axis)
left atrial 0.083 0.66 0.35 0.051 -0.37 0.04*
volum e
LV end- -0.031 0.882 0.4176 0.04* 0.03 0.887
diasto lic
dim ension
LV fractional 0.375 0.068 -0.34 0.101 -0.1 0.658
shortening
LVEF (echo)
LV EF 0.37 0.074 -0.35 0.087 -0.111 0.619
(echo)
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Group 3a (LV aneurysms, no warfarin)
D -d im er
F IB R IN O G E N
r
0.121
P
0.55
D - D IM ER von W illeb ran d  
fac to r
r P
vW F 0.224 0.251 -0.09 0.65
a g e 0.02 0.915 0.361 0.056 0.015 0.94
e je c tio n
fraction
(R N V G )
0.276 0.161 -0.08 0.694 0.0095 0.962
b ody
mass index
-0.186 0.655 -0.192 0.671 0.086 0.662
left atrial 
d im en sio n
(long-axis)
-0.07 0.72 0.076 0.704 -0.236 0.224
left atrial 
vo lu m e
0.043 0.821 0.307 0.109 - 0.11 0.584
LV end- 0.09 0.703 -0.198 0.621 -0.365 0.091
d iasto lic
d im ension
LV fractional 0.095 0.671 0.046 0.83 0.237 0.276
sh o rten in g
LVEF (echo)
LV EF 0.09 0.685 0.027 0.899 0.226 0.299
(e c h o )
*p<0.05
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CHAPTER 9
THROMBOGENESIS
IN
LEFT VENTRICULAR 
DIASTOLIC DYSFUNCTION
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9.1 IS DIASTOLIC DYSFUNCTION IMPORTANT ?
Introduction
Heart failure has been traditionally regarded as due to abnormalities in the 
systolic or contractile function of the heart. However, up to 30-40% of patients with 
congestive heart failure have normal systolic function (Dougherty et al 1984, Johnson 1991, 
Soufer et al 1985). Instead, the majority of this patient group have abnormal diastolic function 
as the prime underlying disorder. The clinical presentation and outcome of these patients 
with congestive heart failure, secondary to diastolic dysfunction, can in fact be identical to 
those with systolic dysfunction making differentiation between the two conditions very 
difficult (Setaro et al 1992). There is therefore debate whether or not diastolic dysfunction is 
clinically important and worthwhile distinguishing from systolic dysfunction in patients with 
heart failure.
Pathophysiology
The normal cardiac cycle consists of two components: systole (contraction; 
ventricular emptying) and diastole (dilatation; ventricular filling). Diastole can be divided into 4 
phases; isovolumetric relaxation, early filling, diastasis, and atrial systole. The amount of left 
ventricular filling occurring during each of these phases depends upon several factors: 
myocardial relaxation, the passive characteristics of the ventricle and characteristics of the left 
atrium, pulmonary veins, mitral valve and heart rate (Little and Downes 1990). Diastolic left 
ventricular function appears, however, to be primarily modulated by diastolic left ventricular 
pressure and other properties of the left ventricular myocardium (Figure 9.1). When diastolic 
function is normal, the net effect is left ventricular filling sufficient to produce an adequate 
cardiac output, while the mean pulmonary venous pressure is maintained below 12mm Hg 
(Little and Downes 1990). If the latter exceeds 12-15mm Hg, as in cardiac failure, pulmonary 
congestion occurs.
The main causes of diastolic dysfunction are left ventricular hypertrophy, 
ischaemic heart disease and restrictive cardiomyopathy (Bonaduce et al 1989, Grossman 
1990, Setaro et al 1992, Shepherd et al 1989). Other causes include valvular disease,
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chronic renal failure, diabetes and restrictive or constrictive states (Grossman 1990). in all 
these conditions, impaired myocardial relaxation, ventricular hypertrophy and fibrosis occur. 
This results in stiff, poorly relaxing, ventricles that fill adequately only under high atrial 
pressure. This problem is exacerbated during exercise when the diastolic filling time is 
reduced. The net result may therefore be pulmonary congestion despite normal systolic 
pumping function, and possible subendocardial ischaemia, development of compensatory 
myocardial hypertrophy and consequent detrimental remodelling of the heart (Harizi et al 
1988, Pouleur et al 1989). The main conditions associated with diastolic dysfunction (as 
discussed above) are also associated with thromboembolism. Hypertrophic cardiomyopathy, 
for example, constitutes an important thromboembolic risk, and poor ventricular compliance is 
present in such patients (Nishide et al 1983, Petrin and Tavel 1979).
Ischaemic heart disease is probably the most common condition associated 
with impaired diastolic function. Importantly, diastolic function is more susceptible to 
ischaemia than systolic function and can take longer to recover. Silent myocardial ischaemia in 
asymptomatic patients with coronary artery disease may result in significant diastolic 
dysfunction (Mahmarian and Pratt 1990) (Figure 9.2). Furthermore, impaired ventricular 
distensibility may adversely affect the Frank-Starling mechanism, thus impairing systolic pump 
function and cardiac output adaptation during exercise (Pouleur et al 1989). Systolic and 
diastolic dysfunction may (and often do) co-exist, for example, in an infarcted segment where 
fibrosis and scar formation may result in both significant wall motion abnormalities and 
decreased diastolic distensibility of the left ventricle (Bonow 1990) (Figure 9.2). Such 
'regional' fibrosis results in increased stiffness of the ventricular chamber; and the presence of 
akinesia or dyskinesia (as in aneurysm formation) creates regional systolic dyssynchrony, 
which adds further to impaired ventricular relaxation (Bonow 1990). In short, when diastolic 
dysfunction is present, there is often a mechanical problem: the ventricular chambers can no 
longer accept, at normal pressure, enough blood to maintain normal stroke volume.
There is some evidence that significant biochemical alterations within the 
myocyte can also cause diastolic dysfunction, although the associated mechanisms may be 
related to ischaemia or hypoxia. Examples of such biochemical changes include increased
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intracellular calcium and decreased adenosine triphosphate and creatine phosphate 
(Grossman 1990).
The measurement of diastolic dysfunction is made difficult as it is associated 
with several clinical parameters, such as cardiac rhythm, heart rate, end-diastolic left ventricular 
volume, systolic left ventricular performance and age (Marcus and Dellsperger 1991, Stewart 
et al 1992). A method of adjusting for the influence of age and heart rate on diastolic function 
however has been described (Stewart et al 1992). Atrial systolic function is also an important 
consideration. In the young healthy individual, under normal circumstances, left atrial systole 
contributes less than 25% of left ventricular stroke volume. However, in the presence of 
diastolic dysfunction, tachycardia or advancing age, the atrial contribution may become much 
more significant, contributing up to 50% of left ventricular stroke volume (Little and Dowes 
1990, Marcus and Dellsperger 1991, Takemoto et al 1992). Exercise has an additional 
influence on this (which is independent of heart rate) and left ventricular diastolic dysfunction 
associated with 'normar aging is less pronounced in those persons who are exercise-trained 
(Takemoto et al 1992).
In summary, impaired early ventricular filling and a greater dependence on 
atrial systole for ventricular filling would typify most cases of diastolic dysfunction (Harizi et al 
1988, Labovitz and Pearson 1987, Little and Dowes 1990, Stauffer and Gaasch 1990).
Methods of diagnosis
The cardinal symptom in patients with diastolic dysfunction is dyspnoea. The 
acute clinical presentation may frequently be identical to that of systolic dysfunction, and the 
clinical differentiation between the two is often difficult, if not impossible, without further 
investigation (such as echocardiography). The presence of diastolic dysfunction is 
suggested by pulmonary congestion in a patient with a normal heart size on the chest X-ray. 
However, cardiomegaly and signs of biventricular failure (elevated jugular venous pressure, 
basal crepitations and oedema) are also frequently present (Dougherty et al 1984, Soufer et al 
1985). In sinus rhythm, a fourth heart sound is invariably present, and although a left 
ventricular third heart sound usually indicates systolic dysfunction, it may also be heard in
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isolated diastolic dysfunction with an extremely elevated left atrial pressure (Dougherty et al 
1984, Soufer et al 1985).
There is unfortunately no single method of investigation that may be used to 
characterise left ventricular diastolic dysfunction, but the two most useful techniques are 
echocardiography and radionuclide ventriculography (Marcus and Dellsperger 1991).
Echocardiography is still the most common and most frequently used non- 
invasive method. Doppler echocardiography has been favourably compared with both 
angiographic (Rokey et al 1985) and radionuclide techniques (Friedman et al 1986, Spirito et 
al 1986) in the assessment of diastolic dysfunction. One of the most frequently used 
methods is to measure the transmitral flow by Doppler echocardiography (Thomas and 
Weyman 1991) (Figure 9.3). Normal transmitral flow can be divided into early and late atrial 
filling phases, the latter resulting from atrial contraction. The typical change seen, for 
example, in severe heart failure, is a rise in early peak flow velocity and an increased ratio 
between early and atrial peak flow velocity when high pressure is present in the left atrium. 
These patterns are however reversed with reduced left ventricular compliance and impaired 
diastolic function (for example, in hypertension, cardiomyopathy and coronary artery disease) 
(Cheng 1990, St Goar et al 1991, Thomas and Weyman 1991). Other empirical indices of 
diastolic dysfunction have been derived from the mitral flow pattern, such as the integrated 
velocities of early rapid filling and atrial contraction, their ratios, and the acceleration and 
deceleration times of the early filling wave, but these indices are not well established (Thomas 
and Weyman 1991). Another measurement is the atrial ejection force, which is a measure of 
atrial systolic function, that allows an assessment of the atrial contribution to diastolic 
performance (Manning et al 1993). Atrial ejection force is dependent upon atrial preload, atrial 
afterload and ventricular stiffness, and as its calculation takes into account the acceleration of 
blood (as ejected by the atria) and the mass of blood ejected through the mitral orifice, it is 
considered as a more physiological index of atrial systolic performance (Manning et al 1993).
The major advantage of Doppler echocardiography is its ease in providing a 
noninvasive evaluation of diastolic function on a beat-by-beat basis with a high success rate 
(Rokey et al 1985). Doppler indices are, however, only indirect measures of diastolic function,
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and provide no direct assessment of either ventricular relaxation or compliance. The use of 
Doppler measurements of mitral inflow velocities has however been validated in comparison 
to angiographic parameters of ventricular filling (Labovitz and Pearson 1987, Rokey et al
1985). The relationship is good, with a strong favourable correlation between the ratio of peak 
early to atrial velocities, the ratio of early to atrial flow velocity integrals and left ventricular 
diastolic pressure (Appleton et al 1988b, Labovitz and Pearson 1987).
Another Doppler pattern of diastolic dysfunction different from the classic E/A 
velocity reversal has been described. This is characterised by a short isovolumetric relaxation 
time, a tall narrow E wave with high peak velocity and steep deceleration, and a small narrow A 
wave. This Doppler pattern is observed in situations with very low ventricular compliance such 
as constrictive pericarditis (Hatle et al 1989), restrictive cardiomyopathy (Appleton et al 1988a, 
St Goar et al 1991) and acute severe aortic insufficiency (Oh et al 1989). It is thought to be 
due to abnormalities in the early, energy dependent diastolic filling period (Doppler E 
velocity), whereas late diastolic dysfunction (the Doppler A velocity) is more affected by the 
passive distensibility of the chamber ("compliance") (Devereux 1989). Therefore, increasing 
chamber stiffness may result in an enhanced peak early filling velocity and volume, with 
decreased filling during atrial systole (Stoddard et al 1989). Impaired relaxation, however, 
correlates with a decreased peak early filling velocity and increased atrial contribution to filling 
(Stoddard et al 1989).
Echocardiography does however have its limitations in the assessment of 
diastolic function. One is the visual measurement of the mitral annulus and the assumption of 
a constant circular geometry to the mitral valve annulus throughout diastole. Secondly, 
measurement of Doppler mitral valve velocities can be inaccurate in the presence of 
associated valvular heart disease and are of limited value during exercise as early and late 
diastolic profiles tend to merge at heart rates of 100 or more beats per minute.
In summary, there are two echocardiographic patterns of diastolic 
dysfunction, the first reflecting abnormal relaxation and characterised by a high peak atrial 
velocity and diminished early filling velocity (and the ratio of these velocities, E/A vel <1); the
217
second reflecting a restrictive or constrictive pattern, with a high early filling velocity and a small 
narrow A wave (with their ratio, E/A vel usually >2). This is illustrated in Figure 9.4.
In multigated radionuclide ventriculography, a reduction in peak left 
ventricular filling rate and prolongation of time to peak filling indicate impaired early ventricular 
filling, which is present in diastolic dysfunction. Radionuclide studies remain the 'gold 
standard' method although they have significant limitations. It is important to acquire a high 
quality study with good target to background ratio. Thus subjects (for example, diabetics) who 
bind the radionuclide label poorly to their erythrocytes and those with frequent ventricular 
ectopics yield poor information. The images should be as 'noise-free' as possible and the 
time activity curve generated with respect to end-diastolic volume subtraction and 
normalisation to ventricular rate for standardisation. Analysis of higher harmonics, other than 
the fundamental total body count can be useful but increases the complexity.
One other technique for assessing diastolic function involves cardiac 
catheterisation, but this has essentially gone out of favour. Using this technique, patients 
with left ventricular dysfunction can be characterised by the following features: (i) an elevated 
left ventricular end-diastolic pressure >15 mm Hg; (ii) normal left ventricular end-diastolic (<90 
mL/m2) and end- systolic (<35 mL/m2) volumes; (iii) normal left ventricular ejection fraction 
(>0.50); and (iv) the absence of valve disease (Brogan et al 1992).
In summary, there is no absolute 'gold standard' for assessing diastolic 
performance. It is difficult to state which method (or index) is the most reliable or accurate 
measure of diastolic function. However, both echocardiography and radionuclide methods 
are minimally invasive, relatively simple, with capability for serial study; and are therefore most 
useful in clinical practice.
Are the differences between systolic and diastolic dysfunction prognostically important for 
cardiovascular events and thromboembolic risk?
Epidemiological studies have established the contributory role of heart failure 
to thromboembolic risk but the individual contributions of systolic and diastolic dysfunction 
have not been established. For example, ischaemic heart disease, hypertension and
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cardiomyopathy are common causes of diastolic dysfunction (Setaro et al 1992) and these 
conditions are also associated with a significant thromboembolic risk. The presence of 
hypertensive heart disease is also additive to the presence of atrial fibrillation as a risk for 
stroke (Stroke Prevention in Atrial Fibrillation Investigators 1992a) and echocardiographic 
abnormalities of diastolic filling are often seen in patients with hypertension and left ventricular 
hypertrophy (Bonaduce et al 1989, Shepherd et al 1989). In addition, a common aetiological 
factor for both atrial fibrillation and diastolic dysfunction is ischaemic heart disease, which was 
present in 47% of acute admissions with atrial fibrillation to my hospital (see chapter 2).
Clinical evidence for the deleterious effects of diastolic dysfunction is 
provided in a follow-up study of 52 patients initially hospitalised with congestive heart failure 
with intact left ventricular systolic function (Ejection Fraction >45%). Combined cardiovascular 
mortality and morbidity at 7 years was 75% whilst noncardiovascular mortality was 10% (Setaro 
etal 1992). Interestingly, cardiovascular mortality in these patients (46%) included refractory 
congestive heart failure and pulmonary oedema, myocardial infarction and stroke (Setaro et al 
1992). These data would suggest that diastolic dysfunction, by virtue of its effects in 
promoting congestive cardiac failure, would predispose patients to thrombotic and embolic 
risks, and an excess was noted in this study although not analysed in detail.
Diastolic dysfunction may, however, have a better overall long-term prognosis 
than systolic dysfunction. For example, both the CASS Registry and the V-HeFT study 
demonstrated a better prognosis for congestive heart failure patients with normal systolic 
function when compared to those with systolic dysfunction (Cohn and Johnson 1990, Judge 
et al 1991). Brogan et al (1992) also showed a low cardiac mortality (14%) but a substantial 
morbidity (45%) in such patients. However, an important consideration is the link between 
diastolic dysfunction and silent myocardial ischaemia (Mahmarian and Pratt 1990). Seemingly 
healthy asymptomatic patients and patients with stable ischaemic heart disease, unstable 
angina, or recent myocardial infarction are all at higher risk of subsequent cardiovascular 
morbidity (and perhaps mortality) if silent ischaemia is present, and underlying diastolic 
dysfunction may in part contribute to this risk (Mahmarian and Pratt 1990). Patients with
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congestive heart failure and intact systolic function therefore do not have a favourable 
outcome (Setaro et al 1992, Warren and Grossman 1991).
Management options
The treatment of patients with diastolic dysfunction is unfortunately difficult. 
This is pertinent as diastolic dysfunction is common in ischaemic heart disease and 
abnormalities of diastolic rather than systolic performance may be important determinants of 
the clinical status and exercise intolerance of patients with heart failure (Packer 1990). Drugs 
that lower ventricular filling pressures are more likely therefore to enhance exercise capacity 
than drugs that primarily increase cardiac output and left ventricular ejection fraction indices 
(Packer 1990).
Along these lines, treatment with verapamil appears to have therapeutic 
benefit (Shepherd et al 1989). Other useful therapies to be considered include xamoterol (a 
partial beta agonist), beta agonists (Pouleur et al 1989, Rousseau et al 1989) and negatively 
inotropic agents such as disopyramide. Beta blockers, however, can also have variable 
therapeutic effects in diastolic dysfunction, due to the associated changes in heart rate and 
afterload (Shepherd et al 1989). In contrast, therapy with cardiac glycosides, such as digoxin, 
appears to be of no benefit and theoretically these drugs could be detrimental (Pouleur et al 
1989). Diuretics and nitrates may also be detrimental in patients with diastolic dysfunction by 
decreasing venous return and filling pressures, resulting in decreased cardiac output and 
hypotension (Pouleur et al 1989, Shepherd et al 1989). The position is less clear for 
angiotensin-converting enzyme inhibitors (Pouleur et al 1989), but some benefits on diastolic 
dysfunction post-myocardial infarction have been shown (Gotzsche et al 1992).
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9.2 STUDIES OF FIBRINOGEN, VON WILLEBRAND FACTOR AND D-DIMER 
IN DIASTOLIC DYSFUNCTION
Introduction
Current clinical and epidemiological data on the contributory role of heart 
failure to thromboembolic risk does not differentiate between systolic and diastolic 
dysfunction, although coronary artery disease, hypertension and cardiomyopathy (all 
commonly associated with thromboembolic risk) are the most frequent causes of diastolic 
dysfunction. Increased ventricular 'stiffness' and poor myocardial compliance may cause 
sufficiently impaired ventricular filling to result in abnormal blood flow characteristics adequate 
to promote thrombogenesis. Indeed, the presence of a large ventricular wall motion 
abnormality (in association with a reduced ejection fraction) may result in an increase in left 
ventricular end-diastolic volume or pressure and diminished overall left ventricular compliance 
(Cheng 1990).
Doppler echocardiography represents an excellent technique capable of 
simply and noninvasively measuring the timing, magnitude and patterns of blood flow in 
cardiac chambers during both diastole and systole. The aim of this echocardiographic study 
was to determine the prevalence of diastolic dysfunction in patients with ischaemic heart 
disease, and whether or not the presence of left ventricular systolic dysfunction (and left 
ventricular aneurysm formation) alters this prevalence. Secondly, I wished to assess whether 
or not diastolic dysfunction contributes to the prothrombotic state (as measured by indices of 
thrombogenesis such as plasma fibrinogen, von Willebrand factor and fibrin D-dimer) of 
patients with left ventricular dysfunction.
Materials and methods
The design was a prospective case controlled study of patients with 
underlying coronary artery disease, all of whom were in sinus rhythm. A diagnosis of coronary 
artery disease was established in all patients as a consequence of either coronary
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angiography or a clinical history of myocardial infarction, or angina with demonstrable 
ischaemia on exercise stress testing.
Left ventricular systolic function (and the presence of an aneurysm) was 
assessed by at least two of three methods described in chapter 8. Briefly these methods are 
review of the dynamic single-plane left ventriculogram (performed at cardiac catheterisation), 
echocardiography and 750 MBq 99m Technetium isotope radionuclide ventriculogram 
(RNVG). Unfortunately our computer in Stobhill Hospital was not sophisticated enough to 
measure indices of diastolic dysfunction using radionuclide venticulography.
Echocardiography was performed using a Hewlett Packard Sonos 500  
machine (Hewlett-Packard, Arondale, Pa, USA) using a standard 2.5 MHz transducer for 
pulsed wave Doppler studies. All subjects were studied in the lateral decubitus position. 
Normal Doppler indices were derived from 14 healthy volunteers who served as controls. 
Patients with significant mitral or aortic regurgitation and those with hypertension or left 
ventricular hypertrophy (left ventricular posterior wall in diastole> 1.1 cm) were excluded. The 
left ventricular mass index was not used as an exclusion criteria as standard formulae for its 
calculation are only valid in left ventricles without wall motion abnormalities or dyskinetic 
segments. In addition, patients with pericardial disease, cardiomyopathy, moderate / severe 
mitral (with an abnormal MV P ti/2) or aortic valve disease, a heart rate <50/min or >100/min or 
rhythm other than sinus rhythm were excluded. Only subjects with good quality Doppler 
echocardiographic recordings were included for analysis.
Doppler examination was performed using colour-flow, pulsed and continuous 
wave modes. Forward transmitral flow was determined in all patients. Peak mitral flow velocity was 
initially identified by continuous wave Doppler and then recorded using the pulsed wave mode 
and a 3mm gate from a position within the left ventricle at the level of the mitral annulus. Using the 
standard video facility of the ultrasound machine, off line analytical methodology was used to 
quantify measurements. Mean values from at least five cardiac cycles were used in the analyses. 
The peak velocities of the early (E) wave and the atrial (A) wave were recorded and their ratio 
(Evmax / Avmax) derived. The velocity time integral (or area under the velocity curve) for the early 
(E) and atrial (A) waves were also measured by tracing the contour of the darkest portion of the
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curve (Figure 9.3). In cases in which the early filling curve overlapped that of the atrial filling curve, 
a line dropped from the point representing the nadir of the two curves was used to separate the 
two integrals.
The following parameters of diastolic function were also calculated by means of 
the mitral inflow velocities: (i) peak filling rate (cm3 per second) = peak early diastolic velocity 
(Evmax) x cross-sectional area of the mitral annulus; (ii) normalised peak filling rate (in seconds'1) 
= peak filling rate divided by the left ventricular end-diastolic volume; and (iii) atrial filling rate = peak 
atrial velocity (Avmax) x cross-sectional area of the mitral annulus. As a measure of the balance 
between early and late diastolic filling, the following ratios were also calculated: (0 the ratio of the 
integral of the early diastolic filling period to that of the atrial filling period (Ejnt / Ajnt ) ; and (ii) the 
ratio of the peak early to peak atrial velocity (Ey/max /  Ay/max )• Finally, as an index of atrial systolic 
function, the atrial ejection force was calculated as 0.5 x p x mitral orifice area x (peak A velocity, 
Avmax)2 [where density of blood, p=1.06g/cm3] (Manning et al 1993).
M-mode recordings of the left ventricular cavity were made at the level just below 
the mitral leaflets to derive the left ventricular fractional shortening fraction and left ventricular end- 
diastolic volume. Fractional shortening was calculated as (LV end-diastolic dimension - LV end- 
systolic dimension) / LV end-diastolic dimension. Left ventricular end-diastolic volume was 
calculated as the cube of the left ventricular end diastolic diameter. To calculate the mitral annulus 
area, measurements were performed from the apical four-chamber and parasternal long-axis views 
during early diastole. Measurements were taken from the inner edge of the lateral bright corner of 
the annulus to the inner edge of the medial corner just below the insertion of the mitral leaflets, 
and the mitral annulus diameter averaged from the two views. The cross-sectional area of the 
annulus was derived as (3.14) x (mitral annular diameter / 2 )2 .
To allow validation of the Doppler measurements, and to assess reproducibility, 
interobserver and intraobserver variability, a sample of 20 patients selected at random were 
studied twice on different occasions by the same observer (myself) and another 20 subjects on 
different occasions by two observers (myself and one other observer). Reproducibility for Doppler 
echocardiographic measurements was expressed as mean difference ± 2s.d (Bland and Altman
1986). A one-sample t-test was performed to determine whether the mean difference was
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significantly different from zero. Methods of blood sampling and assays for plasma fibrinogen 
(CLAUSS), D-dimer (ELISA) and von Willebrand factor (ELISA) are as previously described in 
chapter 3 and 8).
Values are quoted as median ± IQR (interquartile range). For non-parametric 
comparisons, the Kruskal Wallis test and Mann-Whitney U test were used to compare medians. A 
X2 test was used to assess differences in sex, smokers, and the prevalence of diastolic 
dysfunction between groups. Correlations between clinical variables or plasma factors were 
performed using Spearman's Rank correlation method. Analysis of the influence of systolic and 
diastolic dysfunction and their interaction was performed using ANOVA for unbalanced data 
(General Linear Model). A probability value of <0.05 was considered significant. All statistical 
calculations were performed on a microcomputer using a commercially available statistical package 
(MINITAB v8, Minitab INC, PA,USA)
Results
A total of 106 patients (81 male, 25 female; mean age 57.5 years, s.e.m. 
0.87) with ischaemic heart disease were studied. Of these 5 were excluded as Doppler 
echocardiography was technically inadequate for further analysis. The remaining 101 patients 
were sub-divided into 3 groups on the basis of ventricular systolic function: 40 patients with 
normal left ventricular function (Group 1), 31 patients with impaired systolic function (Group 2, 
left ventricular systolic dysfunction); and 30 patients with left ventricular systolic dysfunction 
and aneurysm formation (Group 3, left ventricular aneurysm). They were compared to Doppler 
echocardiographic parameters of diastolic function in 14 healthy controls (8 male, 6 female; 
mean age 53.2 years, s.e.m. 2.2) of similar age in sinus rhythm (Table 9.1).
Whole group There were no significant differences for age (oneway ANOVA F=1.12, 
p=0.35) and sex distribution (X2=6.5, d.f.=3; p= 0.09) between the groups. Body mass index 
(Kruskal-Wallis test H=3.91, d.f=2; p=0.142) and proportion of smokers (X2=1.81,d.f=2; 
p=0.40) were also similar in the patient groups studied. Echocardiographic findings for the 
group as a whole (n=102) are summarised in Table 9.1. Patients in Group 1 (Normal systolic
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function) had significant differences in median Avmax. Ajnt. the Evmax/ A vmax and Eint/ Amt 
ratios, and atrial ejection force when compared to healthy controls (all p<0.05). Patients in 
Group 2 (Left ventricular dysfunction) had significant differences in median normalised peak 
filling rate when compared to Group 1 (p<0.05). There was a higher atrial ejection force in 
Group 3 (Left ventricular aneurysms) when compared to Group 1 (p<0.05), and a trend (non­
significant) towards lower median normalised peak filling rates, Evmax /  Avmax and higher 
Evmax. Avmax and atrial filling rates in Group 3 patients.
Diastolic dysfunction was defined as the presence of an Evmax /  A vmax ratio 
of <0.958. The value of 0.958 was derived from the lower limit of the 95% confidence interval 
for the median Evmax /  A vmax ratio of my healthy control group (median 1.055. 95% c.i. 
0.958-1.148). The prevalence of patients with diastolic dysfunction in each group of patients 
with coronary artery disease is summarised in Table 9.2. Proportions of patients with diastolic 
dysfunction were similar (approximately 60%) in all three groups (X2 =0.28, d.f.=2; p= 0.87).
Group 1 (Normal systolic function) Patients in Group 1 with diastolic dysfunction (Group 
1a, n=24) had a median plasma levels for fibrinogen of 3.02 g/l (IQR 2.53 - 3.34) , plasma D- 
dimer of 46 ng/ml (IQR 30-82) and von Willebrand factor (vWF) of 123% (IQR 95-160). Levels 
of plasma fibrinogen, fibrin D-dimer and vWF were not significantly different when compared 
to the Group 1 patients without diastolic dysfunction (Group 1b, n=16). In Group 1a, the 
correlation between plasma fibrinogen and D-dimer levels was significant (r=0.43,p=0.035) 
(Table 9.3). There was, however, no significant correlation between age, plasma fibrinogen, 
D-dimer or vWF with Doppler indices of diastolic dysfunction, although a trend is noted for the 
correlation between plasma vWF and Evmax (r= -0.42,p=0.06) and with Ejnt (r= 
-0.42,p=0.06). In Group 1b (that is, normal systolic and diastolic function), there is a significant 
correlation between age and peak filling rate (r=0.77, p=0.001) and between D-dimer levels 
and atrial filling rate or atrial ejection force (r= -0.62,p=0.013).
Echocardiographic parameters of diastolic dysfunction of patients in Group 1 
are summarised in Table 9.2. There were significant differences in peak filling rate, atrial filling 
rate (both p<0.05) and atrial ejection force (p=0.004); and also Evmax. Avmax (both p<0.005);
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Ejnt. A int (both p<0.05), Evmax / Avmax and Ejnt/Ajnt (both p<0.0001) in Group 1a when 
compared to Group 1b.
Group 2 (left ventricular systolic dysfunction) Patients in Group 2 with diastolic dysfunction 
(Group 2a, n=19) had median plasma levels for fibrinogen of 3.04 g/l (IQR 2.34-3.47), plasma 
D-dimer of 49 ng/ml (IQR 30-106) and vWF of 110% (IQR 69-160). In these patients levels of 
plasma fibrinogen, fibrin D-dimer and vWF were again not significantly different when 
compared to the Group 2 patients without diastolic dysfunction (Group 2b, n=13).
Echocardiographic parameters of diastolic dysfunction of patients in Group 2 
are summarised in Table 9.2. There were significant differences in peak filling rate, atrial 
ejection force, Evmax. Avmax (and their ratio) (all p<0.05), Ejnt (p<0.01), Ejnt and the 
Eint/Ajnt ratio (both p<0.001) in patients with diastolic dysfunction when compared to controls 
(Table 9.2). In both Group 2a and 2b, there was a negative correlation between vWF levels 
and peak filling and atrial filling rates (all p<0.05).
Group 3 (Left ventricular aneurysm) Patients in Group 3 with diastolic dysfunction (Group 
3a, n=18) had median plasma levels for fibrinogen of 3.46 g/l (IQR 2.92 - 4.25) , plasma D- 
dimer of 96ng/ml (IQR 65-172) and vWF 173% (IQR 88-194). Levels of plasma fibrinogen, 
vWF and fibrin D-dimer in Group 3a were not significantly different when compared to the 
Group 3b (n=12). There was a positive correlation between vWF and Evmax and E mt 
(p<0.05). In addition, there was also a positive correlation between D-dimer and atrial filling 
rate, and between D-dimer and atrial ejection force (p<0.05).
Echocardiographic parameters of diastolic dysfunction of patients in Group 3 
are summarised in Table 9.2. There were significant differences in all Doppler parameters of 
diastolic dysfunction when Group 3a patients were compared with Group 3b (all p<0.05).
Role of aneurysms, systolic and diastolic dysfunction (and their interaction) on 
thrombogenesis The relative contributions of systolic and diastolic function, the 
presence of an aneurysm and their interactions on plasma fibrinogen, D-dimer and vWF levels
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are summarised in Table 9.4. Using ANOVA for unbalanced data (GLM or General Linear 
Model analysis), the presence of an aneurysm or systolic dysfunction was associated with 
difference in plasma fibrinogen (F=9.96,d.f=2, p<0.0001) and vWF levels (F=3.32,d.f.=2, 
p=0.041), with no significant effect of diastolic dysfunction (or the interaction between them) 
on these prothrombotic factors. There was also a trend towards a difference in D-dimer levels 
in patients with systolic dysfunction and aneurysms but this did not reach significance 
(F=2.15, d.f=2, p=0.12). There was no effect of diastolic dysfunction (or the interaction with 
systolic abnormalities) on D-dimer levels.
Discussion
This study represents a detailed Doppler echocardiographic assessment of 
left ventricular diastolic dysfunction in patients with coronary artery disease and systolic 
dysfunction. I have also demonstrated that there were no significant abnormalities in plasma 
fibrinogen, fibrin D-dimer fragment and von Willebrand factor levels in patients with diastolic 
dysfunction when compared to those without diastolic dysfunction.
Diastolic dysfunction secondary to coronary artery disease was common 
(approximately 60%) in each of my patient groups studied. The impairment of diastolic 
function was observed both in patients with and without systolic dysfunction, although the 
degree of diastolic dysfunction appeared to be greater in patients with concomitant systolic 
dysfunction and ventricular aneurysm formation. This high prevalence is not due to factors 
such as age or sex, with no significant differences between the groups studied. Neither is it 
due to an excess of hypertension and significant rheumatic valve disease (which may cause 
alterations in diastolic function (Shaikh and Lavine 1988, Shepherd et al 1989)), as these 
patients were specifically excluded from the study. There was a high proportion of patients 
with prior myocardial infarction in the group with left ventricular aneurysms (as expected) and 
this may have contributed to the prevalence of diastolic dysfunction in Group 3. 
Nevertheless, the proportion of patients with myocardial infarction was not similar to the 
proportion of patients with diastolic dysfunction.
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Whilst I have observed a high prevalence of diastolic dysfunction in this 
study, my results are consistent with previous observations of diastolic dysfunction in a similar 
patient population using radionuclide techniques (Bonow et al 1981, Harizi et al 1988). For 
example, in patients with coronary artery disease and a normal ejection fraction, abnormalities 
of diastolic function have been reported in 52 to 86% of patients; whilst in patients with 
systolic dysfunction, abnormalities of diastolic filling have been noted in 69 to 100% of 
patients (Harizi et al 1988). My study therefore confirms previous observations that diastolic 
abnormalities are common in patients with ischaemic heart disease and may appear even 
before systolic abnormalities are evident (Harizi et al 1988). These observations suggest that 
it may be useful to investigate all patients presenting with congestive cardiac failure to 
establish the relative contributions of systolic and diastolic dysfunction, in order to optimise 
the patient's therapy and thereby reduce their morbidity as much as possible. For example, 
heart failure post-myocardial infarction can result from both systolic and diastolic dysfunction, 
and therefore detailed Doppler echocardiography in the early post-infarction period can be 
predictive of subsequent heart failure and morbidity. In one early (<36 hours) post-infarction 
study, the following predictors of subsequent heart failure were identified: age, anterior 
infarction, early diastolic peak filling velocity (E vmax). peak atrial filling velocity (A vmax). the 
ratio of these velocities (E vmax /  A vmax) and the presence of wall motion abnormalities 
(Finkelhor et al 1991). There is therefore a view that diastolic heart failure may correlate better 
with prognosis for symptoms and survival than traditional indices of systolic function (Packer 
1990, Warren and Grossman 1991). The combined assessment of both systolic and diastolic 
function would therefore be very important in the management of such patients.
However, the use of Doppler echocardiography in the assessment of 
diastolic function has its limitations and caveats. Most studies measure mitral flow velocities 
(Evmax and A\/max) and their ratio, and peak filling rates which have been relatively well 
validated (Harizi et al 1988, Rokey et al 1985). However the mitral annulus does change in 
area over the cardiac cycle, resulting in changes in the mitral flow velocity profile (Nishimura et 
al 1989). This change in mitral flow varies from being directed centrally into the left ventricle in 
early diastole, to posterolaterally during end-diastole (Nishimura et al 1989). Pulsed Doppler
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recording of the flow velocity through the mitral valve annulus may therefore not accurately 
reflect instantaneous volumetric flow (Nishimura et al 1989). The highest velocities across 
the mitral valve are usually recorded with the sample volume at or between the tips of the mitral 
valve leaflets as they open during diastole, and any recording away from this position may 
significantly alter the E and A velocity profiles (Nishimura et al 1989). An altered mitral flow 
velocity curve also occurs with the use of continuous wave Doppler (which sums all the 
velocities along the Doppler beam); continuous wave Doppler should not therefore be used 
in assessment of diastolic function. In addition, in the presence of left-sided valvular 
abnormalities, increased heart rate, multiple ectopics or poor ventricular compliance, mitral 
flow velocities can significantly change with alterations in ventricular filling (Marcus and 
Dellsperger 1991).
A further possible limitation in my study is the comparison of Doppler indices 
with that derived from 14 healthy subjects. Some of these subjects may have occult coronary 
artery disease, but this disadvantage was accepted as coronary artery disease in symptom 
free patients, taking no treatment, has been shown not to influence left ventricular filling 
(Stewart et al 1992).
No significant abnormalities in plasma fibrinogen, fibrin D-dimer fragment and 
von Willebrand factor are found in patients with diastolic dysfunction when compared to those 
without diastolic dysfunction. This finding suggests that the increased fibrinogen, 
intravascular fibrin turnover and endothelial dysfunction in patients with left ventricular 
aneurysms are likely to be due to abnormalities of flow in systolic dysfunction, with no 
significant effect from diastolic dysfunction. This is in keeping with my findings in chapter 8.
Nevertheless, some relationships are seen between these prothrombotic 
factors and certain Doppler indices of flow. For example, in patients with ischaemic heart 
disease but normal systolic and diastolic function (Group 1b), there is a significant negative 
correlation between plasma D-dimer levels, atrial filling rate and atrial ejection force (which is an 
index of atrial systolic function). This suggests that with higher atrial filling rates and greater 
atrial systolic function (and thus, less intra-atrial stasis), plasma D-dimer levels would be lower, 
possibly reflecting less intravascular fibrin turnover and thrombogenesis. Conversely,
229
impaired atrial systolic function (that is, lower atrial ejection force) may result in greater intra- 
atrial stasis and thus, greater thrombogenesis (as reflected by higher plasma D-dimer levels). 
This relationship is however altered by the presence of a left ventricular aneurysm with 
associated diastolic dysfunction (Group 3a). In this group, there is a positive correlation 
between plasma D-dimer and atrial filling rate or atrial ejection force, suggesting that the 
presence of an aneurysm influences the relationship between haemodynamics and 
thrombogenesis. An aneurysm is however associated with both diastolic and systolic bulging, 
which results in severe stasis of blood and a consequent predisposition to thrombus 
formation. A greater atrial filling rate and atrial ejection force (during ventricular diastole) may 
therefore contribute to diastolic bulging of the aneurysm, thus increasing stasis (particularly at 
the dyskinetic segment) and promoting thrombogenesis in such patients.
Endothelial dysfunction may also be related to abnormalities of diastolic 
function seen in ischaemic heart disease. For example, in patients with diastolic dysfunction 
but normal systolic function (Group 1a), an inverse relationship between vWF levels and 
passive ventricular filling was noted (as reflected by the negative correlation between vWF 
and Evmax and Ejnt in this group: r= -0.42, p=0.06). Although this relationship was not 
demonstrable in Group 2 (systolic dysfunction but no aneurysm), a negative correlation 
between vWF and peak and atrial filling rates is found. The findings in Group 1a suggest that 
endothelial (and perhaps endocardial) dysfunction (as reflected by higher vWF levels) could 
be associated with impaired early ventricular filling during diastole, in the presence of the poor 
left ventricular compliance associated with diastolic dysfunction (but normal systolic function). 
In contrast, Group 3a (aneurysms with diastolic dysfunction) patients demonstrate a positive 
correlation between vWF and Evmax (r=0.58, p=0.012). The presence of an aneurysm may 
therefore have complex influences on the relationship between endothelial dysfunction and 
the haemodynamics of left ventricular filling.
In conclusion, this study provides further evidence for the high prevalence of 
diastolic dysfunction in association with coronary artery disease, occurring in over 60% 
irrespective of left ventricular systolic impairment. Proper assessment of diastolic function is 
important particularly for patients with cardiac failure. There is, however, no evidence of a
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significant additional contribution to thrombogenesis (as assessed by plasma fibrinogen, von 
Willebrand factor and fibrin D-dimer) for patients with diastolic dysfunction. Endothelial 
dysfunction (as assessed by vWF levels) is also similar in patients with and without diastolic 
dysfunction. A relationship is noted between some prothrombotic factors and Doppler indices 
of flow which suggests that a relationship exists between cardiac haemodynamics and 
thrombogenesis.
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TABLE 9.1
LEFT VENTRICULAR DIASTOLIC DYSFUNCTION: 
PATIENT CHARACTERISTICS 
AND DOPPLER PARAMETERS 
(WHOLE GROUP)
GROUP 1 
normal LV
GROUP 2
LV systolic 
dysfunction
GROUP 3 
LV aneurysm
HEALTHY
C O N TR O LS
total studied 42 34 30 14
AGE  
mean (s.e.m .)
57.2
(1.4)
58.4
(1.4)
57.0
(1.9)
53.2
(2.2)
M :F 33:9 29:5 19:11 8:6
body mass 
index
median (IQR)
39.5
(37.3-43.1)
40
(38.0-42.3)
38.4
(36.9-40.7)
sm okers 8 10 5
D opplers
stud ied
(n )
40 31 30 14
Evmax
cm /s
(IQ R )
49.3
(43.8-61.1)
51.8
(38.2-62.8)
52.1
(40.1-68.2)
52.1
Avmax
cm /s
(IQ R )
55.3*
(44.9-65.8)
51.8
(44.2-70.8)
62.1
(48.4-70.3)
47.6
Evmax /  
Avmax  
ratio  
(IQ R )
0.905*
(0.79-1.10)
0.87
(0.73-1.02)
0.83
(0.64-1.18)
1.055
E integral 
cm 
(IQ R )
7.42
(6.03-8.74)
7.35
(5.92-9.26)
6.78
(5.28-8.89)
7.12
A integral 
cm 
(IQ R )
5.4*
(3.99-6.32)
4.9
(4.03-6.90)
5 75 
(4.27-6.96)
3.97
E/A integral 
ratio  
(IQ R )
1.38*
(1.15-1.79)
1.28
(1.13-6.64)
1.31 
(0.8-2.0)
1.72
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peak filling  297 344 325 293
rate  (241-358) (230-418) (240-440)
m l/sec  
( IQR)
norm alised 1.96 1.72+ 1 7 7  2.2
peak filling  (1.58-2.64) (1.03-2.20) (1.22-2.47)
rate  
sec"1 
( IQR)
atrial filling 327 345 369 275
ra te  (256-389) (263-467) (301-470)
m l/sec  
( IQR)
atrial ejection 9.9* 8.8 13 8@ 71
fo rc e  (6.6-13.1) (6.6-17.8) (7.0-18.3) (5.0-9.5)
kdynes  
( IQR)
*p<0.05 for Group 1 vs Controls; 
+p<0.05 for Group 1 vs Group 2; 
@p<0.05 for Group 1 vs Group 3.
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TABLE 9.2 
DIASTOLIC DYSFUNCTION 
& THROMBOGENIC FACTORS
GROUP O NE GROUP TW O GROUP TH R E E
NORMAL LV LV DYSFUNCTION LV ANEURYSM
(n=40) (n=3l) (n=30)
1 a 1 b 2a 2b 3a 3b
diastolic no diastolic no diastolic no
dysfunction diastolic dysfunction diastolic dysfunction diastolic
dysfunction dysfunction dysfunction
number 24 16 19 13 18 12
(%) (60%) (40%) (59.4%) (40.6%) (60%) (40%)
AGE 59.5 54.0 58 58.7 59.5 57.0
mean (16) (2.53) (1.7) (2.7) (1.7) (3.8)
(s.e.m.)
Evmax 47.6 61.8* 45.3 57.7+ 42.9 70.1 @
(40.7-54.6) (50.0-66.8) (35.4-59.5) (51.3-68.5) (38.4-52.0) (55.0-92.0)
Avmax 60.5 48.95* 59.9 47.6+ 68.9 46.4@
(53.0-68.7) (40.7-56.2) (49.6-71.2) (36.5-53.2) (60.2-73.9) (42.1-62.3)
v^max / 0.80 1.14* 0.76 1.02+ 0.67 1.21@
A Vmax (0.69-0.87) (1.07-1.32) (0.7-0.86) (1.01-1.55) (0.56-0.79) (1.16-1.60)
E int 6.82 8.25* 6.4 8.8+ 5.91 9.06@
(5.7-8.31) (6.48-9.2) (4.9-8.4) (7.4-12.5) (4.38-7.21) (6.6-10.9)
A int 6.0 4.0* 5.81 4.2 6.1 4.25@
(4.9-6.6) (3.75-5.43) (4.6-6.9) (3.8-5.8) (5.6-7.4) (2.9-5.3)
Eint/Aint 1.2 1.8* 1.16 1.73+ 0.88 2.13@
(1.03-1.37) (1.6-1.9) (0.97-1.28) (1.35-3.03) (0.72-1.29) (1.5-2.4)
*p<0.05; +p<0.05; @p<0.05
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Peak Filling 
Rate 
ml/s 
median 
(IQR) 
Normalized 
peak filling 
rate 
sec-1 
median 
(IQR) 
Atrial filling 
rate 
ml/s 
median 
(IQR)
Atrial
ejection
force
kdynes
median
(IQR)
274
(227-307)
1.91 
(1.5-2.8)
351
(314-406)
342*
(263-461)
2.23 
(1.7-2.9)
279*
(185-369)
10.8 6.9*
(9.2-13.7) (4.0-10.2)
262 380*
(201-416) (308-512)
1.29
(0.93-2.4)
1.79 
(1.6-2 .2)
368 295
(291-537) (237-382)
13.0 6.7*
(4.0-10.2) (4.9-11.4)
253 454@
(219-384) (319-585)
1.32 
(1.1-1.9)
2.32@  
(1.7-3.3)
416 299@
(323-527) (243-436)
15.8 6.9
(11.1-20.2) (4.6-14.0)
FIBRIN­
OGEN
g/i
median
(IQR)
D-D IM ER
ng/ml
median
(IQR)
vW F
%
median
3.02 3.05
(2.53-3.34) (2.84-3.44)
46
(30-82)
123
(95-160)
(IQR) 
kp<0.05, @p<0.05.
42
(30-85)
123
(110-161)
3.04 2.64
(2.34-3.47) (2.33-3.4)
49
(30-106)
110
(69-160)
67
(30-117)
112
(86-157)
3.46 3.59
(2.92-4.25) (3.3-5.2)
96
(65-172)
173
(118-210)
95
(52-265)
104
(88-194)
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TABLE 9.3
Spearman correlations with Doppler characteristics 
of diastolic dysfunction
GROUP 1 NORMAL LV SYSTOLIC FUNCTION
(a) diastolic dysfunction
AGE
r P
FIBRINOGEN  
r P
D-
r
DIMER
P
vWF
r P
fibrinogen -0.10 0.64 0.43* 0.035 0.24 0.304
D-dimer 0.185 0.609 0.43* 0.035 0.012 0.957
vWF -0.35 0.122 0.24 0.304 0.012 0.957
pfr 0.27 0.19 0.147 0.5 -0.25 0.239 -0.09 0.706
npfr 0.34 0.126 0.193 0.59 -0.03 0.877 -0.41 0.098
afr 0.279 0.184 0.127 0.56 -0.19 0.61 0.158 0.512
aef 0.19 0.63 0.08 0.70 -0.27 0.20 -0.12 0.63
Evm ax 0.079 0.713 0.205 0.66 -0.15 0.51 -0.42 0.06
Avmax 0.047 0.822 0.104 0.63 -0.18 0.599 -0.26 0.277
E int 0.02 0.898 0.182 0.603 0.001 0.99 -0.42 0.061
A int 0.22 0.3 0.28 0.178 0.234 0.27 -0.32 0.165
E/A vel -0.16 0.542 -0.03 0.877 -0.26 0.22 -0.03 0.91
E/A int -0.07 0.736 0.248 0.241 -0.09 0.68 -0.17 0.51
*p<0.05
[pfr=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax= maximum E wave velocity; A vmax= maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wave]
GROUP 1
(b) no diastolic dysfunction
(normal systolic and diastolic function)
AGE
r P
FIBRINOGEN  
r P
D-
r
DIMER
P
vWF
r P
fibrinogen 0.01 0.969 0.03 0.915 0.329 0.29
D-dimer 0.27 0.332 0.03 0.91 -0.12 0.708
vWF 0.361 0.247 0.329 0.29 -0.12 0.708
pfr 0.77* 0.001 0.07 0.78 -0.05 0.86 0.51 0.08
npfr 0.117 0.693 0.042 0.88 0.014 0.96 -0.118 0.73
afr 0.286 0.283 0.065 0.81 -0.62* 0.013 0.27 0.59
aef 0.16 0.57 -0.06 0.81 -0.62* 0.01 0.13 0.68
EVmax 0.08 0.766 -0.18 0.52 0.33 0.23 -0.027 0.59
Avmax -0.23 0.61 -0.2 0.53 -0.43 0.103 -0.27 0.59
E int 0.168 0.54 -0.07 0.79 -0.05 0.86 -0.2 0.53
A int -0.18 0.52 -0.14 0.62 -0.42 0.12 -0.31 0.33
E/A vel 0.31 0.24 0.24 0.64 0.35 0.199 0.27 0.59
E/A int 0.24 0.63 -0.18 0.52 0.63* 0.012 0.02 0.947
*p<0.05
[pfr=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax = maximum E wave velocity; A vmax= maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wave]
GROUP 2 LV SYSTOLIC DYSFUNCTION
(a) diastolic dysfunction
AGE FIBRINOGEN D- DIMER vWF
r P r P r P r P
fibrinogen -0.05 0.85 0.16 0.53 -0.50* 0.034
D-dimer 0.56* 0.01 0.16 0.53 -0.22 0.61
vWF -0.03 0.898 -0.50* 0.034 -0.22 0.61
pfr 0.32 0.18 0.22 0.63 0.25 0.31 -0.57* 0.014
npfr 0.07 0.8 0.50 0.057 0.19 0.51 -0.30 0.30
afr 0.44 0.06 0.1 0.68 0.33 0.16 -0.47* 0.046
aef 0.32 0.18 0.22 0.62 0.18 0.54 -0.46 0.054
Evm ax 0.06 0.79 0.37 0.12 0.01 0.96 -0.41 0.09
Avmax 0.18 0.53 0.36 0.13 0.07 0.77 -0.41 0.09
E int -0.14 0.59 0.20 0.59 -0.16 0.52 -0.15 0.57
A int 0.06 0.81 0.03 0.89 -0.20 0.59 -0.10 0.69
E/A vel -0.26 0.29 0.37 0.12 -0.01 0.97 -0.16 0.54
E/A int 0.04 0.85 0.24 0.33 0.09 0.72 -0.27 0.27
*p<0.05
[pfir=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax= maximum E wave velocity; A vmax = maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wave]
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GROUP 2
(b) no diastolic dysfunction
AGE
r P
FIBRINOGEN  
r P
D-
r
DIMER
P
vWF
r P
fibrinogen 0.07 0.82 -0.06 0.84 0.52 0.06
D-dimer 0.43 0.14 -0.06 0.84 0.116 0.71
vWF -0.18 0.56 0.52 0.06 0.116 0.71
Lp(a) -0.51 0.075 -0.35 0.25 -0.51 0.07 -0.33 0.28
pfr 0.5 0.077 -0.16 0.6 0.5 0.08 -0.59* 0.033
npfr 0.11 0.75 -0.41 0.20 0.19 0.58 -0.39 0.23
afr 0.62* 0.02 -0.05 0.86 0.04 0.89 -0.56* 0.046
ae f 0.41 0.18 -0.03 0.91 -0.13 0.69 -0.33 0.30
Evm ax 0.4 0.19 -0.08 0.81 0.55 0.06 -0.31 0.33
Avmax 0.27 0.61 0.15 0.64 -0.34 0.28 0.007 0.98
E int 0.515 0.08 0.29 0.64 0.40 0.197 0.18 0.59
A int 0.39 0.21 -0.02 0.94 -0.13 0.69 -0.02 0.94
E/A vel -0.20 0.52 -0.03 0.92 0.32 0.28 0.08 0.78
E/A int -0.19 0.55 -0.03 0.93 0.41 0.16 -0.21 0.51
*p<0.05
[pfr=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax = maximum E wave velocity; A vmax = maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wave]
GROUP 3 LV ANEURYSMS
(a) diastolic dysfunction
AGE
r P
FIBRINOGEN  
r P
D-
r
DIMER
P
vWF
r P
fibrinogen 0.066 .79 0.312 0.21 0.11 0.066
D-dimer 0.226 0.63 0.312 0.21 0.35 0.149
vWF 0.03 0.90 0.44 0.066 0.35 0.149
pfr 0.09 0.72 -0.11 0.67 0.24 0.65 0.21 0.59
npfr -0.02 0.96 -0.09 0.77 -0.35 0.237 0.40 0.17
afr 0.13 0.62 -0.02 0.91 0.48* 0.042 0.13 0.62
aef 0.30 0.23 0.04 0.88 0.51* 0.03 0.28 0.61
EVmax 0.069 0.78 0.112 0.66 0.01 0.97 0.575* 0.012
Avmax 0.46 0.05 0.19 0.54 0.30 0.22 0.37 0.125
E int -0.278 0.26 -0.13 0.604 -0.11 0.67 0.453 0.056
A int 0.604* 0.008 0.30 0.219 0.18 0.52 0.31 0.21
E/A vel -0.50* 0.035 -0.31 0.21 -0.34 0.17 0.16 0.53
E/A int -0.23 0.64 -0.096 0.71 -0.22 0.61 0.42 0.08
*p<0.05
[pfr=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax = maximum E wave velocity; A vmax = maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wavej
GROUP 3
(b) no diastolic dysfunction
AGE
r P
FIBRINOGEN  
r P
D-
r
DIMER
P
vWF
r P
fibrinogen 0.11 0.73 0.22 0.50 0.04 0.90
D-dimer 0.36 0.25 0.22 0.50 -0.61* 0.045
vWF -0.20 0.57 0.04 0.90 -0.61* 0.045
pfr -0.07 0.83 0.39 0.21 -0.23 0.52 0.35 0.30
npfr -0.43 0.17 -0.084 0.79 -0.14 0.67 0.44 0.18
afr 0.30 0.65 0.018 0.96 -0.13 0.698 0.37 0.26
aef 0.27 0.61 0.04 0.901 -0.16 0.62 0.30 0.63
Evmax -0.165 0.61 0.28 0.63 -0.175 0.59 0.45 0.158
Avmax 0.095 0.766 -0.21 0.52 -0.13 0.68 0.35 0.30
E int -0.42 0.17 -0.03 0.92 -0.22 0.501 0.42 0.20
A int -0.21 0.52 -0.01 0.97 -0.14 0.67 0.42 0.20
E/A vel -0.13 0.69 0.07 0.82 0.17 0.60 -0.19 0.58
E/A int -0.39 0.21 0.33 0.29 -0.06 0.86 0.10 0.77
*p<0.05
[pfr=peak filling rate; npfr=normalised peak filling rate; afr=atrial filling rate; 
aef=atrial ejection force;
E vmax= maximum E wave velocity; A vmax= maximum A wave velocity;
Eint = velocity-time integral of E wave; A int = velocity-time integral of A wave;
E/A vel = ratio of maximum E wave velocity to A wave velocity;
E/A int = ratio of velocity-time integral of E wave to velocity-time integral of A wave]
TABLE 9.4 
EFFECTS OF ANEURYSMS, LV SYSTOLIC 
DYSFUNCTION AND DIASTOLIC DYSFUNCTION 
(AND THEIR INTERACTION) ON PROTHROMBOTIC FACTORS
D IA STO LIC
NORMAL
FUNCTION
DIASTOLIC DYSFUNCTION
LV SYSTOLIC FUNCTION
NORMAL
fibrinogen 3.05 3.02
D-dimer 42 46
vWF 12 123
SYSTOLIC DYSFUNCTION
fibrinogen 2.64 3.04
D-dimer 67 49
vWF 112 110
LV ANEURYSM
fibrinogen 3.59 3.5
D-dimer 95 96
vWF 104 173
(VWF= von Willebrand factor)
*p<0.05 for contribution of aneurysms and systolic function for plasma fibrinogen and vWF 
(GLM-ANOVA)
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TABLE 9.5
INTRA- AND BETWEEN-OBSERVER REPEATABILITY FOR 
DOPPLER ECHOCARDIOGRAPHY
(a) intra-observer repeatability (IOR)
M EASUREM ENT Pearson
r
m ean
d iffe re n ce
± 2 s .d . one  
sam ple  
t-test T
p value
EVmax 0.884 -0.34 3 -0.90 0.38
A Vmax 0.966 0.53 8 0.62 0.54
E/A vel ratio 0.896 -0.07 0.36 -1.67 0.11
E integral 0.993 0.10 0.60 1.64 0.12
A integral 0.942 0.17 0.94 1.65 0.12
E/A int ratio 0.940 -0.02 0.56 -0.37 0.71
(b) between-observer repeatability (BOR)
M EASUREM ENT Pearson
r
mean
d iffe ren ce
± 2 s .d . one  
sam ple 
t-test T
p value
Evmax 0.992 0.5 4 1.11 0.28
AVmax 0.990 0.98 4 2.01 0.06
E/A vel ratio 0.978 -0.01 0.14 -0.90 0.38
E integral 0.996 0.07 0.4 1.59 0.13
A integral 0.984 0.10 0.52 1.76 0.09
E/A int ratio 0.981 -0.03 0.30 -0.97 0.34
p=NS
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FIGURE 9.2 
RELATIONSHIP BETWEEN SYSTOLIC AND DIASTOLIC 
DYSFUNCTION IN ISCHAEMIC HEART DISEASE
The first peak (E wave) is due to early passive filling and the 
second peak (A wave) is due to the atrial contribution to filling.
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10.1 ANTICOAGULATION FOR CHRONIC ATRIAL FIBRILLATION AND LE FT  
VENTRICULAR DYSFUNCTION
ANTICOAGULANT THERAPY IN ATRIAL FIBRILLATION
Atrial fibrillation has a prevalence of 2 to 5 percent in the general population 
over the age of 60, with an incidence that increases with age (Chesebro et al 1990). This is 
pertinent as the presence of this arrhythmia is an important risk for stroke and other 
thromboembolic events (Lowe 1992, Shimomura et al 1989). For example, non-rheumatic 
atrial fibrillation has been associated with a fivefold increase in the risk of ischaemic stroke and 
a five to seven percent yearly risk which also increases with age (Chesebro et al 1990). The 
thromboembolic risks of atrial fibrillation are illustrated by several large studies. For example, 
the annua) rate of stroke in the Framingham study for patients in atrial fibrillation was 
approximately 4% (Wolf et al 1987), a rate which is comparable to two other studies: the 
Copenhagen AFASAK study and the Stroke Prevention in Atrial Fibrillation Study, where the 
annual incidence of stroke amongst placebo patients was 4.9% and 4.9% respectively 
(Petersen et al 1989, Stroke Prevention in Atrial Fibrillation Study Group Investigators 1990). 
In addition, the female sex and other underlying heart disease are contributory factors to the 
risk of stroke and thromboembolism (Cabin et al 1990, Yamanouchi et al 1989). For example, 
the embolic risk of atrial fibrillation is 18 times greater if rheumatic heart disease is also present 
(Cairns and Connolly 1991, Koenig et al 1992). In elderly patients (mean age 79.3), the 
presence of nonvalvular atrial fibrillation was also an important factor in fatal massive cerebral 
infarction (Yamanouchi et al 1989).
Although atrial fibrillation remains an established risk factor for 
thromboembolic events, preventive therapy has, to date, been both empirical and 
controversial. It is only recently that effective prevention against strokes in atrial fibrillation has 
been established by prospective clinical studies; this being the use of anticoagulation therapy 
as prophylaxis against stroke in patients with atrial fibrillation. The purpose of this review is to 
discuss the evidence for anticoagulation in atrial fibrillation and its place in the management of 
such patients.
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Contributory factors to stroke in atrial fibrillation
Contributory risk factors for thromboembolic events in atrial fibrillation include 
the presence of structural heart disease (for example enlarged left atrial size and mitral valve 
disease), hypertension and poor left ventricular function (Hart 1992). In support of this, 
multivariate analysis of the largest cohort of placebo-treated patients yielded three 
independent clinical predictors of an increased risk of stroke: (i) a history of hypertension; (ii) 
recent (within 3 months) congestive heart failure; and (iii) previous cerebrovascular event 
(either stroke or transient ischaemic attack) (Stroke Prevention in Atrial Fibrillation 
Investigators 1992a). Risk stratification on the basis of these three factors allowed the 
identification of three rates of arterial thromboembolism: 2.5% (for patients with no risk 
factors); 7.2% per year (if one risk factor present); and 17.6% per year (if 2 or 3 risk factors 
present) (Stroke Prevention in Atrial Fibrillation Investigators 1992a). Other additive risk 
factors to the risk of thromboembolism may be the female sex, smoking, heart failure and a 
history of previous embolic episodes (Hart 1992).
Recent studies have suggested that left atrial enlargement may be 
consequent upon the duration of atrial fibrillation (Sanfillipo et al 1990, Petersen 1987, Sosa- 
Suarez 1989). However, previous evidence has suggested the converse, that left atrial 
enlargement was the cause rather than a consequence of atrial fibrillation (Takahashi 1982). 
This is important as the left atrial size has been considered to contribute to an increased risk of 
atrial thrombi, arterial embolism or stroke in patients with atrial fibrillation. It is also consistent 
with the observation that the risk of thromboembolism increases with the duration of atrial 
fibrillation (Cabin et al 1990, Caplan et al 1986, Daniel et al 1988). More specifically, a left atrial 
size of £ 4.0 cm has been previously identified as the single strongest predictor of increased 
risk for embolization (Cabin et al 1990). Patients with left atrial enlargement are also 
associated with the presence of spontaneous echo contrast on transoesophageal 
echocardiography, suggesting slow or sluggish blood flow within the enlarged atrial cavity 
(Daniel et al 1988). Spontaneous echo contrast has been associated with the presence of 
intraatrial thrombi, and indeed, emboli from stasis-related left atrial thrombi are the most likely
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source of thromboembolic events in atrial fibrillation. The Theological mechanism for 
spontaneous echo contrast is thought to involve the presence of fibrinogen, or its products, 
and rouleau formation of erythrocytes (Siegel et al 1981).
As mentioned above, the duration and onset of atrial fibrillation may also be of 
importance. The onset of atrial fibrillation may, for example, be temporally related to the 
imminence of stroke. In the Framingham study, atrial fibrillation was present at the time of 
stroke onset in 24% and about a third of the strokes associated with atrial fibrillation occurred 
within six months of onset of the arrhythmia (Wolf et al 1983). In addition, stroke recurrence in 
the first six months following the initial event was more than twice as common in patients with 
continued atrial fibrillation (47% vs 20% in non-atrial fibrillation group)(Wolf et al 1983).
Clinical studies in anticoagulation for atrial fibrillation
Until recently, the only evidence supporting the benefit of anticoagulation 
therapy has been from retrospective studies. One example is the Montreal Heart Institute 
Study, which found that the incidence of thromboembolic events was eight times more 
frequent during the period without anticoagulation therapy, whether or not mitral valve 
disease was present and regardless of whether or not atrial fibrillation was chronic or 
paroxysmal (Roy et al 1986). In the mid-1980s, five randomised prospective clinical trials were 
independently initiated to define the value of antithrombotic therapy with warfarin and/or 
aspirin as prophylaxis in patients with atrial fibrillation. All five studies show consistent results 
(Table 10.1).
In the Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation Study 
(AFASAK Study), 1007 patients (540 men, 467 women; median age 74.2 years) with chronic 
non-rheumatic atrial fibrillation were randomised to receive warfarin, aspirin or placebo 
(Petersen et al 1989). Warfarin was given openly to 335 patients (median age 72.8 years) and 
the warfarin dose was adjusted to a prothrombin-time ratio between 1.5 to 1.9 (international 
normalised ratio (INR) 2.8 to 4.2). Seventy-five milligrams of aspirin once daily was also 
administered to a further 336 patients (median age 75.1 years). Primary endpoints were 
thromboembolic events (such as stroke, transient ischaemic attack or systemic embolism),
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and the secondary endpoint was death. In this study, 5 patients on warfarin had 
thromboembolic complications compared with 20 patients on aspirin and 21 on placebo. 
There was therefore a significant benefit of warfarin in reducing severe thromboembolic 
events but only a small (and non-significant) benefit of aspirin (with a risk reduction 60% and 
16% respectively) (Petersen et al 1989).
The Stroke Prevention in Atrial Fibrillation (SPAF) Study was a multicentre 
randomised trial in which 1330 patients (34% of whom had paroxysmal atrial fibrillation) were 
randomised to two groups (Stroke Prevention in Atrial Fibrillation Study Group Investigators 
1990, Stroke Prevention in Atrial Fibrillation Study Group Investigators 1991). Group 1 
consisted of 627 patients eligible for anticoagulation, and received a warfarin dose adjusted to 
a prothrombin-time ratio of 1.3 to 1.8 (equivalent to an international normalised ratio (INR) of 
1.7 to 4.6) (n=210), aspirin therapy (325mg daily) or placebo. Group 2 consisted of 703 
patients not eligible for warfarin, whom were given aspirin (n=346)or placebo in a double-blind 
study. The end points in this study were ischaemic stroke or systemic embolism. Similar to 
the AFASAK study, the SPAF study demonstrated a significant reduction of primary events 
(by 67%) by the use of warfarin (warfarin vs placebo 2.3% vs 7.4%). In patients assigned to 
aspirin there was also a reduction in primary events (by 42%) although there was no benefit of 
aspirin in patients over 75 years of age and severe strokes were not prevented (Stroke 
Prevention in Atrial Fibrillation Study Group Investigators 1990, Stroke Prevention in Atrial 
Fibrillation Study Group Investigators 1991). The relative value of warfarin compared to 
aspirin is unclear and the SPAF II study is continuing to address this critical question, which is 
further discussed below.
The third major study undertaken addressing this issue was the Boston Area 
Anticoagulation Trial for Atrial Fibrillation (BAATAF) (Boston Area Anticoagulation Trial for 
Atrial Fibrillation Investigators 1990). This was an unblinded, randomised controlled trial of 
420 patients with nonrheumatic atrial fibrillation: 212 patients were allocated to warfarin and 
208 to placebo. The control group in this study could choose to take aspirin at 325mg daily 
but there was, however, no significant benefit shown for aspirin (Boston Area Anticoagulation 
Trial for Atrial Fibrillation Investigators 1990, Singer 1992). There were 2 strokes in the
252
warfarin group compared to 13 strokes in control group, a significant risk reduction with 
warfarin of 86%.
The fourth major clinical study was the Canadian Atrial Fibrillation 
Anticoagulation (CAFA)Study (Connolly et al 1991). This was a randomised double-blind 
placebo-controlled trial with objectives similar to the aforementioned studies. However, 
publication of the AFASAK and SPAF study results, which demonstrated the beneficial 
effects of anticoagulation resulted in the CAFA study being prematurely terminated before its 
target recruitment. However in this study of 378 patients (187 warfarin, 191 placebo) there 
was primary event rate of 3.5% for the warfarin group compared to 5.2% for the placebo 
group, which amounted to a risk reduction of 37% (Connolly et al 1991). Although this result 
from the CAFA study was consistent with previously published studies (Petersen 1989, 
SPAF Investigators 1990, SPAF Investigators 1991, BAATAF Investigators 1990), it did not 
reach statistical significance (95% confidence interval-63.5% to 75.5%, p=0.17) (Connolly et 
al 1991).
The fifth major study of anticoagulation in atrial fibrillation was the Veterans 
Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) study (Ezekowitz et al 
1991). This was a randomised, double-blind placebo-controlled study of 571 men with 
chronic nonrheumatic atrial fibrillation (260 patients on warfarin; 265 placebo). The primary 
end point was cerebral infarction, whilst secondary end-points were cerebral haemorrhage 
and death. There were 19 events in the placebo group compared to 4 events in the warfarin 
group, again a significant risk reduction (of 79%) (Ezekowitz et al 1991). As in the other 
studies, there was substantial protection against cerebral infarction in patients with 
nonrheumatic atrial fibrillation, without an associated excess risk of serious haemorrhage. 
Additionally, the SPINAF study demonstrated the safety and efficacy of warfarin in patients 
aged over 70 years, who have the highest prevalence of atrial fibrillation. This study was also 
fully blinded (whilst its results were consistent with the other, nonblinded studies), which 
allays concern about the lack of blinding in the other trials.
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Discussion
All five of the atrial fibrillation anticoagulation studies discussed above 
demonstrate that anticoagulation with warfarin (aiming for a target International Normalised 
Ratio (INR) of 1.5 to 3.0, or a target prothrombin-time ratio of 1.2 to 1.5) reduces the rate of 
stroke among patients with atrial fibrillation by two thirds or more. All 5 studies were terminated 
early by their data-monitoring boards in view of the marked benefit of warfarin therapy in the 
prevention of thromboembolic events. Remarkably, all five independent contemporaneous 
trials came to the same consistent conclusion, namely the fact that anticoagulation therapy 
significantly reduced the risk of stroke in patients with nonrheumatic atrial fibrillation. The rate 
of bleeding was usually under 1% per year, despite the study patients being predominantly 
elderly.
Despite the evidence of the effectiveness of warfarin, the estimate of this 
preventive efficacy remains imprecise - each trial discussed above had wide confidence 
intervals. Additionally, further studies are required to define which patients with atrial 
fibrillation are at the highest risk of stroke and identify which patients do not require 
prophylactic therapy. Oral anticoagulation therapy does appear to be a relatively safe 
therapeutic stratagem (although the potential of haemorrhage still exists) and should 
therefore be standard therapy for all patients with atrial fibrillation, if no contraindications to 
anticoagulation exist. However, prophylaxis with warfarin has two main problems: 
inconvenience and safety (Lowe 1992). In the BAATAF study, no significant differences 
between warfarin-treated and controls were found for quality of life as demonstrated by 
measures of functional status, well-being, and health perceptions; unless complicated by a 
bleeding episode (Lancaster et al 1991). Patients on warfarin need, however, regular 
education and the effect of warfarin must be regularly monitored (and the dose adjusted). 
Surprisingly, the quality of life assessment of patients on the BAATAF study demonstrated 
that 75.6% did not mind regular blood tests (Lancaster et al 1991). The cost effectiveness 
and safety aspects have also to be considered; in particular, the risk of bleeding. Patients on 
warfarin who sustain a bleeding complication demonstrate a significant decrease in health 
perceptions (Lancaster et al 1991).
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Primary prophylaxis with anticoagulant therapy in atrial fibrillation is cost 
effective if the rate of intracranial bleeding during such therapy is only 0.3%, as in the major 
published trials (Gustafsson et al 1992). However if this rate increases to 2% per year, 
warfarin therapy becomes no longer cost effective (Gustafsson et al 1992). This "cost" has to 
be balanced against the reduction of the annual risk of stroke from 5% to 1.8% (Lowe 1992).
One concern with these five trials is the highly selected nature of the patient 
population. For example, in the SPAF and SPINAF studies, 93% of those screened in each 
study were excluded from entry (Stroke Prevention in Atrial Fibrillation Study Group 
Investigators 1991, Ezekowitz et al 1991). Similarly, in the Canadian study, only 13% of those 
screened were eligible, but of these only 54% gave consent and were randomised (Connolly 
et al 1991). Patients' refusal and physicians' refusal to enrol patients in these studies were the 
most important reasons for exclusion. The patient withdrawal rate was also high, ranging from 
19% to 38% in four of the trials (Connolly et al 1991, Ezekowitz et al 1991, Petersen et al 
1989, Stroke Prevention in Atrial Fibrillation Study Group Investigators 1991). There is 
concern therefore whether or not the results of these studies reflect 'clinical reality1 and can 
be directly translated into clinical practice.
Evaluation of other treatments which are more convenient or less risky is also 
required. For example, aspirin would be preferable to warfarin if it were equally effective, if 
only for the ease of administration. The results however remain inconsistent. For example, 
the AFASAK study demonstrated no benefit from aspirin at 75mg daily, but this was in an 
older population (Petersen et al 1989). The Stroke Prevention in Atrial Fibrillation study 
reported that aspirin at 325mg daily had some beneficial effect, but not in patients over the 
age of 75 years, nor was it effective in preventing severe strokes (Stroke Prevention in Atrial 
Fibrillation Investigators 1990, Stroke Prevention in Atrial Fibrillation Investigators 1991). The 
BAATAF study also indicated no significant effect of aspirin at 325mg daily (Boston Area 
Anticoagulation Trial for Atrial Fibrillation Investigators 1990). The benefit of aspirin when 
compared to warfarin therapy has therefore been addressed in the SPAF II Study. Preliminary 
results of 1100 patients randomised to warfarin or aspirin therapy have been presented at the 
42nd Annual Scientific Session of the American College of Cardiology (JL Halpern, Anaheim,
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16 March 1993). This study demonstrated that a risk stratification of patients with chronic 
nonrheumatic atriai fibrillation was possible and that aspirin therapy does appear suitable for 
certain groups of patients. For example, those patients with chronic atrial fibrillation who 
appear at highest risk are those who are female, aged over 75, systolic blood pressure >160 
mm Hg and with echocardiographic evidence of left ventricular impairment. In these patients, 
aspirin alone is inadequate as prophylaxis (with a relative risk between 2.0 - 2.8 for each of the 
risk factors mentioned) and warfarin is required (JL Halpern, Presentation at the 42nd Annual 
Scientific Session of the American College of Cardiology, Anaheim, 16 March 1993). 
However, patients who are males, aged less than 75 years, with systolic blood pressure <160 
mm Hg and no left ventricular impairment are are low risk for thromboembolism, and aspirin 
(325mg) therapy alone appears sufficient as prophylaxis. Patients who are aged <65 with no 
other risk factors have a very low thromboembolic risk, and antithrombotic therapy may not be 
required. Aspirin may be useful in combination with warfarin therapy in the high risk patient 
group described above and their additive effects, if any, are being studied in the SPAF III 
Study.
In conclusion, patients with chronic atrial fibrillation appear to benefit from oral 
anticoagulation as a prophylaxis against thromboembolic events. When carefully managed, 
warfarin therapy is well tolerated. Aspirin therapy may also have a role for certain patients at 
lower risk. Anticoagulant therapy is, however, not without risk and the need for a method to 
identify those individual patients at highest risk is still required. It is possible that the use of 
certain echocardiographic criteria and suitable markers of thrombogenesis may help 
distinguish these patients.
ANTICOAGULANT THERAPY IN LEFT VENTRICULAR DYSFUNCTION
Introduction
As left ventricular mural thrombus is often associated with disease involving 
the endocardium and/or myocardium of the left ventricle, the precise prevalence of left 
ventricular thrombus is difficult to ascertain. For example, the presence of thrombus within 
the left ventricle has been associated with the following diseases and clinical states: acute
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myocardial infarction, left ventricular aneurysm, congestive cardiomyopathy, blunt chest 
trauma, systemic lupus erythmatosis, carcinoid heart disease, postpartum heart disease, 
Chagas' disease, beri-beri, amyloidosis, infectious myocarditis, endomyocardial fibrosis, 
sarcoidosis, endomyocardial biopsy, diverticulum of the left ventricle and Loffler's 
endocarditis (Nixon 1983). Diagnosis of intracardiac thrombus is further influenced by 
changes in imaging techniques and management strategies for different cardiac problems 
(Nixon 1983). As part of this thesis, I shall be concentrating on the thrombogenic tendency 
(as demonstrated in chapter 8) in patients with left ventricular dysfunction secondary to 
ischaemic heart disease, and the role of anticoagulation therapy.
The size of the problem
Thromboembolism is a frequent cause of death in patients with congestive 
heart failure, occurring in up to 30% of patients (Griffith et al 1952). Despite this, anticoagulant 
therapy has not been widely used as an adjuvant to routine therapy in patients with left 
ventricular dysfunction and left ventricular aneurysms. The reasons for these are uncertain, 
as discussed in chapter 8. However, the frequency of left ventricular thrombi in aneurysms 
seen at postmortem can range between 14 to 68% which is consistent with aneurysmectomy 
findings (50 to 95%) (Nixon 1983). The reported incidences of systemic embolism, in 
patients with left ventricular aneurysm, demonstrates however a wide range, from 0 to 52% 
(Lapeyre et al 1985, Mullen et al 1977, Nixon 1983, Schlichter et al 1954).
There are few data supporting routine use of oral anticoagulant therapy in 
patients with left ventricular aneurysm. In one study (390 patients) there was a significant 
reduction in the incidence of thromboembolism in patients with chronic heart failure, 
especially in those with coexisting rheumatic heart disease (Griffith et al 1952). Warfarin 
therapy has also been associated with higher resolution of thrombus at echocardiography 
when compared to patients on no therapy (59% vs 29% respectively) (Stratton et al 1988). In 
a study of patients with congestive heart failure, the use of anticoagulant therapy reduced 
mortality by 5.8 to 8%, with a 6 to 9% reduction in the incidence of thromboemboli (Griffith et al 
1952). Importantly, cardiac arrhythmia, a past history of congestive cardiac failure or a past
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history of thromboemboli did not influence the outcome in these patients (Griffith et al 1952). 
In addition, anticoagulant therapy also reduces the risk of left ventricular thrombus and 
embolisation following acute myocardial infarction (Weinreich et al 1984). Many authorities 
therefore recommend prophylactic anticoagulation of large anterior myocardial infarctions.
Anticoagulant therapy may therefore provide protection against embolic 
events, but in contrast to the results discussed earlier, an echocardiographic study has 
demonstrated that the presence of thrombi at six months follow-up was the same regardless 
of anticoagulant treatment (Weinreich et al 1984). In addition, two surgical studies showed no 
apparent effect of anticoagulation on the prevalence of mural thrombus identified at 
aneurysmectomy (Reeder et al 1981, Simpson et al 1980). However, the duration of therapy 
correlates inversely with the presence of thrombus, and this may account for the discrepancy 
of these findings (Reeder et al 1981).
As discussed in chapter 8, echocardiography is the method most commonly 
used for diagnosing left ventricular thrombi. Although up to 15 % of studies are technically 
inadequate and cannot exclude the presence of thrombus, echocardiography may still be 
helpful in the stratification of patients into high and low risk for the development of mural 
thrombi and embolization. Similarly to patients with atrial fibrillation, the availability of a suitable 
plasma marker of ongoing thrombogenesis would also help in the risk stratification of such 
patients, especially those with intracardiac thrombi too small to be visualised by transthoracic 
echocardiography.
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10.2 STUDIES OF PLASMA FIBRINOGEN AND D-DIMER IN PATIENTS WITH 
CHRONIC ATRIAL FIBRILLATION, LEFT VENTRICULAR DYSFUNCTION 
AND LEFT VENTRICULAR ANEURYSMS: THE EFFECTS OF
INTRODUCING ANTICOAGULANT THERAPY
Introduction
Five large studies have now established the role of oral anticoagulation 
therapy as prophylaxis against thromboembolism in patients with chronic nonrheumatic atrial 
fibrillation (Lowe 1992). In chapter 3 of this thesis I have demonstrated that patients with 
chronic atrial fibrillation on no antithrombotic therapy had significant abnormalities of plasma 
fibrinogen and fibrin D-dimer levels. The latter marker was however significantly lower in 
patients who were established on warfarin when compared to patients on no antithrombotic 
therapy. Chapter 8 of this thesis demonstrated similar findings for patients with left ventricular 
aneurysms, in which those established on warfarin therapy also had significantly lower plasma 
fibrin D-dimer levels when compared to patients who were not on warfarin. As plasma D-dimer 
is a marker of intravascular thrombus formation, my results are consistent therefore with the 
beneficial effects of warfarin in reducing thrombus formation. The effect of the introduction of 
warfarin therapy upon these plasma prothrombotic indices has not been previously 
investigated. If significant change does occur with warfarin, measurement of these markers 
may provide further information upon the action of warfarin in thromboembolic prophylaxis, 
the possible roles for these markers in identifying 'high risk' patients and monitoring the 
effectiveness of warfarin in reducing intravascular thrombogenesis.
The aim of this study therefore was to investigate the effects of introducing 
anticoagulant therapy in patients with atrial fibrillation and left ventricular aneurysms on 
markers of increased thrombogenesis as measured by plasma fibrinogen and fibrin D-dimer.
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Methods
A prospective study of al! patients with atrial fibrillation or left ventricular 
aneurysms undergoing prophylactic anticoagulation was undertaken. The oral anticoagulation 
used was warfarin in all cases.
Prior to anticoagulation, all patients underwent echocardiography, primarily to 
assess for the presence of intracardiac thrombus. All patients were managed on an outpatient 
basis. At their initial visit, clinical examination and echocardiography was performed and 
baseline blood samples taken . Patients subsequently attended on Day 3, Day 5, Day 7 and 2 
months following the introduction of warfarin for an INR (International Normalised Ratio) check 
to ensure satisfactory anticoagulation response.
Blood samples were also taken atraumatically at each visit and placed in citrate 
tubes (trisodium citrate 0.11M, 9:1 v:v) for assay of plasma fibrinogen and fibrin D-dimer. The 
plasma was immediately separated and frozen at -40 °C . Plasma fibrinogen and D-dimer 
antigen levels were measured in all samples, as described in previous chapters.
All the values of the rheological measurements were expressed as median ± 
interquartile range (IQR). Initial (prewarfarin) levels of plasma fibrinogen and D-dimer were 
compared to normal population 'values', derived from 158 subjects in a healthy population survey, 
the 2nd North Glasgow MONICA study (as in previous chapters). Statistical comparison of 
sequential results was performed using the two-sample paired Wilcoxon test for non-parametric 
distributions. Other comparison of discontinuous results was performed using the Mann-Whitney 
test for non-parametric distributions and the 95% confidence intervals (c.i.) calculated. 
Correlations between the INR and prothrombotic markers were performed using Spearman's Rank 
correlation method. A probability of <0.05 was considered statistically significant.
Results
A total of 30 patients were studied: 20 with chronic atrial fibrillation (13 male, 6 
female; mean age 63.9 years, age range 32-74 years, s.e.m. 2.35) whilst 10 had left 
ventricular dysfunction with aneurysm formation (mean age 52.5 years, age range 28-66 
years, s.e.m. 4.33). Patient characteristics are summarised in Table 10.2.
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In patients with chronic atrial fibrillation, there was a significant elevation of 
initial (prewarfarin) levels of plasma fibrinogen (median difference 0.38 g/l; 95%C.I. 0.10 to 
0.71, Mann Whitney p=0.009) and fibrin D-dimer (median difference 96 ng/ml; 95% C.l. 63 to 
134, p<0.0001) when compared to population controls in sinus rhythm. In addition, there was 
a significant reduction in median plasma fibrin D-dimer levels at 2 months following the 
introduction of warfarin (181 ng/ml vs 80 ng/ml; paired Wilcoxon test, p<0.001) (Table 10.3, 
Figure 10.1). Sequential plasma D-dimer results were also available for 16 patients at Days 3, 
5 and 7 following the introduction of warfarin. There was a significant reduction in median 
plasma D-dimer at Day 3 following warfarin (162 ng/ml vs 136 ng/ml; paired Wilcoxon test, 
p=0.02) when compared to prewarfarin levels. There were however no significant differences 
in median plasma D-dimer at Day 5 (173 ng/ml; p=0.75) and Day 7 (130 ng/ml; p=0.07) 
following the introduction of warfarin therapy. A median reduction of plasma fibrin D-dimer by 
41% (95% c.i. 32% to 64%) following the 2 months of anticoagulant therapy was therefore 
achieved. There were no significant changes in plasma fibrinogen levels at any of the 
sampling points following the introduction of warfarin therapy. (Table 10.4, Figure 10.1)
In patients with sinus rhythm, ischaemic heart disease and left ventricular 
aneurysms (n=10), there was a significant elevation of initial (prewarfarin) levels of plasma 
fibrinogen (median difference 0.82 g/l; 95%C.I. 0.4 to 1.22, p=0.0005) and fibrin D-dimer 
(median difference 50 ng/ml; 95% C.l. 20 to 104, p=0.003) when compared to population 
controls in sinus rhythm. There was a significant reduction in median plasma fibrin D-dimer 
levels at 2 months following the introduction of warfarin (148ng/ml vs 61 ng/ml; paired 
Wilcoxon test, p=0.0l), although there were no significant differences in median plasma D- 
dimer at Day 3 (128 ng/ml; p=0.47), Day 5 (136 ng/ml; p=0.92) or Day 7 (113 ng/ml; p=0.76) 
following the introduction of warfarin therapy when compared to prewarfarin levels (Table 
10.3, Figure 10.2). In these patients, there was therefore a median reduction of plasma fibrin 
D-dimer by 58% (95% c.i. 29% to 77%) following 2 months of anticoagulation. There were 
again no significant differences in plasma fibrinogen levels in these patients following the 
introduction of warfarin therapy (Table 10.4, Figure 10.2).
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In the population controls, the upper limit of the interquartile range (IQR) [the 
75th percentile] for plasma D-dimer was 103ng/ml (Table 10.3). If we consider all the 30 
patients studied and only selected those with a pre-warfarin plasma fibrin D-dimer level of 
>100 ng/ml [an approximation of the 75th percentile value for plasma D-dimer in the 
population] (23 patients; mean age 61.2 years, s.e.m. 2.79), the reduction of median plasma 
D-dimer levels following 2 months of warfarin therapy was highly significant (200 ng/ml vs 68 
ng/ml; paired Wilcoxon test, p<0.0001) with a median reduction of 49% (95 % c.i. 36% to 
72%). There were no significant differences in median plasma D-dimer at Day 3 (145 ng/ml; 
p=0.27) or Day 5 (175ng/ml; p=0.59) following the introduction of warfarin therapy. At Day 7, 
however, there was also a significant reduction in plasma D-dimer (200 vs 150ng/ml; p=0.02). 
In this group, there were no significant differences in plasma fibrinogen levels at any of the 
sampling points (when compared to initial values) following the introduction of warfarin.
There was no significant correlation between plasma fibrinogen or fibrin D- 
dimer and INR levels at any of the sampling points in any of the groups studied (Table 10.5).
Discussion
This study demonstrates that plasma fibrinogen does not alter significantly 
following the introduction of warfarin therapy. As epidemiological studies have demonstrated 
that an elevated plasma fibrinogen level is a predictor of cardiovascular events, patients with 
chronic atrial fibrillation and left ventricular aneurysm demonstrate underlying haemo- 
rheological abnormalities and may continue to be at some cardiovascular risk despite being 
anticoagulated. This risk (and whether measurement of plasma fibrinogen is predictive of 
future cardiovascular events) remains to be demonstrated prospectively for patients with atrial 
fibrillation. Warfarin therapy is not known to influence any underlying pathological process 
and plasma fibrinogen levels would not have been expected to change after the introduction 
of warfarin therapy, as demonstrated in this study.
In contrast, there is a sequential reduction of plasma fibrin D-dimer following 
the introduction of warfarin therapy. This reduction was significant at 2 months or more 
following the introduction of warfarin. In addition, if we select patients with a high initial plasma
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fibrin D-dimer (>100 ng/ml), the reduction is significant at Day 7 (p=0.02) and is highly 
significant (p<0.0001) at two months, with a median reduction of 49%. If warfarin effectively 
prevented intravascular fibrin turnover and thrombus formation, then plasma D-dimer levels 
would be expected to be much lowered in patients following the introduction of warfarin, and 
this effect of warfarin is clearly demonstrated in my study. The lack of correlation between 
plasma fibrin D-dimer and INR value suggests that two distinctly separate processes in 
thrombogenesis are being quantified: the INR would be assessing clotting factor activity 
(Factors II, VII, IX and X, which are vitamin K dependent factors) in the formation of clot, whilst 
the measurement of plasma fibrin D-dimer is an indirect quantification of fibrin turnover, which 
is the step that follows fibrin deposition in thrombus formation. In addition, quantification of 
INR (or prothrombin time) may not be directly related to the efficacy of warfarin in reducing 
thrombogenesis. This is demonstrated in a randomised, prospective trial in which the risk of 
thrombosis associated with a long-term central venous catheter was reduced by 65% in 
patients receiving only 1 mg/day of warfarin, with no measurable change in coagulation values 
(Bern et al 1990). At this ultra-low-dose of warfarin, the in-vivo function of vitamin K 
coagulation factors may be affected in ways not detectable by (ex-vivo) functional assays such 
as the INR or prothrombin time (Bern et al 1990). A reduction in fibrin turnover may be a 
mechanism by which ultra-low-dose warfarin exerts its benefits but this remains to be 
demonstrated.
My results are also consistent with the findings of the five large-scale clinical 
trials of anticoagulation therapy in atrial fibrillation (discussed in section 10.1). These studies 
show consistently that warfarin therapy reduces the risk of stroke and thromboembolism by 
approximately two-thirds (Lowe 1992). As increased plasma fibrin D-dimer levels suggest 
ongoing intravascular fibrin turnover and thrombus formation, patients with chronic atrial 
fibrillation and left ventricular dysfunction on no antithrombotic therapy are at increased risk of 
thrombogenesis. As anticoagulation therapy is itself not without risk, clinicians contemplating 
antithrombotic therapy for prophylaxis against stroke and thromboembolic events in patients 
with atrial fibrillation or left ventricular aneurysm have to balance the benefit of risk reduction 
against the risks of potentiating haemorrhage with warfarin therapy (Lowe 1992). The risk of
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any bleeding with the use of anticoagulation therapy ranges from 11% to 40% (Levine et al 
1990). There is, of course, a potentially higher risk of bleeding with a greater level 
anticoagulation (for example, INR 2.5) when compared to patients with 'low lever 
anticoagulation (for example, INR 1.5) (Levine et al 1990, Saour et al 1990). Nevertheless, in 
a study of patients with prosthetic heart valves, no difference in the prophylactic effect against 
thromboembolism was detected between the two groups (Saour et al 1990). Similar 
conclusions were obtained in another study of patients with atrial fibrillation who were 
anticoagulated, in which bleeding was most frequent in patients with unstable anticoagulation 
control and those with a previous history of thromboembolism (Lundstrbm and Ryd6n 1989). 
Bleeding complications may, however, occur frequently, even when the INR (or Thrombotest) 
is within the therapeutic range (Levine et al 1990, Lundstrbm and Ryd6n 1989). In summary, 
although warfarin will prevent stroke and other thromboembolic events in 3.5% of treated 
patients per year, with the risk of important bleeding in 0.5% per year, there is (at present) no 
easy way to stratify patients for baseline risk and potential benefit (Ramsay 1993). My study 
suggests that the measurement of plasma fibrin D-dimer may identify a subgroup of patients at 
high risk of thrombogenesis (e.g. plasma D-dimer >1 OOng/ml) whom would particularly benefit 
from the introduction of warfarin therapy. It may also identify those with the highest levels of 
intravascular clotting (that is, those with the highest plasma D-dimer levels) whom are 
theoretically at highest thromboembolic risk and these patients could possibly therefore be 
selected for more intense (or 'high level') anticoagulation. This would, however, need to be 
studied in a large scale prospective study to determine whether or not plasma levels of 
prothrombotic markers are predictive of future thromboembolic events.
The ability to select out patients at high risk of thrombogenesis may be 
particularly relevant in patients with heart failure. This is particularly pertinent as a recent 
survey of British cardiologists indicated that anticoagulant therapy would not be initiated in 
patients with heart failure due to dilated cardiomyopathy or ischaemic heart disease who 
remained in sinus rhythm (Cleland et al 1993). Reasons cited for not prescribing 
anticoagulant therapy included the fear of complications (54%), inconvenience (17%), lack of 
importance of thromboemboli (13%) and lack of manpower resources (9%) (Cleland et al
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1993). The presence of heart failure or ventricular impairment is known however to be 
additive to the risk of thromboembolism in patients with atrial fibrillation (Stroke Prevention in 
Atrial Fibrillation Investigators 1992a, Stroke Prevention in Atrial Fibrillation Investigators 
1992b). High risk patients with heart failure may be potentially identified therefore by the 
measurement of plasma fibrinogen and fibrin D-dimer, allowing the identification of those with 
a high prothrombotic state whom would particularly benefit from anticoagulant therapy.
This study is the first demonstration that the introduction of warfarin therapy 
in patients with atrial fibrillation and left ventricular aneurysms significantly reduces a laboratory 
index of thrombogenesis and fibrin turnover (that is, plasma fibrin D-dimer). The reduction of 
these processes by warfarin is consistent with the beneficial effect of warfarin therapy in 
reducing thromboembolic risk. It additionally suggests that measurement of plasma fibrin D- 
dimer may be useful as a marker of ongoing intravascular fibrin turnover and thrombogenesis, 
allowing further identification of those patients at high risk of thrombo-embolism. This marker 
may aid in decision-making when introduction of warfarin therapy is being considered.
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TABLE 10.1
RANDOMISED TRIALS OF 
ANTITHROMBOTIC PROPHYLAXIS 
IN ATRIAL FIBRILLATION
DESIG N S P A F AFASAK BAATAF CAFA S PIN A F
(n) 1330 1007 420 383 538
mean age 
(years)
67 74 68 68 67
mean follow-up 
(years)
1.3 1.2 2.2 1.3 1.7
maJe
%
71 54 72 75 100
INR range 
PTR range 1.3-1.8
2.8-4.2 11 >
1.2-1.5
2.0-3.0
1 1 9
1 9 9
1.2-1.5
Aspirin dose 
(mg/day)
325 75
Ischaemic stroke 
(%)
placebo group 
warfarin group 
aspirin group
6.3
2.3 
3.6
5.5
2.2
4.7
0 A
4.6
3.0
3.9
1.0
Major bleeding 
(% per year) 
warfarin group 1.5 0.5 0.8 2.1 1.3
[AFASAK=Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation Study; SPAF=Stroke 
Prevention in Atrial Fibrillation Study; BAATAF=Boston Area Anticoagulation Trial for Atrial 
Fibrillation; CAFA=Canadian Atrial Fibrillation AnticoagulationStudy; SPINAF=Veterans Affairs 
StrokePrevention in Nonrheumatic Atrial Fibrillation study]
nage 
mean (s.e.m.)
sex
M:F
smokers
TABLE 10.2
ANTICOAGULANT THERAPY 
PATIENT CHARACTERISTICS
GROUP I 
atrial fibrillation
20
63.4
(2.4)
14:6
7
GROUP II 
left ventricular aneurysm
10
52.5
(4.3)
3:2
2
body mass 
index 
mean (kg/m2)
41.2
(35.9-43.5)
39.9
(38.9-41.0)
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TABLE 10.3
PLASMA D-DIMER LEVELS 
AND ANTICOAGULATION
PLASMA D-DIMER median (IQR) ng/ml 
P A TIE N T Pre-warfarin Day 3 Day 5 Day 7 2 months
G RO UPS ___________
ATRIAL
FIBRILLATION
(n=20)
181
(111-235)
136*
(90-200)
173
(125-244)
130
(92-209)
80*
(61-137)
LV ANEURYSM 
(n=10)
115
(96-223)
128
(108-259)
136
(91-227)
113
(94-172)
61*
(54-67)
Whole group 
with initial plasma 
D-DIMER 
>100ng/ml
200
(136-271)
145
(119-242)
175
(126-230)
150*
(95-200)
68**
(57-98)
Median plasma D-Dimer values for population controls (n=158): 76mg/dl (IQR 53-103) 
(*p<0.05; **p<0.0001 when compared to pre-warfarin levels)
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TABLE 10.4
PLASMA FIBRINOGEN LEVELS 
AND ANTICOAGULATION
PLASMA FIBRINOGEN median (IQR) g/l 
P A TIE N T Pre-warfarin Day 3 Day 5 Day 7 2 months
G RO UPS
ATRIAL
FIBRILLATION
(n=30)
3.0
(2.5-3.42)
3.17
(2.69-3.66)
3.12
(2.52-3.54)
2.92
(2.38-3.66)
3.30
(2.77-4.02)
LV ANEURYSM 
(n=10)
3.37
(3.01-3.84)
3.22
(2.57-3.82)
3.28
(2.71-3.71)
3.71
(2.81-3.45)
3.24
(3.02-3.15)
Whole group 
with Initial plasma 
D-DIMER 
>100ng/ml 
(n=23)
3.09
(2.53-4.03)
3.35
(2.56-3.73)
3.18
(2.61-3.79)
3.05
(2.58-3.85)
3.10
(2.87-3.78)
Median plasma Fibrinogen values for population controls (n=158): 2.6g/l (IQR 2.24-2.99) 
(p=NS)
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TABLE 10.5
SPEARMAN CORRELATIONS 
BETWEEN PLASMA D-DIMER LEVELS 
AND ANTICOAGULATION
DAY 3 DAY 5 DAY 7 2 m onths
D -D im er 
vs INR r P r P r P r P
ATRIAL 
FIBRILLATION 
group (n=30)
0.33 0.216 0.065 0.81 0.22 0.57 0.24 0.65
LV ANEURYSM 
group (n=10)
-0.16 0.68 -0.35 0.64 -0.24 0.57 -0.37 0.29
P=NS
(INR= International Normalised Ratio)
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FIGURE 10.1 (a)
ANTICOAGULATION AND PLASMA FIBRINOGEN IN
ATRIAL FIBRILLATION
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ANTICOAGULATION AND PLASMA D-DIMER
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FIGURE 10.2 (a)
ANTICOAGULATION AND PLASMA FIBRINOGEN IN
LEFT VENTRICULAR ANEURYSMS
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11.1 LIPOPROTEIN (a) IN CHRONIC ATRIAL FIBRILLATION AND LEFT 
VENTRICULAR DYSFUNCTION
Introduction
In earlier chapters of this thesis, I have demonstrated significant abnormalities 
of plasma fibrinogen, fibrin D-dimer and von Willebrand factor in patients with atrial fibrillation 
and left ventricular aneurysms, suggesting roles for fibrinogen, intravascular fibrin turnover 
and endothelial dysfunction in the process of thrombogenesis in these patients.
Lipoprotein (a), another serum factor, may also be associated with thrombosis 
(Rees 1991, Scott 1991). This is in part based on the structural similarity of apolipoprotein (a) 
(contained in lipoprotein (a)) to plasminogen. In view of this finding, lipoprotein (a) may 
theoretically have thrombolytic properties, but clinical evidence for this is still lacking. In 
contrast, lipoprotein (a) may competitively inhibit the binding (by competing with plasminogen 
for plasminogen receptors) of plasminogen to fibrin, thereby preventing the process of 
fibrinolysis (Loscalzo et al 1990, Rees 1991, Scott 1991) and thus creating a potential 
thrombogenlc state. Theoretically, high levels of lipoprotein (a) may, therefore, significantly 
inhibit fibrinolysis and fibrin turnover. As plasma fibrin D-dimer is a measure of fibrin turnover, 
an inverse relationship between lipoprotein (a) levels and plasma fibrin D-dimer levels may 
exist. However, the contribution of lipoprotein (a) to the mechanisms of thrombogenesis (for 
example, clotting factor abnormalities, fibrin turnover, endothelial dysfunction) has not been 
defined.
Few epidemiological studies have specifically investigated the association 
between lipoprotein(a) levels and thromboembolic risk. However, there is evidence that 
lipoprotein (a) is an independent risk factor for myocardial infarction, being associated with 
atherosclerotic disease and coronary graft restenosis (Dahlen et al 1986, Hoff et al 1988, 
Rosengren et al 1990), and stroke (Pedro-Botet et al 1992, Woo et al 1991, Zenker et al 
1986). In addition, it has been suggested that apolipoprotein (a) (contained in lipoprotein (a)) 
could offer some selective advantage in tissue or wound repair, as it may help deliver 
cholesterol by attaching (due to its fibrin-binding capability) to thrombus (Lawn 1992, Scanu
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1992). Although higher levels of lipoprotein (a) are seen in patients with ischaemic heart 
disease, relatively lower lipoprotein (a) levels in certain patients may, for example, contribute 
to poor tissue healing post-myocardial infarction. In patients with large myocardial infarctions, 
such poor healing may lead to aneurysm formation.
The aim of this chapter was to determine whether or not lipoprotein (a) levels 
are associated with thrombogenesis, by a study of the two major patient groups in which the 
highest intravascular thrombogenesis has been demonstrated: patients with chronic atrial 
fibrillation and left ventricular aneurysm. In addition, I also wished to determine whether or not 
there was a relationship between lipoprotein (a) and fibrin turnover (as assessed by plasma 
fibrin D-dimer) and an association with aneurysm formation.
Patients and methods
A prospective case-controlled study was undertaken of male and female 
outpatients with established chronic atrial fibrillation (Group A) and ischaemic heart disease 
and left ventricular dysfunction (Group B). Chronic atrial fibrillation was defined as per chapter 
3, whilst left ventricular dysfunction and aneurysm formation were defined using methods 
described in chapter 8. The relationship between lipoprotein (a) and left ventricular diastolic 
dysfunction was also determined using methods described in chapter 9. Exclusion criteria for 
this study were similar to chapters 3, 8 and 9.
Blood samples were obtained from outpatients who were either fasting (if 
studied in the morning) or after a light breakfast (if studied in the afternoon) by careful 
venepuncture. In patients in Group A (chronic atrial fibrillation), the blood was placed in citrate 
tubes (trisodium citrate 0,11M, 9:1 v:v), the plasma was separated and frozen at -40°C. As 
patients in Group B (left ventricular dysfunction) were studied at a later period, a clotted 
sample was obtained, the serum separated, and frozen similarly. Plasma and serum samples 
were also obtained and frozen for a control group of 22 healthy volunteers of similar age (± 5 
years) and sex. Assays for lipoprotein (a) were performed using two methods, based on the 
type of sample. Plasma lipoprotein (a) levels were assayed using a commercially available 
ELISA method (IMMUNOZYM Lp(a) assay, IMMUNO, Vienna, Austria) whilst serum lipoprotein
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(a) was assayed using an immuno-turbidometic assay (INCSTAR Corp., Stillwater, Minnesota, 
USA). The coefficient of variation was 2-9% between assays for the immuno-turbidometic 
method (INCSTAR) and 11% for the ELISA method (IMMUNOZYM). Serum cholesterol and 
triglycerides were also determined in Group B patients using an enzymatic method (Olympus 
AU5223 Analyser, Olympus Corp., Japan). A comparison between lipoprotein (a) levels and 
corresponding plasma fibrinogen, fibrin D-dimer and von Willebrand factor, as described in 
earlier chapters, was also performed to assess the relationship, if any, with these factors.
All measured values of the serum and plasma factors were expressed as 
median ± interquartile range (IQR). Statistical comparisons were performed using the Kruskal- 
Wallis test and Mann-Whitney two sample rank test for non-parametric distributions, and the 
95% confidence intervals (c.i.) calculated for the point estimate of the difference between 
medians. Correlations between clinical variables and serum/plasma measurements were 
performed using Spearman's Rank correlation method. Analysis of the influence of systolic 
and diastolic dysfunction and their interaction on lipoprotein (a) was performed using ANOVA 
for unbalanced data (General Linear Model). A probability of <0.05 was considered statistically 
significant. Reproducibility for measurement of lipoprotein (a) by the two methods was made 
using linear regression and the method described by Bland and Altman (1986).
Results
Fifty-seven patients were enrolled into Group A (chronic atrial fibrillation) and 
105 patients into Group B (ischaemic heart disease). In Group A, there were 20 patients on 
no antithrombotic therapy, 25 on warfarin, and 12 on aspirin. In Group B, left ventricular 
systolic function was defined (as described in chapter 8) for 101 patients: 29 patients had 
normal left ventricular function (Group 1); 30 patients had left ventricular dysfunction (Group 
2); 23 patients had left ventricular aneurysms and were not on warfarin (Group 3a); and 19 
patients had left ventricular aneurysms and were taking warfarin therapy (Group 3b). Doppler 
echocardiography was performed to define diastolic dysfunction in 86 patients (in whom 
systolic function was previously categorised as in chapter 9), whom were not on warfarin 
therapy. Results for lipoprotein (a) were compared to 22 healthy volunteers of similar age and
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sex as a control group. Serum and plasma lipoprotein (a) levels were measured in controls to 
allow corresponding comparisons.
In Group A, there were no significant differences between plasma lipoprotein 
(a) levels in patients with chronic atrial fibrillation (irrespective of warfarin or aspirin therapy) 
when compared to healthy controls (Kruskal-Wallis H=2.03, d.f.=3; p=0.565) (Table 11.1, 
Figure 11.1). There were no significant correlations with corresponding levels of plasma 
fibrinogen, fibrin D-dimer or von Willebrand factor (see chapter 3). There was also no 
significant correlation with atrial size, left ventricular end-diastolic dimension and left ventricular 
function (as measured by fractional shortening).
In Group B, there were no significant differences in serum lipoprotein (a) 
between patients with left ventricular aneurysm or left ventricular dysfunction when compared 
with patients having normal left ventricular function and with healthy controls. (Table 11.2, 
Figure 11.2). There was also no difference between lipoprotein (a) levels in patients on 
warfarin therapy (Group 3b) when compared with Group 3a (Table 11.2). No significant 
differences in lipoprotein (a) (Kruskal-Wallis H=1.41, d.f.=4; p=0.842), cholesterol (Kruskal- 
Wallis H=6.48, d.f.=4; p=0.167) and triglycerides (Kruskal-Wallis H-8.21, d.f.=4; p=0.085) 
were demonstrable between the groups. There were no significant correlations between 
lipoprotein (a) levels and corresponding levels of plasma fibrinogen, fibrin D-dimer, von 
Willebrand factor, cholesterol or triglycerides in these patients (Table 11.2).
In the subgroups of Group B with normal systolic function and left ventricular 
systolic dysfunction, there were no significant differences in lipoprotein (a) levels in patients 
with or without diastolic dysfunction. In those with left ventricular aneurysms, however, 
plasma lipoprotein (a) was significantly elevated in those without diastolic dysfunction when 
compared to those with diastolic dysfunction (point estimate of difference between medians 
33mg/ml, 95% c.i. 11 to 49, p=0.024). Using ANOVA for unbalanced data (GLM or General 
Linear Model analysis), there was no significant effect of the presence of an aneurysm or 
systolic dysfunction and diastolic dysfunction (or the interaction between them) upon 
lipoprotein (a) levels.
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When the two lipoprotein (a) assay methods on the 22 control samples were 
compared the mean difference between them was 5.5mg/dl ± 21 (2s.d.). The Pearson 
correlation for the two methods was however excellent (r=0.968).
Discussion
Lipoprotein (a) is associated with atherogenesis and thrombogenesis (Rees 
1991, Scott 1991). However, there is little information on whether or not it is increased in 
conditions of high thromboembolic risk. I have therefore investigated changes of lipoprotein 
(a) in two cardiac conditions in which I have previously demonstrated increased 
thrombogenesis; that is, chronic atrial fibrillation and left ventricular aneurysms. This study, 
however, demonstrates no significant differences in median plasma lipoprotein(a) levels in 
patients with chronic atrial fibrillation when compared to controls. There were also no 
significant differences in median serum lipoprotein (a) in patients with left ventricular 
aneurysms or left ventricular dysfunction when compared to patients with normal left 
ventricular function and controls. In addition, despite the association with increased 
thrombosis, there was no significant alteration of lipoprotein (a) levels in the patients 
established on warfarin therapy. It is conceivable therefore that the 'strong' genetic influence 
upon Lp(a) levels (Sandholzer et al 1992, Scott 1991) may explain these differences. For 
example, perhaps some Lp(a) phenotypes do not contribute to thrombogenesis and as a 
result, some patients with high Lp(a) may not be at risk of thrombogenesis. Some evidence 
for such a dissociation has already been provided by population comparisons. For example, 
black Americans have higher Lp(a) levels than whites, despite having lower rates of coronary 
artery disease (Guyton et al 1985, Scanu 1992). By a similar analogy, phenotypes associated 
with high Lp(a) levels but not with thrombogenic complications might be common in the 
population studied in this chapter.
Subgroup analysis of patients in Group B into those with and without diastolic 
dysfunction (by echocardiographic criteria, as defined in chapter 9) shows that Lp(a) levels are 
higher in patients with left ventricular aneurysms without diastolic dysfunction when compared 
to similar patients with diastolic dysfunction. Two possible mechanisms may explain this
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finding. Firstly, patients with high Lp(a) levels may have the greatest atherogenic and 
thrombogenic risk, thus sustaining the largest myocardial infarctions, which lead to large 
aneurysms with major impairment of systolic function. Alternatively, patients with low Lp(a) 
levels may have poor tissue healing post-myocardial infarction, leading to aneurysm formation 
with marked fibrosis, reduced ventricular compliance and increased wall stiffness; these 
factors resulting in diastolic dysfunction. It should be noted however that the values of Lp(a) 
are widely spread, even in these subgroups.
Although I have used healthy volunteers as controls, the level of lipoprotein 
(a) [median 22mg/dl by ELISA, 24mg/dl by immunoturbidometric assay] appears higher than 
levels quoted in the large Framingham Offspring Study for patients free of cardiovascular 
disease (Jenner et al 1993). In this latter study, mean concentrations of Lp(a) were 14mg/dl 
(s.d.17) in men and 15 mg/dl in women (s.d.17) (Jenner et al 1993). This difference may be a 
reflection of my small sample size of ’healthy' volunteers, as several subjects could have 
underlying coronary artery disease and a different prevalence of apolipoprotein (a) 
phenotypes (which were not studied). Larger studies, with local population-based healthy 
controls may be required therefore to define the 'normal' value of the local population.
It has been suggested that lipoprotein (a) may interfere with fibrinolysis 
through its competition with plasminogen for binding on fibrin and/or on endothelial cells. If 
significant interference with fibrinolysis occurs, high lipoprotein (a) levels may inhibit 
fibrinolysis sufficiently to reduce fibrin turnover, thereby reducing plasma levels of fibrin D- 
dimer. In my study, there was however no relationship between lipoprotein (a) and fibrin D- 
dimer demonstrable. This finding is consistent with clinical observations that raised lipoprotein 
(a) levels do not adversely affect coronary recanalization (demonstrated angiographically) with 
the use of thrombolytic or fibrinolytic agents (saruplase (Armstrong et al 1990) and alteplase 
(Tranchesi et al 1991)) in patients with myocardial infarction. My findings also complement the 
results of Garcia Fradeetal (1991), in which no correlation was found between lipoprotein (a) 
and fibrinolytic parameters in a study of 34 patients with chronic angina and 12 with myocardial 
infarction. All these results are, however, in contrast to previous observations that plasma 
lipoprotein(a) can inhibit the fibrinolytic activity generated by streptokinase, although this
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thrombolytic agent was not used in the studies discussed earlier. For example, streptokinase 
may bind to lipoprotein (a), resulting in inhibition of streptokinase-mediated activation of 
human plasminogen to plasmin (Edelberg et al 1989, Karadi et al 1988). Differences between 
thrombolytic agents may therefore exist.
The PROCAM study demonstrated a weak association between lipoprotein 
(a) and fibrinogen levels (Heinrich et al 1991a), although this investigated considerably more 
patients than here. In my study, however, I was unable to demonstrate any significant 
association between fibrinogen and lipoprotein (a), but this may possibly be a reflection of 
smaller numbers and differences in the populations studied. However, if any major 
associations were present, it might have been expected that some evidence would have 
been found in this study. In addition, there were also no significant correlations between 
lipoprotein (a) and cholesterol, triglycerides, plasma fibrinogen, D-dimer or von Willebrand 
factor. This lack of any relationship is consistent with previous studies (Zenker et al 1986) and 
is most probably a reflection of the major genetic influence on lipoprotein (a) levels.
In conclusion, no significant abnormalities of lipoprotein (a) levels have been 
demonstrated in the two previously described groups of patients with the highest 
intravascular fibrin turnover (and therefore, thrombogenesis). This study suggests therefore 
that there may be no important interactions between lipoprotein (a) and thrombogenesis, and 
if any relationship does exist, it is probably weak.
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TABLE 11.1
CHRONIC ATRIAL FIBRILLATION 
AND LIPOPROTEIN (a)
(a) Lipoprotein (a) levels in atrial fibrillation groups:
CHRONIC A TRIAL FIB R ILLA TIO N
no therapy warfarin aspirin C O N TR O LS
n 20 25 12 23
lip o p ro te in  1 2 8 7 2 2
(a ) (5 -3 1 ) (5 -2 9 ) (2 -2 3 ) (4 -4 6 )
median
mg/dl
(IQR)
(b) Spearman correlations for Lipoprotein (a) in patients not on 
warfarin:
r P
Fibrinogen 0.064 0.73
D-dim er -0.09 0.65
von W illebrand factor -0.345 0.075
AGE -0.172 0.65
BODY MASS INDEX -0.11 0.554
LEFT ATRIAL dimension -0.049 0.788
LEFT ATRIAL volume -0.063 0.732
RIGHT ATRIAL volume 0.289 0.133
LV end diastolic dimension 0.193 0.325
LV fractional shortening -0.118 0.557
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TABLE 11.2
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
AND LIPOPROTEIN (a)
GROUP 1 GROUP 2 
normal LV LV  LV
dysfunction aneurysm  
no warfarin
GROUP 3a GROUP 3b 
LV
H EALTHY
C O N TR O LS
aneurysm
warfarin
n 29 30 23 19 21
lipopro te in
(a )
mg/dl 31 21 32 24 27
median (13-60) (12-46) (11-61) (10-46) (6-73)
(IQR)
cho lestero l
mmol/l 6.5 6.7 6.3 6.7 5.7
median (5.6-7.1) (5.7-7.5) (6.0-6.95) (5.9-7.1) (5.0-6.7)
(IQR)
trig lycerid es
mmol/l 1.9 1.9 2.1 1.9 1.4
median (1.6-3.2) (1.5-2.9) (1.3-2.7) (1.2-2.5) (1.0-1.8)
(IQR)
p=NS
(b) Spearman correlations for Lipoprotein (a):
GROUP 1 GROUP 2 GROUP 3a
r P r P r P
fib rin o g en -0.194 0.304 -0.203 0.289 -0.061 0.785
D -dim er -0.06 0.76 -0.32 0.091 0.007 0.973
vW F -0.03 0.87 -0.082 0.686 -0.336 0.122
C H O LESTER O L 0.177 0.639 -0.25 0.183 -0.077 0.73
TR IG LYC ER ID E -0.119 0.545 0.086 0.657 -0.22 0.323
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TABLE 11.3
LEFT VENTRICULAR DIASTOLIC DYSFUNCTION AND 
LIPOPROTEIN (a)
GROUP 1 GROUP 2 GROUP 3
NORMAL LV LV DYSFUNCTION LV ANEURYSM(
diastolic no diastolic no diastolic no
dysfunction diastolic dysfunction diastolic dysfunction diastolic
dysfunction dysfunction dysfunction
(n=21) (n=12) (n=16) (n=13) (n=13) (n = H )
Lipopro te in 26 36 27 12 12 46*
(a ) (10-65) (13-61) (13-41) (7-60) (6-25) (35-62)
median
(IQR)
*p<0.05
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CHAPTER 12
CONCLUDING REMARKS 
AND FUTURE DIRECTIONS
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Introduction
Identification of patients at risk of cardiogenic thromboembolism poses a 
daunting challenge. Because of the multifactorial contributory aetiology to thromboembolic 
risk, it is becoming increasingly difficult to provide a cost-effective assessment of risk which is 
easily applicable to the clinical situation. Identification of measurable plasma or serum factors 
may help therefore to identify those patients at particular risk of thrombogenesis, and whom 
may benefit from prophylactic anticoagulant therapy. This is clinically relevant as anticoagulant 
therapy is not without its risks or inconvenience. I have therefore investigated the roles of 
fibrinogen, fibrin turnover, endothelial dysfunction and lipoprotein(a) in contributing to 
thrombogenesis associated with two cardiovascular conditions at high thromboembolic risk, 
that is, atrial fibrillation and left ventricular dysfunction.
Findings in this thesis
Atrial fibrillation was found to be a common cardiac arrhythmia amongst 
emergency admissions to a district general hospital. Heart failure and cerebrovascular events 
were the commonest presenting features, accounting for about half of all emergency 
admissions over a six month period who were found to be in atrial fibrillation (chapter 2). This 
survey gave a comprehensive profile of admissions with atrial fibrillation and how they were 
investigated and managed in a district general hospital. In this survey, I identified a suboptimal 
application of standard investigations in these patients. For example, two-dimensional 
echocardiography was infrequently used although it is established as being a useful 
technique for evaluating and defining structural cardiac lesions associated with atrial fibrillation 
and thromboembolism. There was also a reluctance to perform cardioversion or to commence 
anticoagulant therapy, despite the increasingly important roles for these two therapeutic 
interventions in the current management of atrial fibrillation. One possible reason for the low 
rate of introducing anticoagulation may be the uncertainty of many physicians in identifying 
patients at high thromboembolic risk or concerns about the adverse reactions of such 
therapy. The availablity of a suitable plasma marker of thrombogenesis may therefore assist 
decision-making in these patients.
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Factors such as fibrinogen, von Willebrand factor and lipoprotein (a) have 
been associated with thrombosis, embolism and stroke. In addition, the fibrin D-dimer 
fragment is a marker of fibrin turnover and is thus an indirect measure of intravascular 
thrombus formation. Present clinical data suggests, for example, that plasma fibrinogen plays 
a major role in the thrombogenic and atherosclerotic process; to the extent that measurement 
of plasma fibrinogen should probably be included in the cardiovascular risk profile. My thesis 
provides further evidence for this viewpoint, as I have identified abnormalities of these plasma 
markers suggesting a prothrombotic state in patients with atrial fibrillation and left ventricular 
aneurysms. A better understanding of the mechanisms involved in thrombogenesis could 
possibly lead to more effective methods of prevention and treatment of cardiovascular 
disorders.
In chapter 3, patients with chronic atrial fibrillation were found to have 
significant elevations of plasma fibrinogen and von Willebrand factor when compared to 
normal population values, and this was irrespective of aspirin or warfarin therapy. Patients with 
atrial fibrillation whom are on no antithrombotic therapy had the highest levels of plasma fibrin 
D-dimer, suggesting that these patients had the highest levels of intravascular fibrin turnover. 
In contrast, those whom were established on warfarin prophylaxis had the lowest fibrin D- 
dimer levels, consistent with the beneficial effect of warfarin in reducing thrombogenesis. No 
significant effect on these factors with respect to atrial size, ventricular function (as measured 
by echocardiography), underlying valve disease or ischaemic heart disease was noted.
Cardioversion of atrial fibrillation to sinus rhythm replaces the irregular atrial 
activity of atrial fibrillation with the regular atrial systole of sinus rhythm. If thrombogenesis has 
a simple mechanical basis, cardioversion of atrial fibrillation should be expected to immediately 
normalise plasma fibrinogen and fibrin D-dimer levels. This does not appear to be the case, as 
in patients without warfarin therapy, plasma fibrin D-dimer falls sequentially over two weeks 
following cardioversion (chapter 4). This is most probably partly due to the clearance of D- 
dimer from the circulation and that atrial mechanical function may not resume immediately. In 
addition, there was little change in plasma fibrinogen levels, which may in part be due to the 
individual variation in the return of atrial systole and small numbers in my study. Although
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clinical studies suggest a 'high risk1 period for thromboembolism following cardioversion, no 
significant peak in plasma fibrinogen or fibrin D-dimer was noted. This is in keeping with the 
hypothesis that any emboli are due to pre-formed thrombus rather than formation of new 
thrombus following cardioversion. Patients who were anticoagulated with warfarin pre- and 
post-cardioversion had low plasma D-dimer levels which did not alter over the two week follow- 
up period. This is consistent with the prophylactic effects of warfarin in reducing 
thromboembolic risks during cardioversion.
If plasma fibrin D-dimer is a suitable indicator of intravascular thrombogenesis, 
further evidence may be obtained by a study of patients with paroxysmal atrial fibrillation. 
These patients are regarded as at intermediate thromboembolic risk when compared with 
chronic atrial fibrillation and sinus rhythm. In chapter 5, I demonstrated that patients with 
paroxysmal atrial fibrillation (on no warfarin therapy) had intermediate levels of plasma 
fibrinogen and fibrin D-dimer, in keeping with previous clinical observations of an intermediate 
thromboembolic risk. This also suggests that flow abnormalities may be important in 
thrombogenesis, as sustained irregular atrial activity (chronic atrial fibrillation) causes greater 
abnormalities in markers of thrombogenesis when compared with intermittent irregular atrial 
contractions (paroxysmal atrial fibrillation) and those with normal, regular atrial systolic function 
(sinus rhythm).
Flow abnormalities secondary to the irregular atrial activity in atrial fibrillation 
may account therefore for the abnormalities in the plasma levels of fibrinogen and fibrin D- 
dimer. To further clarify this matter, I compared patients with paroxysmal supraventricular 
tachycardia (whom have a paroxysmal tachycardia with normal regular atrial contractions) to 
matched patients manifesting paroxysmal atrial fibrillation (who have a paroxysmal tachycardia 
with intermittent irregular atrial activity) in chapter 6. In this small study, patients with 
paroxysmal supraventricular tachycardia had lower levels (which were similar to population 
values) of plasma fibrinogen and fibrin D-dimer compared with matched patients having 
paroxysmal atrial fibrillation. This appears to confirm the importance of flow abnormalities in 
association with atrial fibrillation as being a major determinate of plasma fibrinogen and fibrin D- 
dimer levels.
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Epidemiological evidence suggests that valvular heart abnormalities 
significantly adds to the thromboembolic risk of patients with atrial fibrillation. However, in 
patients with chronic atrial fibrillation (chapter 3), I was unable to demonstrate any significant 
effect of valvular heart disease upon plasma fibrinogen, D-dimer or von Willebrand factor. 
However, all patients with valvular heart disease may not have similar risks of thrombo­
embolism and this may be in part related to their inherent flow characteristics. In chapter 7, I 
studied a small series of patients with aortic stenosis and mitral regurgitation. Both groups had 
higher plasma fibrinogen levels when compared with population levels, which is in keeping 
with flow abnormalities in these patients. However, patients with mitral regurgitation had lower 
plasma D-dimer levels, indicating lower intravascular fibrin turnover in these patients. This is 
consistent with observations that the presence of mitral regurgitation reduces spontaneous 
echo contrast (associated with thrombus and embolism) and intraventricular thrombus 
formation (for example, in patients with dilated cardiomyopathy). This also suggests that 
plasma fibrin D-dimer may be associated with stasis within the atrial cavity. Such stasis would 
contribute to thrombus formation, which appears reduced by the presence of mitral 
regurgitation (perhaps by a 'stirring' effect on flow). Patients with aortic stenosis, however, 
had similar plasma D-dimer levels to population values, in keeping with a different 
pathophysiology (calcific emboli and platelets) of associated emboli.
Epidemiological evidence also suggests that a further factor contributing to 
the risk of stroke in atrial fibrillation is the presence of heart failure. In chapter 8, I have 
demonstrated that patients with ischaemic heart disease had higher plasma fibrinogen and 
von Willebrand factor levels when compared with population controls (in keeping with present 
epidemiological evidence). Those with left ventricular aneurysms (as defined by radionuclide 
ventriculography), however, had the highest levels of plasma fibrinogen, fibrin D-dimer and 
von Willebrand factor. This indicates the highest risk of intravascular thrombogenesis in 
patients with left ventricular aneurysms and may inpart explain the association of heart failure 
(associated with left ventricular impairment) and thromboembolic events. As in patients with 
chronic atrial fibrillation, patients with left ventricular aneurysms whom were established on 
warfarin therapy had low fibrin D-dimer levels, consistent with a reduction in thrombogenesis.
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Clinical or epidemiological studies investigating the contribution of heart 
failure to thromboembolic risk do not, however, make a distinction between systolic and 
diastolic dysfunction. This is pertinent as 30% or more of admissions with clinical heart failure 
have normal systolic function. In chapter 9, I studied the prevalence of diastolic dysfunction 
using echocardiography in patients with ischaemic heart disease, with and without systolic 
dysfunction and aneurysm formation. There was, however, no significant difference in the 
prevalence of diastolic dysfunction in these patient groups. In addition, there were no 
differences in plasma fibrinogen, fibrin D-dimer and von Willebrand factor between patients 
with and without diastolic dysfunction. This suggests that the flow abnormalities associated 
with systolic (rather than diastolic) impairment have a greater influence upon fibrinogen and 
fibrin turnover (and consequent thrombogenesis).
Recent prospective studies of patients with nonvalvular atrial fibrillation have 
shown that prophylactic anticoagulant therapy is beneficial in reducing thromboembolic risk. 
In chapter 10, this aspect has been investigated in patients with chronic atrial fibrillation and 
left ventricular aneurysms in whom anticoagulant therapy was introduced. In these patients 
there was a significant sequential reduction in plasma fibrin D-dimer (but not fibrinogen) levels 
with the introduction of warfarin therapy. In addition, in those with the highest initial D-dimer 
levels (>100ng/ml) this reduction was highly significant. This is once again consistent with the 
beneficial effect of warfarin in reducing stroke and thromboembolism. Patients at highest risk 
of thrombogenesis may therefore be selected by measurement of plasma fibrin D-dimer 
levels.
Lipoprotein (a) is another factor associated with thrombogenesis, especially 
in relation to ischaemic heart disease and stroke. In chapter 11,1 have attempted to determine 
whether there is an association between lipoprotein (a) and plasma fibrinogen and fibrin D- 
dimer. I therefore measured lipoprotein (a) levels in the two conditions in which I previously 
had demonstrated the highest intravascular fibrin turnover, that is, chronic atrial fibrillation and 
left ventricular aneurysms. There were, however, no significant differences between patients 
and healthy controls, even with warfarin therapy. This is consistent with observations that
293
lipoprotein (a) is predominantly genetically determined and varies little with environmental 
influences.
Suggestions for further study
This thesis has identified plasma fibrin D-dimer as a potential marker of 
thrombus formation. Other prothrombotic markers such as fibrinogen and von Willebrand 
factor may also be useful in identifying those at risk of thrombogenesis and cardiovascular 
events. This may in turn allow the investigation of thrombogenic mechanisms in other 
conditions with a high thromboembolic event rate and the effects of therapeutic 
interventions. However, the precise clinical role of lipoprotein (a) measurement in assessing 
thrombogenesis remains to be demonstrated. A study of these plasma factors associated 
with thrombogenesis will allow further studies in risk factor modification.
For example, low-dose anticoagulant therapy has been established to reduce 
stroke in atrial fibrillation. There is also evidence, however, that the risk of thrombosis 
associated with a long-term central venous catheter was reduced by 65% in patients receiving 
only 1 mg/day of warfarin, despite no measurable change in coagulation values (Bern et al 
1990). This 'ultra-low-dose' warfarin may be a future area of research for stroke prevention in 
atrial fibrillation, the measurement of plasma D-dimer being possibly used to ensure suitable 
'titration' of therapy.
Prospective studies are also required to assess the predictive nature of 
plasma prothrombotic markers for thromboembolic and cardiovascular risk, for example, 
whether or not a high D-dimer level predicts stroke or death in patients with atrial fibrillation. 
This aspect has recently been investigated, for example, in patients with peripheral vascular 
disease, where a high initial plasma D-dimer was predictive of cardiovascular events (Fowkes 
et al 1993). Based on current clinical evidence, most patients with chronic atrial fibrillation 
should now be considered for oral anticoagulation therapy, and it may no longer be 
reasonable or feasible (or even ethical) to investigate a prospective study of such patients 
without anticoagulation therapy.
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Measurement of prothrombotic factors may also give us a further 
understanding of the mechanisms of thrombogenesis, for example, in patients who 
demonstrate spontaneous echo contrast on transoesophageal echocardiography. This 
'visual' evidence of stasis may be associated with the highest levels of prothrombotic markers 
(particularly D-dimer). This would be in keeping with experimental work associating 
spontaneous echo contrast with fibrinogen, platelets and rouleau formation of erythrocytes 
(Sigel et al 1981, Merino et al 1992).
Conclusion
Plasma levels of fibrinogen, D-dimer and von Willebrand factor are elevated in 
patients with chronic atrial fibrillation (without antithrombotic therapy) and patients with left 
ventricular aneurysms. Intermediate levels are seen in patients with paroxysmal atrial 
fibrillation. My thesis therefore suggests possible roles for fibrinogen, increased fibrin 
turnover (as measured by plasma D-dimer) and endothelial dysfunction (as reflected by von 
Willebrand factor) in thrombogenesis in these patients. Lipoprotein (a) appears to be little 
changed in these patients, with no relationship to other plasma factors, in keeping with a major 
genetic influence on this prothrombotic factor. In addition, levels of these markers in patients 
with atrial fibrillation were not significantly influenced by cardiac chamber size or structural 
abnormalities. In patients with left ventricular dysfunction, the presence of systolic 
dysfunction (but not diastolic dysfunction) and particularly left ventricular aneurysms were 
found to be important influences upon these prothrombotic markers.
Therapeutic intervention may also alter the tendency towards 
thrombogenesis. For example, cardioversion and anticoagulation both reduced plasma D- 
dimer levels, suggestive of the beneficial effect of these interventions. My initial survey of 
admissions with atrial fibrillation showed, however, that both of these procedures are 
infrequently considered. Physicians might therefore be aided in considering these 
interventions more frequently with the availability of a suitable plasma marker which could help 
select patients at high risk (whom would benefit most from intervention). My thesis suggests 
that measurement of plasma fibrin D-dimer may fulfil this role as a marker of thrombogenesis.
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Measurement of other factors such as fibrinogen and von Willebrand factor will also contribute 
to the overall cardiovascular risk profile, allowing the risk stratification for thrombogenesis in 
such patients.
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